Meta-analysis of risk prediction studies by Ahmed, Ikhlaaq
 META-ANALYSIS OF  
RISK PREDICTION STUDIES 
by 
IKHLAAQ AHMED BSc. MSc.  
A thesis submitted to the 
University of Birmingham 
for the degree of 
DOCTOR OF PHILOSOPHY 
Public Health, Epidemiology & Biostatistics 
School of Health and Population Sciences 
College of Medical and Dental Sciences 
University of Birmingham 
January 2015 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
META-ANALYSIS OF RISK PREDICTION STUDIES 
Ikhlaaq Ahmed BSc. MSc. 
_____________________________________________________ 
Abstract 
 
A statistical model that quantifies the relationship between outcome risk and one or 
more predictors (prognostic factors) is regarded as a risk prediction model. In this thesis 
I identify and demonstrate the methodological challenges of meta-analysing risk 
prediction models using either aggregate data or individual patient data (IPD).  
Firstly, a systematic review of published breast cancer models is performed, to 
summarise their content and performance using published aggregate data. It is found 
that models were not available for comparison, as they were not presented in most 
cases. This reveals poor reporting standards in primary studies. To address this issue, 
meta-analysis of individual patient data (IPD) is proposed and a systematic review 
performed to examine articles that develop and/or validate a risk prediction model using 
IPD from multiple studies. This identifies that most articles only use the IPD for model 
development, and thus ignore external validation, and also ignore clustering of patients 
within studies.  In response to these issues, IPD is obtained from one of the articles and 
used as a case study. This article uses parathyroid hormone (PTH) assay (a continuous 
variable) to predict postoperative hypocalcaemia after thyroidectomy. It is shown 
statistically that ignoring clustering is inappropriate, as it ignores potential between-
study heterogeneity in discrimination and calibration performance, potentially 
producing misleading inferences for clinical practice. In particular, post-model 
probabilities are shown to calibrate better if heterogeneity is accounted for by tailoring 
model results to the prevalence in the intended population.  
This dataset was also used to evaluate an imputation method for dealing with missing 
thresholds when IPD are unavailable, and the simulation results indicate the approach 
performs well, though further research in other datasets is also required.  
This thesis therefore makes a positive contribution towards meta-analysis of risk 
prediction models to improve clinical practice. Nonetheless, many methodological 
issues are outlined for further research. 
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 INTRODUCTION CHAPTER 1:
1.1 Overview 
A statistical model that quantifies the relationship between outcome risk and one or 
more predictive factors is regarded as a risk prediction model; such models allow the 
risk of an outcome to be predicted for a new patient based on their specific predictive 
values [1-4]. For example, a risk prediction model has been developed to predict the 
risk of an unfavourable six month outcome [5] for patients with traumatic brain injury 
by using the predictive factors of age, motor score, pupillary reactivity, CT 
characteristics, and laboratory parameters. Risk prediction models have many potential 
uses. In particular, they may help determine treatment for a patient and help clinicians 
make decisions based on the patient's predicted risk. For example, those patients at 
high-risk may be given therapies which are expensive or have harmful potential side-
effects. 
Although many risk prediction models are proposed in the medical literature, only a 
small proportion seems to be used in practice [6, 7]. In particular, after their 
development, risk prediction models require validation in a different dataset (external to 
that used for model development) but many models do not perform well when they are 
externally validated and most are never externally validated. 
Meta-analysis of individual patient data (IPD) offers an innovative opportunity for risk 
prediction model research. In this situation, patient-level data are available from 
multiple studies for the purposes of model development and validation, which provides 
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unique opportunities. In particular, models can be developed using data from a subset of 
studies and assessed on data from the remaining studies. For example, the IMPACT 
consortium developed a prognostic model for mortality and unfavourable outcome in 
traumatic brain injury by using IPD shared by 11 studies (8509 patients), with 
successful external validation using IPD from another large study (6681 patients) [5]. 
This allowed the developed model to be validated successfully and increased the chance 
it would be used in practice.  
The overall aims of the thesis are to evaluate, apply and develop methods for risk 
prediction research within the context of meta-analysis, with particular consideration of 
the benefits of IPD over and above other meta-analysis approaches (e.g. by using 
published model results). The full aims and overview of the thesis are provided at the 
end of this chapter, but to begin with some key aspects of prognosis and prediction that 
are fundamental to the thesis are introduced. 
1.2 Prognosis research 
Prognosis means to predict or estimate the probability of a future outcome. In medical 
research, prognosis is related to the risk or probability of an individual developing an 
outcome over a specified time period (based on their profile/characteristics, which are 
termed prognostic or predictive factors). The outcome can vary from death to disease 
progression in those with disease, or onset of a disease if the patient is healthy to begin 
with, along with changes in quality of life (QOL) or pain. 
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1.2.1 Why is prognosis research important? 
Prognosis research is important in a medical setting due to its ability to guide and 
inform individuals about the estimated future course of their illness, or to inform 
healthy individuals of their risk of developing an illness or disease. It allows the 
investigation of relationships between future outcomes and baseline health to help 
improve health [8]. This makes a huge difference in clinical practice as it allows doctors 
to predict, and thus understand, the likely course of an illness in a particular individual 
based on the individuals’ characteristics. For example, a breast cancer screening tool 
can be used to determine if an individual has a probability of developing the cancer. 
This can help guide decisions regarding treatments (what changes the individual can 
make, or which treatment is the better one to use, or if a change in treatment is required 
etc.). 
There are quite a few similarities between aetiological and prognostic research, with the 
design often being a cohort study where patients have factors measured at baseline and 
their outcomes recorded prospectively over time. However aetiological research is often 
more focused on causality, whereas prognosis research is more focused on prediction. 
Predicting an outcome is different to explaining the cause of an outcome, as every 
causal factor is a predictor, but not every predictor is a cause [9]. 
1.2.2 What is meant by a predictive factor and a risk prediction model? 
Predictive factors are ultimately any patient characteristic or measure that can be used to 
predict the most likely clinical outcome for that patient [10]. These can include simple 
factors like age, sex, stage of disease, or more complex factors such as unusual genetic 
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mutations. These can be used to predict the response to treatment, the most appropriate 
treatment or to aid patient counselling. 
Due to the clinical importance of prognostic factors there is an ongoing need for 
individual primary studies to identify suitable prognostic factors that can be used in 
practice. The next stage is to combine prognostic factors together in a statistical model, 
to identify individuals who have a high risk of developing an adverse outcome, so they 
can be subject to early preventative strategies and possible treatment. For example, an 
individual that appears healthy but is found to have a high risk of developing 
cardiovascular disease could be recommended to modify their lifestyle choice (e.g. 
smoking, exercise etc.) or be prioritised for a clinical investigation which could lead to 
early diagnosis of an underlying condition (e.g. diabetes, high blood pressure). 
Therefore, there is a growing interest in risk prediction modelling for the purpose of 
prognostic risk assessments [11-13], where a statistical model is used to estimate the 
risk of a future outcome based on one or more characteristics. A risk prediction model is 
also referred to as a prognostic model (when the outcome risk is for patients with a 
defined disease) or more generally a clinical prediction model (used for both diseased 
and non-diseased settings). Similarly the word ‘model’ is often replaced with ‘score’, 
‘tool’, ‘index’ or ‘rule’. Patient characteristics are simple predictors, but can be termed 
as prognostic factors, risk factors, prognostic markers and prognostic variables. 
A risk prediction model uses predictors (covariates) to estimate the absolute risk of an 
outcome using an individual’s predictive profile. A diagnostic prediction model predicts 
the absolute risk that an outcome is present (i.e. disease) and a prognostic prediction 
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model predicts the absolute risk that an outcome will occur in a specified time period 
(i.e. relapse in the next year) [11]. 
1.3 Basic statistical concepts for risk prediction model 
There are two main phases for risk prediction model research: model development 
(including internal validation using the same data or data source) and external validation 
(using new data from a different data source) [12, 14, 15]. 
1.3.1 Model development 
A risk prediction model is developed to enable the estimation of the outcome risk using 
either a single or multiple predictive factors [11]. Commonly used statistical models for 
risk prediction are the Cox regression and logistic regression models [16]. There are two 
strategies often utilised in selecting predictors for a model. First is a selection 
procedure, which is usually forwards or backwards (and eliminates those not 
statistically significant from the model), and the second is simply including every 
predictor in the model [11]. Logistic and Cox regression are now described. 
1.3.1.1 Logistic regression 
Logistic regression is used for prediction of the probability of occurrence of an event by 
a particular time, by fitting data to a logistic probability function. This, like many other 
forms of regression analysis, uses several predictor variables that are either continuous 
or categorised. For example, the probability that a woman has first onset of breast 
cancer could be predicted by her age, Body Mass Index (BMI), smoking habits, alcohol 
consumption and family history of breast cancer. 
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We begin by explaining the logistic function, from which logistic regression comes 
from. If we call the probability of an event p, then we start by taking the odds, p / (1-p) 
and then take the log of the odds to get ln (p / (1-p)). Now this logistic function is useful 
as it maps p from a value between 0 and 1 to ± ∞. 
                       ln (
p
1−p
) =  β0 + β1x1 + β2x2 + ⋯ + βkxk , where 0 ≤ k ≤ ∞   
          (Equation 1.1) 
Here, 𝛽0  is called the intercept term, and 𝛽1, 𝛽2 etc are called the regression coefficients 
of 𝑥1, 𝑥2 etc. The intercept term is the value of ln (
𝑝
1−𝑝
) when all other variables are 
equal to zero, also known as the baseline risk. Each regression coefficient describes the 
size of the risk increase (the risk is quantified on the logit / log odds scale) for a 1-unit 
increase in the predictor. A positive coefficient means that an increase in the variable 
increases the probability of the outcome whereas a negative coefficient means that a 
decrease in the variable decreases the probability of the outcome. The 𝛽𝑠 relate to the 
increase in log odds, or equivalently log odds ratios. Once the model has been 
estimated, it can be rearranged to give a predicted probability for a new patient by: 
?̂? =  
𝑒𝑥𝑝(β0+β1x1+β2x2+⋯+βkxk)
1 +  𝑒𝑥𝑝(β0+β1x1+β2x2+⋯+βkxk)
 
(Equation 1.2) 
1.3.1.2 Cox model 
Cox regression model is used to analyse survival data, where the exact time of the event 
is important. It can describe the associations of different variables with survival; adjust 
for other confounding factors to look at the relationship of a particular variable and 
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survival; and predict the prognosis of an individual based on their characteristics 
(variables in the model, i.e. age, sex etc.). 
With a single prognostic factor, the Cox proportional hazards model can be written as: 
h1(t) = h0(t)exp(βX) 
(Equation 1.3) 
Where X=1 is a binary prognostic factor, 𝑒𝑥𝑝(𝛽) here gives the hazard ratio, ℎ0(𝑡) is 
the baseline hazard and its distribution is difficult to specify. A simple choice would be 
to use the exponential distribution, so ℎ0(𝑡) =  𝜆 𝑓𝑜𝑟 𝑡 ≥ 0 ; or a much more flexible 
approach would be the Weibull distribution, with ℎ0(𝑡) =  𝑘𝜆(𝜆𝑡) 
𝑘−1𝑓𝑜𝑟 𝑡 ≥ 0. 
If the primary interest is in the comparison of groups (i.e. hazard ratio), rather than 
estimating the actual hazard rate in each group, Cox [17] proposed a semi-parametric 
approach that estimates the hazard ratio but makes no assumption about the baseline 
hazard.  
Given several covariates of interest, the Cox model can be written as: 
h1(t) = h0(t) exp(β1X1 +β2X2 + … ) 
(Equation 1.4) 
The quantity 𝛽1𝑋1 + 𝛽2𝑋2 +  … is sometimes known as the risk score or the prognostic 
index, and categorising this creates risk groups (e.g. low, medium or high-risk etc.). 
Risk groups can be shown by plotting the categories of the prognostic index on Kaplan 
Meier curves. The International Prognostic Index (IPI) is used to determine low risk 
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(91% OS), intermediate risk (78% OS) and high risk (53% OS) [18] for patients with 
aggressive non-Hodgkin’s lymphoma. 
If the baseline hazard is known, equation (1.4) can be used to make survival predictions 
over time by the following: 
 
𝑆(𝑡) =  𝑆0(𝑡)
exp(β1X1+β2X2+ … ) 
(Equation 1.5) 
Where 𝑆0(𝑡) is the baseline survival function that corresponds to the baseline hazard. 
1.3.2 Model validation 
Model validation is important as it shows whether a risk prediction model is accurate. It 
is not regarded as being sufficient to show it works well in the development dataset 
alone [11], as usually the model performs well in the development data, but this may not 
carry over to a different population. This can be due to differing patient characteristics, 
model over fitting or non-inclusion of important predictors [11]. 
The purpose of validation is to show that the model is accurate in the population of 
individuals for whom it is intended. Predictive performance of a model is often 
optimistic when assessed using the development data (internal validation), so it is 
important to validate the model using individuals that were not in the development data 
and in a different setting (external validation) [19], i.e. using a dataset from a different 
study which is assessing the same outcome. 
To validate the performance of a risk prediction model, it is important to assess 
calibration and discrimination. Calibration compares observed and expected (predicted) 
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event rates for groups of patients. Discrimination is the ability of the risk prediction 
model to distinguish between those patients who do or do not get the event. An example 
to illustrate the difference between calibration and discrimination is a model that 
predicts every Premier League football team has a three out of twenty chance of being  
relegated: as 3 teams are always relegated, this model will have perfect calibration 
overall. However, this model does not discriminate between teams, i.e. the predicted 
probability of survival is always 3 out of 20, as it does not take in to account any 
prognostic factors such as their league results from previous years, their home and away 
form, or whether this is their first year in the premier league. So the discrimination will 
be poor in this instance. 
Model performance should ideally be assessed using an external dataset; this assesses 
generalizability, i.e. transporting the model to assess performance when taken to 
different populations [14]. There are three validation approaches discussed [14]: 
1. Internal validation approach often involves splitting the data (i.e. by studies or 
number of patients) in to two parts (ratios such as 2:1 or 4:1) [14]. The risk prediction 
model is developed on the first proportion and then validated on the second proportion; 
due to the datasets being similar this can give over optimistic results. Internal validation 
only provides information on how well the model performs in the same population as it 
was developed on. Techniques such as cross-validation or bootstrapping can also be 
used toward internal validation.  
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Bootstrapping 
Bootstrapping reflects the procedure of sampling from an approximating distribution 
[13]. A bootstrap sample can be taken from the underlying distribution which reflects 
the original data and are usually the same size; approximately 200 bootstrap samples 
can be enough to obtain steady estimates [13]. In the context of risk prediction model 
validation, the model is developed in each bootstrap sample and then validated in that 
same sample and the original data; the difference between the two validations is 
regarded as optimism, this optimism is then taken away from the performance of the 
original model in the original dataset [13]. 
2. Internal-external cross-validation (IECV) involves developing the risk prediction 
model on a proportion of a dataset (regarded as the ‘internal’ data) and then validating it 
on the remaining proportion (regarded as the ‘external’ data); this process is then 
repeated. For example, we can split the data in to five proportions, with each one fifth 
proportion being left out in turn as the validating dataset, thus allowing all the patients 
to take part in both the development and the validation of the risk prediction model [13]. 
The overall performance is usually regarded as the average of all the validations (across 
all omitted datasets).  
3. Temporal validation, this is similar to internal validation, but the difference is that the 
data is split by time, thus being regarded as external in time [14]. This is independent of 
the development stage and is a prospective evaluation of the model; it is regarded as 
being in-between internal and external validation. 
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4. External validation examines the generalizability of the model and must use new data 
from a similar or different population [14]. The new dataset must contain the same 
prognostic factors recorded that the risk prediction model contains; otherwise the 
developed model cannot be implemented. 
1.3.2.1 Performance statistics 
The validation must determine the model’s ability to differentiate between patients with 
different outcomes (discrimination) and show the agreement among observed and 
predicted risks in groups of individuals with similar risk predictions (calibration) [11]. 
1.3.2.2 Discrimination 
The concordance (C) statistic is most often used to measure performance of a prediction 
model to indicate its discriminative ability [20]. It is a rank order statistic for predictions 
against the true outcomes and does not take in to account the errors in calibration in 
terms of the differences between average outcomes [13]. For binary outcomes the area 
under the Receiver Operating Characteristic (ROC) curve is identical to the C statistic, 
which plots sensitivity against 1-specificity [20]. C statistic also exists for survival 
outcomes [21]. 
Sensitivity and Specificity 
If the risk prediction model equation is dichotomised (i.e. the prognostic index is split 
into two groups), or if a single predictor ('test') is evaluated, then sensitivity and 
specificity can be derived, which are measures of discrimination. Sensitivity (Equation 
1.6) relates to a predictor's ability to identify a patient with the outcome correctly, i.e. 
the predictor result will be positive for a patient with the outcome [22]. Specificity 
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(Equation 1.7) relates to a predictor's ability to identify a non-diseased patient correctly, 
i.e. a predictor result will be negative for a patient without the outcome [22]. Both are 
either reported as proportions or percentages. 
Sensitivity =  
number of true positives
number of true positives + number of false negatives
 
(Equation 1.6) 
Specificity =  
number of true negatives
number of true negatives + number of false positives
 
(Equation 1.7) 
1.3.2.3 Calibration 
When more than two predicted probabilities are possible (i.e. when the single predictor 
or prognostic index is left on a continuous scale), a graphical assessment of calibration 
is possible by plotting the predicted outcome risk on the x-axis and the observed 
outcome risk on the y-axis, and a perfect calibration would result in prediction being on 
the 45 degrees line [20]. This calibration plot can be understood by an intercept a which 
indicates whether the predictions are too high or too low (this is known as calibration- 
in-the-large which should be zero) as well as a calibration slope b, which should be 
equal to 1 [20]. When the model is developed a=0 and b=1 for regression models, but at 
validation calibration-in-the-large problems can occur and b can be smaller than 1 
indicating the model is over estimating the true risk [20]. Calibration plots for survival 
can be done by plotting observed risks in Kaplan-Meier plots, against expected risks 
from the derived 𝑆(𝑡) function. A calibration plot does not purely assess calibration (in 
the same way that E/O assesses calibration only); despite the name it also shows some 
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aspects of discrimination by visually displaying the range of predicted risks across the 
range of 0 to 1.   
Predictive values 
The positive predictive value (PPV) (Equation 1.8) of a predictor is the probability that 
a patient with a positive result does truly have the outcome [22]. The negative predictive 
value (NPV) (Equation 1.9) is the probability that a patient with a negative result does 
truly not have the outcome [22]. Both predictive values are usually reported as 
proportions or percentages. 
PPV =  
(sensitivity) ∗ (prevalence)
(sensitivity) ∗ (prevalence) +  (1 − specificity) ∗ (1 − prevalence)
 
(Equation 1.8) 
NPV =  
(specificity) ∗ (1 − prevalence)
(specificity) ∗ (1 − prevalence) + (1 − sensitivity) ∗ (prevalence)
  
(Equation 1.9) 
E/O statistic 
Expected (E) events can be calculated using PPV and NPV for a predictive test and the 
observed (O) events are those that are known. By dividing the expected by the observed 
we can get a statistic that tells us how well this model predicts and calibrates. An E/O 
value of over 1 indicates that the model is over predicting, a value of less than 1 
indicates the model is under predicting and a value of 1 implies that there is perfect 
prediction and calibration. 
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1.4 What is a systematic review and meta-analysis? 
In this thesis, the development and validation of risk prediction models will be 
considered in the context of systematic reviews and meta-analysis. Systematic reviews 
are increasingly important in the process of establishing the performance and clinical 
effectiveness of a risk prediction model. Many risk prediction models are developed, 
and systematic reviews and their subsequent meta-analysis allow the opportunity to gain 
a better overview and understanding of how well a risk prediction model actually 
performs by synthesising results from different studies. 
1.4.1 Systematic review 
A systematic review is a transparent framework for identifying, appraising, 
summarising and (if appropriate) synthesising research evidence from multiple studies 
of the same risk prediction model. Systematic reviews can examine quantitative or 
qualitative evidence. It should aim to be based on a protocol that can easily be replicated 
[23]. A systematic review of high quality should always aim to identify all the published 
and unpublished evidence that is related to the research question. There should be pre-
defined inclusion criteria for the studies that will be systematically reviewed, with there 
being a method to assess the quality of those reports and studies that have been 
included. In an unbiased manner, the results or findings from those studies and reports 
should be synthesised. The review should aim to interpret the results or findings and 
present them in an impartial summary [23]. 
Systematic reviews are needed in risk prediction research because there may be many 
studies published for a single risk prediction model, or many different models 
specifically proposed for that disease and outcome area (i.e. breast cancer and survival). 
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Many of these studies may give unclear and confusing results and a lack of clarity in the 
findings makes it difficult to comprehend for clinicians and healthcare decision makers. 
Each study may offer little insight to the research question, but it is hoped that when a 
systematic review is performed, we are able to gain a clearer picture of the key findings 
or results [23]. A systematic review is important as otherwise non-systematic reviews 
are performed, e.g. literature/narrative/critical review/commentary. The problem with 
these types of reviews is that they do not have a protocol that they set and follow, so 
their findings are usually very difficult to replicate. A larger problem with these types of 
reviews is that small study effects are not being picked up, as different conclusions were 
reached by researchers using the same research base [23]. 
The systematic review process typically involves defining a particular question or aim, 
then a literature review with a transparent search strategy. Potential biases that may 
occur in this search are publication bias [23-25], language bias and selection bias. 
Searching for unpublished material, also known as the grey literature is therefore very 
important, as it may help reduce the effect of publication bias [23]. Whilst searching the 
literature it is common to contact the key authors of a study to ask for clarification on 
the article if required. Once the literature has been searched, the studies will be assessed 
based on inclusion criteria and for those that have been included, the full text papers 
will be obtained and usually an assessment of study quality is made. A data extraction 
form is then used to extract the findings or results from all the studies, the findings or 
results are then combined and this is known as evidence synthesis. When quantitative 
data is extracted about the risk prediction model (e.g. model predictor estimates or 
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validation performance statistics) then a meta-analysis might be performed [23], which 
gives a statistical summary of the predictors or model performance. 
1.4.2 Meta-analysis 
The formal definition of meta-analysis is ‘the statistical analysis of a large collection of 
analysis results from individual studies for the purpose of integrating the findings’ [26]. 
This has now become a corner stone of evidence based medicine due to its ability to 
combine the results of individual studies. Meta-analysis, for example, could show 
whether a risk prediction model has a good or poor model performance by pooling 
validation statistics across studies [27]. 
A well conducted systematic review is essential for a good meta-analysis [28]. There are 
checklists available for the assessment of the quality of reporting of systematic reviews 
(note: quality of reporting is not the same as quality of conduct), with the PRISMA [29, 
30]  statement (quality of reporting of meta-analyses) being particularly recommended, 
though this is specific to intervention research rather than prediction modelling. 
1.4.2.1 Why is meta-analysis important? 
Meta-analysis is used to synthesise study results (predictor estimates or validation 
statistics), with explicit criteria for study inclusion or exclusion from the meta-analysis 
[31]. Meta-analysis helps reduce problems of interpretation due to the variability of 
observed effect estimates across trials (i.e. due to sampling variation, caused by the 
limited sample sizes of individual studies) [31]. It is generally used to quantify effect 
sizes and their uncertainty which is represented by a mean value and its 95% confidence 
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interval. One of the main purposes of meta-analysis is to facilitate synthesis of large 
numbers of study results. 
A good conduct criterion for a meta-analysis would involve the meta-analysis being 
specified in a formal protocol [31]. There would be a compilation of complete set of 
studies and common validation statistics would be identified. There would be a 
standardised data extraction protocol, with an analysis allowing for sources of variation 
[31]. A sensitivity analysis to assess study quality or impact of each study on the results 
would usually be performed. 
There are different approaches and methods that exist for meta-analysis; such as the 
vote counting method, combining p-values method, but the method used the most is 
combining estimates of effect using either a fixed-effect model or a random-effects 
model [31]. Different summary measures can be used depending on the measure of 
interest; for example, the odds ratio, relative risk, or hazard ratios for predictor effects, 
and c statistics, sensitivity or specificity, and calibration slope for model performance. 
Regardless, similar approach is taken where the estimate from each study is weighted 
by the precision of the estimate [28], as now described. 
1.4.2.2 Aggregate data meta-analysis 
An aggregate data meta-analysis essentially involves taking the value of the main effect 
estimate (validation or model predictor estimates) in a study along with its standard 
error and using it to perform a meta-analysis.  
An aggregate data meta-analysis typically uses two models: the fixed-effect model or 
the random-effects model.  
18 
 
1.4.2.3 Fixed-effect model 
A fixed-effect model assumes that there is no between-study heterogeneity and that all 
the studies are estimating the exact same predictor or validation performance; this may 
not be reasonable as studies often differ in design and population. By assuming a single 
(fixed) predictor/performance effect across studies, the pooled estimate then gives the 
best estimate of this single predictor/performance effect. The fixed-effect model can be 
written as follows, where 𝑌𝑖  is the predictor/validation effect estimate for each 
study (𝑖 = 1 … 𝑛). We interpret the coefficient  𝛽 to represent the best estimate of a 
common effect across studies, and 𝑠𝑖
2 denotes Var ( iY ) and is assumed known: 
𝑌𝑖 =  𝛽 +  𝑒𝑖 
𝑒𝑖 ~ 𝑁 (0, 𝑠𝑖
2) 
(Equation 1.10)
 
For ratios such as Relative Risk (RR), Odds Ratio (OR) or Hazard Ratio (HR); 𝑌𝑖= 
ln(RR), ln(OR), or ln(HR). To calculate the weighted mean, each study needs to have a 
weight assigned to it: 
𝑊𝑖 =
1
𝑠𝑖
2 
(Equation 1.11) 
𝑠𝑖
2is the within-study variance for study i. The weighted mean is calculated: 
𝑀 =
∑ 𝑊𝑖𝑌𝑖
𝑘
𝑖=1
∑ 𝑊𝑖
𝑘
𝑖=1
 
(Equation 1.12) 
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It is the effect size multiplied by the weight divided by the sum of the weights. The 
variance of this weighted mean is:  
𝑉𝑀 =
1
∑ 𝑊𝑖
𝑘
𝑖=1
 
(Equation 1.13) 
The estimated standard error is the square root of the variance: 
𝑆𝐸𝑀 = √𝑉𝑀 
(Equation 1.14) 
These results are equivalent to maximum likelihood solutions. 
1.4.2.4 Random-effects model 
The random-effects model allows the between study variability in effect to be accounted 
for. Therefore, it is now estimating a different effect for each study. This approach 
assumes a distribution of effects across studies and each study can then have a different 
effect. The pooled estimate then gives the estimate of the average effect across the 
studies. The random effect point estimates are usually similar to the fixed-effect one. 
However, the 95% confidence interval are usually wider [31] than the fixed-effect 
model, with studies being given a more equal weighting in a random-effects synthesis 
than a fixed-effect model. Equation (1.10) can be extended to a random-effects model 
(1.15), where 𝑌𝑖 is the effect estimate for each study (𝑖 = 1 … 𝑘). Now, 𝛽 is the average 
effect from the distribution of effects across studies, and 𝜏2 the between-study variance, 
where 𝜃𝑖 =  𝛽 + 𝑢𝑖 and 𝑠𝑖
2 is still assumed known: 
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𝑌𝑖 =  𝛽 + 𝑢𝑖 +  𝑒𝑖 
𝑢𝑖  ~ 𝑁 (0, 𝜏
2) 
𝑒𝑖  ~ 𝑁 (0, 𝑠𝑖
2) 
(Equation 1.15) 
𝜏2 is calculated by: 
𝜏2 =
𝑄 − 𝑑𝑓
𝐶
 
(Equation 1.16) 
Where 
𝑄 = ∑ 𝑊𝑖𝑌𝑖
2 −  
(∑ 𝑊𝑖𝑌𝑖
𝑘
𝑖=1 )
2
∑ 𝑊𝑖
𝑘
𝑖=1
𝑘
𝑖=1
 
(Equation 1.17) 
𝑑𝑓 = 𝑘 − 1 
(Equation 1.18) 
Here k is the number of studies, and: 
∑ 𝑊𝑖
𝑘
𝑖=1
− 
∑ 𝑊𝑖
2𝑘
𝑖=1
∑ 𝑊𝑖
𝑘
𝑖=1
 
(Equation 1.19) 
The same notations as fixed-effect will be used but with an asterisk to indicate it is the 
random-effects model. The weight for each study is: 
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𝑊𝑖
∗ =
1
𝑉𝑌𝑖
∗  
(Equation 1.20) 
𝑉𝑌𝑖
∗ is the within-study variance for study i plus 𝜏2: 
𝑉𝑌𝑖
∗ =  𝑉𝑌𝑖 + 𝜏
2 
(Equation 1.21) 
The weighted mean is calculated: 
 
𝑀∗ =
∑ 𝑊𝑖
∗𝑌𝑖
𝑘
𝑖=1
∑ 𝑊𝑖
∗𝑘
𝑖=1
 
(Equation 1.22) 
It is the effect size multiplied by the weight divided by the sum of the weights. The 
variance of this weighted mean is:  
𝑉𝑀∗ =
1
∑ 𝑊𝑖
∗𝑘
𝑖=1
 
(Equation 1.23) 
The estimated standard error is the square root of the variance: 
𝑆𝐸𝑀∗ = √𝑉𝑀∗ 
(Equation 1.24) 
1.4.2.5 Random-effects meta-analysis and the prediction interval 
Following a random-effects meta-analysis, researchers often use the average effect and 
its confidence interval. To consider the potential effect when applied to a new study is 
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also important, as this could differ from the average, and this can be assessed by 
calculating a prediction interval. The prediction interval gives a range of values for the 
predicted effect in a new study [32]. 
The 95% prediction interval is approximately: 
μ̂ −  tk−2√τ̂2 +  SE(μ̂)2,  μ̂ +  tk−2√τ̂2 +  SE(μ̂)2 
(Equation 1.25) 
Where μ̂ is the estimate of the average estimate (i.e. of the predictor/performance 
statistic) across studies from the random-effects meta-analysis, SE(μ̂) is the standard 
error of μ̂, τ̂ is the estimate of between-study standard deviation, tk−2 is the 100(1 −
α 2⁄ ) percentile of the t-distribution with k-2 degrees of freedom, where k is the number 
of studies in the meta-analysis and α is usually chosen as 0.05, to give a 5% significance 
level and thus 95% prediction interval [32]. 
1.4.3 Individual patient data (IPD) meta-analysis 
The meta-analysis of IPD (note: sometimes alternatively called individual participant 
data) involves obtaining and then synthesising the raw individual level data from 
multiple related studies [33]. The raw data collected for each individual in a study is 
regarded as IPD. Aggregate data relates to information which has been summarised or 
averaged across all individuals in a study, for example the mean treatment effect, 
proportions of individuals in sub-groups. This aggregated data is derived from the IPD, 
and the IPD is regarded as the original source [33]. 
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Like the aggregate meta-analysis method, the IPD meta-analysis method aims to 
synthesise evidence to answer a clinical research question, e.g. a predictive factor being 
statistically significant. It is important for an IPD meta-analysis to preserve the 
clustering of patients within studies as it would be inappropriate and introduce possible 
bias if they were all regarded as being from one study.  The preservation of patient 
clusters can be achieved by using two different approaches [33], the first being a two-
step approach [33, 34] where the IPD are analysed separately for each study and 
aggregate data is then obtained for each study and synthesised using an appropriate 
meta-analysis method (fixed-effects or random-effects). The one step approach [33] 
requires simultaneous modelling of the IPD from the studies and can either regard the 
IPD as coming from one study or account for the cluster of patient within studies. 
However, there has been very little consideration of one-step and two-step models in 
risk prediction research [35], which will be discussed in Chapter 3.  
1.4.3.1 Why is it potentially useful? 
IPD meta-analysis is the gold-standard as there are many advantages over aggregate 
data method, as the aggregate data are usually poorly presented and reported and may 
not be available at all in some studies [33]. It can be derived differently for different 
studies, e.g. some studies may look at odds ratios whilst others may look at the risk 
difference. Aggregate results that are clinically or statistically significant are more likely 
to be published, and this causes publication bias [24, 33]. With IPD it is possible to 
calculate the aggregate data for oneself, so you are not reliant on published reports. IPD 
allows the assessment of more patients and more outcomes than those that were 
considered in the original study, which in turn means that IPD meta-analyses are 
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probably more reliable than aggregate data meta-analyses [33]. IPD also has the ability 
to identify common patient characteristics within subgroups of patients and tailor the 
meta-analysis results to them. It also allows the modelling of non-linear effects and time 
dependent treatment effects, and potentially allows longer follow-up times. Further 
details about statistical models for IPD meta-analysis are given elsewhere (Stewart et al. 
[36], Simmonds et al. [37],  Riley et al. [38], Higgins et al. [39]). Clearly, when 
developing risk prediction models from multiple studies, it is fundamental to have the 
IPD available for model development. Further, when evaluating model performance, 
one might extract aggregate data results from published validation studies; however, if 
IPD are available one can calculate the performance statistics directly. Thus, IPD would 
appear preferable for risk prediction research; however this has not been evaluated in 
detail. 
1.4.3.2 Limitations of IPD 
There are also a few limitations of IPD. One of the limitations involves trying to obtain 
the IPD [40], as it may be difficult to contact the authors or trialists as they may have 
changed institutes or their contact details may be out of date (e.g. e-mail address). By 
the same token, issues regarding the IPD can be solved through personal contact or 
travel to ensure the transfer of data, but this may be time-consuming and expensive. 
Also, researchers may be reluctant to share their data as they have spent a lot of money 
on the trial, are possessive over their data, or have confidentiality agreements in place 
[35]. Success may be improved if one has a clear end goal, such as a joint publication in 
which collaborators are named co-authors.  
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1.5 Aims and thesis summary 
The aim of this thesis is to consider meta-analysis of risk prediction research using both 
aggregate data and IPD, to gain further insight into these approaches and make 
methodological applications, evaluations and advancements. In particular, to: 
 evaluate the benefit of a meta-analysis of aggregate data for summarising and 
comparing the performance of risk prediction models, using a real example in 
breast cancer 
 review the methods and reporting used in existing risk prediction research that 
utilised IPD from multiple studies 
 examine the impact of accounting for (versus ignoring) clustering of patients 
within studies, when using IPD from multiple studies to summarise the 
performance of a risk prediction tool 
 use simulation and IPD from real studies to evaluate a recently proposed method 
for imputing missing predictor results when given only aggregated data from 
multiple risk prediction studies 
To this end, the research should add important value to the current understanding of 
how meta-analysis methods, and their application, can facilitate risk prediction research. 
 An overview of chapters is now given. 
1.5.1 Chapter 2 
This chapter empirically examines the feasibility of summarising the performance of 
risk prediction models using a systematic review and meta-analysis of published studies 
that have developed and/or validated such models. For this purpose a systematic review 
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is performed and, when possible, a meta-analysis of risk prediction models for the first 
onset of breast cancer. This work has been published (second author publication) [41]. 
1.5.2 Chapter 3 
The aim of this chapter is to perform a systematic review to assess how risk prediction 
models are being developed and validated when IPD is sought from multiple studies and 
combined. The aim is to identify current research techniques and standards; the role of 
IPD meta-analysis methods towards development and validation; the methodological 
challenges and problems faces by researchers; and reporting standards. This work has 
been published (first author publication) [16]. 
1.5.3 Chapter 4 
The aim of this chapter is to illustrate the benefits of having IPD for meta-analysis of 
risk prediction studies, and to compare how a simple analysis (unstratified) that treats 
all IPD as coming from a single study compares to a more sophisticated analysis that 
accounts for clustering. The focus is on a single predictive test and its discrimination 
ability when using unstratified and meta-analysis approaches. This work has been 
published (second author publication) [42]. 
1.5.4 Chapter 5 
This chapter extends chapter 4, and aims to examine how the analysis approaches 
(unstratified, meta-analysis or internal-external cross-validation) impact on the 
calibration performance of a test for risk prediction and its optimal threshold. This work 
has been published (second author publication) [42]. 
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1.5.5 Chapter 6 
The aim of this chapter is to empirically evaluate the use of a linear imputation method, 
as suggested by Riley et al. [43], for meta-analysis of test accuracy studies when the 
thresholds reported by each study differ (where 'threshold' relates to the cut-point used 
to define positive and negative test results). In each study, the method imputes two by 
two tables for any missing thresholds that are bounded between two reported thresholds; 
this enables additional studies to be included in each threshold's meta-analysis. A 
simulation study is used to compare the true performance of the test (from IPD) to its 
performance when missing thresholds are generated. This work has been published 
(second author publication) [43]. 
1.5.6 Chapter 7 
This is the discussion chapter, which will recap the findings from the previous five 
chapters, discussing their key findings and impact, and outlining limitation and potential 
extensions.
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 RISK PREDICTION OF BREAST CHAPTER 2:
CANCER: SYSTEMATIC REVIEW AND META-
ANALYSIS OF AGGREGATE DATA FROM 
PUBLISHED STUDIES 
2.1 Introduction 
This chapter empirically examines the feasibility of using a systematic review and meta-
analysis of published studies for the purpose of summarising the performance of risk 
prediction models. For this purpose a systematic review will be performed and, if 
possible, a meta-analysis of risk prediction models for the first onset of breast cancer. 
There are many breast cancer models in the literature, with either single or multiple 
factors, it is important to identify what these models are telling us. This review will only 
include models that have a modifiable risk factor, this is important as women are 
interested in whether they can reduce their risk of first onset of breast cancer [41]. The 
aims of this systematic review are to identify relevant primary studies that develop or 
evaluate such a risk prediction model; to qualitatively summarise the content and 
quantitatively summarise the performance of the models they develop; and to assess if 
and how the proposed models have been validated. Further, to then consider whether 
meta-analysis of such primary studies is possible using the aggregate results from study 
publications. For example, to synthesise reported predictor effect estimates or validation 
performance statistics across multiple studies of the same prediction model, to reveal 
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how good these models are and how consistent (or heterogeneous) model parameter 
estimates are.  
This systematic review was performed in conjunction with Dr Catherine Meads, a 
Senior Lecturer with expertise in systematic reviews at Queen Mary, University of 
London, and Dr Richard Riley. Dr Meads conceived the project, developed the search 
strategy and did the literature review. My contributions were to re-check the review 
classifications from its initial to final phase, to find any discrepancies and resolve them 
with Dr Meads and Dr Riley; to obtain a final list of relevant articles and extract 
suitable data (e.g. details about the fitted models, their performance and validation 
statistics etc.); to appraise the quality of reporting in the articles identified; and to 
perform meta-analysis where possible. The review has now been published in Breast 
Cancer Research and Treatment (Meads et al. [41]) and is now described in detail, 
focusing mainly on my contributions. 
2.2 Breast cancer 
The systematic review focuses on prediction of breast cancer, which refers to a 
malignant tumour that has developed from cells in the breast. Malignant tumours are 
cancerous. Left unchecked, malignant cells eventually spread beyond the original 
tumour to other parts of the body. Usually breast cancer either begins in the cells of the 
lobules, which are the milk-producing glands, or the ducts, the passages that drain milk 
from the lobules to the nipple [44].  
Breast cancer is the most common cancer in the UK. In 2008, there were 48,034 new 
cases of breast cancer diagnosed in the UK: 47,693 (over 99%) in women and 341 (less 
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than 1%) in men. Breast cancer is by far the commonest cancer in women in the UK 
accounting for 31% of all cases in women. It has been estimated that the lifetime risk of 
developing breast cancer in 2008 is 1 in 8 for women in the UK [45].  
Risk prediction models for breast cancer are very important as they allow assessment of 
cancer risk in individuals based on their characteristics (predictors). Such models will 
contain predictors that are deemed clinically and/or statistically significant, and will 
allow the assessment of risk and prognosis for an individual based on their specific 
predictor values. These models thus have the potential to save time, money, suffering 
and death, by identifying in advance those at high risk of developing cancer. Such 
individuals could then be closely monitored, seek to modify predictor values (and thus 
reduce cancer risk), and even have early preventative treatment (e.g. breast removal). 
2.3 Objectives of the systematic review 
The following were the pre-defined objectives of the systematic review: 
1) To identify and summarise all articles reporting the development and/or the 
validation of a prediction model for breast cancer, where the model contained at 
least one modifiable predictor. It was important to look at prediction models 
containing at least one modifiable risk factor as this can help inform women of 
how they can reduce their risk of breast cancer and, if altered, to what extent 
their risk of breast cancer is reduced [41]. 
2) To document the proposed risk prediction models, including the variables in 
each model and the modifiable predictors included. 
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3) To perform, where possible, meta-analysis of model performance by: 
i) combining validation statistics for the same model reported in different 
studies, for both discrimination and calibration performance 
ii) combining parameter estimates from the same model estimated in 
different populations (studies), and to examine between-study 
heterogeneity of parameter values 
4) To evaluate the reporting quality of the studies identified. 
2.4 Methods 
2.4.1 Searching and screening 
2.4.1.1 Searching for potentially relevant articles 
Dr Meads developed a protocol and undertook a search for published articles in 
November 2009. The databases that were searched were:  the Cochrane library, 
MEDLINE, EMBASE, CAB Abstracts and PsychINFO. The search terms that were 
used were ‘breast cancer’ and ‘prediction’ or ‘risk model’ as index terms and text 
words. Reference lists of systematic reviews were also thoroughly checked [41].  
2.4.1.2 Inclusion and Exclusion Criteria 
The inclusion criteria were studies that either developed and/or validated a breast cancer 
risk prediction model for first onset of breast cancer in females. In addition, the review 
focused only on models with at least one modifiable predictor in order to be able to 
inform policies and health decisions. A modifiable predictor is one that can be altered 
by the individual, i.e. alcohol consumption, BMI, weight or physical activity. For 
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example, many women are interested in whether they can reduce their risk of breast 
cancer so it would be useful to know which modifiable predictors are included within 
existing prediction models. Clinicians and health policy makers may also aim to lower 
the population rate of breast cancer by public health interventions intended to reduce 
modifiable predictors. Studies with multiple models are presented. Studies were 
excluded if they had models with just a single risk factor (it is important to identify 
models that include a modifiable risk factor as well as other known risk factors, as it is 
important to know the effect of the modifiable risk factor after it has been adjusted for 
the other risk factors within the model); had models including only genetic mutations or 
genes; or predicted anything other than first onset of breast cancer. Early detection, 
screening and any models published more than 25 years before (i.e. before 1985) were 
also excluded. This was because of the advancements in medical research in the last 25 
years and it would be more useful to assess models that have been developed or 
validated on data that is reasonably recent. 
2.4.1.3 Screening 
All identified citations (titles with or without abstracts) were screened by Dr Meads, and 
then I checked approximately 10% of Dr Meads classifications. Of those that were 
regarded as potentially relevant, the full articles were ordered and screened further to 
assess their relevance. The classification was first conducted by Dr Meads and then later 
checked and modified by myself with a few discrepancies resolved through discussion 
with Dr Riley. Each relevant article was classified as developing a new model, 
validating a model, or a combination of these.  
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2.4.2 Data extraction 
2.4.2.1 Quality of included studies 
When the review was undertaken, there were no specific quality assessment checklists 
for prediction modelling studies. However,  a list of key criteria was available by 
Altman [46]. Based on this paper I developed a quality assessment checklist and 
extracted the data (shown in Tables 2.1 and 2.3), which was checked by Dr Riley; any 
disagreements found were resolved via discussion. The quality factors that Altman [46] 
discusses, which are relevant to prediction models and thus used in this review are as 
follows: 
 Study design – It is advantageous to have a cohort with a long enough follow-up 
so that enough events are observed (for breast cancer this would be at least five 
years) for assessment of a number of outcomes (e.g. disease recurrences, disease 
onset or death)  
 Patient sample – a well-defined cohort of patients is required with patient 
characteristics recorded; eligible patients should not be excluded because of 
missing data or loss of follow-up  
 Sample size – it is important to recognize the power of a study depends on the 
number of observed events and not the number of patients; a small sample with a 
longer follow up may be better than a large sample with a short follow up 
 Incomplete data, missing or losses to follow up – these are common and serious 
problem for studies developing a prediction model. This can reduce power and 
introduce a risk of bias. Completeness of data should be reported by predictor 
and overall. 
34 
 
 Predictors – It is better to keep continuous variables on their original scale rather 
than dichotomizing the variables which reduces power and loses important 
information, as a constant risk is assumed for all the patients in a dichotomized 
group 
 Presentation of multivariate model - whether full presentation of the model is 
given including all of the predictors, their parameter estimates (predictive 
factors, i.e. betas (Equations 1.1-1.5)), standard errors or confidence intervals of 
the parameter estimates, and the baseline risk estimate (alpha or intercept term); 
these are essential if the model is to be applied in practice 
 Validation of the model – the model should be validated; at the very least it 
should be validated internally which would involve splitting the sample to use a 
proportion to develop the model and the other part to validate it. Ideally the 
model should be validated in an external population to give more independent 
validation results and an indication of generalisability.  
For each study in the review, I extracted information relating to each of these quality 
criteria and noted when important information (e.g. missing data, model parameter 
estimates, etc.) were not reported.  Study characteristics were also extracted and 
summarised qualitatively. All data extractions were checked by either Dr Riley or Dr 
Meads. 
2.4.2.2 Performance (validation) statistics 
For studies aiming to validate a prediction model, I extracted any metric of model 
performance (such as the E/O statistic and the C statistic (section 1.3.2.2)) alongside 
their uncertainty (e.g. their confidence interval or standard error); this was checked by 
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Dr Riley. Where observed over expected (O/E) rates were given in papers, I converted 
these to E/O statistics to give a consistent scale for meta-analysis. Some studies gave a 
relevant statistic (e.g. E/O or C) but without the associated standard error. When these 
situations occurred I needed to indirectly estimate the standard error, to facilitate 
subsequent meta-analysis. For the C statistic, an equation for the calculation of the CI of 
the C statistic was used, where C is the C statistic: 
(𝐶 ± 𝑍1− 𝛼 2⁄  𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐸𝑟𝑟𝑜𝑟(𝐶) ) 
(Equation 2.1) 
Thus if a confidence interval was given, this equation would be rearranged to calculate 
the standard error. Regarding the E/O statistic, Tice et al. [47] present an equation they 
used to calculate the 95% CI of the E/O statistic by assuming the observed events 
follow a Poisson distribution:  
((𝐸 𝑂⁄ ) × exp(± 1.96 ×  1 √𝑂⁄ )) 
(Equation 2.2) 
It is fine in this instance to use 1 √𝑂⁄  as the standard error as this event is rare. Thus the 
standard error of the ln(E/O) statistic is the inverse of the square root of the observed 
events, and  this was used when the observed number of events was reported; or, if only 
the confidence interval was reported, equation (2.2) was rearranged to calculate the 
standard error of the ln(E/O) statistic when only the confidence interval was given. If a 
study did not provide variance information, and this could not be derived from other 
information (such as the confidence interval), then it would not be included in the 
statistical analysis. 
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2.4.2.3 Model parameter estimates 
For model development studies, the full model estimates were extracted where possible, 
which included the baseline risk (intercept term), predictors and their parameter (beta) 
estimates and their uncertainty (confidence intervals or standard errors). Where the full 
model was not given as the baseline/intercept term was missing, only the coefficients of 
the predictors in the model and their uncertainty were extracted. If these were not 
available then the Odds Ratios or Risk Ratios (i.e. exp(beta) estimates) were extracted 
along with their uncertainty, and these were used to obtain the model beta coefficients if 
possible. In model validation studies, if the model of interest was re-estimated in the 
new data then the new intercept, parameter estimates and their uncertainty was extracted 
in the same manner. Extracted results were checked by Dr Riley. 
2.4.3 Meta-analysis 
2.4.3.1 C statistic and E/O statistic 
Where multiple studies reported the same performance statistic for a model, a random-
effects meta-analysis was performed, using the DerSimonian and Laird method [48] via 
STATA 11 [49], to summarise model performance. This approach estimates the average 
performance of the model, the between-study heterogeneity in model performance, and 
a 95% prediction interval [32] for the model performance when it is applied in a single 
population setting. The random-effects meta-analysis framework was introduced in 
Chapter 1 (Equation 1.15). For the C statistic, the estimates of the C statistic and their 
standard errors were synthesised. A new paper [27] suggests this is the correct scale to 
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use for the C statistic. For the E/O statistic, the ln(E/O) statistics and its standard error 
was synthesised, and then meta-analysis results were transformed back to the E/O scale.  
2.4.3.2 Model parameter estimates 
Where the same model was estimated in multiple studies (e.g. in the development study 
and then in validation studies), the beta coefficient estimate for each predictor were 
synthesised using a random-effects meta-analysis, again via the DerSimonian and Laird 
method using STATA 11 [48, 49]. This enabled the effect of each predictor to be 
summarised and heterogeneity in its effect to be evaluated. This was of particular 
interest for modifiable predictors, for which the predictive value is of key importance if 
one considers it to be causal (and thus modifying it can potential reduce breast cancer 
risk). 
2.5 Results 
2.5.1 Search results 
From the database searches, 7317 references were found of which 1265 were duplicates. 
The flow of papers toward inclusion or exclusion is shown in Figure 2.1. Dr Meads 
classified 79 of the 7317 articles as potentially relevant; I went through a random 
sample of 600 of these classifications (about 10%) and found no discrepancies. 
However, one article of the 79 retrieved for full assessment was in Spanish and – after 
discussion with Dr Meads and Dr Riley – it was deemed necessary to exclude this (as 
we could not translate it), and thus focus only on English language articles.  So this left 
78 potentially relevant articles, for which the full paper was obtained. 
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Citations retrieved for 
assessment of full 
paper = 79 
Papers included in 
this systematic 
review = 26 
Development of a new risk 
prediction model only = 6 
Both development of a new model and 
validation of one or more models = 11 
 
Excluded from systematic review = 53 
(Reasons: Systematic/semi systematic 
reviews = 2, Irrelevant = 49, In Spanish=1) 
Insufficient detail = 1) 
Total number of 
citations found = 
7317 
Irrelevant = 5973 
Duplicates = 1265 
Independent validation of one or more 
models = 9 
 
Figure 2.1: PRISMA diagram for systematic review 
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Dr Meads and I independently went through the 79 papers and further assessed their 
relevance. A total of 26 articles were deemed relevant by both, with no disagreements, 
and these were each classed as development and/or validation articles. Of the 26 
articles, Dr Meads classified 16 as developing new models and ten as validations of an 
existing model. In contrast, I classified six as developing a new model, nine as 
validation of existing model, and 11 as both development of a new model and validation 
of an existing model. After discussion with Dr Meads and Dr Riley, the classifications 
by me were accepted and used for the remainder of the review (Figure 2.1). 
The 26 articles were grouped as follows: 
 Six studies describing the development of a new prediction model (Gjorgov 
[50], Colditz et al. [51], Cook et al. [52], Gail et al. [53], Tyrer et al. [54] and 
Wacholder et al. [55]) 
 Nine studies validating one or more prediction models in a new sample from a 
potentially different population (Amir et al. [56], Bondy et al. [57], Costantino et 
al. [58], Rockhill et al. [59], Speigelman et al. [60], Schonfield et al. [61], 
Ulusoy et al. [62], Rockhill et al. [63] and Viallon et al. [64]) 
 Eleven studies both describing  the development and validation of one or more 
models (Barlow et al. [65], Boyle et al. [66], Chen et al. [67], Decarli et al. [68], 
Gail et al. [69], Novotny et al. [70], Rosner et al. [71], Rosner et al. [72], Rosner 
et al. [73], Tice et al. [74] and Tice et al. [47] ) 
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2.5.2 Study quality and reporting 
The quality and reporting of the 17 articles developing a risk prediction model is 
summarised in Table 2.1, and briefly summarised here. None of the 17 papers gave a 
justification for the sample size used. Fifteen of the 17 papers gave the number of 
eligible patients for inclusion in to the study for model development (e.g. Barlow et al. 
[65]) which had index screening mammograms from 1,007,600 patients), but two 
papers did not, (e.g. Gjorgov [50]). Seven of the 17 gave the number of events per 
predictor (e.g. Barlow et al. [65]); eight of the 17 (e.g. Boyle et.al [66]) summarised the 
sample characteristics (e.g. mean age, proportion post-menopausal) in a table; nine of 
the 17 stated whether there was any missing risk factor data for some participants (e.g. 
Barlow et al. [65]); and 15 of the 17 stated how they handled continuous variables (i.e. 
whether kept continuous or categorized) (e.g. Chen et al. [67]). Only six of the 17 
reported the full specification of the final developed model(s) (e.g. Cook et al. [52]), i.e. 
they reported the alpha term with its standard error, as well as parameter values (beta 
estimates) and their standard errors or 95% confidence intervals for all included 
variables. Of those 11 papers that did not report the full model, eight of them ignored 
the intercept but did report beta values or transformed beta values (e.g. odds ratios or 
risk ratios) for some or all variables, sometimes with a confidence interval (Table 2.1).  
2.5.3 Articles developing a prediction model 
The statistical model / methods used to obtain the model parameter estimates are shown 
in Table 2.2 for each of the 17 articles. Nine of those articles used logistic regression, 
three articles used Poisson regression, two used Cox proportional hazards, two used 
Bayes' theorem and one article used linear regression. Out of those 17, two have used 
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Bayes’ theorem and one of those articles by Gjorgov [50] has stated: "by calculating 
exposure to barrier contraceptive practice (condom use and withdrawal practice) along 
with the factors of parity, age and other (non-barrier) birth-control methods, within a 
five-year time period and the life span 20-54 years of age, by employing the Bayes' 
Probability Theorem" [50]. 
The predictors included in each of the 17 developed risk prediction models are shown in 
Table 2.3. Note that this does not mean all these gave their full model, as most of these 
predictors were extracted from tables giving odds ratios or relative risks rather than the 
full model estimates, as explained above. The modifiable predictors that were included 
in the models were alcohol consumption, BMI/weight, condom use, exogenous 
hormone use (HRT, contraceptive pill), and physical activity. The most common 
predictors included in the models were age, age at first live birth and/or age at 
subsequent births and family history of breast cancer. The predictors only included in 
one model were condom use, family history of any cancer, physical activity and 
reproductive age period. Where condom use was included the justification provided by 
Gjorgov [50] to include condom use was: "risk-assessment models failed to consider the 
defined, main, and perhaps the sole most important risk factor and determinant of breast 
cancer, the exposure to (use of) condoms in marital relations, quantified according to 
duration ('persistency') of the exposure to condom use (in months and years) during the 
reproductive-age span of women, from puberty to the peri-menopausal years of 54" 
[50]. Condom use has only been mentioned by one study, this could be an anomaly and 
should not be regarded as a predictor solely based on this study [50].  
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A brief description is now provided of the six risk prediction models developed in these 
17 articles. 
Gail 1 model [53] used data from a case control study to calculate the parameter 
estimates for the predictors using logistic regression. These parameter estimates were 
then combined with the baseline risk estimated using data from the BCDDP Cohort (a 
population of white women from USA), to allow individualised probabilities to be 
calculated [41], giving the risk for any breast cancer. Gail 2 model is a development of 
the original Gail 1 model and was published in 1992 as a technical report which is not 
widely available. This model [69] predicts invasive breast cancer only, and the baseline 
risk is estimated using the SEER database [75]. This means that Gail 1 and Gail 2 have 
different baseline risks, and indeed are predicting two separate risks. 
Tyrer-Cuzick model [54] is based on a Bayesian statistical analysis and was developed 
in the UK. The population used was from the dataset acquired from the International 
Breast Intervention Study (IBIS) [76] and UK national statistics. The authors stated: 
"For an individual woman her family history is used in conjunction with Bayes' theorem 
to iteratively produce the likelihood of her carrying any genes predisposing to breast 
cancer, which in turn affects her likelihood of developing breast cancer. This risk was 
further refined based on the woman’s personal history. The model has been 
incorporated into a computer program that gives a personalised risk estimate." 
Pike model [77] is a breast cancer incidence model, based on the observed age-
incidence curve and known relations between age at menarche, first birth, and 
menopause, parity, and the risk of breast cancer [71]. Rosner & Colditz (1) [63] model 
is a development of the Pike model [77] with an additional predictor allowing for more 
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than one birth. Rosner & Colditz (2) [73] model is a modification of the Rosner & 
Colditz (1) [63] model with focus on predicting oestrogen-positive breast cancer. This 
has been summarised in Table 2.1 below. 
Table 2.1 Models and their outcomes 
Model Outcome 
Gail 1 model Any breast cancer 
Gail 2 model Invasive breast cancer only 
Tyrer-Cuzick model Any breast cancer 
Pike model Any breast cancer 
Rosner & Colditz (1) model Any breast cancer 
Rosner & Colditz (2) model Oestrogen-positive breast cancer 
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Table 2.2: Risk prediction models - reporting and analysis characteristics 
 Description of key aspects 
of study design: 
Sample 
characteristics: 
Data quality: Handling of continuous 
variables: 
Presentation of model:   
Article Number of 
eligible 
patients 
given 
Number of 
events per 
variable 
Were they 
summarised in  a 
table (e.g. mean 
age, proportion 
males, …) 
Missing data for 
each variable 
mentioned/ stated 
in the paper? 
Were they kept 
continuous or 
categorized in the 
model? 
Was the complete model 
given (i.e. alpha term, 
parameter estimates and 
their uncertainty, i.e. s.e. or 
CI)? 
If not, was any part of 
the model given? 
What 
statistical 
model / method 
was used? 
Gjorgov 2009 No Not stated No No Not given No No Bayes' theorem 
Barlow 2006 Yes, 
1007600 
Stated Yes Yes Categorised (test for 
trend across categories 
of a continuous factor 
performed) 
No Yes – ORs and CIs for 
each category of each 
variable relative to the 
reference category 
Logistic 
regression 
Boyle 2004 Yes, 5157 Not stated Yes No Categorised No;  (only some of the final 
model variables are given) 
Yes; ORs and CIs given 
for a partial set of the 
included variables; score 
chart provided 
Logistic 
regression 
Chen 2006 Yes, 
284780 
Not stated No Yes Categorised No Yes (variable names 
with coefficients, but no 
CIs) 
Logistic 
regression 
Colditz 2000 Yes, 58520 Not stated No No Kept continuous Yes  Poisson 
regression 
Cook 2009 Yes, 45281 Not stated Yes Yes, as complete 
data available  
Kept continuous Yes  Logistic 
regression 
Decarli 2006 Yes, 5157 Stated Yes Yes – patients with 
missing data 
excluded 
Categorised No Yes; ORs and CI given 
for variables 
Logistic 
regression 
Gail 1989 Yes, 5998 Stated No No All Continuous except 
age (categorized)  
Yes (estimates and their 
standard errors given) 
 Logistic 
regression 
Gail 2007 Yes, 3254 Stated Yes Yes, as complete 
data available) 
Categorised Yes (estimates and their 
standard errors given) 
No Logistic 
regression 
Novotny 2006 Yes, 4598 Not stated No No Categorised No Yes; ORs and parameter 
estimates given, but no 
standard errors or CIs 
Logistic 
regression 
Rosner 1994 Yes, 91523 Not stated No Yes, patients with 
missing data 
excluded 
Continuous 
 
No Yes – some parameter 
estimates and some CIs 
given 
Poisson 
regression 
Rosner 1996 Yes, 89132 Not stated No No Continuous Yes  Poisson 
regression 
Rosner 2008 Yes, 59812 Not stated No No Continuous Yes  Linear 
regression 
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 Description of key aspects 
of study design: 
Sample 
characteristics: 
Data quality: Handling of continuous 
variables: 
Presentation of model:   
Article Number of 
eligible 
patients 
given 
Number of 
events per 
variable 
Were they 
summarised in  a 
table (e.g. mean 
age, proportion 
males, …) 
Missing data for 
each variable 
mentioned/ stated 
in the paper? 
Were they kept 
continuous or 
categorized in the 
model? 
Was the complete model 
given (i.e. alpha term, 
parameter estimates and 
their uncertainty, i.e. s.e. or 
CI)? 
If not, was any part of 
the model given? 
What 
statistical 
model / method 
was used? 
Tice 2005 Yes, 81777 Stated Yes Yes Categorised, as in the 
Gail model 
No Yes – some parameter 
estimates and CIs given 
Cox 
proportional 
hazards 
Tice 2008 Yes, 
1095484  
Stated Yes Yes A mixture of continuous 
and categorisation used 
No No Proportional 
hazards model 
(probably cox 
but not stated) 
Tyrer 2004 No Not stated No No Not given No No Bayes' theorem 
Wacholder 2010 Yes, 11588 Stated Yes Yes  Categorised  No Yes, ORs and CIs for the 
variables 
Logistic 
regression 
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Table 2.3: Breast cancer risk prediction models - comparison of predictors included 
Predictors 
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Age  Y Y Y Y  Y  Y Y Y Y Y Y Y Y Y Y Y 1,2,3 
Age at menarche     Y  Y  Y Y Y Y Y Y Y Y Y  Y 1,2,3 
Age at first live birth and/or age at 
subsequent births 
  Y Y Y Y  Y  Y Y Y Y Y Y Y  Y 1,2,3 
Age at menopause      Y  Y     Y Y Y   Y  
Atypical hyperplasia / benign 
breast disease 
  Y   Y  y    Y    Y   Y  
Breast density   Y Y  Y          Y Y   
Birth history/ parity Y     Y         Y   Y  
Birth index       Y  Y            
Breast biopsy number  Y Y  Y   Y Y Y Y   Y  Y Y  1,2,3 
Ethnicity    Y             Y   
Family history of breast cancer Y Y Y Y Y Y  Y Y Y Y Y    Y Y Y  1,2,3 
Family history of any cancer            Y        
Height       Y  Y       Y   Y  
Number of contraceptives           Y        
Reproductive age period  Y                  
Surgical menopause    Y   Y  Y        Y     
Modifiable Predictors                   
Alcohol consumption    Y  Y  Y       Y     
BMI or weight   Y Y Y Y  Y    Y    Y   Y  
Condom use  Y                  
Exogenous hormone use (pill, 
HRT) 
  Y Y  Y  Y       Y     
Physical activity    Y                
**Five models were presented in Wacholder 2010 but only three had modifiable predictor and have been presented here 
1,2,3 represent the three Wacholder 2010 models 
A total of 21 predictors have been identified 
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2.5.4 Articles externally validating a model 
2.5.4.1 Qualitative summary 
The characteristics and results of the 20 articles externally validating one or more 
prediction models are shown in Table 2.4. These are now summarised qualitatively. 
There were four papers with external validations of the Gail 1 model (Bondy et al. [57],  
Costantino et al. [58], Novotny et al. [70], Spiegelman et al. [60]) and 12 papers with 
external validations of the Gail 2 model (Amir et al. [56], Barlow et al. [65], Boyle et al. 
[66], Chen et al. [67], Costantino et al. [58], Decarli et al. [68], Gail et al. [69], Rockhill 
et al. [59], Schonfeld et al. [61], Tice et al. [74], Tice et al. [47], Ulusoy et al. [62]). 
Costantino et al. [58] evaluated both Gail models, and several other papers presented 
more than one validation using different cohorts. The validation populations were 
generally from USA, but there was also one study from each of Czech Republic, France, 
Great Britain, Italy and Turkey. 
None of the four papers assessing Gail model 1 reported a C statistic, but three of them 
reported an E/O statistic. Nine of the 12 papers that assessed Gail model 2 gave the C 
statistic, while seven of the 12 papers gave the E/O ratios.  Five of these papers [58, 59, 
61, 69, 74] refitted the original model and gave the new parameter estimates and their 
uncertainty. 
Two papers [63, 64] assessed the Rosner and Colditz (1) model and two papers [63, 73] 
assessed the Rosner and Colditz (2) model; one paper from these has assessed both 
models. Two papers gave the C statistic for Rosner and Colditz (2) model, and one 
paper gave the C statistic for Rosner and Colditz (1) model. Two papers gave the E/O 
48 
 
ratio for Rosner and Colditz (1) model, and one gave the E/O ratio for Rosner and 
Colditz (2) model. Only one paper refitted the Rosner and Colditz (2) model in a new 
data set and gave the parameter estimates and their uncertainty. 
Two papers [71, 72] assessed the Pike model but neither gave the C statistic or the E/O 
ratio.  
One study (Amir et al. [56]) (Table 2.4) was found which assessed the performance of 
several models (Gail, Claus, Ford, Tyrer-Cuzick and Manual) on the same data set from 
South Manchester, UK. The population of 4536 women had been assessed in a hospital 
clinic for breast and other cancer risks and were a high risk sample. Amir et al. [56] 
investigated the total population and the screened population, and they concluded that 
the Tyrer-Cuzick model was the most accurate for this high risk sample with a C 
statistic of 0.762 (0.700-0.824) (see Table 2.4). It is not clear whether the Tyrer-Cuzick 
model would also be the best predictive model for a general population sample (a 
general setting), but this study is helpful as it gives an insight as to how some of the 
proposed risk prediction models perform on the same dataset. Tyrer-Cuzick has a better 
C statistic value than the other models, and therefore it appears to discriminate better 
than the other models.
49 
 
Table 2.4: Breast cancer risk prediction models - validation statistics 
Article Model 
validated  
C Statistic 
(95%CI)  
Other validation stats Validation population  Comments  
Amir 2003 Gail 2 0.735 (0.666 to 
0.803) 
E/O = 0.69 (0.54 to 0.90) High risk hospital cases and 
controls from UK  
Also evaluated three genetic models  
Tyrer-Cuzick 0.762 (0.700 to 
0.824) 
E/O = 1.09 (0.85 to 1.41 ) 
Barlow 2006  Gail 2 0.598 (CI and SE 
not given) 
Not given  Mammogram registry in USA 
population  
Differences in time intervals for cancer 
ascertainment meant validation unreliable 
Bondy 1994 Gail 1  O/E = 0.76 (CI not given, but calculated 
for meta-analysis when converted to 
E/O and using Equation 2.2)  
High risk white women in Texas 
USA 
Subgroup analysis based on American Cancer 
Society mammogram screening guidelines given  
Boyle 2004  Gail 2 Not given  O/E = 0.89 (0.70 to 1.09) RCT of adjuvant tamoxifen in USA, 
all had hysterectomies 
2 validations, above with original USA data set, 
below with Italian registry dataset. Unclear if for 
pre- or post-menopausal women or both.  
0.582 (CI and SE 
not given) 
O/E = 0.96 (0.75 to 1.16) 
Chen 2006 Gail 2 0.602 (CI and SE 
not given) 
Not given  Unclear   
Costantino 1999 Gail 1 Not given  E/O = 0.84 (0.73 to 0.97) Women at increased risk of breast 
cancer in USA RCT of adjuvant 
tamoxifen 
Distinguished clearly between total breast cancer 
(Gail 1) and invasive breast cancer (Gail 2) 
Gail 2 E/O = 1.03 (0.88 to 1.21) 
Decarli 2006 Gail 2 0.588 (0.546 to 
0.631) 
E/O = 0.93 (0.81 to 1.08) Italian case control and registry 
studies  
- 
Gail 2007 Gail 2 0.636 (0.617 to 
0.655) 
O/E = 1.08 (0.97 to 1.20) Black women from USA Recalculated c statistic and O/E from data in paper 
Novotny 2006 Gail 1 Not given  Not given  Mammogram registry in Czech 
population 
Only parameter estimates (ORs) with no standard 
errors of CIs given 
Rockhill 2001 Gail 2  E/O = 0.94 (0.89 to 0.99) White nurses in USA Subgroup analyses for high risk and mammogram 
in past year also given 
Rockhill 2003 Rosner & 
Colditz (1) 0.57 (0.55, 0.59) 
E/O = 1.00 (0.93 to 1.07) Nurses from USA Validation on same cohort as original model but 
using different time ranges 
Rosner & 
Colditz (2) 
0.63 (0.61, 0.65) E/O = 1.01 (0.94 to 1.09) 
Rosner 1994 Pike Not given Not given Nurses from USA - 
Rosner 1996 Pike Not given Not given Nurses from USA - 
Schonfield 2010  Gail 2 Not given  Early SEER E/O = 0.87 (0.85 to 0.89) 
Late SEER E/O = 1.03 (1.00 to 1.05) 
White postmenopausal women from 
USA (NIH-AARP study) 
Split SEER cohort by date from 1983-87 and 1995-
2003 and validated using two different populations.  
Early SEER E/O = 0.86 (0.82 to 0.90) 
Late SEER E/O = 1.01 (0.97 to 1.06) 
White postmenopausal women from 
USA (PCLO trial) 
Rosner 2008 Rosner & 
Colditz (2) 
0.635 (0.628 to 
0.642) 
Not given  Nurses from USA Focus of paper on oestrogen receptor-positive 
breast cancer 
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Article Model 
validated  
C Statistic 
(95%CI)  
Other validation stats Validation population  Comments  
Speigelman 1994 Gail 1 Not given  E/O = 1.33 (1.28 to 1.39) Nurses from USA Over prediction attributed to higher baseline 
incidence rates of breast cancer 
Tice 2005  Gail 2 0.67 (0.65 to 0.68) Not given  Mammography register in USA ROC curve symmetrical  
Tice 2008  Gail 2  0.613 (0.604 to 
0.622) 
Not given  7 mammogram registries from USA  Some data missing so authors recommend 
interpretation with caution  
Ulusoy 2010 Gail 2 Not given  Using cut off risk  >=1.67 sensitivity = 
13.3%, specificity = 92%, PPV = 63%, 
NPV = 51.9% 
Turkish cases and controls from one 
hospital  
Small validation sample 
Viallon 2009 Rosner & 
Colditz (1) 
Not given  E/O = 0.947 (0.912 to 0.982) French teacher, spouses and 
employees 
Most of paper describes mathematical simulations.  
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2.5.4.2 Meta-analysis of external validation statistics 
Random-effects meta-analyses of the C Statistic (Figure 2.2) and the E/O ratio (Figure 
2.3) were conducted for each model that had the external validation statistic extracted 
from two or more different articles (or populations). Validation statistics were often not 
reported, thus only a few meta-analyses were possible which usually contained a small 
number of studies. In most analyses there was considerable between-study 
heterogeneity in the validation statistic; for example, for the Gail 2 model the proportion 
of the total variability due to between-study heterogeneity (I
2
) was 94.5% and 92.5% in 
the meta-analyses of the C statistic and E/O ratio respectively. Such heterogeneity is 
perhaps unsurprising given the variations in populations used for the validations (Table 
2.4). However, I-squared is also large because the within-study variances are small (due 
to the number of patients being extremely large in each study), and so the between-
study variance (tau-squared) always dominates. Rucker et al. [78] refers to this as a 
‘misleading’ nature of the I2 statistic when the within-study variances are very small. 
It was only possible to do a meta-analysis of the C statistic for Gail 2 and Rosner & 
Colditz (2), for which only five and two studies gave results (Figure 2.2). Rosner & 
Colditz (1) is included in Figure 2.2 as that was the only other article to give a C 
statistic with its uncertainty, so it was included so all available data can be viewed on 
the graph. It is difficult to make strong inferences.  In terms of discriminatory 
performance of the models, generally the C statistics across studies seem to be around 
0.6, and thus only moderate; but nevertheless, they are adding some potentially 
important information about increase in breast cancer risk when compared to a null 
model with no predictors (i.e. where the C-statistic would be 0.5, a 50:50 (tossing a 
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coin) prediction). No result contains 0.5 in the 95% CI, so it seems these models can 
discriminate between those women who develop breast cancer and those who do not, 
but not too well.  
Figure 2.2: Meta-analysis of the C statistic for breast cancer risk prediction models 
 
For meta-analyses of the Gail 2 model, the average C statistic was 0.63 (95% CI: 0.59 to 
0.67, based on 5 articles) which indicates only moderate performance. Gail 2 has a 95% 
prediction interval of (0.49, 0.77), which indicates that (based on the 5 studies in the 
meta-analysis) we predict that the C statistic in a new study (population) would be 
between 0.49 and 0.77. This reveals that the potential C statistic in a particular clinical 
NOTE: Weights are from random effects analysis
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setting may be substantially different from the average effect [32], with the 95% 
prediction interval indicating a wide-range of patient values, including even 0.50, and 
therefore it is unclear whether the model will have adequate discrimination in a 
particular setting of application. One can formally check if the model results are actually 
different if all the models were applied to the same data and then the C statistics were to 
be compared, i.e. Amir et al. [56] who do this for Gail 2 model and Tyrer and Cuzick 
model. This shows how well the models perform against each other in the same setting. 
Figure 2.3: Meta-analysis of the E/O ratio for breast cancer risk prediction models 
 
NOTE: Weights are from random effects analysis
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In terms of calibration of the models, the meta-analysis of E/O statistics is shown in 
Figure 2.3.  Such a meta-analysis was only possible for Gail 1, Gail 2, and Rosner & 
Colditz (1) as the results were presented for three, seven and two studies respectively. 
Rosner & Colditz (2) is included in Figure 2.3 as that was the only other article to give 
an E/O statistic with its uncertainty so it was included so all available data can be 
viewed on the graph. There appears to be a high level of heterogeneity in the meta-
analyses for Gail model 1 (95%) and Gail model 2 (92.5%), again likely to be due to the 
range of different populations considered and the ‘misleading’ nature of I2 given small 
within study variances (alternatively tau-squared can be used, as it is less sensitive to 
the sample size [78]). 
For Gail model 2, this heterogeneity is very important to acknowledge. On average the 
model has good calibration, with the summary E/O statistic close to 1 and its confidence 
interval contains 1  (pooled E/O = 0.95; 95% CI: 0.88 to 1.01). However it can be seen 
in Figure 2.3 that in individual studies E/O is sometimes less than 1 and in others it is 
greater than 1; on average it is close to 1 and the 95% CI contains 1, this shows on 
average it is a good model – but there is considerable heterogeneity in calibration across 
studies. This is revealed by the 95% prediction interval of 0.75 to 1.19 which gives the 
range of possible E/O ratios when the Gail model 2 is applied in any given study 
population. On average it performs well but it may not do as well in an individual 
clinical setting, potentially underestimating the number of events (0.75) or 
overestimating them (1.19).  This is similar for Gail model 1; although the prediction 
interval is extremely wide given there are only 3 studies in the meta-analysis (Figure 
2.3). The meta-analysis of the C statistic in Figure 2 shows the discrimination is quite 
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low, but the calibration for those similar studies is much better. For a model to be 
considered good it should have good discrimination (which depends on the clinical 
context, but ideally it should have a C statistic somewhat greater than 0.50) and 
calibration (e.g. being as close to 1 as possible for E/O) [13]. 
2.5.4.3 Meta-analysis of the refitted parameter estimates 
In validation studies that refitted the original model under investigation, the new 
parameter estimates and their 95% confidence intervals or standard errors (uncertainty) 
were directly or indirectly available for just 5 articles. All 5 articles refitted the Gail 2 
model, which contains seven different variables: Age at menarche, Number of 
biopsies*Age categorised interaction variable (No biopsies <50, No biopsies ≥50), and 
four interaction terms for number of affected first degree relatives*age at first 
birth*with age in four different categories. A separate random effects meta-analysis of 
the parameter estimates for each of the variables is presented in Figures 2.4 to 2.10. 
This is another approach of checking the consistency of model parameter estimates 
across different settings: if there is little heterogeneity and similar direction and 
magnitude of effects, it enhances the credibility of the model’s generalisability. The 
motivation for this meta-analysis is to assess whether these predictors show consistent 
predictive value when pooled together across different studies. Ideally, parameter 
estimates would be available for the modifiable risk factors, so that they can be meta-
analysed and the obtained summary results would help ascertain whether these 
modifiable risk factors (consistently) reduce the risk of breast cancer in all populations. 
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Figures 2.4-2.10 show that the parameter estimates are similar across studies in terms of 
direction, although the heterogeneity is sometimes a concern, ranging from an I-squared 
of 0% (Figure 2.10) to 84.2% (Figure 2.5).  
The summary meta-analysis results reveal that, at least on average, each parameter is a 
predictor of breast cancer risk, and so there is strong evidence that these are genuinely 
important predictors to consider in breast cancer risk prediction models. Age at 
menarche is a predictive factor as shown by its pooled result of 1.08 (1.02, 1.14). The 
number of biopsies is contained within some of the parameters in this model as an 
interaction term with age (Figures 2.5-2.6). Comparing the summary results of Figure 
2.5 (one biopsy × age <50) and 2.6 (one biopsy × age ≥50), the summary result is very 
similar and so there is no clear evidence that age categorised is important (a different 
threshold for age may provide different results), but both meta-analysis results do 
suggest that having had one biopsy is a predictive factor. 
Figure 2.4: Meta-analysis of age at menarche for Gail 2 models 
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Figure 2.5: Meta-analysis of one biopsy × age categorised interaction term (age <50) for Gail 2 
models 
 
Figure 2.6: Meta-analysis of one biopsy × age categorised interaction term (age ≥50) for Gail 2 
models 
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Figure 2.7: Meta-analysis of one affected first degree relatives × age at first live birth × age <20 
interaction term for Gail 2 models 
 
Figure 2.8: Meta-analysis of one affected first degree relatives × age at first live birth × age 20-24 
interaction term for Gail 2 models 
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Figure 2.9: Meta-analysis of one affected first degree relatives × age at first live birth × age 25-29 
interaction term for Gail 2 models 
 
Figure 2.10: Meta-analysis of one affected first degree relatives × age at first live birth × age ≥30 
interaction term for Gail 2 models 
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pooled result of 1.70 (1.43, 2.04) for age<20; for age 20-24 (Figure 2.8) the pooled 
result is 1.24 (1.14, 1.34) which rises to 1.42 (1.29, 1.56) (Figure 2.9, age 25-29) and 
1.58 (1.46, 1.71) (Figure 2.10, age≥30). Figure 2.4 shows that as age increases the risk 
increases. The interactions here show how family history plays an important role in the 
risk in those aged <20 and >30. 
2.6 Discussion 
This chapter has described a systematic review which identified and then summarised 
proposed prediction models for risk of breast cancer, to clarify the models available, 
their predictive performance, reporting standards, and contained predictors. The 
systematic review found 7317 citations, which subsequently resulted in 26 papers being 
chosen for inclusion in this review. Of these, six developed a new risk prediction model 
only, nine independently validated one or more models and 11 both developed a new 
model and validated one or more models. The evaluation of study quality and reporting 
for papers that developed a model was found to be quite poor in general, as only six of 
the 17 reported the full specification of the final developed model(s) and the uncertainty 
for all included variables. The modifiable risk factors found in the models were alcohol 
consumption, BMI/weight, condom use, exogenous hormone use (HRT, contraceptive 
pill) and physical activity. A total of 21 different risk factors were included in all the 
models. 
A meta-analysis of C statistics was performed to compare model performance through 
discrimination, with only five studies providing C statistics along with their uncertainty 
and two studies providing these for Rosner & Colditz (2). The pooled values for the C 
statistic for Gail2 was 0.63 (0.59, 0.67) and for Rosner & Colditz (2) was 0.63 (0.63, 
61 
 
0.64). As the 95% CI does not contain 0.5 (which is the null value) these C statistic 
values indicate the models do provide some moderate discrimination between those who 
will and will not develop breast cancer, and may thus be potentially useful to identify 
those at higher risk. A similar meta-analysis was performed for the E/O ratio, with three 
studies providing data for Gail 1 model (pooled result of 1.13 (0.80, 1.60)), six studies 
(10 models) providing data for Gail 2 model (pooled result of 0.95 (0.88, 1.01)) and two 
studies providing data for Rosner & Colditz (1) model (pooled result of 0.96, (0.92, 
1.02)). These pooled results for Gail 2 and Rosner & Colditz (1) are close to 1 with the 
95% CI being quite narrow and containing 1, suggesting that these models calibrate 
almost perfectly over all patients.  This meta-analysis examined the average 
performance of particular models, and quantified the heterogeneity in model 
performance across settings. Further, meta-analyses of predictor estimates to check for 
consistency of parameter estimates across different settings found that they are still 
significant parameters in the populations examined. 
2.6.1 Limitations and strengths of the review 
There are a few limitations to this review. For example only 10 % of the initial 
reference list was checked by a second reviewer; if the entire reference list was checked 
there is a possibility more articles could have been identified.  Another limitation was 
only including models with modifiable predictors, which reduced the number of studies 
that could be included in the review.  Also, the meta-analyses and evaluation were 
limited by poor reporting of the identified studies: in particular, a number of papers did 
not report the model with its parameters and uncertainty. The model was generally 
presented in tables as either odds ratios or relative risk ratios, but many of the papers did 
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not provide the C statistic or E/O ratio, or if they did present those, few also provided 
their uncertainty. Only the papers that did provide these values with their uncertainty 
could be used in the meta-analysis. 
On a positive note a large data extraction was performed during this review and the 
results were synthesised as far as possible, to give a quantitative summary of the state of 
the field. Meta-analysis was possible for some models where they had either the C 
statistic, E/O ratio or predictor estimate along with its uncertainty. The studies were also 
qualitatively assessed using a checklist which provided especially useful for evaluated 
the quality in reporting. 
2.6.2 The best model for predicting breast cancer risk? 
The review identified six different models proposed for predicting breast cancer risk; 
the most widely assessed models were Gail models 1 and 2. Gail model 1 and Gail 
model 2 have different baseline risks, and are predicting two separate risks (any breast 
cancer versus invasive breast cancer). 
From the findings of this review it is very difficult to determine the best model. It was 
not possible to compare most of the models, as the non-Gail model articles often did not 
present validation results. Further, the two Gail models both predict two different risks, 
and thus are not directly comparable. The C statistics are generally low for all models, 
which means that the models do not discriminate very well between those who will and 
those who will not develop breast cancer. The meta-analysis of the E/O ratio helps 
reveal the performance of these models in terms of calibration of observed and model 
expected events. Gail model 2 on average performs well, which shows on average these 
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models are predicting risk well in populations; however, the prediction interval for E/O 
in a new population shows this may not be the case in an individual setting, as they are 
very wide and contain values far from 1. Prediction intervals have been developed and 
used for disseminating random-effects meta-analyses of treatment effect studies [32, 
79], but here they have been used to help evaluate model performance.  As seen in 
Figure 3, meta-analysis of the E/O ratio gives a 95% prediction interval for Gail 1 
which is very wide, due to the small numbers of studies and the observed heterogeneity. 
The prediction interval for Gail 2 is much narrower than the prediction interval for Gail 
1, but there is still considerable potential variability in model calibration performance 
across settings, and importantly it may not be close to 1 always. Thus it is difficult to 
conclude that Gail 1 or Gail 2 models will give reliable enough predictions for use in 
practice: the predictive performance appears to depend on the setting of application, and 
discrimination only appears moderate.  
The meta-analysis of the parameter estimates in the Gail 2 model confirms that the 
included predictors are likely to be important, as the summary risk ratios in the 
validation datasets are all in support of an association between the predictors and the 
risk of breast cancer.  Future risk prediction models in this field should consider starting 
with these predictors, therefore. 
2.6.3 Reporting standards 
The quality and reporting of the 17 articles developing a risk prediction model is 
summarized in Table 2.2. The quality of reporting was very poor, which again makes it 
hard to determine the best model to predict the first onset of breast cancer.  
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Altman [46] has investigated the reporting standard for papers that propose a prediction 
model. Although his findings are from studies using prognostic models (start point is 
disease), the issues are very similar and applicable to studies that generally use risk 
prediction models (in healthy or diseased people), as found here. The article by Mallet 
et al. [80] has similar findings as the Altman paper [46], they state: “Many published 
prognostic models have been developed using poor methods and many with poor 
reporting, both of which compromise the reliability and clinical relevance of models, 
prognostic indices and risk groups derived from them.” 
Our review found that the description of key aspects of study designs was very poor, 
patient characteristics were poorly reported and data completeness was poorly reported. 
Also, of concern was the handling of continuous predictors as a number of studies 
categorized some or all of the continuous predictors. Of critical importance is the 
finding that many authors did not even present the prediction model in full, but instead 
chose to present risk groups derived from the model or some of the parameter estimates 
but without the intercept (baseline risk).  
2.6.4 Next steps for prediction model research in breast cancer 
It is imperative from this review that future risk prediction model papers improve the 
quality of their reporting, and for the models used to be presented in their entirety (with 
intercept terms and all variables along with standard errors or 95% confidence 
intervals). For those papers that externally validate it is important for them to report 
validation statistics (e.g. a C statistic and E/O ratio, with confidence intervals) that will 
help the reader understand how well the validation has performed and increase/decrease 
confidence in the model accordingly. It is also important that when these models are 
65 
 
developed they are not only validated on the same dataset they were developed on 
(internal validation), but they validate it externally on a different dataset, which will 
show how well it performs in a different clinical setting.  
The TRIPOD statement [81] was published after this work was completed, but it echoes 
similar thoughts. It is a very important publication in prognostic research, as it provides 
a checklist of 22 items deemed essential for transparent reporting of prediction model 
studies [81]. If this checklist is adopted by the wider research community, it can help to 
minimise poor reporting in primary studies. Some of the recommendations include the 
full model being presented, how to use the model, its performance measures along with 
95% CIs, as well as discussing the potential use of the model and its implications [81]. 
Based on this review, no model has been identified as being consistently adequate. To 
compare the performance of all models identified in our review, preferably we require 
IPD from multiple studies and in each study all the predictors within all the different 
models are recorded. Then it would be possible to compare the models directly across 
multiple settings. Only the paper by Amir et al. [56] tried to perform such a comparison 
(Table 2.3), which assessed the performance of models on the same data set from South 
Manchester, UK. The population of 4536 women had been assessed in a hospital clinic 
for breast and other cancer risks and were a high risk sample. Amir et al. [56] 
investigated the total and screened population; concluding that the Tyrer-Cuzick model 
was the most accurate for this high risk sample. It is not clear whether the Tyrer-Cuzick 
model would also be the best predictive model for a general population sample (a 
general setting), but this study is helpful as it gives an insight as to how the models 
perform on the same dataset.  
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2.6.5 Difficulties of doing an aggregate data meta-analysis of risk prediction 
models 
This review serves as an empirical study of the feasibility of doing a review and meta-
analysis of risk prediction model studies. The findings observed are specific to the 
breast cancer literature, but are likely to generalise more widely. Clearly, meta-analysis 
based on the published evidence is difficult  as reporting standards are poor, validation 
statistics and parameter estimates are often not available, and most models do not 
receive adequate external validation. Thus key information desired, such as C statistics, 
E/O statistics, parameter estimates, standard errors and CIs are often not available, and 
so meta-analysis is limited. Furthermore, different models are proposed by different 
studies, and these are then validated in different studies, with many not receiving any 
validation. Furthermore, many models are developed using inferior methodology. For 
example, continuous variables often dichotomised in the model and non-linear trends 
are not considered [15]. Thus, being reliant on the standards of analysis and reporting of 
the primary studies is a major problem for synthesis of existing risk prediction studies. 
2.6.6 What would be the advantages of IPD? 
Many of the aforementioned issues would be overcome if IPD were available. For 
example, if an article were to present just the results and no confidence intervals or 
standard errors, then it would still be possible to use the IPD from this study to derive 
the missing information. This would allow the computation of the E/O ratio and C 
statistic for every article if IPD were available. The causes for high levels of between 
study heterogeneity could be explored if IPD were available. Even if an article did not 
present any validation results, it would be possible to use the IPD and calculate the 
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validation results and their uncertainty. Sometimes one may be able to validate 
additional models, in addition to those that were originally considered in the validation 
paper, if the relevant predictors are recorded in the IPD.  Thus, if IPD were available it 
would make it much easier to reach an overall conclusion or get closer to which model 
performs the best. With IPD one could also consider re-estimating a model using all the 
available studies, to pool parameter estimates from all studies in meta-analysis and 
investigate heterogeneity more easily.  
2.6.7 Next steps for the thesis 
Aside from the findings about the breast cancer risk prediction models themselves, this 
review has identified interesting methodological issues for meta-analysis of risk 
prediction models. For example the poor quality of reporting and the often lack of 
validation statistics (or presenting them without CI or SEs), limits meta-analysis 
considerably. Therefore evidence synthesis of risk prediction models is important but 
potentially problematic using the traditional systematic review approach and when 
attempting to do a meta-analysis based on extracted results. Ideally evidence synthesis 
would be improved by using IPD from multiple studies, so not to be reliant on 
extracting results and to enable multiple models to be evaluated in the same datasets. To 
illustrate this, in Chapter 4 statistical methods for an IPD meta-analysis will be 
evaluated, in the context of developing and validating a model for predicting who 
develops hypocalcaemia in patients with a thyroidectomy. Before this, in Chapter 3 a 
review will be performed on how others have developed and/or validated a prediction 
model using IPD from multiple studies, so to identify current practice and ascertain 
whether the IPD lives up to the promise. 
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2.6.8 What this chapter adds? 
Table 2.5 summarises the key findings of this chapter, and the review has been 
published in the journal Breast Cancer Research and Treatment [41]. 
Table 2.5: What chapter two adds 
What is known / what is the problem? 
 Many breast cancer risk prediction models published, but rarely compared against each other  
 How do we determine which is the best model to use?  
 How do we compare the performance of these models?  
 These models are poorly reported (or not at all) and validation statistics are not always reported 
What this study adds? 
 The models themselves were not available for comparison 
 This research has used a novel approach of comparing models by meta-analysing discrimination 
and calibration statistics, and presenting their average performance across different populations 
 This research indicates proposed models calibrate well on average and the predictors used in 
these models appear important, so they should help to inform clinicians and patients how they 
can reduce their breast cancer risk  
 However, discrimination is rather weak and further research may look at the inclusion of 
additional predictors 
 There is a need to validate these models in either similar or the same population to then be able 
to judge which of the models are better in comparison 
What is needed next? 
 The papers that publish these models and their results need to improve the quality of their 
reporting, i.e. the models should be presented in their entirety  
 For those models that have been validated (internally and ideally externally), the validation 
statistics should be presented for discrimination and calibration 
 More validation studies are required for these models to compare directly in the same 
populations  
 If raw data and the models were available, then it would be possible to calculate model estimates 
and validation statistics, raw data and models need to be made available 
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 SYSTEMATIC REVIEW OF ARTICLES CHAPTER 3:
DEVELOPING OR VALIDATING A PREDICTION 
MODEL USING IPD FROM MULTIPLE STUDIES 
3.1 Introduction 
The articles on risk prediction models usually report model development, but only a few 
report external validation, and this was evident in the breast cancer review of Chapter 2. Lack 
of external validation could be a possible explanation as to why few models are being 
adopted in practice when so many are being developed [19]. The approach of using IPD from 
multiple studies offers a novel opportunity to overcome this lack of validation, for example 
using some of the studies to develop the model and use the remaining studies to validate the 
model. 
There has been relatively little methodological research in relation to using IPD from 
multiple studies for development and validation of risk prediction models, though interest is 
growing [19, 82]. Thus it is important to ascertain what researchers are doing in current 
practice when IPD from multiple studies are available. For example, do they treat IPD as if 
all coming from one study? How do they identify which IPD to use? Do they assess 
heterogeneity in predictive factor effects? Do they keep back some studies for validation, and 
if so, how many? Is model performance checked in each study separately, or just one study?  
The aim of this chapter is to perform a qualitative review to assess how risk prediction 
models are being developed and validated when IPD are sought from multiple studies and 
then combined. The aim is to identify current research techniques and standards; the role of 
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IPD meta-analysis methods towards development and validation; and the methodological 
challenges and problems faced by researchers. This review will allow recommendations for 
how research can be improved and flag those methodological techniques and issues 
researchers should recognise when modelling risk prediction using IPD. The findings will 
also direct research in the remainder of the thesis. 
This review has now been published in BMC Medical Research Methodology (Ahmed et al. 
[16]) and I am the first author as this work is based entirely on the methods, results and 
recommendations of this chapter.  
3.2 Methods 
The review aims to identify and evaluate published articles that developed and/or validated a 
risk prediction model using IPD from multiple studies. The review methods are now 
described in detail. 
3.2.1 Identifying potentially relevant articles 
To identify potentially relevant articles, an existing database of 385 IPD meta-analyses 
articles was used. This database had already been formed by a systematic search in Medline, 
Embase and the Cochrane library using a search strategy previously described [83, 84]. The 
articles in this database were published from 1991 to March 2009, and formed the largest 
collection of IPD meta-analyses already available when the review was under taken. The 
database contained IPD meta-analyses for any purpose (e.g. treatment effects, diagnostic 
tests), and thus contained those for risk prediction (see below). 
Note that the aim was not to review an exhaustive set of all risk prediction research using IPD 
from multiple studies, but rather to identify the main methods used and the key 
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methodological limitations and challenges. It was considered that qualitative saturation could 
be achieved with the existing database, and therefore it was not considered necessary to 
update the review with articles published since 2009. 
3.2.2 Inclusion and exclusion criteria 
A relevant article was defined as one which developed and/or validated a risk prediction 
model (i.e. a model aiming to predict individual outcome risk using single or multiple 
prognostic factors) using IPD from multiple studies. Note that the review does not consider 
articles which used an existing database containing multiple sources (e.g. practices). This has 
similar issues, but the focus here is on situations where IPD was firstly obtained from 
multiple studies and then meta-analysed (the standard framework for an IPD meta-analysis). 
The term ‘model’ is used here for any developed equation, tool, or classification approach 
that allowed an individual’s risk to be predicted. There were no restrictions on the type of 
outcome being predicted or baseline disease/health of the patients under investigation, or the 
types of study (observational studies, randomised trials etc.) being utilised. Articles that 
aimed to identify factors which predict treatment effect were excluded, as treatment effects 
were of no interest. Articles that evaluated one or more factors for prognostic ability, but not 
in relation to absolute outcome risk were excluded (i.e. prognostic factor studies were 
excluded) [84]. 
Two independent reviewers (Ikhlaaq Ahmed and Dr Thomas Debray) screened and classified 
the abstracts and titles of each of the 385 articles. The articles were classified in regards to the 
risk prediction model status as either ‘yes’, ‘unsure’, or ‘no’. Any discrepancies that arose 
between the two reviewers were identified by me, and then solved through discussion if 
possible. A third reviewer, Dr Richard Riley then checked the ‘yes’ and any remaining 
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‘unsure’ articles, and a random 10% sample of the ‘no’ articles. Any further discrepancies 
between the three reviewers were resolved through discussion after reading the full papers 
and a final decision was then made. 
3.2.3 Data extraction and in-depth evaluation of articles 
Each article classified as a ‘yes’ was used for in-depth evaluation. A data extraction form was 
developed that included 77 questions. These 77 questions covered the rationale, conduct, 
analysis, reporting, and feasibility of the project developing and/or validating a risk 
prediction model using IPD from multiple studies. These questions formed the data extraction 
plan of the review (see APPENDIX A for a complete list of questions), which was 
documented and agreed upon by all authors in advance of the review. 
I read each article in full and extracted information that answered these 77 questions, and 
then Dr Debray also independently answered these questions for each article. Both sets of 
extractions were compared and any discrepancies were identified by me, and resolved 
through discussion with Dr Riley and Dr Debray. 
A summary of the questions used to evaluate each article is as follows: 
Background 
 Questions to ascertain the background information presented in the articles that relate 
to the central location of the IPD projects, the protocol, and ethics approval. 
Objectives 
 Questions to establish the research objectives, the baseline condition of the patients 
and the outcome being predicted. 
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Identifying IPD studies 
 Questions to determine how they identified the relevant studies for inclusion, what 
types of studies were included in the meta-analysis, (RCT, observational etc.) and if 
they determined the number of studies required or the sample size for model 
development and/or validation. 
Obtaining IPD 
 Questions to establish how they asked for and obtained IPD, how the relevant study 
authors were approached, how many were approached and what proportion of these 
actually provided IPD, and whether there was any assessment regarding study quality 
 Questions to assess if some of the requested IPD was not obtained and if any reasons 
were stated for this, and whether the number of patients/events was described within 
each study (if not, then overall). 
Missing data 
 Questions to ascertain whether missing data was considered; for example, if data was 
missing for patients and/or studies, and how any missing data was handled. 
Model development 
 Questions to determine how they developed their models. In particular, whether a 
statistical plan was presented for this process; how they handled data coming from 
multiple studies; what statistical models were used, and whether heterogeneity 
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between studies was considered. Also, how continuous predictors were handled, what 
criteria and procedure were used for inclusion of a predictor in the model, and 
whether the final model (e.g. with alphas, betas and their uncertainty) was presented.  
Model validation 
 Questions to establish how they validated (if at all) their prediction model, both 
internally and externally; the statistics used and presented, and the number of patients 
and number of studies used towards the validation; and whether bootstrapping or 
shrinkage was considered to assess model accuracy or adjust for over-optimism. 
Bias 
 Questions to ascertain if they stated anything in regards to those studies not 
willing/able to provide IPD; in particular whether there were any 
qualitative/quantitative differences between those studies that provided IPD and those 
that did not; whether the number of patients or events were stated from those studies 
not contributing to the analysis; and any suggestion that the studies obtained were a 
biased set of studies (if appropriate). 
Conclusions 
 Questions to determine the main conclusion from the analysis, and any limitations and 
problems discussed. 
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3.3 Results 
The key findings of the review are now summarised. 
3.3.1 Classification results 
The classification process of the 385 articles identified 15 relevant articles that each 
developed and/or validated a prediction model using IPD from multiple studies [85-99]. They 
were published between 1994 and 2008. All 15 of these articles developed a model, and 11 
also undertook some form of validation of their model [85-88, 90, 92-95, 98, 99]. See Figure 
3.1 for publication dates for these 15 articles. 
Figure 3.1: Graph showing distribution of the year of publication of the 15 articles identified  
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3.3.2 Background information 
The central location of the 15 IPD projects (where the first author was located) included 
North America and Australasia, but most of the articles were from Europe (11); mainly 
Netherlands (4) and the UK (3). Just three of the 15 articles referred to a protocol for their 
IPD project (e.g. Yap et al. [99]), and only six of the articles mentioned ethics approval (e.g. 
Heffner et al. [86]), see Table 3.1 for full details. 
3.3.3 Research objectives 
All 15 articles stated their key research aims in relation to risk prediction; in particular the 
condition of the patients assessed at baseline and the clinical outcomes or onset of diseases of 
interest for prediction (see Table 3.1). Thirteen articles included patients who were diseased 
at baseline (e.g. Sylvester et al. [93], who predicted the probability of recurrence and 
progression at one and five years in patients with superficial bladder cancer) and two articles 
included patients who were healthy at baseline (e.g. Fowkes et al. [97], with outcome of 
interest being total and cardiovascular mortality in healthy individuals). The diseases 
considered at baseline included pancreatic cancer, chronic hepatitis C, bladder cancer and 
post-myocardial infarction among others (see Table 3.1). The outcomes predicted were either 
general (e.g. mortality) or disease-specific (e.g. development of radiation myelopathy, fatal 
coronary heart disease (CHD) within 10 years and postoperative symptomatic 
hypocalcaemia). 
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Table 3.1: Background information for each article 
Paper Author 
location 
What was the key research aims of the 
paper in relation to prognosis/risk 
prediction? 
At baseline what was the condition of the patients 
being assessed? 
What outcomes or diseases were of 
interest for prediction? 
Approach used 
to identify 
studies? 
Number of 
studies providing 
IPD / Number of 
studies 
approached 
Was the 
number of 
patients 
within each of 
the IPD 
studies given?  
1994 
Pagliaro[85] 
Italy To identify predictors of short-term and 
sustained Alanine transaminase(ALT) 
normalization after interferon treatment in 
adult patients with hepatitis C 
Adult patients with transfusion-related chronic hepatitis 
C (trial 1) 
Adult patients with community-acquired chronic 
hepatitis C (trial 2) 
Short term and sustained response (ALT 
normalization) 
Collaborative 
group  
2 Yes 
2000 
Heffner[86] 
USA To determine the predictive accuracy of 
pH for identifying patients with malignant 
pleural effusions who will fail pleurodesis 
Patients with malignant pleural effusions Failure of pleurodesis 
 
Literature 
review 
6/12 Yes 
2000 
Raboud[87] 
Canada To determine the ability of intermediate 
plasma viral load (pVL) measurements to 
predict virologic outcome at 52 weeks of 
follow-up in clinical trials of antiretroviral 
therapy 
Patients with CD4 cell counts between 200 and 600 
cells/mm3, naive to antiretroviral therapy and not been 
previously diagnosed with AIDS (INCAS) 
Patients had CD4 counts between150 and 300 
cells/mm3, naive to antiretroviral therapy, including 
nucleoside and nonnucleoside analogues or protease 
inhibitors.(AVANTI-2, AVANTI-3) 
Virologic outcome at 52 weeks of follow-up Collaborative 
group 
3 Yes 
2000 
Terwee[88] 
Holland To develop a prognostic tool for patients 
with unresectable pancreatic cancer to 
distinguish between with low or high 
probabilities of survival 3 to 9 months after 
diagnosis. 
Patients diagnosed with pancreatic cancer Overall survival 
 
Literature 
review 
8 /15 Yes 
2004 Chau[89] United 
Kingdom 
To identify baseline patient- or tumour-
related prognostic factors  
To assess whether pre-treatment quality of 
life (QoL) predicts survival in patients with 
locally advanced or metastatic esophago-
gastric (EG) cancer. 
Patients with histologically confirmed inoperable 
adenocarcinoma, squamous cell carcinoma (SCC), or 
undifferentiated carcinoma of the oesophagus, 
esophago-gastric junction(EGJ), or stomach; adequate 
hematologic, renal, and hepatic function and Eastern 
Cooperative Oncology Group performance status (PS) 
0 to 2. 
Overall survival Collaborative 
group 
3 Yes 
2005 Horn[90] Holland Investigate whether Transcranial Doppler 
(TCD) monitoring for micro embolic 
signals (MES), directly after carotid 
endarterectomy (CEA) may identify 
patients at risk of developing ischaemic 
complications. 
Carotid endarterectomy patients (CEA) 
 
Cerebral ischaemic complications, defined 
as new neurological 
deficits(amaurosisfugax, transient ischemic 
attack(TIA), minor and major ischaemic 
stroke) developing within the 1st week after 
CEA 
Literature 
review 
7/10 Yes 
2005 
Nieder[91] 
Germany Identifying the predictive value of 
biologically effective dose as function of 
the risk of myelopathy 
Patients with spinal cord retreatment  Development of radiation myelopathy Literature 
review 
8/8 Yes 
        
2006 Asia 
Pacific[92] 
Australia To investigate the generalisability of 
current definitions of the metabolic 
syndrome in Asia-Pacific populations, and 
Healthy patients aged 30–75 Fatal CHD within 10 years Collaborative 
group 
26 Yes 
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Paper Author 
location 
What was the key research aims of the 
paper in relation to prognosis/risk 
prediction? 
At baseline what was the condition of the patients 
being assessed? 
What outcomes or diseases were of 
interest for prediction? 
Approach used 
to identify 
studies? 
Number of 
studies providing 
IPD / Number of 
studies 
approached 
Was the 
number of 
patients 
within each of 
the IPD 
studies given?  
determine the prognostic value of 
metabolic risk factors to discriminate fatal 
coronary heart disease (CHD) risk 
2006 
Sylvester[93] 
Belgium To predict a superficial bladder cancer 
patient’s probability of recurrence and 
progression at one and five years 
Stage Ta, T1, and Tis bladder cancer patients who have 
undergone transurethral resection (TUR) 
Time to first recurrence (disease-free 
interval) and time to progression to muscle 
invasive disease 
Collaborative 
group 
7 Yes 
2007 
Noordzij[94] 
USA Early prediction of hypocalcaemia after 
thyroidectomy using parathyroid hormone 
 
Patients undergoing thyroidectomy Postoperative symptomatic hypocalcaemia Literature 
review 
9/15 Yes 
2007 
Rovers[95] 
Holland To determine the predictors of a prolonged 
course for children with acute otitis media 
(AOM)to discriminate between children 
with and without poor outcomes 
Children with acute otitis media The primary outcome was a prolonged 
course of AOM, (defined as pain and/or 
fever at 3 to 7 days) 
Literature 
review 
6 /10 No, only 
overall given. 
2007 
Schaich[96] 
Germany To identify prognostic indicators in acute 
myeloid leukaemia (AML)to provide a 
new prognostic model for risk stratification 
of AML patients with +8 
AML patients Overall survival and relapse-free survival Collaborative 
group 
8 Yes 
2008 
Fowkes[97] 
United 
Kingdom 
To determine if the Ankle Brachial 
Index(ABI) provides information on the 
risk of cardiovascular events and mortality 
independently of the Framingham Risk 
Score(FRS) and can improve risk 
prediction 
Participants of any age and sex derived from a general 
population 
Total and cardiovascular mortality Literature 
review 
16/20 Yes 
2008 
Steyerberg[98] 
Holland To develop prediction model for predicting 
unfavourable outcome according to the 
Glasgow Outcome Scale (GOS) at 6 
months after injury 
Patients with moderate and severe TBI (GOS >= 12) 6-months mortality and unfavourable 
outcomes defined by 6 months GOS 
Collaborative 
group 
11 Yes 
2008 Yap[99] United 
Kingdom 
To design a prognostic indicator using 
demographic information to select patients 
at risk of dying after Myocardial Infarction 
(MI) 
Patients at day 45 post-MI up to 2 years All-cause, arrhythmic and non-arrhythmic 
cardiac mortality within 2 years 
Not stated 4 /not stated Yes 
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3.3.4 Identifying studies 
Fourteen of the 15 articles stated the process they used to identify the studies for the IPD 
project (see Table 3.1), either a literature review or a collaborative group approach. A 
literature review is a review process where studies are identified through a keyword search on 
one or several databases containing potentially relevant literature. A collaborative group 
approach is a non-systematic approach where the researcher is part of a group, or has a 
contact within a group, and this group has access to IPD from multiple studies that are 
relevant for inclusion. Seven articles used a collaborative group approach, e.g. Chau et al. 
[89], Asia Pacific Cohort Studies Collaboration [92] and Pagliaro et al. [85].  
Seven articles used a literature review approach. and all of these described the databases and 
sources searched (e.g. Terwee et al. [88]). However, only Fowkes et al. [97] and Noordzij et 
al. [94] gave the keywords used within this search, and only Fowkes et al. [97] gave a 
flowchart of the process of searching, classifying and retrieving IPD studies. Only three of 
the seven articles described how authors of identified studies were approached for their IPD 
and this included e-mail, postal mail, and telephone. 
All 15 articles did not calculate a required sample size for model development and/or 
validation; i.e. they just sought all IPD available from the studies identified in the review or 
the studies available in the collaboration. 
3.3.5 Obtaining IPD from multiple studies 
All seven literature review articles gave the number of studies they obtained IPD from and 
the number of studies they approached for IPD. Six of the seven articles did not obtain IPD 
for all studies desired; this raises concern of availability bias. Availability bias relates to 
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when studies that provide their IPD are a biased subset of all existing studies [100]. The 
percentage of IPD obtained ranged from 50% to 100% (see Figure 3.2).Only three articles 
gave reasons as to why they could not obtain IPD for the desired studies. For example 
Heffner et al. [86] stated that data was no longer available or not saved for those studies not 
providing IPD. 
Figure 3.2: IPD obtained and total IPD studies desired in the seven articles using a literature review to 
identify relevant studies 
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Table 3.2: Summarising the IPD 
Paper Types of studies 
included: 
Was the number of 
patients within each of 
the IPD studies given? 
If not, was it given 
overall? 
Number of events per 
study given? If not, was 
it given overall? 
Was the number of 
events per candidate 
variable (predictor) 
given in each study? If 
not, was it given 
overall? 
1994 Pagliaro[85] RCT Yes Yes Yes 
2000 Heffner[86] Observational Yes Yes No 
2000 Raboud[87] RCT Yes No Yes, there is only 1 
predictor 
2000 Terwee[88] Follow-up studies 
(unclear) 
Yes Yes Yes, table 2 for overall 
2004 Chau[89] RCT Yes No, only overall given Yes 
2005 Horn[90] Not clear Yes Yes No, only overall given 
2005 Nieder[91] Not clear Yes Yes Yes  (the actual IPD is 
given) 
2006 Asia Pacific[92] Observational Yes No, only overall given Yes 
2006 Sylvester[93] RCT Yes No, only overall given No, only overall given 
2007 Noordzij[94] Observational Yes No, only overall given Yes 
2007 Rovers[95] RCT No, only overall given. No, only overall given Yes 
2007 Schaich[96] RCT Yes No, only overall given Yes 
2008 Fowkes[97] Observational Yes Yes Yes 
2008 Steyerberg[98] RCT (8) and 
observational (3) 
Yes No, only overall given No, only overall given 
2008 Yap[99] RCT Yes Yes No 
3.3.6 Details of IPD obtained 
The types of studies providing IPD were stated by 12 of the 15 articles (Table 3.2).Seven 
articles used IPD from RCT’s (e.g. Pagliaro [85]), four used observational studies (e.g. 
Heffner et al. [86]), and Steyerberg et al. [98] used both RCT’s and observational studies. In 
the eight articles that included RCTs, five used data from all treatment groups, two only used 
the placebo group, and Steyerberg et al. [98] used all the data in their primary analysis but 
just the placebo group for their secondary analysis. 
A summary of the sample population (i.e. baseline patient characteristics) was given 
separately for each IPD study in eight of the 15 articles, (e.g. Pagliaro [85]), whilst five 
articles just gave a summary across the overall, combined IPD (e.g. Sylvester et al. [93]); two 
articles did not give this information at all (e.g. Raboud et al. [87]). Only one of the 15 
articles (Rovers et al. [95]) mentioned assessing the quality of studies; though it was not clear 
if this had any implications for the IPD they analysed. 
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Fourteen of the 15 articles gave the number of patients within each of the IPD studies, and 
Rovers et al. [95] gave just the overall number of patients across all studies (Table 3.2). 
Seven of the 15 articles gave the total number of events for each predicted outcome within 
each of the IPD studies (e.g. Yap et al. [99]); whilst seven articles just gave the overall 
number of events across all studies (e.g. Noordzij et al. [94]) and one article did not give this 
information at all (Raboud et al. [87]). Nine of the 15 articles reported the number of events 
per candidate predictor in each IPD study (e.g. Pagliaro [85]), whilst three articles gave this 
information for the overall IPD across all studies (e.g. Terwee et al. [88]), and three articles 
did not report this information. 
3.3.7 Missing data 
Eleven of the 15 articles mentioned missing data (see Table 3.3). Eight of the 15 articles 
mentioned having missing patient data for some predictors; for example in Noordzij et al. 
[94] only six of the nine studies that supplied IPD obtained preoperative PTH values, whilst. 
Steyerberg et al. [98] state “pupillary reactivity was not recorded in two trials”.  
If an article reported that missing patient data occurred for a variable (candidate predictor), 
then generally the article either excluded patients with missing data from the analysis (e.g. 
Heffner et al. [86]), or used a (multiple) imputation approach (e.g. Rovers et al. [95]). 
Additionally three of the 15 articles entirely deleted some studies due to absence of a 
predictor or outcome of interest; for example Terwee et al. [88] excluded three of the eight 
studies, and state: “one study was excluded because we could not distinguish between 
patients with tumours of the pancreatic head and tumours of the pancreatic body or tail, and 
two others were excluded because information on metastases was lacking or incomplete”. 
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Table 3.3: Details of missing data in the IPD projects and how it was handled 
Paper Was missing data 
mentioned/indicated within the 
article?  
If stated, how was missing data handled in the analysis? 
1994 Pagliaro[85] Not stated NA 
2000 Heffner[86] Yes Missing values were excluded from the analysis. Analysis was performed and 
then repeated with an undefined imputation approach (similar results) 
2000 Raboud[87] Yes Those patients were excluded from ROC curve (analysis) 
2000 Terwee[88] Yes Missing values for age were imputed by using the sample mean 
2004 Chau[89] Yes Those patients were excluded from the prognostic model 
2005 Horn[90] Not stated NA 
2005 Nieder[91] Yes  Those patients were excluded from the analysis 
2006 Asia 
Pacific[92] 
Yes Those studies that did not measure each of those risk factors at baseline were 
excluded from the analysis 
2006 Sylvester[93] Yes Not stated 
2007 Noordzij[94] Yes Those three studies were excluded from the analysis 
2007 Rovers[95] Yes Missing data was imputed for each trial by using the linear regression method 
(missing value analysis) 
2007 Schaich[96] Not stated NA 
2008 Fowkes[97] Yes Missing data was imputed using the expectation-maximization procedure for 
multivariate normal data 
2008 
Steyerberg[98] 
Yes Missing data was imputed using Multivariate Imputation by Chained Equations 
(MICE) algorithm 
2008 Yap[99] Not stated NA 
3.3.8 Model development 
The statistical analysis methods used for model development are now summarised. The main 
focus here is how IPD from multiple studies were handled. 
3.3.8.1 Analysis method 
The number of patients and events used from each study separately towards the prediction 
model development was stated for 10 of the 15 articles (e.g. Yap et al. [99]), with the 
remaining articles focussing on the overall numbers.  
A statistical analysis plan for prediction model development was stated in the methods 
section for all 15 articles (see Table 3.4). The two articles that considered a single predictor in 
their model examined predictive performance by calculating ROC curves from the data. In 
the 13 articles developing a multivariable model, six used a Cox regression model (e.g. 
Terwee et al. [88]), five used a logistic regression model (e.g. Heffner et al. [86]), and the 
Asia Pacific Cohort Studies Collaboration [92] used both Cox and logistic regression models.  
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All 15 articles used IPD from multiple studies to develop their models. Of these 15 articles, 
10 developed the risk prediction model via ‘one-step meta-analysis ignoring clustering’ 
which is an unstratified approach, where authors (e.g. Horn et al. [90]) pool all the data 
together into one big dataset, and ignore clustering by study or collaborative group, usually 
without explaining why clustering was ignored. A notable exception is Terwee et al. [88], 
who justify their approach by examining whether stratification by study was necessary, 
stating: “The homogeneity assumption was checked by including treatment as a dummy-
coded variable into both models (stratification per study). Initially we found a significant 
survival benefit for patients treated by surgical bypass procedures compared with endoscopic 
stents. However, this effect disappeared after adjustment for Karnofsky’s index (a measure of 
functional status) in the study in which this variable was available, which legitimises 
pooling.” 
Three of the remaining five articles (e.g. Steyerberg et al. [98]) developed their model via the 
‘one-step meta-analysis accounting for clustering’, where the data from all 
studies/collaborative groups are analysed together but with clustering by study/group 
accounted for (e.g. using a dummy variable for study). In another article, Fowkes et al. [97] 
developed their model using 'a two-step approach', where the data are first analysed 
separately in each study, and then their model estimates are pooled together in the second-
step. They looked at mortality by study and use a two stage approach to look at the predicted 
value of ABI (Ankle Brachial Index) in addition to FRS (Framingham Risk Score).They 
estimated Kaplan-Meier curves for each combination of ABI (four categories) and FRS (five 
categories) in each study, and then performed a random effects meta-analysis across studies 
of the survival percentages obtained at different time-points (to give an average predicted 
survival percentage). In the remaining article, Schaich et al. [96] used a hierarchical cluster 
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approach, but it is not clear whether this cluster approach specifically included clustering by 
study. 
None of the 15 articles developed their model using only a portion of the IPD available, i.e. 
no IPD was kept separate for validation, and so it was always all used for development. 
3.3.8.2 Heterogeneity of predictor effects 
Only three of the 12 articles considered between-study heterogeneity in the predictors within 
the prediction model (Table 3.4). Of these, Steyerberg et al. [98] state: “Similarly, study-
specific effects were assessed with interaction terms between study and each predictor. 
Interaction terms between predictors were examined with likelihood ratio tests, but none was 
of sufficient relevance to extend the models beyond the main effects for each predictor”. 
Rovers et al. [95] assessed heterogeneity through the I
2
 statistic and state: “To determine 
whether pooling was justified, heterogeneity between studies was assessed with the I
2
 
statistic. Because the I
2
 value was 25%, pooling was performed”. Fowkes et al. [97] 
performed a test of heterogeneity in Ankle Brachial Index (ABI) (using Chi-square test and 
I²), for one of their predictors; they then applied random effects in their analysis, which was 
likely due to heterogeneity being detected, although not explicitly stated. 
3.3.8.3 Handling of continuous predictors 
Continuous predictors were analysed on a continuous scale in four of the 15 articles. For 
example, Steyerberg et al. [98] state: “For the continuous predictor’s age, glucose, and Hb, a 
linear relationship with outcome was found to be a good approximation after assessment of 
non-linearity using restricted cubic splines”. The remaining 11 articles either categorised or 
dichotomised the continuous predictors of interest. For example, Heffner et al. [86] state that 
“continuous variables were entered as dichotomous indicator variables with test thresholds 
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determined by ROC analysis”, and Chau et al. [89] state “Laboratory variables were initially 
coded as continuous variables and subsequently dichotomised with the cut-off points chosen 
at the median value of each variable”. 
3.3.8.4 Need for standardisation 
Three of the 15 articles mentioned the need to standardise the coding of predictors and 
outcome definitions. For example, Terwee et al. [88] state “To standardise definitions among 
the different studies, the presence of metastases and of pain and weight loss at diagnosis were 
classified as ‘present’ or ‘absent’”, whilst Noordzij et al. [94] handled different methods of 
measuring PTH values by analysing percentage change in PTH from baseline, rather than 
analysing PTH on its original scale. In order to use and compare candidate predictor factors 
measured on different continuous scales, Steyerberg et al. [98] standardised the reporting of 
odds ratios so that they corresponded to a change from the 25
th
 percentile to the 75
th
 
percentile of the predictor distribution. 
3.3.8.5 Strategy for inclusion of predictors 
Of the 13 articles that developed a multivariable model (i.e. a model with two or more 
included predictors), the most common approach (used by 6 articles) was to use p-values to 
decide which predictors were included (Table 3.4). For example, Heffner et al. [86] state: 
“Variables that were found by univariate analysis to be associated with pleurodesis failure 
with a value for p < 0.10 were entered into a logistic regression model. Continuous variables 
were entered as dichotomous indicator variables with test thresholds determined by ROC 
analysis. Variables were removed from the model if their p values were ≥ 0.05”. Five other 
articles used a selection procedure (Table 3.4), for example Pagliaro [85] used a stepwise 
procedure, and Chau et al. [89] used forwards and backwards selection procedures. 
87 
 
3.3.8.6 Reporting of developed model 
In the 13 articles that developed a multivariable model, the model was adequately reported in 
terms of the predictor effects (e.g. with the six articles using the Cox model reporting either 
log hazard ratios or hazard ratios). However, none of the six articles that used logistic 
regression reported the alpha term (baseline risk) for their final model, with all six presenting 
the odds ratio (either as log odds ratio or on its original scale). However, Steyerberg et al. 
[98] do present a simplified version of their logistic regression model (based on a simple 
score chart), in which they do present both the alpha and beta terms.  
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Table 3.4: Model development 
Paper Statistical 
analysis plan for 
model 
development 
given? 
In developing the 
prediction model, 
how was IPD from 
multiple studies 
synthesised? 
Details of the 
approach (or 
statistical models) 
used in 
synthesising IPD 
from multiple 
studies: 
Was between-study heterogeneity in 
the predictors/alpha term considered 
within the prediction model? If so how 
(e.g. using random-effects in the 
analysis; assessing heterogeneity using 
I-squared) 
What criteria were used to decide 
inclusion of a predictor in the model? 
(e.g. statistical criteria, such as p< 
0.1, or clinical criteria such as a 
hazard ratio > 2 or inclusion of 
‘smoking’ variable regardless) 
What selection 
procedure was 
used?  
How was the 
final model 
reported? 
1994 
Pagliaro[85] 
Yes  One-step ignoring 
clustering 
Logistic regression No Significance of each predictor was 
checked by maximum likelihood 
approach with 2 tailed p-values 
Stepwise The beta, 
SE(beta), 95%CI 
and p-values for 
each variable 
were reported 
2000 
Heffner[86] 
Yes One-step ignoring 
clustering 
Logistic regression No P<0.1 was used to find significance in 
univariate analysis, and those that were 
significant were included in the logistic 
regression model. Variables were 
removed from the model if their p 
values were > 0.05 
P values The final model 
consists of only 1 
variable. The OR 
and 95% CI are 
stated for its 
predictor 
2000 
Raboud[87] 
Yes One-step ignoring 
clustering 
ROC graphs  No NA (only 1 predictor is considered) NA NA 
2000 
Terwee[88] 
Yes One-step ignoring 
clustering,  
Cox regression  No The variables age, sex, and presence of 
metastases were available for all studies 
and included in the model. 
Additionally, an extended model that 
also containing pain, jaundice, and 
weight loss at diagnosis was developed 
on a subset of the four studies that 
provided this information. 
Not used Relative risks 
with 95%CI are 
provided 
2004 Chau[89] Yes One-step analysis 
accounting for 
clustering 
Cox regression 
 
No Univariate assessment of the prognostic 
effect of each factor, leading to a 
multivariate analysis. A two-sided 
P<0.01 was considered significant. 
Forward and 
backwards 
stepwise 
Hazard ratio with 
99% CI, and risk 
ratios with 
99%CI reported 
2005 Horn[90] Yes One-step ignoring 
clustering 
Logistic regression  No Predictors with statistically significant 
univariate associations (p<0.05) were 
included in the multivariate analysis 
P values OR’s and 95% CI 
reported 
2005 
Nieder[91] 
Yes One-step ignoring 
clustering 
Not stated No Not stated Not stated The weights of 
the risk score are 
presented alone 
2006 Asia 
Pacific[92] 
Yes One-step ignoring 
clustering 
Cox and logistic 
regression 
No 
 
All five ‘‘metabolic’’ risk factors at 
baseline were used 
NA Only variable 
names reported 
2006 
Sylvester[93] 
Yes One-step analysis 
accounting for 
Cox regression No Variables that represented the prior 
recurrence rate, number of tumours, 
P values HR with CI 
reported 
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Paper Statistical 
analysis plan for 
model 
development 
given? 
In developing the 
prediction model, 
how was IPD from 
multiple studies 
synthesised? 
Details of the 
approach (or 
statistical models) 
used in 
synthesising IPD 
from multiple 
studies: 
Was between-study heterogeneity in 
the predictors/alpha term considered 
within the prediction model? If so how 
(e.g. using random-effects in the 
analysis; assessing heterogeneity using 
I-squared) 
What criteria were used to decide 
inclusion of a predictor in the model? 
(e.g. statistical criteria, such as p< 
0.1, or clinical criteria such as a 
hazard ratio > 2 or inclusion of 
‘smoking’ variable regardless) 
What selection 
procedure was 
used?  
How was the 
final model 
reported? 
clustering tumour size, T category, grade, and CIS 
were included in the final multivariate 
model. Age and gender were likewise 
not retained in the final models, as they 
were not significant at the 5% level 
(P<0.05)  
2007 
Noordzij[94] 
Yes One-step ignoring 
clustering 
Sensitivity, 
specificity and ROC 
used 
No Only one predictor used, PTH NA NA 
2007 
Rovers[95] 
Yes One-step ignoring 
clustering 
Logistic regression, 
fixed-effects 
Heterogeneity was assessed (through I2 
statistic, but not mentioned on which 
variables). To justify whether pooling 
was appropriate, they assessed 
heterogeneity between studies, found the 
I2 to be 25% and pooled the data 
Predictors with P≤0.10 in the univariate 
analysis were included in the 
multivariate analysis. The model was 
reduced through exclusion of predictors 
with P>0.05 
Backwards 
selection 
Odds ratios and 
CI of the 
predictors 
reported 
2007 
Schaich[96] 
Yes. Hierarchical cluster 
(unclear whether 
cluster was study) 
Cox regression, 
fixed-effects 
No Not stated Limited backwards 
selection was 
stated 
Hazard ratios and 
CI only provided 
2008 
Fowkes[97] 
Yes Two-step approach Cox regression, 
random-effects 
Test on heterogeneity on ABI (using Chi² 
and I²) was performed and random 
effects were applied 
NA NA Not reported 
2008 
Steyerberg[98] 
Yes One-step analysis 
accounting for 
clustering 
Logistic regression  Yes, study-specific effects were assessed 
with interaction terms between study and 
each predictor. Interaction terms between 
predictors were examined with 
likelihood ratio tests, but none provided 
enough evidence to extend the models 
beyond the main effects for each 
predictor. 
Combination of practical (widely 
available) and statistical (based on 
Nagelkerke) arguments to select 
variables. 3 different models are 
explored: a core model, an extended 
model (core + information on 
secondary insults) and a lab model 
(extended + additional information on 
glucose and haemoglobin) 
NA (it 
approximates a 
forward approach, 
based on a 
restricted set of 
variables) 
Predictors were 
reported with 
their odds ratios 
2008 Yap[99] Yes One-step ignoring 
clustering 
Cox regression  No, but they have justified pooling all 
the data due to the overall lack of 
significant interaction between risk 
factors and studies across the four 
populations 
Only variables that were significantly 
associated with mortality were included 
Not stated. Only the variable 
names were 
reported 
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3.3.9 Model validation 
Now considered is whether articles validated their developed model and, if so, how. Findings 
are summarised in Table 3.5. ‘Internal validation’ is referred to when the same data is used to 
validate the model as to develop it; and ‘external validation’ is referred to when different data 
is used to validate the model (e.g. data from other studies that were not used to develop the 
model). Another type of validation is ‘internal-external cross-validation’ (Royston et al. 
[101]), which is an external validation approach that allows validation studies to also be 
included in the model development in rotation. In short, this technique excludes one of the 
IPD studies from the available set, and the remainder are used to develop the prediction 
model; the excluded study is then used to validate the model externally. This process is 
repeated for each study omitted in turn, and this allows the consistency of the developed 
model and its performance to be examined on multiple occasions. If the model performs 
consistently well in all omitted datasets, then all IPD studies can be used for model 
development. However, if the model performs poorly in some datasets, this may indicate 
heterogeneous studies (populations) for which the model does not generalise to and may 
require exclusion. 
3.3.9.1 Internal, external or internal-external validation 
Four articles did not validate their model (Table 3.5), such as Chau et al. [89]. Nine of the 
other 11 articles used only an internal validation approach. For example, Noordzij et al. [94] 
calculated ROC curves to assess the discrimination accuracy of the single predictor using all 
the IPD available. However, a few of these nine also recognised that model accuracy may be 
over optimistic in the development data, and so tried to correct apparent performance (in the 
original data) with an optimism-adjusted performance estimate. For example, Pagliaro et al. 
[85] took a random test set of 100 patients from their development data of 261 patients; they 
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show that the area under the ROC curve was slightly lower in the test data than the full 
original data (e.g. model 1: AUC =0.728 (n=261) vs. AUC=0.659 (n=100)). Sylvester et al. 
[93] were the only authors to perform bootstrap re-sampling of all the IPD available and they 
then examined model performance in these samples, leading to a bias-corrected C statistic. 
None of the articles considered or mentioned shrinkage. 
Two articles did use a form of external validation: Steyerberg et al. [98] and Yap et al. [99]. 
Steyerberg et al. [98] used both external validation and internal-external cross-validation. For 
external validation, they use IPD from a trial different to that used to develop the model, but 
note problems with missing variables: “We aimed to validate all models externally using data 
from selected patients in the CRASH trial. However, lab values were not recorded in this 
trial, nor were hypoxia, hypotension, and EDH. We therefore validated the core model, and a 
variant of the extended model, in which only the Marshall CT classification and presence of 
tSAH were added to the core model (i.e., the core + CT model).” Interestingly, their 
developed model was stratified by study and so had multiple intercepts to choose from. 
However, in their validation they appear to choose one intercept related to a single trial as "it 
represented typical proportions of mortality (278/1,118, 25%) and unfavourable outcome 
(456/1,118, 41%)”. When performing internal-external cross-validation, Steyerberg et al. [98] 
state: “AUC was calculated in a cross-validation procedure, where each study was omitted in 
turn. Results were pooled over the ten imputed datasets for eight studies with sufficient 
numbers for reliable validation (n > 500).” They found that cross-validation performance was 
better for the three observational studies but slightly lower for the RCTs. 
Yap et al. [99] also used internal-external cross-validation, stating: “The use of several 
different studies provided an opportunity to validate the general method using data drawn 
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from a different patient population using an internal–external cross-validation system 
proposed by Royston et al. [101] that leave-one-out cross-validation on a cohort basis. We 
therefore, sequentially designated one of the trials as a test study. The remaining studies acted 
as a training data set, which was used to generate the risk scores as above.” They did not state 
their cross-validation results. 
3.3.9.2 Reporting of validation performance criteria 
The number of studies used for validation was reported in seven articles, and these articles 
also reported the number of events and patients from each study used towards the validation. 
Validation performance criteria focussed on discrimination, calibration, reclassification or 
goodness of fit (Table 3.5). Of the 11 articles that examined validation, 10 gave 
discrimination statistics such as sensitivity, specificity, AUC and the C Statistic. Three 
articles reported calibration statistics such as Hosmer-Lemeshow goodness-of-fit).  
Eight articles provided figures to show model discrimination, accuracy or calibration. The 
most common figure was an ROC curve (presented by six articles, e.g. Horn et al. [90], 
Figure 3.3). Steyerberg et al. [98] presented calibration figures depicting the agreement 
between predicted and actual outcome probabilities, and Yap et al. [99] presented survival 
curves for each test study, to illustrate the consistency of the model in identifying risk 
categories. 
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Figure 3.3: Horn et al. ROC curve 
 
Figure 3.3 shows discriminative ability, as stated by Horn et al. [90]: “To investigate the 
discriminative ability of MES monitoring and to determine the optimal cut-off value, a ROC 
curve was constructed, plotting sensitivity versus ‘one minus specificity’ for all possible cut-
off values”. 
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Table 3.5: Model validation methods and results reported in the articles 
Paper Validation 
type: 
(Internal or 
external) 
How was this done? How good was the performance 
of the model after the validation? 
What discrimination, 
calibration, 
reclassification or 
other statistics (e.g. 
goodness of fit or R2) 
were used? 
Were any figures 
given to show model 
discrimination / 
accuracy / 
calibration? If so, 
what? 
Was the 
number of 
studies used in 
the validation 
stated? 
Was the number 
of patients and 
events used from 
each study 
toward the 
prediction model 
validation given? 
1994 
Pagliaro[85] 
Internal Derived a random test set of 100 patients and 
calculated ROC curve and compared AUC to 
the remaining patients for both models. 
AUC =0.728 (n=261) vs. 
AUC=0.659 (n=100) (model 1) and 
AUC = 0.703 (n=234) vs. 
AUC=0.673 (n=100) (model2) 
Discrimination: AUC Yes, Response rate 
charts and ROC curve 
Yes Yes, for each 
study 
2000 
Heffner[86] 
Internal Internal validation (limited descriptions) Sensitivity& specificity are 
provided, although no AUC values 
given for the model. 
Discrimination: AUC 
(for each predictor), 
Calibration: Hosmer-
Lemeshow goodness-
of-fit 
Yes, a ROC curve is 
given for the predictor 
pleural fluid pH (the 
only predictor in the 
final model) 
No No 
2000 
Raboud[87] 
Internal The ROC curves were calculated for each 
predictor in the corresponding (and 
combined) datasets 
The performance increased as the 
time approached the endpoint.  
Discrimination: AUC, 
Sensitivity, Specificity 
Yes, ROC graphs, and 
AUC trends for 
different follow-up 
times 
Yes, the 
original studies 
are used 
(internal 
validation) 
Yes 
2000 
Terwee[88] 
Internal ROC curve. AUC = 0.75, 0.74, and 0.74 in the 
first 3, 6, and 9 months after 
diagnosis respectively 
Discrimination: AUC No No No 
2004 Chau[89] Not 
performed 
NA NA NA NA NA NA 
2005 Horn[90] Internal ROC curve. AUC = 0.83 Discrimination: AUC, 
Sensitivity, Specificity 
Yes, ROC graph No No 
2005 
Nieder[91] 
Not 
performed 
NA NA NA NA NA NA 
2006 Asia 
Pacific[92] 
Internal AUC, ROC curves. The whole cohort of 5 
studies was used 
- AUC = 0.586 (modified NCEP- 
ATPIII definition) 
- AUC = 0.733 
(model with 5 continuous risk 
factors) 
- AUC = 0.788 (model with 
age+sex) 
Discrimination: AUC Yes figure 2 shows 
ROC curve (graph) 
Yes (although 
not explicitly) 
Yes (although not 
explicitly) 
2006 
Sylvester[93] 
Internal To assess model accuracy (discrimination) at 
one and five years, C statistic was calculated 
using bootstrap re-sampling technique 
C-stat = 0.74 at one year and 0.75 
at five years. 
Discrimination: C 
Statistic 
No Yes Yes, same as 
derivation data 
2007 
Noordzij[94] 
Internal All data was directly used for validation AUC = 0.967 (6 hours), AUC = 
0.943 (2 hours) 
Discrimination: AUC, 
Sensitivity, Specificity, 
Yes, ROC curve Yes Yes 
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Paper Validation 
type: 
(Internal or 
external) 
How was this done? How good was the performance 
of the model after the validation? 
What discrimination, 
calibration, 
reclassification or 
other statistics (e.g. 
goodness of fit or R2) 
were used? 
Were any figures 
given to show model 
discrimination / 
accuracy / 
calibration? If so, 
what? 
Was the 
number of 
studies used in 
the validation 
stated? 
Was the number 
of patients and 
events used from 
each study 
toward the 
prediction model 
validation given? 
PPV, NPV 
2007 
Rovers[95] 
Internal ROC curves and goodness of fit Hosmer-
Lemeshow test. 
AUC = 0.63 for primary outcome. 
goodness-of-fit test with p-value of 
0.93 
Discrimination: AUC, 
Calibration: goodness-
of-fit 
No No No 
2007 
Schaich[96] 
Not 
performed 
NA NA NA NA NA NA 
2008 
Fowkes[97] 
Not 
performed 
NA NA NA NA NA NA 
2008 
Steyerberg[98] 
 
Internal-
external 
cross-
validation 
Cross-validation procedure, where each study 
was omitted in turn and results were pooled 
over the ten imputed datasets for eight studies  
AUC>0.80 in the 3 observational 
studies. Lower AUC in RCTs 
Discrimination: AUC, 
Calibration: Hosmer-
Lemeshow 
Yes. There are figures 
depicting predicted and 
actual outcome 
probabilities 
Yes, Internal-
external(1 
study at a time 
excluded), 
external was on 
CRASH RCT.  
Yes 
 External Individual trial (CRASH) was used for 
external validation, although they develop the 
model stratifying by study, they take the 
intercept term from one trial and use that in 
their model to apply it; so they can validate 
it. Logistic regression was subsequently used 
to calibrate the risks of mortality and 
unfavourable outcome according to the 
scores, with the model intercept referring to 
the Tirilazad international trial 
AUC = 0.776 and 0.780 for 
mortality and unfavourable 
outcome (core model). Lower AUC 
for the more advanced models. 
Calibration Hosmer-Lemeshow 
tests indicate miscalibration for 
core and core+CT models 
(p<0.001). Improved calibration for 
extended model p > 0.1 in 
particular group of patients 
    
2008 Yap[99] Internal-
external 
cross-
validation 
Internal–external cross-validation There is no real measure of 
performance presented. There is a 
qualitative comparison of Kaplan-
Meier curves 
None given Survival curves are 
presented for each split-
validation sample, and 
illustrate consistency of 
the model in identifying 
risk categories 
Yes Yes 
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3.3.10 Dealing with those studies not willing / able to provide their IPD 
In six of the seven literature review articles, IPD was not obtained for all desired studies 
(Table 3.1), but only three of these articles discussed this as a potential limitation of their 
project. For example Horn et al. [90] stated “We may not have identified all centres, which 
monitor MES after carotid surgery: it is likely that small series of patients remain 
unpublished and have therefore escaped our attention". None of the six articles report the 
number of patients and events in the missing IPD studies, and only Rovers et al. [95] 
discussed the qualitative or quantitative differences between those studies providing IPD and 
those studies not able to. They were not able to include four trials, as IPD were not available 
for them; however, they found the excluded trials to be similar to those included in terms of 
aggregate data results, so they do not expect the results of the meta-analysis to change. 
3.3.11 Conclusions and limitations 
The developed risk prediction models had large potential for use in clinical practice, 
according to the discussion of the 15 articles. For example Noordzij et al. [94] state “PTH 
assay, when checked 1 to 6 hours after thyroidectomy, has excellent accuracy in determining 
which patients will become symptomatically hypocalcemic.” Similarly, Yap et al. [99] state 
"our study suggests that in post-MI patients, pre-selected using LVEF or frequent ventricular 
premature beats, the additional use of a simple prognostic indicator based on demographic 
and baseline information was able to segregate patients that were at high risk of dying, for 3 
different modes of mortality." 
There were also numerous limitations and problems of the IPD project noted in the articles’ 
discussion sections. Some common limitations were: lack of standardisation in data collected 
between different studies, variability in definition of predictors, missing data and potential for 
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bias, lack of external validation, between-study heterogeneity, and loss of information due to 
categorisation or dichotomisation. The key limitations and methodological problems are 
summarised in Table 3.6. 
Table 3.6: Limitations and methodological problems noted in discussion of the 15 articles 
Paper What limitations and problems of the IPD project were noted in the Discussion? 
1994 
Pagliaro[85] 
- An untreated control group was excluded 
- The predictor ‘disease duration’ is inaccurate 
2000 Heffner[86] - They constantly mention the limitations of the primary studies, their design and data 
- Plus potential for bias and missing data 
2000 Raboud[87] - Distortion of PPV and NPV due to no intention-to-treat 
- Selective drop-out 
2000 Terwee[88] - Pooling does not solve problems regarding the lack of standardisation in the measurement of risk factors as a result 
of retrospective designs, differences in diagnostic procedures, and missing data 
- Few variables available for all studies to enter in a prognostic model 
- Important risk factors may not have been included 
2004 Chau[89] - Prognostic index requires validation 
2005 Horn[90] - Small number of patients experiencing cerebral ischaemic complications shortly after surgery => large CI 
- Other baseline characteristics, which could possibly be risk factors were not analysed 
- The outcome measure was not ideal 
- Potential underestimation because assessment may not always have been performed by suitably qualified clinicians 
- Lack of external validation 
2005 Nieder[91] - Retrospective data analysis is subject to several sources of error and bias 
- Small number of patients, inconsistent use of chemotherapy, and uncertainty in dose calculation resulting from both 
the BED model and the differences in dose prescription and reporting among the different institutions in which the 
patients were treated 
- Potential bias in reported doses to the spinal cord in each individual paper 
- Differences in radiation sensitivity 
- Follow-up time may not have identified all patients with myelopathy 
- Validation should be undertaken 
2006 Asia 
Pacific[92] 
- Few cohorts measured all five risk factors at baseline, which limits the precision of our estimates and our ability to 
explore differences by age, gender and region 
- Most of these studies were initiated at time when the importance of waist circumference as a determinant of CHD 
risk was not well-recognized 
- Lack of standardization in data collection between studies, including in outcome ascertainment 
2006 
Sylvester[93] 
- No external validation 
- Characteristics and prognoses of patients may have changed (old data: study published in 1996, data collected 
between 1979 and September 1989) 
- Recurrence and progression rates reported here may be higher than those found in current clinical practice 
2007 
Noordzij[94] 
- Prospective outcomes studies need to be performed 
- Inherent variability that exists between various PTH assays and the variability in the definition of hypocalcaemia 
(outcome) used in the studies included in this meta-analysis 
- Considerable variability in the mean preoperative PTH values in the studies included in this analysis 
2007 Rovers[95] - Generalizability & power: 4/10 trials not included 
- Generalizability: only children from trials included and from observational arm 
- Bias: not all studies used objective diagnostic methods 
- Loss of information & bias due to dichotomization and completely missing variables 
2007 Schaich[96] - Small sample size 
- Time-selection bias 
- Heterogeneity 
2008 Fowkes[97] - No recalibration for FRS model 
2008 
Steyerberg[98] 
 
- "Old" time period 
- Motor score is not always available and may be unreliable 
- Missing variables 
- Potential misclassification bias in dichotomizing the outcome 
2008 Yap[99] - Limited survival follow-up 
- Different mortality endpoints (heterogeneity) 
- Retrospective analysis vs. prospective application 
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3.4 Discussion 
In this Chapter, a systematic review has identified and evaluated the methodology of risk 
prediction models that were developed or validating in an IPD meta-analysis. The findings 
inform current standards, gaps in methodology, and future research needs. The review found 
15 relevant articles, all of which developed a model and 11 also undertook some form of 
validation. The publication dates for these articles ranged from 1994-2008. The key findings 
were as follows. Seven of the articles used a literature review approach to identify studies, of 
which six did not obtain IPD for all studies desired; this raises concern of availability bias 
[100]. The percentage of IPD obtained ranged from 50% to 100%. Missing data was 
mentioned by 11 of the 15 articles, where three articles deleted some studies due to an 
absence of a predictor or outcome of interest. Of key importance was the finding that 10 of 
the 15 articles have developed their model using a ‘one-step meta-analysis ignoring 
clustering’, this is an unstratified approach, and this may be inappropriate [102]. All 15 
articles developed their model using all of the available IPD, but only 11 validated their 
model, with 9 only using an internal validation approach. Thus only two articles used some 
form of external validation, via either internal-external cross-validation approach and/or a 
fully external validation approach. Also, although ten articles provided discrimination 
statistics, only three provided calibration statistics, and thus calibration performance is rarely 
evaluated. 
Risk prediction models have the potential ability to inform strategies for disease prevention, 
care, early diagnosis and patient counselling [11]. Their use should be evidence based as with 
all clinical practice. There must be consistent evidence that a model is reliable and applicable 
to the intended populations of individuals [16]. This preferably requires the model to be 
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externally validated in multiple datasets successfully. This can take years to achieve, but with 
growing access to IPD from large databases, there is an increasing opportunity to develop and 
validate risk prediction models simultaneously. 
This review has allowed an evaluation of current practice and applied statistical methods, 
identified common methodological challenges, and flagged limitations in current reporting 
and methodology. These findings will thereby inform those wishing to develop and/or 
validate a model using IPD from multiple studies, and recommendations are provided below 
to enhance this. Firstly, the review limitations are discussed. 
3.4.1 Limitations of the review  
This review has some limitations. Firstly, it only covers articles published up to 2009 which 
was a restriction due to the database used. However, the key findings are unlikely to be 
altered if the review were updated; as it was felt qualitative saturation was achieved with this 
sample in regard the methods used and areas for improvement. However, a second limitation 
is that, by evaluating published articles, the findings are clearly dependent on the reporting 
standards within the articles, thus any research deficiencies or methodological gaps may 
reflect poor reporting (as absence of reporting is not absence of performing). For example, 
only three articles have referenced a protocol for the IPD project; however this absence of 
reporting does not necessarily mean the other 12 articles did not have a protocol.  
Thirdly, the focus in this review was on articles that utilised IPD from multiple studies, and 
did not consider a single database containing clusters (e.g. practices). Such articles have 
similar issues, but the focus was on a typical IPD meta-analysis scenario where IPD studies 
are obtained and synthesised. Such articles are likely to have similar methods and standards, 
but this review cannot quantify that.  
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3.4.2 Methodological challenges to consider 
The review identified some key areas for improvement and methodological challenges for 
researchers to consider when planning to develop/validate a prediction model using IPD from 
multiple studies. These are summarised in Table 3.7. A major finding is that often clustering 
of patients within studies is ignored during model development, and this may affect the 
model estimates and model performance [102]. Dichotomisation/categorisation of predictors 
is also often performed, and may have resulted in poorly-fitted models and loss of 
information. There was often a lack of standardisation in data collection between studies, and 
heterogeneity in predictor effects was often not measured or accounted for (when data is 
pooled) in the analysis. Missing data was also an issue, with multiple variables often not 
recorded within each dataset, leading to multiple imputation or omission of prediction 
variables.  
The review has highlighted that those articles that perform a literature review do not always 
obtain all the IPD that they desire, as some studies are unwilling to provide their data for 
various reasons. There needs to be a better assessment of the quality of IPD identified, and 
indeed assessment of study quality as a whole is currently rather neglected. The issue is of 
bias and whether there is something different about those studies for which IPD can’t be 
obtained. 
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Table 3.7: Methodological challenges, extending those identified for prognostic factors by Abo-Zaid et al. 
Methodological challenges  
- Identifying relevant studies 
- Unavailability of IPD in some studies[100] 
- Issues within studies 
- How to assess quality of studies identified  
- Inability of IPD to overcome deficiencies of original studies, such as missing participant data or of 
being low methodological quality, etc.  
- Heterogeneity 
- Different definitions of disease or outcome, e.g. Noordzij et al. [94] note different definitions of 
hypocalcaemia across studies 
- Different (or out-dated) treatment strategies, especially when a mixture of older and newer studies are 
combined; e.g. Yap et al. [99] state that a large proportion of their patients in their included trials did 
not receive a common post-myocardial infarction therapy  
- Statistical issues for meta-analysis and model development 
- Missing data, including: missing values and outcome data for some participants within a study, and 
unavailable factors in some studies  
- Difficulty in using a continuous scale for continuous factors in meta-analysis when some studies give 
IPD values on a continuous scale and others do not (see Rovers et al. [95])  
- Whether to account for clustering or not 
- Examining and incorporating heterogeneity between-study for predictors / alpha term 
- Assessment of potential biases 
- How to assess the impact of excluded studies who did not provide IPD [100] 
- Model validation 
- Sample size required for internal-external approach 
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3.4.3 Areas for improvement - Recommendations 
This review has highlighted areas for improvement and subsequently recommendations 
have been provided in Table 3.8 for how to improve the conduct and reporting of future 
research in this field. 
Table 3.8: Areas for improvement and recommendations 
Areas for improvement and recommendations 
Rationale and initiation 
- Produce a protocol for the project, detailing rationale, conduct and statistical analysis and 
reference this  
Obtaining IPD 
- Report how the primary study authors were approached for their IPD  
- Report search strategy used, i.e. literature review / collaborative group 
- Report strategies used for searching the literature for relevant studies (if applicable), including 
search keywords and databases   
- Provide a flowchart showing the search strategy, classification of identified articles, and retrieval 
of IPD from relevant studies  
- Report sample size requirements and how the amount of IPD was decided upon 
Details of IPD 
- Report the number of patients and events for each study used in model development and / or 
validation 
- Report the missing data for each study (whether excluded entirely or some data is missing within 
a study) 
- Detail the reasons why IPD was unavailable (if applicable), if available then report the number 
of patients and events from those studies 
- Compare and report the quality of IPD obtained for each study 
Statistical methods for model development 
- Account for clustering of patients within studies, (do not merge all the IPD as if it was one 
study), using a one-step accounting for clustering approach 
- Assess and report any between study heterogeneity in the predictors / alpha term (if applicable) 
- If large heterogeneity does exist, then try to reduce by including more variables or remove 
heterogeneous variable 
- Report selection criteria and procedure used to decide inclusion of a predictor in the model 
- Keep predictors continuous whilst developing a model, unless it is important to categorise with 
good clinical or statistical reason 
- Report the final developed model in original format with alpha (if applicable) and beta-
estimates, i.e. not just HR, OR, RR 
- Detail the missing data and variables in each study and how this was dealt with 
Assessment of publication and availability biases 
- If applicable, consider the potential impact of publication bias and / or availability bias if studies 
are not providing IPD, by comparing those studies to the studies providing IPD [100] 
Model validation 
- Validate the model that has been developed using both internal and external IPD where possible 
- If all IPD is desired for model development, perform internal-external cross-validation as 
recommended by Royston et al. 
- Report the number of studies used in validating the developed model 
- Report the number of patients and events used from each study towards validation 
- Explain the choice of intercept (baseline hazard) to be used when implementing the model in 
practice 
- Report validation statistics both in each study and overall 
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Two important recommendations are discussed here now. The first recommendation is 
to account for clustering. This is very important because most of the articles did not 
account for the clustering of patients within different studies, and this can make a 
difference when interpreting the results for individual studies, because (i) ignoring 
clustering can bias model estimates [102], and (ii) a model may perform adequately on 
average but may not do as well for specific populations, for which setting-specific 
intercepts may be required. This is also highlighted in Chapter 5. The second 
recommendation is to include some form of external validation where possible; most of 
the articles did not do this, even though multiple studies are available, as all data was 
used for model development and then usually internal validation. As multiple studies 
are available and it may be hard to obtain further data for external validation post meta-
analysis, it is imperative to at least consider the use of internal-external cross-validation, 
as it offers a more robust method of assessing validation outside the model development 
data. 
3.4.3.1 Recommendation One: Allow for different baseline risks in each of the IPD 
studies 
In this review, 10 of the 15 articles did not account for clustering of patients within 
different IPD studies and therefore their developed prediction model did not allow for 
any study differences in baseline risk. Although such models can still perform 
adequately on average (across all studies combined), when applied in practice to 
specific populations the model performance may not be as good if the population's 
baseline risk is very different from the average estimated baseline risk. This means that 
the developed model may require re-calibration in specific populations. Statistically it is 
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known that omission of an important predictor (i.e. study) can lead to biased effect 
estimates and reduced power [82]. To address this, Debray et al. [103] recommended 
the prediction model should be developed with a separate intercept (baseline risk) per 
study, and then the model's performance can be examined using internal-external 
validation alongside a strategy for choosing the intercept upon application to the 
excluded study. Such strategies may include using external knowledge of the intercept 
in the excluded study population; using the intercept as estimated from the IPD from the 
excluded study; or taking the intercept estimated from a study used in the model 
development that contains a similar population to the excluded study. The latter strategy 
is recommended within Steyerberg et al. [98], where they propose others apply their 
model using the intercept for one particular trial in their analysis, as this trial reflects the 
population it is intended for. 
Where the intercept can be well-matched to the excluded study, Debray et al. [103] 
show that their framework allows an IPD meta-analysis to produce a single, integrated 
prediction model that can be implemented in practice and has improved model 
performance and generalisability. This echoes other recommendations to account for 
clustering in an IPD meta-analysis [102]. For survival data, this means that the baseline 
hazard should be modelled during model development and so researchers should move 
away from using Cox regression (a common approach used by the articles in the review, 
but one which does not estimate the baseline hazard) and rather use other approaches 
such as flexible parametric methods, like the Royston-Parmar model that estimates the 
baseline hazard using restricted cubic splines [11, 18]. 
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3.4.3.2 Recommendation Two: Implement a framework that uses internal-external 
cross-validation 
An important finding from this review is that, although multiple studies are available, 
most researchers develop their model by using IPD from all available studies, thus 
performing an internal validation (on the same data used to develop the model) rather 
than an external validation (different data). Only two of the 15 articles performed a form 
of external validation, and therefore most models require further validation to assess 
true performance. A possible explanation why researchers choose not to use IPD for 
external validation is to maximise the data available for model development, which is 
understandable given the large number of predictors and possible non-linear 
relationships. Also, if researchers were to consider holding back some IPD for external 
validation, there is no easy way to decide how much IPD (number of studies) should be 
held for validation. 
However, external validation should be performed if possible as this is ultimately the 
gold standard for model validation, with an appropriate dataset. For those researchers 
that wish to use all their data for model development, then this can be achieved 
alongside some form of external validation, using the internal-external cross-validation 
approach [101] used by Steyerberg et al. [98] and Yap et al. [99] in the articles 
reviewed. This approach involves removing one study from the development phase of 
the model, then fitting the model on the remaining IPD, and then testing performance in 
the excluded study. The framework is then repeated by rotating the omitted study and 
assessing validation in all the possible scenarios. Thus model estimates are based on the 
majority of IPD in each cycle, and the models fit and predictive ability can be compared 
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across all possible combinations of omitted study. If performance looks adequate, a 
final step can be to utilise IPD from all studies to provide the final specification of the 
model. In scenarios where the model fit appears to be poor in some studies, this can 
indicate a lack of generalisability of the model, highlighting which populations the 
model is not appropriate for. 
Internal-external validation may not always be possible, for example if studies have 
small sample sizes. But it appears to be an ideal approach to utilise as much IPD for 
both model development and validation. The article by Royston et al. [101] proposing 
the internal-external cross-validation approach has been cited 35 times [16, 82, 98, 99, 
104-134] between 2004-2015 as of 01/01/2015, by articles that investigate prognostic 
factors, developing risk prediction models, updating prognostic factor studies and 
externally validating them, and articles looking at multiple imputation methods and 
three theses. Nine articles [98, 99, 104, 107, 109, 113-115, 124] have used the internal-
external cross-validation method to develop their risk prediction / prognostic model. 
Figure 3.4 shows the number of citations per year for the Royston et al. [101] paper. 
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Figure 3.4: Number of articles that have cited the Royston et al. paper, by each year 
 
3.4.4 Conclusions 
It is important to consider the statistical and methodological issues when planning to 
develop and/or validate a risk prediction model from multiple datasets, in order to avoid 
models that perform poorly and are not generalisable. This review highlights that the 
IPD meta-analysis approach is very appealing, as it allows the use of internal-external 
cross validation to develop a model and at the same time evaluate its performance 
across multiple populations. However, an IPD meta-analysis does not solve all the 
problems, as numerous challenges remain, particularly missing data and heterogeneity 
in study quality and methods of measurement. Perhaps an ideal way forward is a 
prospective IPD meta-analysis, where researchers agree at their study onset to use set 
quality standards and record particular variables in a common way so that, upon their 
own study completion, they can supply their IPD to those developing/validating a risk 
prediction model. Heterogeneity can then be limited by researchers agreeing before data 
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collection to standardize predictor definitions, measurement methods, and outcome 
recoding.  
3.4.5 Findings in context for the thesis 
This review has been published in BMC Medical Research Methodology [16]. The 
findings raise many methodological challenges, and the next two chapters are motivated 
by one of the key findings:  the issue of clustering of studies, and whether there is a 
difference in outcome prediction when accounting for between study heterogeneity. In 
particular, articles such as Noordzij [94] do not account for clustering of studies, and it 
is of interest if and how this affects absolute risk predictions.  
3.4.6 What this chapter adds? 
A short summary of this chapter in terms of what the problem is, what this chapter adds 
and what is needed next, is provided in Table 3.9. 
Table 3.9: What chapter three adds? 
What is known / what is the problem? 
 Important to do a systematic review of articles using IPD to develop and validate risk prediction 
models  
 Assess whether the issues found in Chapter 2 are prevalent in the wider research community 
What this study adds? 
 A systematic review such as this has not been performed before for studies that use IPD 
 This study highlights an important issue, where multiple studies are used to develop a model but 
their heterogeneity is not accounted for and IPD is instead regarded as coming from one study 
 A key contribution of this work is that more researchers should consider clustering 
 This study has found that models are usually internally validated and rarely externally validated, 
with a few articles recently using an approach called internal-external cross-validation 
 Internal-external cross-validation is a novel approach that more researchers should be thinking 
about and helps to get a better assessment of the generalisability of the model 
What is needed next? 
 In the next two chapters, discrimination and calibration will be assessed for an already published 
set of results for a risk prediction model found through this review  
 The results will be compared to the standard approach of not accounting for heterogeneity 
 As well as assessing internal-external cross-validation 
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 UNSTRATIFIED VERSUS META-CHAPTER 4:
ANALYTIC APPROACHES FOR EVALUATING 
PREDICTIVE TEST ACCURACY USING IPD: PART 1 
- DISCRIMINATION 
4.1 Introduction and objectives 
The previous chapter reviewed risk prediction model projects that used IPD from multiple 
studies, and found that many ignore clustering and treat IPD as if it is all from one study. 
Here, one of those articles is taken and the implications of ignoring clustering are explored. 
The aim of this chapter is to illustrate the benefits of having IPD for meta-analysis of risk 
prediction studies, and to compare how an unstratified analysis that treats all IPD as coming 
from a single study compares to a more sophisticated analysis that accounts for clustering 
using more sophisticated meta-analysis methods. The focus is on a single predictive test (in 
other words, a risk prediction model that contains a single predictor) and its discrimination 
ability when using unstratified and meta-analysis approaches. Discrimination is the ability of 
a test or prediction model to differentiate high risk patients from low risk patients [135], as 
introduced in Chapter 1. Calibration is considered separately in Chapter 5. 
The chapter uses a dataset from a paper identified in Chapter 3 through the systematic review. 
This paper is Noordzij et al. [94] who use IPD from nine observational studies to predict 
hypocalcaemia after thyroidectomy using parathyroid hormone (PTH). This chapter begins 
with a summary of this article and then introduces, applies and compares meta-analytic 
approaches that do or do not account for clustering. 
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The discrimination and calibration work performed in Chapters 4 and 5 has been published in 
Statistics in Medicine (Riley et al. [42]), where I am the second author. PTH has been used as 
a case study within the paper and my analysis for discrimination and calibration is used as 
illustrated examples; I also contributed heavily to writing these sections within the paper and 
drafting and finalising the paper. 
4.2 Summary of Noordzij article 
Noordzij et al. [94] conducted a systematic search for papers which describe the use of 
parathyroid hormone (PTH) assay (a continuous variable) to predict postoperative 
hypocalcaemia after thyroidectomy. To be included, a study had to record PTH assay 
checked within hours of completing thyroidectomy and link this to a subsequent diagnosis of 
hypocalcaemia defined by low calcium levels. A thyroidectomy is an operation that involves 
the surgical removal of all or part of the thyroid gland [136]. The issue is that monitoring for 
hypocalcaemia after thyroidectomy using only serum calcium levels can delay the discharge 
of patients who will remain normocalcaemic patients, and also delay the treatment of 
hypocalcaemia patients [94]. Thus earlier identification of those at high risk of 
hypocalcaemia would help decide which patients not to send home, and conversely which 
patients are low risk and could be discharged. 
Hypocalcaemia is a condition where low serum calcium levels are present in the blood [137, 
138]. Calcium is vital for the development of healthy bones and teeth. It is also needed for 
muscle contraction, heartbeat regulation and formation of blood clots. A calcium deficiency 
can lead to brittle-bone disease. The parathyroid glands are responsible for regulating the 
calcium levels in the body. When calcium levels drop the parathyroid glands secrete PTH. 
PTH causes calcium to be released from bones, so more can be reabsorbed by the kidneys 
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and also from food in the intestines. Low levels of calcium can cause muscular spasms and 
numbness in the hands, feet, mouth and even throat, as well as depression and seizures. In the 
case of hypocalcaemia, vitamin D and calcium supplements are needed. Hypocalcaemia may 
be caused by chronic kidney failure, pancreatitis or problems with parathyroid glands which 
means they do not produce enough PTH. This often occurs after damage to the parathyroid 
glands during surgery on the thyroid glands. PTH is measured through a sample of a patients’ 
blood. 
Noordzij et al. 2007 [94] performed a medical literature search in PubMed using the 
keywords: ‘PTH’ (parathyroid hormone) and ‘thyroidectomy’ for all English articles that 
were published between 1996 and January 2006. They included studies if PTH was obtained 
within 24 hours of completing total or completion thyroidectomy, and only included 
observational studies. A total thyroidectomy is when the entire thyroid gland is removed 
[139], and completion thyroidectomy involves removing the remaining thyroid tissue after 
the patient has previously had partial removal [140]. Noordzij et al. [94] excluded studies if 
all the patients were treated with postoperative calcium, or if early PTH values were used to 
change how the patient was managed. Fifteen papers met the inclusion criteria and the 
authors of those 15 papers were e-mailed to request ‘their’ IPD, of which only 9 provided it. 
IPD containing preoperative PTH and calcium levels, and whether they developed 
hypocalcaemia, were obtained for 457 patients from the 9 studies and Noordzij et al. [94] 
pooled these to yield the unstratified results across the studies. PTH was checked up to three 
time periods after removal of the thyroid gland (0 to 20 minutes, 1 to 2 hours, and 6 hours); 
PTH levels were found to be substantially lower in patients who became hypocalcaemic 
compared with those who remained normocalcaemic. The accuracy of PTH in determining 
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hypocalcaemia increased with time, and was best when checked from 1 to 6 hours 
postoperatively. IPD, including original PTH values, enabled % change in PTH from baseline 
to be calculated. This was used by the authors, rather than the absolute change in PTH, due to 
different methods of measuring PTH across studies. A single PTH threshold (65% decrease in 
PTH compared with preoperative level), checked 6 hours after completing thyroidectomy had 
a sensitivity of 96.4% and specificity of 91.4% in detecting postoperative hypocalcaemia, and 
was recommended by the authors as the optimal threshold to detect hypocalcaemia.  
Noordzij et al. [94] conclude from their analysis of the data that routine use of this assay 
should be considered because it may allow earlier discharge of the normocalcaemic patient 
and earlier identification of patients requiring treatment of post-thyroidectomy 
hypocalcaemia [94]. However, a potential limitation of their work is their analysis, which has 
merged all the IPD together and ignored both clustering of patients within studies 
(unstratified) and heterogeneity of test accuracy across studies. 
Noordzij kindly provided the data for the purposes of this thesis. In this chapter, their original 
analysis has been replicated using the original thresholds used, and then extended to properly 
model clustering and heterogeneity. The results of the different approaches are then 
compared. Noordzij [94] dichotomised PTH into high and low using a threshold, and 
examined multiple choices for the cut off. To be consistent this has also been done in this 
thesis. Possible extensions for modelling PTH on its continuous scale are discussed in the 
Discussion, Chapter 7. 
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4.3 Summary of the IPD available 
The 6 IPD studies of Noordzij are summarised in Table 14. Although there was data for 
457 patients from the full set of nine studies, three of these studies were eventually 
excluded for not providing pre-operative values, which is why in Table 4.1 the overall 
number of patients in the reported articles is reduced down to 388. 
Table 4.1: Summary of the 6 IPD studies 
Study No of 
patients 
in 
reported 
article 
No of 
events in 
reported 
article 
Outcome 
Prevalence 
in reported 
article 
Prospective? Definition of 
hypocalcaemia 
(equivalent 
cCa (mg/dL)) 
IPD 
provided: 
no. of 
patients 
(events) 
Outcome 
Prevalence 
in IPD 
Times at 
which 
PTH was 
measured 
Lam 2003 
[141] 
40 12 0.30 Yes <7.6 39 (12) 0.31 Pre-op, 1 
and 6 hour 
post-op 
Lo 2002 
[142] 
155 32 0.21 Yes <7.2 100 (11) 0.11 Pre-op and 
intra-op 
Lombardi 
2004 
[143] 
53 16 0.30 Yes <8.0  52 (16) 0.31 Pre-op, 
intra-op, 
2, 4, 6, 24  
and 48 
hour post-
op 
Mcleod 
2006 
[144] 
60 15 0.25 Yes <8.0 60 (14) 0.23 Pre-op, 
intra-op 
and 1 hour 
post-op 
Warren 
2002 
[145] 
53 5 0.09 Yes <8.0 22 (4) 0.18 Pre-op, 
Intra-op 
and 1 hour 
post-op 
Warren 
2004 
[146] 
27 3 0.11 Yes <8.0 27 (3) 0.11 Pre-op, 
intra-op 
and 1 hour 
post-op 
Overall 388 83 0.21   300(60) 0.20  
 
The number of patients reported differs throughout each study as Table 4.1 shows, from 
27 to 155, with a mean of 64.7. All six studies are prospective studies and the definition 
of hypocalcemia ranges from <7.2 mg/dL to <8.0 mg/dL, with 4 studies using the value 
of <8.0 mg/dL. So the reference standard is fairly consistent across studies. The IPD 
used by Noordzijet al. [94] differs from the number of patients reported in the original 
studies as there are data missing for 88 patients. No reason is given by Noordzij [94] as 
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to why a reduced number of patients was given in the IPD provided by 4 of the 6 of the 
studies.  
Note also that the prevalence of the outcome varies across studies, from 0.09 to 0.30 (as 
reported in the original articles)  and 0.11 to 0.31 (in the IPD provided), potentially due 
to the different clinical settings and patient groups included in each study. Noordzij et 
al. [94] have used the following thresholds: 40%, 50%, 60%, 65%, 70%, 72%, 80% and 
90%. For consistency, the same thresholds will be used in this analysis. Discrete 
thresholds are being used because clinical decisions will use thresholds, and I wanted to 
compare directly to the original paper by Noordzij, who focused on thresholds. 
4.4 Methods 
The IPD analysis in this chapter aims to compare statistical approaches for examining 
the discriminatory ability of PTH, for a variety ofthresholds for % change from 
baseline, when measured 0-20 minutes, 1-2 hours and 6 hours from end of surgery. The 
methods are now described. 
Initially t-tests are used as a preliminary analysis to compare mean values, as this has 
also been performed by Noordzij et al. [94] to summarise the separation between those 
with and without the outcome. The following two approaches are used: 
i) t-test at each time point in the unstratified dataset 
ii) t-test repeated for each study separately 
In both of these approaches, the mean PTH values are calculated in the two groups 
hypocalcemia and normocalcemia (patients who do not have hypocalcemia) and p-
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values are calculated which indicate whether there is a difference in the means of these 
two groups, a p-value <0.05 is regarded as being statistically significant. The difference 
in the mean PTH values is calculated for pre-operative values, 0-20 minutes, 1-2 hours 
and 6 hours. 
However, discrimination is better considered in terms of sensitivity, specificity and the 
C statistic (area under the curve). Different meta-analysis approaches are now described 
for obtaining a summary sensitivity, specificity and C statistic across studies. Firstly, the 
unstratified analysis approach of Noordzij et al. [94], followed by some alternative 
meta-analysis approaches that properly account for clustering and heterogeneity. 
4.4.1 Noordzij analysis: unstratified approach 
In the unstratified approach, IPD from all studies are combined and treated as one 
dataset, with clustering and heterogeneity ignored. Sensitivity and specificity for a range 
of thresholds, and the C statistic is calculated for percentage PTH decrease (percentage 
decrease from pre-op level to either: 0-20 minutes, 1-2 hours or 6 hours). 
% PTH decrease 
% PTH decrease is calculated by: 
% PTH decrease = ((preoperative PTH - post operative PTH)/preoperative PTH) × 100 
(Equation 4.1) 
 
 
 
116 
 
Then using a threshold value, the IPD is summarised by: 
Table 4.2: Two by two table for each threshold 
 Hypocalcaemic Normocalcaemic 
Positive (> threshold %) a b 
Negative (≤ threshold %) c d 
Where a is the true positive b is the false positive, c is the false negative and d is true negative 
Sensitivity 
Sensitivity in the unstratified analysis is calculated using: 
Sensitivity =  
number of true positives
number of true positives + number of false negatives
 
= probability of a positive PTH test given that a patient becomes hypocalcaemic 
Also, from a 2 by 2 table (Table 4.2): 
Sensitivity =  
a
a + c
 
(Equation 4.2) 
Specificity 
Specificity in the unstratified analysis is calculated using: 
Specificity =  
number of true negatives
number of true negatives + number of false positives
=  probability of a negative PTH test given that the patient does not 
become hypocalcaemic   
Also, from a 2 by 2 table (Table 4.2): 
Specificity =  
d
b + d
 
(Equation 4.3) 
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Youden’s J statistic 
This is a statistic that is used to determine the performance of a diagnostic test. This was 
suggested by Youden [147] to summarise the performance of a test, a value of 0 
indicates the test is useless and a value of 1 indicates the test is perfect. This statistic 
gives equal weighting to false positives and false negatives. It is applicable to a 
predictive test such as this which is being investigated and will be used to determine the 
best threshold. This will be multiplied by 100 as sensitivity and specificity have been 
multiplied by 100 as well. 
𝐽 = 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 + 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 − 1 
(Equation 4.4) 
C statistic 
To calculate the C statistic, sensitivity versus 1-specificity was plotted on an ROC curve 
and then integrated using the trapezoid function to get the area under the curve [148]. 
The trapezoid function integrates trapeziums under the curve, to work out their area and 
then add them up to give the AUC, with points at (0, 0) and (1, 1) added manually to 
give the full AUC. To plot an ROC curve for continuous data for each time-point, the 
ROCTAB command was used in STATA 12.1 [149]. ROCTAB gave a C statistic with 
its standard error and a 95% confidence interval. 
4.4.2 Meta-analysis approaches 
Rather than regarding the data as coming from one study only, a meta-analysis that 
accounts for clustering and potential between-study heterogeneity is also possible. The 
meta-analysis models are now explained.  
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4.4.2.1 Univariate meta-analysis for sensitivity and specificity 
A univariate meta-analysis of sensitivity is: 
r+vei  ~ Bin (ρSensi , Ndiseasedi) 
Logit (ρSensi) ~ N (θSens, τSens
2 ) 
(Equation 4.5) 
Where r+veiis the number of true positives, ρSensi is the true sensitivity in study i, 
Ndiseasedi represents the total number with hypocalcaemia, θSens is the average logit-
sensitivity across studies, τSens
2  is the between-study heterogeneity in the logit-
sensitivity. 
For specificity: 
r−vei  ~ Bin (ρSpeci , Nnon−diseasedi) 
Logit (ρSpeci) ~ N (θSpec, τSpec
2 )  
(Equation 4.6) 
Where r−veiis the number of true negatives, ρSpeci is the true specificity in study i, 
Nnon−diseasedi represents the total without hypocalcaemia, θSpec is the average logit-
specificity across studies, and τSpec
2  is the between-study heterogeneity in the logit 
specificity. 
The meta-analysis models utilise the exact binomial distribution within each study, and 
estimate the average sensitivity and specificity across studies[150, 151], and the 
variability of sensitivity and specificity across studies.  
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4.4.2.2 Bivariate meta-analysis for sensitivity and specificity 
In this bivariate meta-analysis approach recommended by the Cochrane Screening and 
Diagnostic Test Methods Group [22], sensitivity and specificity are jointly analysed to 
account for any between-study correlation as follows: 
r+vei  ~ Bin (ρSensi , Ndiseasedi) 
r−vei  ~ Bin (ρSpeci , Nnon−diseasedi) 
Logit (ρSensi)
Logit (ρSpeci)
 ~ N (
θSens
θSpec
 , [
τSens
2 τSens,Spec
τSens,Spec τSpec
2 ]) 
(Equation 4.7) 
In this model, the parameters are as defined previously, with the addition of τSens,Spec 
which is the between-study covariance in logit sensitivity and logit specificity. 
Covariance might arise because both sensitivity and specificity are being estimated 
together, so there may be some correlation between them. Usually this is caused by 
changes in the threshold across studies, but here a common threshold is used and so the 
correlation should be close to 0 and thus the univariate approach may be sensible. 
The XTMELOGIT command is used in STATA 12.1 [149] to perform both univariate 
and bivariate meta-analyses, and STATA 12.1 [149] is used for all other analyses 
performed in this chapter. Maximum likelihood estimation method is used and 
numerical integration. Different numbers of quadrature points can be specified, as the 
number of points increases so does the estimation accuracy but this also increases the 
computational time. Five quadrature points were chosen for this analysis  as it gave 
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estimates close to those when using >10 points but with a much faster computational 
time.  
4.4.2.3 C statistic 
There are a number of ways that a summary C statistic could be derived from a meta-
analysis. The aforementioned bivariate or univariate meta-analyses can be done for each 
threshold separately, to give a summary of sensitivity and specificity at each, enabling a 
summary ROC curve to be plotted and the area under it gives a summary C statistic. 
Alternatively, and perhaps preferably, a C statistic can be obtained for each study 
separately and then pooled to give a summary C statistic. This is the approach taken 
here, and the C statistic estimates are combined in a random-effects meta-analysis (see 
1.4.2.4) to obtain an average C statistic [27], with the C statistic analysed on its original 
scale as recommended by Klaveren et al. [27]. The random-effects model can be written 
as: 
𝑐𝑖 ~ 𝑁(𝜃𝑖 , 𝑠𝑖
2) 
𝜃𝑖~ 𝑁(𝜇𝑐, 𝜏𝑐
2) 
(Equation 4.8) 
Where 𝑐𝑖 is the 𝐶 estimate in study 𝑖 and 𝑠𝑖
2 is its variance, which is assumed to be 
known; 𝜃𝑖 if the true 𝐶 statistic in study 𝑖, which is assumed to be from a normal 
distribution with a mean of 𝜇𝑐 and between-study variance 𝜏𝑐
2. 
A 95% prediction interval for this C statistic, which gives a range for the predicted 
value of the C statistic in a new study, is approximately: 
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μ̂ −  tk−2√τ̂2 +  SE(μ̂)2,  μ̂ +  tk−2√τ̂2 +  SE(μ̂)2 
(Equation 4.9) 
Where μ̂ is the estimate of the average C statistic across studies from the random-effects 
meta-analysis, SE(μ̂) is the standard error of μ̂, τ̂ is the estimate of between-study 
standard deviation, tk−2 is the 100(1 − α 2⁄ ) percentile of the t-distribution with k-2 
degrees of freedom, where k is the number of studies in the meta-analysis, and α is 
usually chosen as 0.05, to give a 5% significance level and thus 95% prediction interval 
[32]. 
4.5 Results 
In this section, presented and compared are the results of the unstratified, univariate 
meta-analysis and bivariate meta-analysis approaches described in 4.4. There are three 
comparisons (i) t-test analysis, (ii) sensitivity and specificity, and (iii) C statistic, with 
each done at every time-point that PTH was measured. 
Firstly, Table 4.3 summarises the data available, and the t-test results for any difference 
of mean PTH values in hypocalcaemic and normocalcaemic patients.  
Table 4.3: Summary of the PTH values before and after thyroidectomy pooled across the 6 studies 
and in each study separately 
Patients Preoperative  P-value 
H0:d=0 
Ha:d≠0 
0-20 
minutes  
P-value 
H0:d=0 
Ha:d≠0 
1-2 hrs  P-value 
H0:d=0 
Ha:d≠0 
6 hrs  P-value 
All 59.57 ± 
31.51  
(n=292) 
 29.91 ± 
24.35 
(n=256) 
 28.52± 
24.41 
(n=169) 
 24.80± 
20.23 
(n=84) 
 
Normocalcaemic 60.48 ± 
32.37 
(n=232) 
P=0.17 34.24 ± 
24.16 
(n=209) 
P<0.0001 36.08± 
23.66 
(n=124) 
P<0.0001 34.41± 
17.59 
(n=56) 
P<0.0001 
Hypocalcaemic 56.03 ± 
28.35 
(n=60) 
10.66 ± 
13.56 
(n=47) 
7.70± 
10.32 
(n=45) 
4.52 ± 
3.31 
(n=28) 
McLeod[144] 
Normocalcaemic 
75.81 ± 
38.93 
(n=46) 
P=0.35 37.57 ± 
21.54 
(n=43) 
P=0.0002 36.76 ± 
17.45 
(n=25) 
P<0.0001   
McLeod[144] Hypocalcaemic 71.41 ± 
24.59  
13.97 ± 
11.23 
8.28 ± 
5.71 
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Patients Preoperative  P-value 
H0:d=0 
Ha:d≠0 
0-20 
minutes  
P-value 
H0:d=0 
Ha:d≠0 
1-2 hrs  P-value 
H0:d=0 
Ha:d≠0 
6 hrs  P-value 
(n=14) (n=13) (n=12) 
Warren 2002[145] 
Normocalcaemic 
50.41 ± 
17.43 
(n=12) 
P=0.63 38.47 ± 
28.04 
(n=18) 
P=0.12 41.93 ± 
36.26 
(n=14) 
P=0.39   
Warren 2002[145] 
Hypocalcaemic 
54.53 ± 
28.83 
(n=4) 
20.10 ± 
26.10 
(n=4) 
34.00 ± 
38.18 
(n=2) 
  
Warren 2004[146] 
Normocalcaemic 
65.41 ± 
35.12 
(n=23) 
P=0.93 37.57 ± 
21.54 
(n=43) 
P=0.26 36.76 ± 
17.45 
(n=25) 
P=0.05   
Warren 2004[146] 
Hypocalcaemic 
99.70 ± 
55.15  
(n=3) 
28.80 ± 
32.44 
(n=3) 
18.33 ± 
17.10 
(n=3) 
  
Lam[141] Normocalcaemic 45.56 ± 
33.16 
(n=27) 
P=0.71   33.00 ± 
21.24 
(n=26) 
P<0.0001 36.04 ± 
20.00 
(n=23) 
P<0.0001 
Lam[141] Hypocalcaemic 51.83 ± 
27.76 
(n=12) 
  3.83 ± 
1.95 
(n=12) 
3.92 ± 
2.39 
(n=12) 
Lo[142] Normocalcaemic 60.17 ± 
29.42 
(n=89) 
P=0.09 28.16 ± 
20.89 
(n=89) 
P<0.0001     
Lo[142] Hypocalcaemic 47.97 ± 
20.26 
(n=11) 
1.86 ± 
3.24 
(n=11) 
    
Lombardi[143] 
Normocalcaemic 
52.87 ± 
21.98 
(n=35) 
P=0.07 35.90 ± 
18.32 
(n=35) 
P<0.0001 32.04 ± 
16.65 
(n=35) 
P<0.0001 33.30 ± 
15.99 
(n=34) 
P<0.0001 
Lombardi[143] 
Hypocalcaemic 
43.44 ± 
19.80 
(n=16) 
8.26 ± 
4.20 
(n=16) 
4.87 ± 
3.73 
(n=16) 
5.01 ± 
3.91 
(n=16) 
#P-values from t-test, d represents the difference in means 
4.5.1 Comparison of mean values  
i) t-test at each time point (unstratified approach) 
Two-sample mean comparison test results are shown in Table 4.3 with the p-values next 
to their corresponding groups that have been tested. When all the IPD is put together 
and analysed unstratified, a p-value of 0.17 is obtained for the difference between the 
means of normocalcaemic and hypocalcaemic patients at the preoperative level. This 
indicates there is not a statistically significant difference present here. For the other 
three time points, they have all got p-values <0.0001 which indicate there is a 
statistically significant difference present between the means of normocalcaemic and 
hypocalcaemic patients. PTH values are lower for hypocalcaemia patients. This result is 
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encouraging as it suggests that PTH is a potential predictive factor (i.e. low levels are 
associated with being hypocalcaemic) when measured post-surgery. 
ii) t-test repeated for each study separately 
When looking at each study separately for the preoperative level (Table 4.3), none of 
the six studies which have the preoperative PTH levels have a statistically significant p-
value for difference of means between normocalcaemic and hypocalcaemic patients, 
although the Lo [142] study (p=0.09) and Lombardi [143] (p=0.07) have very low p-
values that are close to significance. 
For the 0-20 minutes time point (Table 4.3): McLeod [144], Lo [142] and Lombardi 
[143] have a very small p-value that is statistically significant and shows a visible 
difference in means, whereas the Warren 2002 & 2004 [145, 146] studies do not have 
statistically significant p-values. 
For the 1-2 hour time point (Table 4.3): McLeod [144], Lam [141] and Lombardi[143] 
all have very small p-values that are statistically significant in showing there is a 
difference in means of normocalcaemic and hypocalcaemic patients. Warren 2002 [145] 
study has a p=0.39 which is not statistically significant and Warren 2004 [146] has a 
p=0.05 which is borderline significant. 
For the 6 hour time point (Table 4.3): Lam [141] and Lombardi [143] studies have all 
got very small p-values that are statistically significant for difference of means between 
normocalcaemic and hypocalcaemic patients. 
In summary, building on the unstratified analysis of Noordzij et al, these results show 
that for the majority of studies there is a statistically significant difference between the 
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post-operative PTH means of normocalcaemic and hypocalcaemic patients. This 
strongly indicates again that PTH is a prognostic factor, but discriminative ability for 
individual patients is better summarised by sensitivity, specificity and the C statistic. 
4.5.2 Sensitivity and Specificity 
4.5.2.1 Comparison of discrimination results at 0-20 minutes 
Table 4.4 shows the univariate and bivariate meta-analysis pooled results and 
confidence intervals are generally very similar to the unstratified analysis for both 
sensitivity and specificity. However, the confidence intervals are slightly wider in the 
meta-analysis approaches, as they additionally include the between-study heterogeneity 
which is often non-zero. Also, at a 90% PTH decrease, the summary sensitivity is much 
lower in the meta-analysis approaches e.g. the sensitivity is 20.27% in univariate meta-
analysis and 34.04% in the unstratified analysis, showing that the unstratified approach 
can indeed give different summary results. Similarly, specificity is higher in the meta-
analysis than the unstratified analysis from the thresholds 60%-72%. The results 
between unstratified analysis and meta-analysis are fairly similar and only differ 
substantially at the 90% threshold where there is between-study heterogeneity present 
(4.33 and 3.41 for univariate and bivariate respectively) in the sensitivity values. In 
most analyses heterogeneity is close to zero for sensitivity, but above 0.2 for specificity. 
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Table 4.4: Sensitivity and Specificity of PTH assay in predicting postoperative hypocalcaemia for 0-
20 minutes: unstratified, univariate and bivariate results 
0-20 minutes Summary 
Sensitivity 
95% CI Summary 
Specificity 
95% CI Ʈ2Sens Ʈ
2
Spec Between-
study 
Correlation 
% PTH 
Decrease 
Lower Upper Lower Upper    
Unstratified analysis         
>40 93.62 82.84 97.81 44.06 37.39 50.95 - - - 
>50 93.62 82.84 97.81 56.44 49.54 63.09 - - - 
>60 85.11 72.31 92.59 70.79 64.18 76.63 - - - 
>65 80.85 67.46 89.58 74.26 67.81 79.79 - - - 
>70 80.85 67.46 89.58 75.74 69.39 81.14 - - - 
>72 80.85 67.46 89.58 76.73 70.44 82.03 - - - 
>80 68.09 53.83 79.60 85.64 80.14 89.81 - - - 
>90 34.04 22.17 48.33 95.54 91.75 97.64 - - - 
Univariate meta-analysis         
>40 93.62 82.00 97.93 46.75 35.83 58.00 0.00 0.13 - 
>50 93.62 82.00 97.93 56.44 49.52 63.11 0.00 0.00 - 
>60 85.11 71.91 92.73 75.58 63.36 84.72 0.00 0.20 - 
>65 80.85 67.12 89.72 79.05 67.03 87.50 0.00 0.24 - 
>70 80.85 67.12 89.72 79.78 68.59 87.70 0.00 0.20 - 
>72 80.85 67.12 89.72 81.55 69.71 89.46 0.00 0.27 - 
>80 70.21 55.78 81.50 85.15 79.55 89.42 0.00 0.00 - 
>90 20.27 2.51 71.53 96.17 89.29 98.69 4.33 0.27 - 
Bivariate meta-analysis         
>40 94.00 81.32 98.26 47.01 36.03 58.29 0.09 0.13 -1 
>50 93.62 82.00 97.93 56.44 49.52 63.11 0.00 0.00 -0.98 
>60 85.19 67.94 93.98 75.86 63.93 84.79 0.34 0.20 -1 
>65 81.69 63.22 92.05 79.10 67.71 87.23 0.34 0.21 -1 
>70 81.91 62.94 92.36 79.96 69.30 87.58 0.34 0.21 -1 
>72 82.21 63.42 92.49 81.62 70.44 89.22 0.37 0.24 -1 
>80 70.64 54.78 82.69 85.88 78.87 90.83 0.07 0.03 -1 
>90 23.98 3.96 70.70 96.42 91.16 98.60 3.41 0.10 -0.99 
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Figure 4.1: ROC curves comparing the unstratified and meta-analysis approaches for 0-20 minutes 
                               
Figure 4.1 illustrates the difference between the three methods is generally small in 
terms of the actual estimates of sensitivity and specificity. However, the C statistic 
(AUC) is slightly higher for the bivariate meta-analysis compared to the unstratified and 
univariate approaches (0.85 compared to 0.84).  
In summary of the analysis of PTH at 0-20 minutes post-surgery, differences in 
unstratified and meta-analysis approaches are often small, but can occur for the 
summary sensitivity and specificity, especially when there is between-study 
heterogeneity, which can further impact upon the summary ROC and AUC. Here the 
unstratified approach is slightly lower in terms of the summary specificity between 
thresholds 60 to 72, and assumes no between-study heterogeneity when often it exists.  
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The univariate and bivariate results are generally very similar, but interestingly the 
correlation in the bivariate models is often poorly estimated at -1 [152]. The bivariate 
approach is therefore perhaps unnecessarily complex here. 
Table 4.5: Table for Youden’s statistic comparing the different approaches for 0-20 minutes 
0-20 minutes Youden’s statistic 
% PTH Decrease Unstratified analysis Univariate meta-analysis Bivariate meta-analysis 
>40 37.68 40.37 41.01 
>50 50.06 50.05 50.06 
>60 55.90 60.69 61.05 
>65 55.11 59.90 60.79 
>70 56.59 60.64 61.87 
>72 57.58 62.40 63.83 
>80 53.73 55.36 56.52 
>90 29.58 16.43 20.40 
Table 4.5 shows that unstratified and meta-analysis approaches find that Youden’s 
statistic is at its highest for the cut off of 72% PTH decrease, which is encouraging as it 
agrees with the original authors’ conclusion about the best threshold. This assumes 
sensitivity and specificity are equally important in this clinical setting as Noordzij did, 
but this may not be true (see Chapter 5, section 5.5). 
4.5.2.2 Comparison of sensitivity and specificity at 1-2 hours and 6 hours 
Results for sensitivity and specificity using PTH at 1-2 hours and 6 hours are 
summarised in Tables 4.6 to 4.9, and Figures 4.2-4.3. Generally there is very little 
difference between the unstratified, univariate and bivariate approaches, as the between-
study heterogeneity for all thresholds is very small or zero. The bivariate model again 
struggles to estimate the correlation, and all methods agree about the optimal choice of 
threshold.  
As threshold increases, sensitivity should decrease. However, interestingly in Table 4.6 
and Table 4.8, the bivariate results give a larger sensitivity at 50% than 40% (and also 
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70% is higher than 65% in Table 4.6). This occurs because Ʈ2Sens changes at each 
threshold and this impacts the pooled result. 
Table 4.6: Sensitivity and Specificity of PTH assay in predicting postoperative hypocalcaemia for 1-
2 hours: unstratified, univariate and bivariate results 
1-2 hours Summary 
Sensitivity 
95% CI Summary 
Specificity 
95% CI Ʈ2Sens Ʈ
2
Spec Correlation 
% PTH 
Decrease 
Lower Upper Lower Upper    
Unstratified analysis         
>40 95.56 85.17 98.77 52.14 43.16 60.98 - - - 
>50 95.56 85.17 98.77 63.25 54.22 71.43 - - - 
>60 95.56 85.17 98.77 80.34 72.23 86.53 - - - 
>65 93.33 82.14 97.71 81.20 73.17 87.24 - - - 
>70 93.33 82.14 97.71 88.03 80.91 92.74 - - - 
>72 89.36 77.41 95.37 89.74 82.93 94.04 - - - 
>80 77.78 63.73 87.46 93.46 87.11 96.80 - - - 
>90 55.56 41.18 69.06 100.0 96.82 100.00 - - - 
Univariate meta-analysis         
>40 95.56 83.89 98.89 52.14 43.11 61.02 0.00 0.00 - 
>50 95.56 83.89 98.89 63.31 53.83 71.85 0.00 0.01 - 
>60 95.56 83.89 98.89 80.34 72.15 86.57 0.00 0.00 - 
>65 93.33 81.27 97.83 82.19 74.69 88.86 0.00 0.02 - 
>70 93.33 81.27 97.83 88.03 80.81 92.78 0.00 0.00 - 
>72 88.89 75.95 95.30 89.74 82.80 94.08 0.00 0.00 - 
>80 77.78 63.41 87.61 94.02 87.98 97.12 0.00 0.00 - 
>90 55.56 40.98 69.24 100.00 Not 
given 
100.00 0.00 0.06 - 
Bivariate meta-analysis         
>40 95.60 83.14 98.97 52.23 42.68 61.63 0.05 0.01 -1 
>50 95.92 79.58 99.30 63.16 53.00 72.28 0.30 0.03 1 
>60 95.56 83.89 98.89 80.34 72.15 86.57 0.00 0.00 0.55 
>65 92.90 78.16 97.95 82.59 71.41 90.01 0.15 0.07 1 
>70 93.33 81.27 97.83 88.03 80.81 92.78 0.00 0.00 1 
>72 88.89 75.95 95.30 89.74 82.80 94.08 0.00 0.00 -1 
>80 77.80 63.14 87.77 94.12 87.19 97.42 0.02 0.04 1 
>90 55.56 40.98 69.24 100.00 Not 
given 
100.00 0.00 4.66 -0.06 
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Figure 4.2: ROC curves comparing the unstratified and meta-analysis approaches for 1-2 hours 
 #The differences are barely visible due to near identical curves, as they are superimposed on each other 
Table 4.7: Table for Youden’s statistic comparing the univariate approach to the unstratified 
approach for 1-2 hours 
1-2 hours Youden’s statistic 
% PTH Decrease Unstratified analysis Univariate meta-analysis Bivariate meta-analysis 
>40 47.70 47.69 47.83 
>50 58.81 58.86 59.08 
>60 75.90 75.90 75.90 
>65 74.53 75.53 75.49 
>70 81.36 81.37 81.36 
>72 79.10 78.63 78.63 
>80 71.24 71.80 71.92 
>90 55.56 55.56 55.56 
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Table 4.8: Sensitivity and Specificity of PTH assay in predicting postoperative hypocalcaemia for 6 
hours: unstratified, univariate and bivariate results 
6 hours Summary 
Sensitivity 
95% CI Summary 
Specificity 
95% CI Ʈ2Sens Ʈ
2
Spec Correlation 
% PTH 
Decrease 
Lower Upper Lower Upper    
Unstratified analysis         
>40 96.43 82.29 99.37 63.16 50.18 74.48 - - - 
>50 96.43 82.29 99.37 75.44 62.90 84.77 - - - 
>60 96.43 82.29 99.37 85.96 74.68 92.71 - - - 
>65 96.43 82.29 99.37 91.23 81.06 96.19 - - - 
>70 92.86 77.35 98.02 92.98 83.30 97.24 - - - 
>72 89.29 72.80 96.29 94.74 85.63 98.19 - - - 
>80 78.57 60.46 89.79 94.74 85.63 98.19 - - - 
>90 60.71 42.41 76.43 98.25 90.71 99.69 - - - 
Univariate meta-analysis         
>40 96.43 78.58 99.50 63.16 50.02 74.60 0.00 0.00 - 
>50 96.43 78.58 99.50 75.44 62.69 84.88 0.00 0.00 - 
>60 96.43 78.58 99.50 85.97 74.36 92.82 0.00 0.00 - 
>65 96.43 78.58 99.50 91.23 80.60 96.30 0.00 0.00 - 
>70 92.86 75.52 98.21 92.98 82.75 97.34 0.00 0.00 - 
>72 90.70 58.83 98.52 94.79 84.73 98.35 0.27 0.00 - 
>80 78.89 56.57 91.47 94.75 84.84 98.31 0.02 0.00 - 
>90 60.71 41.99 76.74 98.25 88.57 99.75 0.00 0.00 - 
Bivariate meta-analysis         
>40 96.32 79.44 99.44 63.39 47.31 76.95 0.25 0.04 1 
>50 96.43 78.58 99.50 75.44 62.69 84.88 0.00 0.00 1 
>60 96.43 78.58 99.50 85.97 74.36 92.82 0.00 0.00 1 
>65 96.43 78.58 99.50 91.23 80.60 96.30 0.00 0.00 0.14 
>70 92.86 75.52 98.21 92.98 82.75 97.34 0.00 0.00 -1 
>72 90.70 58.83 98.52 94.79 84.73 98.35 0.31 0.01 1 
>80 78.89 56.57 91.47 94.75 84.84 98.31 0.04 0.00 1 
>90 60.71 41.99 76.74 98.25 88.57 99.75 0.00 0.00 1 
Figure 4.3: ROC curves comparing the unstratified and meta-analysis approaches for 6 hours 
  #Only one is visible as all three ROC curves are identical, they are superimposed on each other 
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Table 4.9: Table for Youden’s statistic comparing the two approaches for 6 hours 
6 hours Youden’s statistic 
% PTH Decrease Unstratified analysis Univariate meta-analysis Bivariate meta-analysis 
>40 59.59 59.71 59.71 
>50 71.87 71.87 71.87 
>60 82.39 82.39 82.40 
>65 87.66 87.66 87.66 
>70 85.84 85.84 85.84 
>72 84.03 85.49 85.49 
>80 73.31 73.65 73.64 
>90 58.96 58.96 58.96 
 
4.5.3 C statistic 
The ROC curves for each method at each time-point of PTH measurement are presented 
in Figures 4.4-4.6. Due to the similar results from all three approaches, the curves were 
either very close or super-imposed. Now, the C statistic is compared for the unstratified 
and meta-analysis methods. 
(i) Unstratified summary ROC curves 
Figures 4.4-4.6 show the unstratified summary ROC curves for PTH measured at 0-20 
minutes (C statistic=0.86 (0.80, 0.93)), 1-2 hours (C statistic=0.90 (0.85, 0.94)) and 6 
hours (C statistic=0.88 (0.82, 0.95)). 
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Figure 4.4: 0-20 minutes unstratified ROC curve 
 
Figure 4.5: 1-2 hours unstratified ROC curve 
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Figure 4.6: 6 hours unstratified ROC curve 
 
(ii) Meta-analysis of C statistics 
Table 4.10 shows the C statistic estimate for each study at each time-point along with its 
95% confidence interval. Figures 4.7-4.9 display the ROC curves for each study at each 
time-point. 
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Table 4.10: C statistic for each study, within each time-point 
Study C statistic 95% CI Standard Error 
  Lower Upper   
0-20 Minutes     
McLeod 0.86 0.74 0.97 0.06 
Warren 02 0.70 0.35 1.00 0.18 
Warren 04 0.88 0.74 1.00 0.07 
Lo 0.96 0.92 1.00 0.02 
Lombardi 0.92 0.84 1.00 0.04 
1-2 hours     
McLeod 0.94 0.87 1.00 0.03 
Warren 02 0.63 0.00 1.00 0.38 
Warren 04 0.93 0.82 1.00 0.05 
Lam 1.00 1.00 1.00 0.00 
Lombardi 0.94 0.87 1.00 0.04 
6 hours     
Lam 0.98 0.94 1.00 0.02 
Lombardi 0.95 0.89 1.00 0.03 
 
Figure 4.7: 0-20 minutes study-specific ROC curves 
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Figure 4.8: 1-2 hours study-specific ROC curves 
 
Figure 4.9: 6 hours study-specific ROC curves 
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A random effects meta-analysis (Equation 1.15) of the C statistic from each study was 
done for each time-point, and the results are summarised in Table 4.11. The summary C 
statistic is larger as time goes on; it is improving its accuracy in discriminating between 
those patients who are hypocalcaemic and those whom are not. This is expected, as the 
later times are closer to when the true diagnosis of hypocalcaemia is made. Although 
there is heterogeneity in the C statistic across studies, the 95% prediction interval 
suggests it will be above 0.77 in most applications, and so will always be at least 
moderately high. Crucially, this finding is hidden when just looking at the C statistic 
from the unstratified approach or the C statistic for the summary ROC curves from the 
univariate or bivariate meta-analysis, as heterogeneity in the C statistic is not directly 
modelled. 
Table 4.11: C statistic random-effects meta-analysis  
   95% CI 95% Prediction 
Interval 
 
Time 
point 
No of 
studies 
Summary C 
statistic 
Lower Upper Lower Upper Tau-
squared 
0-20 min 5 0.92 0.86 0.97 0.77 1.00 <0.001 
1-2 hour 5 0.94 0.89 0.99 0.84 1.00 <0.001 
6 hour 2 0.97 0.94 1.00 # # <0.001 
#Not able to estimate as <3 studies 
Table 4.12: C statistic meta-analysis across all studies 
Approaches Unstratified 95% CI Meta-analysis 
of  
 
95% CI 
Time point C statistic Lower Upper C statistic Lower Upper 
0-20 min 0.86 0.80 0.95 0.92 0.86 0.97 
1-2 hour 0.90 0.85 0.94 0.94 0.89 0.99 
6 hour 0.88 0.82 0.95 0.97 0.94 1.00 
Table 4.12, presents the C statistics calculated in this chapter, the first-third columns 
refer to the unstratified results and the fourth-sixth columns refer to the values in Table 
4.11. Both the approaches give similar C statistic for 1-2 hours and 6 hours, but 0-20 
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minutes is different with the meta-analysis value being higher 0.92 compared to 0.84. 
This is mainly because specificity is often estimated lower in the unstratified analysis 
compared to meta-analysis results, between thresholds 60 to 72, which in turn reduces 
the C statistic. Note: that that observed C statistics are larger from the meta-analysis 
approach compared to the unstratified approach, even though the 95% confidence 
intervals overlap considerably. 
4.6 Discussion 
In the systematic review of chapter 3 a major finding was that, when modelling risk 
prediction using IPD from multiple studies, most studies ignored clustering. To 
investigate this issue, and the potential consequences on the findings, in this chapter the 
unstratified analysis performed by Noordzij et al. [94] was replicated and compared to 
univariate and bivariate meta-analysis results that account for clustering. The focus has 
been on a single predictor and its discriminatory ability in terms of t-test results and, 
more importantly, the summary sensitivity, specificity and C statistics.  
Methodology findings 
The main methodological message from this work is that discrimination results are 
often similar for the unstratified and meta-analysis approaches, however important 
differences can arise especially when there is heterogeneity. This was most evident in 
the PTH results at 0-20 minutes. At a 90% PTH decrease, the summary sensitivity is 
20.27% in univariate meta-analysis and 34.04% in the unstratified analysis. Even when 
summary pooled estimates are very similar, the unstratified approach gives too narrow 
confidence intervals. Further a novel finding is that a meta-analysis of C statistics can 
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obtain a different summary C statistic than the area under the summary ROC curve from 
either an unstratified, univariate or bivariate meta-analysis. For example, for PTH at 0-
20 minutes, the summary C statistic when using meta-analysis was 0.92, but 0.84 in the 
unstratified analysis. Further, correlation is poorly estimated in most meta-analyses 
when there is little heterogeneity and the same threshold is used in each study; thus the 
bivariate method used by the Cochrane Collaboration for pooling test accuracy reviews 
may be unnecessary, and could often be replaced with univariate meta-analysis. 
Clinical findings 
The ROC curves and tables for specificity and sensitivity for 1-2 hours and 6 hours 
suggest these two time points were very good in terms of the PTH assay being able to 
accurately discriminate between patients who get hypocalcaemia and those who do not, 
compared to the 0-20 minute’s time point which was less accurate. This is backed -up 
by a meta-analysis of the C statistic from each study, which found that the C statistic 
improves as time goes on (0-20 minutes: 0.92, 1-2 hours: 0.94 and 6 hours: 0.97) and 
the 95% CI gets narrower (see Table 4.11). The 95% prediction interval provided in 
Table 4.11 also suggests that the C statistic will be above 0.77 in most applications, and 
so will always be high as that is the lower bound for 0-20 minutes. Further, at thresholds 
around 65%, when PTH is measured 1-6 hours post-surgery, there is very little 
heterogeneity in sensitivity and specificity performance. Thus, the meta-analysis 
findings would appear to generally agree with the unstratified findings of Noordzij et al. 
[94]: “Patients identified as low risk for hypocalcemia could be discharged sooner. 
Conversely, patients identified as high risk for hypocalcemia developing could be 
treated earlier, potentially shortening the duration of their hypocalcemic symptoms and 
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hospitalization.” However, this will also be evaluated in terms of calibration in Chapter 
5. 
4.6.1 Limitations 
The limitations in this chapter were regarding the data used. Not all studies provided 
pre-operative PTH levels so three studies were not used in the analysis as PTH % 
reduction was examined from the time-point compared to the preoperative level. No 
other variables or factors were provided as part of the dataset, so only PTH was 
available, thus rendering it not possible to assess the addition of possibly important 
factors such as age, sex, or diet.  
A further limitation is that there is only one example to base methodology conclusions 
on; in particular, this dataset has very little to no heterogeneity and differences between 
unstratified and meta-analysis approaches are likely to be more dramatic in other 
datasets that contain more heterogeneity across studies. 
4.6.2 What this chapter adds? 
This chapter has shown that PTH values measured between 1-6 hours are a good 
discriminator, and using the average sensitivity and specificity values from meta-
analysis is fine in this situation, as there is little to no heterogeneity present in these 
values when going from study to study for most thresholds. But there are papers that 
highlight the need to account for clustering in IPD meta-analysis [102]. Table 4.14 
summarises what the problem is, what this study adds and what is required next. 
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Table 4.13: What Chapter four adds? 
What is known / what is the problem? 
 Investigated the issue of clustering by obtaining data from an article from the systematic review 
in Chapter 3 
 The original analysis was performed by Noordzij and disregarded clustering  
 Heterogeneity was not assessed or considered within the IPD from multiple studies 
What this study adds? 
 This compares the original unstratified values to a meta-analysis version of the same values for 
sensitivity, specificity and C statistic and how clustering affects these values  
 Not much difference was found between these values due to almost no heterogeneity in the 
estimates  
 A key contribution is this study has found there is no heterogeneity in the data as this is very 
important to know, otherwise it would be very difficult to generalise these results across 
populations (important for a predictive test)  
 On average discrimination stays the same; at the key thresholds there is no heterogeneity which 
shows the values are consistent across settings  
 65% found to be the optimal threshold using Youden’s J statistic, backing up the original 
conclusions [94], assuming sensitivity and specificity are equally important 
 Univariate and bivariate meta-analysis results were are often similar to unstratified results for 
sensitivity and specificity with a few occasional discrepancies 
 Bivariate estimates of heterogeneity are greater than univariate estimates of heterogeneity for 
sensitivity and specificity; important as more heterogeneity leads to wider confidence intervals 
for summary results  
 But correlation is poorly estimated in bivariate results 
 Important to use a meta-analysis approach to account for clustering 
 Heterogeneity in sensitivity and specificity needs to be quantified: a predictive test is preferred if 
it is consistently good in terms of discrimination across populations 
 Prediction intervals allow the computation of the range of potential C, sensitivity and specificity 
values across populations 
 Novel to combine C statistics in this manner, by assessing the values in each dataset and meta-
analysing; and not using the overall value  
 This analysis has shown that by using a meta-analysis approach to summarise values such as C 
statistic are better (higher, which indicate better discriminative ability) than using the unstratified 
approach, as shown in Table 4.12  
 An important finding, as it is common in literature to collect IPD and then use an unstratified 
approach for analysis, as found in Chapter 3 
What is needed next? 
 This analysis has shown that the original analysis indicated PTH is a good predictive factor 
across all studies on average  
 But its ability in making individualised predictions in each study was not assessed 
 In Chapter 5, this important extension is assessed for the calibration of this predictive test 
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 UNSTRATIFIED VERSUS META-CHAPTER 5:
ANALYSIS APPROACHES FOR EVALUATING 
PREDICTIVE TEST ACCURACY USING IPD: 
PART II – CALIBRATION AND CHOICES OF 
THRESHOLD 
5.1 Introduction and objectives 
Sensitivity, specificity, ROC curves and C Statistics mainly inform the discriminate 
ability of a test for distinguishing between diseased and non-diseased. However, they do 
not fully reveal whether a test will be useful for making accurate predictions; in other 
words, whether the predicted probability of having an outcome is well calibrated for 
individuals. For a predictive test, calibration can be investigated by obtaining the 
observed number of events (O) and comparing it to the expected number of events (E) 
from the test, by using the E/O ratio (Expected/Observed). This was introduced in 
section 1.3.2.3. An assessment of calibration is therefore required to build on the 
examination of discrimination in Chapter 4. In Chapter 4, it was found that sensitivity 
and specificity have very little to no heterogeneity. Where heterogeneity exists, this can 
be accounted for by using random-effects models that allow variability across studies 
[153, 154]. But, the aim of a meta-analysis is to estimate the average performance of a 
test across all the populations. The objective is to translate these average meta-analysis 
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results about PTH into clinical practice. However, calibration also depends on 
prevalence of disease outcome, which is needed to derive PPV and NPV, and thus the 
expected numbers with and without the outcome. If the outcome prevalence is very 
different in a particular population in comparison to the average outcome prevalence 
across all populations, the post-test probabilities (PPV & NPV) may be inaccurate. This 
chapter consider methods to formally evaluate this issue. For example, one method 
considered is an internal-external cross-validation (IECV) approach for examining how 
to use existing meta-analysis results to derive PPV and NPV for use in particular 
clinical populations. The IECV framework provides the opportunity to examine the 
calibration performance of approaches (or statistical equations) that will tailor (or 
predict) a test’s meta-analysis results for use in clinical practice. Application is made to 
the PTH test introduced in Chapter 4, and thus the IECV method may help to examine 
the calibration of PPV and NPV results for the PTH test for use in clinical practice. 
In Chapter 3, in terms of model validation, it was found that rarely is external validation 
performed, with internal validation being preferred. A few papers used Royston’s IECV 
approach [101]. Recall that this is a novel approach that involves removing one study 
from the development phase of the model, then fitting the model on the remaining data, 
taking the average parameter estimate values and testing performance in the excluded 
study. The final step involves repeating this process by rotating the omitted study and 
assessing the validation in all the possible scenarios. The IECV method will be used in 
the novel setting of test accuracy here. An approach to determine the 'best threshold' 
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will also be investigated, which will build on the unstratified highest sum of sensitivity 
and specificity method used by Noordzij et al. [94].  
5.2 Statistical methods for summarising calibration 
To translate meta-analysis results to an individualised probability, one can combine the 
sensitivity and specificity pooled results from Chapter 4 (Equations 4.2 and 4.3)  with 
the prevalence of hypocalcaemia, using the formula given in Equations 5.1 and 5.2 
(given below), to give PPV and NPV.  
The issue is, however, what prevalence to use? Noordzij et al [94] used the prevalence 
in the overall dataset which is 0.20; however they do not consider heterogeneity, as 
prevalence may vary from study to study, across clinical settings. Thus, heterogeneity is 
assessed and different options for prevalence are considered in this chapter. The IECV 
approach is then introduced as a way to evaluate the approaches further. 
5.2.1 Approaches for assessing calibration 
At each threshold, the pooled PPV and NPV can be estimated by substituting suitable 
values for the sensitivity, specificity and prevalence within Equations 5.1 and 5.2. There 
are six approaches that are considered and summarised as follows. Note, we do not 
consider the summary bivariate meta-analysis results from here on, due to their 
similarity with the univariate meta-analysis results and the difficulty estimating the 
between-study correlation. 
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5.2.1.1 Approach 1: Unstratified 
The unstratified values of sensitivity, specificity and prevalence are used to calculate 
PPV and NPV from Equations 5.1 and 5.2. In other words, PPV and NPV are calculated 
by taking the prevalence of hypocalcaemia in the unstratified data, and combining with 
the unstratified sensitivity and specificity, in the following equations: 
PPV =  
(sensitivity) ∗ (prevalence)
(sensitivity) ∗ (prevalence) +  (1 − specificity) ∗ (1 − prevalence)
 
= predicted probability of developing hypocalcaemia for a patient who is test positive 
Also, from a 2 by 2 table (Table 4.2): 
𝑃𝑃𝑉 =  
𝑎
𝑎 + 𝑏
 
(Equation 5.1) 
NPV =  
(specificity) ∗ (1 − prevalence)
(specificity) ∗ (1 − prevalence) + (1 − sensitivity) ∗ (prevalence)
 
= predicted probability of not developing hypocalcaemia for a patient who is test 
 negative 
Also, from a 2 by 2 table (Table 4.2): 
𝑁𝑃𝑉 =  
𝑑
𝑐 + 𝑑
 
(Equation 5.2) 
These predicted probabilities from (5.1) and (5.2) can be examined with the observed 
outcome risk using the Expected/Observed (E/O) ratio. For example for test positive 
patients the expected number of hypocalcaemia cases is: 
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Expected =  (PPV) ∗ (Number of patients testing positive in the PTH test)(Equation 
And for test negative patients it is: 
Expected =  (1 −  NPV) ∗ (Number of patients testing negative in the PTH test)
= E2 
(Equation 5.4) 
And therefore total expected 𝐸 = 𝐸1 + 𝐸2 
(Equation 5.5) 
The E/O (Expected/Observed) ratio can then be easily obtained, where E refers to the 
total expected number of events or patients as predicted by the model and O refers to the 
total observed number of events or patients. To work out the 95% confidence interval 
for the E/O ratio, this formula was used, where p = Observed/n(total) and is given 
approximately by [155]: 
95% 𝐶𝐼 =  
𝐸
𝑂
 ∗  𝑒
(±1.96∗ √
1−𝑝
𝑛𝑝
)
 
(Equation 5.6) 
Where √
1−𝑝
𝑛𝑝
 is the standard error of ln(E/O). 
5.2.1.2 Approach 2: Univariate summary sensitivity and specificity, and univariate 
summary prevalence 
The summary meta-analysis values for sensitivity, specificity and prevalence (see 
Equation 5.7) are used to calculate PPV and NPV, by plugging their values into 
Equations 5.1 and 5.2. In this chapter only univariate meta-analysis results are 
considered, due to their similarity with the bivariate results (see Chapter 4) for 
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sensitivity and specificity. To obtain a meta-analysis summary for the prevalence, 
Equation 5.7 can be performed, using a binomial within-study distribution, to compute 
its average value, the heterogeneity in it, and a 95% prediction interval (Equation 5.8) 
for the prevalence in a single study.  
𝑟𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑖  ~ 𝐵𝑖𝑛 (𝑃𝑟𝑒𝑣𝑖, 𝑁𝐸𝑣𝑒𝑟𝑦𝑜𝑛𝑒𝑖) 
𝐿𝑜𝑔𝑖𝑡 (𝑃𝑟𝑒𝑣𝑖) ~ 𝑁 (𝜃𝑃𝑟𝑒𝑣, 𝜏𝑃𝑟𝑒𝑣
2 ) 
(Equation 5.7) 
Where 𝑟𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑖 is the number of patients with hypocalcemia, 𝑃𝑟𝑒𝑣𝑖 is the prevalence, 
𝑁𝐸𝑣𝑒𝑟𝑦𝑜𝑛𝑒𝑖 represents the total sample in the study 𝑖, 𝜃𝑃𝑟𝑒𝑣 is the average logit-
prevalence across studies, 𝜏𝑃𝑟𝑒𝑣
2  is the between-study heterogeneity in the logit-
prevalence and the index 𝑖 represents the study 𝑖 in the meta-analysis. 
The 95% prediction interval for the prevalence is approximately: 
μ̂ −  tk−2√τ2 +  SE(μ̂)2,  μ̂ +  tk−2√τ2 +  SE(μ̂)2 
(Equation 5.8) 
Where μ̂ is the estimate of the summary prevalence across studies from the random-
effects meta-analysis, SE(μ̂) is the standard error of μ̂, τ is the estimate of between-
study standard deviation, tk−2 is the 100(1 − α 2⁄ ) percentile of the t-distribution with 
k-2 degrees of freedom, where k is the number of studies in the meta-analysis and α is 
usually chosen as 0.05, to give a 5% significance level and thus 95% prediction interval 
[32]. 
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Once PPV and NPV are derived from the meta-analysis, then E and O can be compared 
in each study using Equation 5.5. A random-effects meta-analysis of ln(E/O) can then 
be performed using Equation 1.15. 
5.2.1.3 Approach 3: Univariate summary sensitivity and specificity, lower 
predicted prevalence 
The summary univariate meta-analysis values for sensitivity and specificity (see 
Equations 4.5-4.6) are combined with the lower 95% prediction value for prevalence 
(see Equation 5.8) to calculate PPV and NPV using (5.1) and (5.2). 
5.2.1.4 Approach 4: Univariate summary sensitivity and specificity, upper 
predicted prevalence 
The summary univariate values for sensitivity and specificity (see Equations 4.5-4.6) 
along with the upper 95% prediction value for prevalence (see Equations 5.8) are used 
to calculate PPV and NPV using (5.1) and (5.2). 
These approaches (3 & 4) have been used to simply show the extreme variability in 
deriving PPV and NPV results when using the lower and upper prevalence’s as given by 
the 95% prediction interval. This illustrates what happens when we take a value of 
prevalence that is quite different to the summary (average) prevalence across studies, 
and that – when applying our test accuracy results in practice - we need to be sure that 
the chosen prevalence is pertinent to the population for application. 
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5.2.1.5 Approach 5: Univariate summary sensitivity and specificity, study-specific 
prevalence 
The summary univariate values for sensitivity and specificity (see Equations 4.5-4.6) 
along with the observed prevalence from an individual study are used to calculate PPV 
and NPV via (5.1) and (5.2). The observed prevalence is study-specific, as it is for those 
patients within that study setting. 
5.2.1.6 Approach 6: Internal-external validation 
Approach 6 uses the internal-external cross-validation (IECV) approach to examine 
different choices of the prevalence when tailoring test accuracy results about PPV and 
NPV to the clinical populations of interest. Indeed, all of approaches (1) to (5) can 
rather be embedded in this framework, where a study is omitted so that the performance 
of meta-analysis PPV and NPV results (derived from other studies) is then evaluated in 
it. However, for brevity only approach 5 is examined using IECV (that is, only the use 
of the study-specific prevalence combined with summary meta-analysis results for 
sensitivity and specificity to derive PPV and NPV is evaluated using IECV). To 
generate and validate NPV and PPV within the IECV framework, the following nine 
steps are used: 
i. Select a study l to be excluded 
ii. In the remaining k-1 studies, fit a univariate meta-analysis model (Equations 
4.5-4.6) and obtain summary values for sensitivity and specificity 
iii. Choose a prevalence for the excluded study; here the observed prevalence in 
the excluded study is used (akin to approach 5) 
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iv. Calculate PPV and NPV using the summary sensitivity and specificity 
values from step ii and the prevalence from step iii, by plugging them into 
equations (5.1) and (5.2) 
v. In the excluded study l, calculate total observed (O) and total expected (E) 
outcomes, using equations 5.3-5.5 
vi. In the excluded study, calculate (E/O), ln(E/O) and the standard error of 
ln(E/O) as stated in equation 5.6 
vii. Repeat steps (i) to (vi) for each excluded study, giving a set of k values for 
ln(E/O) and its standard error 
viii. Perform a random-effects meta-analysis of the ln(E/O)l values and then 
transform the results back to (E/O) 
ix. Finally summarise the calibration across all the studies by displaying the 
meta-analysis results of the summary E/O value, its 95% confidence interval 
and a 95% prediction interval in a forest plot 
IECV is considered relevant to Chapter 5 (calibration) but not Chapter 4 
(discrimination), because discrimination is independent of the prevalence (intercept) 
term, as it is based on just the predictors (here, the single predictor of PTH). There is 
not a meta-analysis equation to predict the exact C statistic in a new study (only the 
range of possible C statistic values from a prediction interval), and thus IECV is not 
relevant to examine predictive performance (this is akin to not using IECV in a meta-
analysis of trials that aim to summarise a treatment effect; the meta-analyst may derive a 
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prediction interval for the range of possible treatment effects in a new population, but 
do not usually want to predict the exact new treatment effect).  
However, calibration depends on both the prevalence (intercept) and the predictors, and 
the total equation is used to provide risk predictions. It is then of crucial interest for 
these risk predictions to calibrate well in new data, independent to the data used to 
estimate the predictor effects (and ideally the intercept). Therefore, IECV is more 
important for the calibration, to check whether predictions from the model agree with 
observed risks in new data, and hence why IECV was used in this Chapter 5 but not 4.  
Further, the choice of intercept term in the prediction equation is optional, and the IECV 
allows the user to examine which is the best intercept to take (summary prevalence, or 
tailored prevalence to new population) to improve the accuracy of predictions 
5.3 Results I – Calibration of PPV and NPV 
The six IPD studies available are summarised in Table 5.1. This table was described 
already in detail in Chapter 4 but is presented here again for ease. The prevalence of 
hypocalcaemia varies across studies, from 0.11 to 0.31, and the unstratified prevalence 
in the pooled IPD is 0.20. 
A random-effects meta-analysis of the prevalence estimates, using Equation 5.6, gave 
an average prevalence of 0.22, similar to the prevalence when not accounting for 
clustering in the data, but a 95% prediction interval of 0.09 to 0.42 reveals the 
heterogeneity and that across settings; prevalence could be between 0.09 and 0.42. As 
prevalence can vary considerably across settings, this could affect the calibration 
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performance of the PTH test when applied to individual settings by using the average. 
Note that all six studies have been used in this chapter. But not all six provide data at 
each time point i.e. 0-20 minutes (McLeod, Warren 02, Warren 04, Lo and Lombardi), 
1-2 hours (McLeod, Warren 02, Warren 04, Lam and Lombardi) and 6 hours (Lam and 
Lombardi). 
Table 5.1: Summary of the 6 IPD studies 
Study No of 
patients 
in 
reported 
article 
No of 
events in 
reported 
article 
Outcome 
Prevalence 
in reported 
article 
Prospective? Definition of 
hypocalcaemia 
(equivalent 
cCa (mg/dL)) 
IPD 
provided: 
no. of 
patients 
(events) 
Outcome 
Prevalence 
in IPD 
Times at 
which 
PTH was 
measured 
Lam 2003 
[141] 
40 12 0.30 Yes <7.6 39 (12) 0.31 Pre-op, 1 
and 6 hour 
post-op 
Lo 2002 
[142] 
155 32 0.21 Yes <7.2 100 (11) 0.11 Pre-op and 
intra-op 
Lombardi 
2004 
[143] 
53 16 0.30 Yes <8.0  52 (16) 0.31 Pre-op, 
intra-op, 
2, 4, 6, 24  
and 48 
hour post-
op 
Mcleod 
2006 
[144] 
60 15 0.25 Yes <8.0 60 (14) 0.23 Pre-op, 
intra-op 
and 1 hour 
post-op 
Warren 
2002 
[145] 
53 5 0.09 Yes <8.0 22 (4) 0.18 Pre-op, 
Intra-op 
and 1 hour 
post-op 
Warren 
2004 
[146] 
27 3 0.11 Yes <8.0 27 (3) 0.11 Pre-op, 
intra-op 
and 1 hour 
post-op 
Overall 388 83 0.21   300(60) 0.20  
 
5.3.1 Comparison of PPV and NPV estimates 
The NPV & PPV are now compared across the first five approaches in this section. 
Approach 6, which is the internal-external validation method, will be assessed in section 
5.3.4. 
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Table 5.2: PPV and NPV for 0-20 minutes 
0-20 minutes      
% PTH 
Decrease 
Prevalence Sensitivity Specificity PPV NPV 
Approach (1) Unstratified Unstratified Unstratified   
>40 0.21 93.62 44.06 31.00 96.26 
>50 0.21 93.62 56.44 36.59 97.05 
>60 0.21 85.11 70.79 43.89 94.66 
>65 0.21 80.85 74.26 45.75 93.53 
>70 0.21 80.85 75.74 47.22 93.64 
>72 0.21 80.85 76.73 48.26 93.72 
>80 0.21 68.09 85.64 56.00 90.91 
>90 0.21 34.04 95.54 67.20 84.36 
Approach (2) Univariate Univariate Univariate   
>40 0.22 93.62 46.75 32.57 96.39 
>50 0.22 93.62 56.44 37.12 96.99 
>60 0.22 85.11 75.58 48.91 94.87 
>65 0.22 80.85 79.05 51.46 93.76 
>70 0.22 80.85 79.78 52.35 93.81 
>72 0.22 80.85 81.55 54.62 93.94 
>80 0.22 70.21 85.15 56.50 91.23 
>90 0.22 20.27 96.17 59.25 81.45 
Approach (3) Lower 95% 
PI 
Univariate Univariate   
>40 0.09 93.62 46.75 15.48 98.60 
>50 0.09 93.62 56.44 18.30 98.84 
>60 0.09 85.11 75.58 26.64 97.99 
>65 0.09 80.85 79.05 28.68 97.54 
>70 0.09 80.85 79.78 29.41 97.56 
>72 0.09 80.85 81.55 31.34 97.61 
>80 0.09 70.21 85.15 33.00 96.48 
>90 0.09 20.27 96.17 35.54 92.05 
Approach (4) Upper 95% 
PI 
Univariate Univariate   
>40 0.42 93.62 46.75 56.02 91.00 
>50 0.42 93.62 56.44 60.89 92.43 
>60 0.42 85.11 75.58 71.63 87.51 
>65 0.42 80.85 79.05 73.65 85.07 
>70 0.42 80.85 79.78 74.34 85.19 
>72 0.42 80.85 81.55 76.04 85.46 
>80 0.42 70.21 85.15 77.40 79.78 
>90 0.42 20.27 96.17 79.31 62.48 
Approach (5) Studies own 
prevalence 
Univariate Univariate   
McLeod      
>40 0.23 93.62 46.75 34.86 96.01 
>50 0.23 93.62 56.44 39.54 96.67 
>60 0.23 85.11 75.58 51.47 94.34 
>65 0.23 80.85 79.05 54.01 93.13 
>70 0.23 80.85 79.78 54.89 93.19 
>72 0.23 80.85 81.55 57.15 93.33 
>80 0.23 70.21 85.15 59.00 90.38 
>90 0.23 20.27 96.17 61.70 79.85 
Warren 02      
>40 0.18 93.62 46.75 28.09 97.06 
>50 0.18 93.62 56.44 32.32 97.55 
>60 0.18 85.11 75.58 43.65 95.81 
>65 0.18 80.85 79.05 46.17 94.89 
>70 0.18 80.85 79.78 47.05 94.94 
>72 0.18 80.85 81.55 49.34 95.04 
>80 0.18 70.21 85.15 51.24 92.79 
>90 0.18 20.27 96.17 54.05 84.44 
Warren 04      
>40 0.11 93.62 46.75 18.02 98.32 
>50 0.11 93.62 56.44 21.17 98.61 
>60 0.11 85.11 75.58 30.34 97.60 
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0-20 minutes      
% PTH 
Decrease 
Prevalence Sensitivity Specificity PPV NPV 
>65 0.11 80.85 79.05 32.54 97.06 
>70 0.11 80.85 79.78 33.32 97.09 
>72 0.11 80.85 81.55 35.39 97.15 
>80 0.11 70.21 85.15 37.14 95.81 
>90 0.11 20.27 96.17 39.81 90.61 
Lo      
>40 0.11 93.62 46.75 17.85 98.34 
>50 0.11 93.62 56.44 20.99 98.62 
>60 0.11 85.11 75.58 30.11 97.62 
>65 0.11 80.85 79.05 32.29 97.09 
>70 0.11 80.85 79.78 33.07 97.12 
>72 0.11 80.85 81.55 35.13 97.18 
>80 0.11 70.21 85.15 36.88 95.86 
>90 0.11 20.27 96.17 39.54 90.71 
Lombardi      
>40 0.31 93.62 46.75 43.86 94.28 
>50 0.31 93.62 56.44 48.86 95.22 
>60 0.31 85.11 75.58 60.77 91.95 
>65 0.31 80.85 79.05 63.17 90.28 
>70 0.31 80.85 79.78 63.99 90.36 
>72 0.31 80.85 81.55 66.07 90.55 
>80 0.31 70.21 85.15 67.76 86.54 
>90 0.31 20.27 96.17 70.17 73.07 
Table 5.2 shows for PTH at 0-20 minutes that the PPV can be very different when using 
the summary results from a univariate meta-analysis (approach 2) compared to the 
unstratified results (approach 1). For example, at a threshold of 72% the PPV is 48% 
using the unstratified value and 55% using the meta-analysis values, but at threshold 
90% it is lower, 59% (approach 2) compared to 67% (approach 1). Differences also 
occur for NPV; e.g. at a 90% threshold, unstratified (approach 1) and  meta-analysis 
(approach 2) approaches give a NPV of 84% and 81% respectively.  
When the lower and upper bounds of the prevalence’s prediction interval are used 
(approaches 3 and 4), the NPV and PPV considerably change as expected. This reveals 
how important the choice of prevalence is. For example, at a 72% threshold the PPV is 
55% based on the meta-analysis average prevalence, 31% based on the lower prediction 
bound and 76% based on the upper prediction bound. Tables 5.3 and 5.4 reveal similar 
findings for 1-2 hours and 6 hours. 
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Table 5.3: PPV and NPV for 1-2 hours 
1-2 hours      
% PTH 
Decrease 
Prevalence Sensitivity Specificity PPV NPV 
Approach (1) Unstratified Unstratified Unstratified   
>40 0.21 95.56 52.14 34.89 97.77 
>50 0.21 95.56 63.25 41.11 98.15 
>60 0.21 95.56 80.34 56.61 98.54 
>65 0.21 93.33 81.20 57.13 97.84 
>70 0.21 93.33 88.03 67.67 98.01 
>72 0.21 89.36 89.74 70.04 96.92 
>80 0.21 77.78 93.46 76.15 94.00 
>90 0.21 55.56 100.0 100.00 89.34 
Approach (2) Univariate Univariate Univariate   
>40 0.22 95.56 52.14 35.42 97.71 
>50 0.22 95.56 63.31 41.71 98.11 
>60 0.22 95.56 80.34 57.18 98.50 
>65 0.22 93.33 82.19 59.01 97.82 
>70 0.22 93.33 88.03 68.17 97.96 
>72 0.22 88.89 89.74 70.42 96.71 
>80 0.22 77.78 94.02 78.13 93.90 
>90 0.22 55.56 100.00 100.00 89.12 
Approach (3) Lower 95% 
PI 
Univariate Univariate   
>40 0.09 95.56 52.14 17.22 99.12 
>50 0.09 95.56 63.31 21.34 99.27 
>60 0.09 95.56 80.34 33.62 99.43 
>65 0.09 93.33 82.19 35.32 99.16 
>70 0.09 93.33 88.03 44.82 99.22 
>72 0.09 88.89 89.74 47.44 98.73 
>80 0.09 77.78 94.02 57.54 97.60 
>90 0.09 55.56 100.00 100.00 95.57 
Approach (4) Upper 95% 
PI 
Univariate Univariate   
>40 0.42 95.56 52.14 59.12 94.19 
>50 0.42 95.56 63.31 65.36 95.17 
>60 0.42 95.56 80.34 77.88 96.15 
>65 0.42 93.33 82.19 79.15 94.45 
>70 0.42 93.33 88.03 84.96 94.80 
>72 0.42 88.89 89.74 86.26 91.77 
>80 0.42 77.78 94.02 90.40 85.38 
>90 0.42 55.56 100.00 100.00 75.65 
Approach (5) Studies own 
prevalence 
Univariate Univariate   
McLeod      
>40 0.23 95.56 52.14 37.36 97.52 
>50 0.23 95.56 63.31 43.76 97.95 
>60 0.23 95.56 80.34 59.21 98.38 
>65 0.23 93.33 82.19 61.02 97.63 
>70 0.23 93.33 88.03 69.96 97.79 
>72 0.23 88.89 89.74 72.13 96.43 
>80 0.23 77.78 94.02 79.53 93.41 
>90 0.23 55.56 100.00 100.00 88.28 
Warren 02      
>40 0.18 95.56 52.14 30.47 98.17 
>50 0.18 95.56 63.31 36.38 98.48 
>60 0.18 95.56 80.34 51.62 98.80 
>65 0.18 93.33 82.19 53.50 98.25 
>70 0.18 93.33 88.03 63.12 98.36 
>72 0.18 88.89 89.74 65.54 97.35 
>80 0.18 77.78 94.02 74.06 95.07 
>90 0.18 55.56 100.00 100.00 91.11 
Warren 04      
>40 0.11 95.56 52.14 19.79 98.96 
>50 0.11 95.56 63.31 24.35 99.14 
>60 0.11 95.56 80.34 37.53 99.32 
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1-2 hours      
% PTH 
Decrease 
Prevalence Sensitivity Specificity PPV NPV 
>65 0.11 93.33 82.19 39.31 99.01 
>70 0.11 93.33 88.03 49.08 99.07 
>72 0.11 88.89 89.74 51.71 98.49 
>80 0.11 77.78 94.02 61.65 97.16 
>90 0.11 55.56 100.00 100.00 94.79 
Lam      
>40 0.31 95.56 52.14 47.29 96.32 
>50 0.31 95.56 63.31 53.92 96.95 
>60 0.31 95.56 80.34 68.59 97.58 
>65 0.31 93.33 82.19 70.19 96.48 
>70 0.31 93.33 88.03 77.79 96.71 
>72 0.31 88.89 89.74 79.56 94.73 
>80 0.31 77.78 94.02 85.39 90.40 
>90 0.31 55.56 100.00 100.00 83.36 
Lombardi      
>40 0.31 95.56 52.14 47.29 96.32 
>50 0.31 95.56 63.31 53.92 96.95 
>60 0.31 95.56 80.34 68.59 97.58 
>65 0.31 93.33 82.19 70.19 96.48 
>70 0.31 93.33 88.03 77.79 96.71 
>72 0.31 88.89 89.74 79.56 94.73 
>80 0.31 77.78 94.02 85.39 90.40 
>90 0.31 55.56 100.00 100.00 83.36 
 
Table 5.4: PPV and NPV for 6 hours 
6hr      
% PTH 
Decrease 
Prevalence Sensitivity Specificity PPV NPV 
Approach (1) Unstratified Unstratified Unstratified   
>40 0.21 96.43 63.16 41.27 98.51 
>50 0.21 96.43 75.44 51.31 98.75 
>60 0.21 96.43 85.96 64.83 98.90 
>65 0.21 96.43 91.23 74.69 98.96 
>70 0.21 92.86 92.98 78.03 97.98 
>72 0.21 89.29 94.74 82.00 97.05 
>80 0.21 78.57 94.74 80.04 94.28 
>90 0.21 60.71 98.25 90.30 90.31 
Approach (2) Univariate Univariate Univariate   
>40 0.22 96.43 63.16 41.83 98.47 
>50 0.22 96.43 75.44 51.89 98.72 
>60 0.22 96.43 85.97 65.38 98.87 
>65 0.22 96.43 91.23 75.13 98.94 
>70 0.22 92.86 92.98 78.42 97.93 
>72 0.22 90.70 94.79 82.71 97.38 
>80 0.22 78.89 94.75 80.50 94.23 
>90 0.22 60.71 98.25 90.50 90.10 
Approach (3) Lower 95% 
PI 
Univariate Univariate   
>40 0.09 96.43 63.16 21.43 99.41 
>50 0.09 96.43 75.44 29.03 99.51 
>60 0.09 96.43 85.97 41.73 99.57 
>65 0.09 96.43 91.23 53.39 99.59 
>70 0.09 92.86 92.98 57.95 99.21 
>72 0.09 90.70 94.79 64.46 98.99 
>80 0.09 78.89 94.75 61.02 97.73 
>90 0.09 60.71 98.25 78.33 96.00 
Approach (4) Upper 95% 
PI 
Univariate Univariate   
>40 0.42 96.43 63.16 65.47 96.07 
>50 0.42 96.43 75.44 73.99 96.69 
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6hr      
% PTH 
Decrease 
Prevalence Sensitivity Specificity PPV NPV 
>60 0.42 96.43 85.97 83.27 97.08 
>65 0.42 96.43 91.23 88.85 97.24 
>70 0.42 92.86 92.98 90.55 94.73 
>72 0.42 90.70 94.79 92.65 93.36 
>80 0.42 78.89 94.75 91.59 86.10 
>90 0.42 60.71 98.25 96.17 77.54 
Approach (5) Studies own 
prevalence 
Univariate Univariate   
Lam      
>40 0.31 96.43 63.16 53.78 97.55 
>50 0.31 96.43 75.44 63.57 97.94 
>60 0.31 96.43 85.97 75.34 98.19 
>65 0.31 96.43 91.23 83.01 98.29 
>70 0.31 92.86 92.98 85.46 96.7 
>72 0.31 90.70 94.79 88.55 95.82 
>80 0.31 78.89 94.75 86.98 90.99 
>90 0.31 60.71 98.25 93.91 84.91 
Lombardi      
>40 0.31 96.43 63.16 53.78 97.55 
>50 0.31 96.43 75.44 63.57 97.94 
>60 0.31 96.43 85.97 75.34 98.19 
>65 0.31 96.43 91.23 83.01 98.29 
>70 0.31 92.86 92.98 85.46 96.7 
>72 0.31 90.70 94.79 88.55 95.82 
>80 0.31 78.89 94.75 86.98 90.99 
>90 0.31 60.71 98.25 93.91 84.91 
Tables 5.2-5.4 also use a fifth approach which uses each study’s observed prevalence 
along with the summary univariate meta-analysis values for sensitivity and specificity.  
5.3.2 Comparison of the calibration of predicted values 
When choosing PPV and NPV values, it is important to know that they calibrate well 
when applied to the populations of interest, and so the E/O statistic is now examined for 
approaches 1 to 5, at each time-point for measuring PTH. 
5.3.2.1 0-20 minutes 
First the E/O ratio is estimated when the IPD are regarded as coming from one big 
study, using the unstratified prevalence combined with unstratified sensitivity and 
specificity (approach 1) to derive PPV and NPV, and then rather the univariate 
prevalence combined with univariate sensitivity and specificity (approach 2) to derive 
PPV and NPV. 
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Table 5.5: E/O ratios for all the patients combined using the unstratified and univariate meta-
analysis approaches at the 0-20 minute’s time-point 
Overall No. of hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia who 
tested negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
 E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
Approach 1               
>40 48.67 44 1.11 0.82 1.49 3.44 3 1.15 0.37 3.56 52.11 47 1.11 0.83 1.48 
>50 48.30 44 1.10 0.82 1.48 3.45 3 1.15 0.37 3.57 51.75 47 1.10 0.83 1.47 
>60 43.45 40 1.09 0.80 1.48 8.01 7 1.14 0.55 2.40 51.46 47 1.09 0.82 1.46 
>65 41.18 38 1.08 0.79 1.49 10.29 9 1.14 0.59 2.20 51.46 47 1.09 0.82 1.46 
>70 41.08 38 1.08 0.79 1.49 10.30 9 1.14 0.60 2.20 51.38 47 1.09 0.82 1.46 
>72 41.02 38 1.08 0.79 1.48 10.30 9 1.14 0.60 2.20 51.32 47 1.09 0.82 1.45 
>80 34.16 32 1.07 0.75 1.51 17.09 15 1.14 0.69 1.89 51.25 47 1.09 0.82 1.45 
>90 16.80 16 1.05 0.64 1.71 35.03 31 1.13 0.79 1.61 51.83 47 1.10 0.83 1.47 
Approach 2               
>40 51.13 44 1.16 0.86 1.56 3.32 3 1.11 0.36 3.43 54.46 47 1.16 0.87 1.54 
>50 49.00 44 1.11 0.83 1.50 3.52 3 1.17 0.38 3.64 52.52 47 1.12 0.84 1.49 
>60 48.42 40 1.21 0.89 1.65 7.70 7 1.10 0.52 2.31 56.12 47 1.19 0.90 1.59 
>65 46.31 38 1.22 0.89 1.67 9.92 9 1.10 0.57 2.12 56.24 47 1.20 0.90 1.59 
>70 45.54 38 1.20 0.87 1.65 10.03 9 1.11 0.58 2.14 55.57 47 1.18 0.89 1.57 
>72 46.43 38 1.22 0.89 1.68 9.94 9 1.10 0.57 2.12 56.37 47 1.20 0.90 1.60 
>80 34.47 32 1.08 0.76 1.52 16.49 15 1.10 0.66 1.82 50.95 47 1.08 0.81 1.44 
>90 14.81 16 0.93 0.57 1.51 41.55 31 1.34 0.94 1.91 56.36 47 1.20 0.90 1.60 
Table 5.5 shows the combined E/O for all the patients at the 0-20 minutes time point for 
the unstratified approach is around 1.10 for all the thresholds; thus, the PPV and NPV 
derived from the unstratified approach slightly over predict. The 95% CI includes 1, 
reflecting a wide CI due to small number of events.  
Interestingly, when using the PPV and NPV values based on univariate meta-analysis, 
the combined E/O for all threshold points is even further away from 1, with it being 
around 1.2. The 95% CI again includes 1. Thus it might appear that using the 
unstratified approach to derive PPV and NPV is better in terms of calibration 
performance of the predictive test. However, assessment of E/O in the unstratified 
approach is naive and misleading, as we have already seen that prevalence varies across 
studies. So let’s now check calibration in each study separately. 
First, the McLeod [144] study is presented, and all 5 approaches are considered for 
calculating PPV and NPV, to then obtain E and O. 
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Table 5.6 shows the E/O ratios, and clearly when using the unstratified approach (1) to 
derive PPV and NPV for clinical practice, there is an under-prediction of the numbers of 
events in this study, for example with an E/O of 0.85 for the 65% threshold. Using 
approach (2) to derive PPV and NPV gives improved calibration performance of the 
predictive test with E/O values closer to 1, for example with an E/O ratio of 0.93 at 
65%. Using PPV and NPV estimates derived from the prevalence based on the lower 
(approach 3) or upper (approach 4) prediction interval values, dramatically over-
predicts or under-predicts the calibration performance of the predictive test 
Crucially, it seems using approach (5) (which uses the observed prevalence of 0.23 in 
this clinical population of interest) to derive PPV and NPV helps to improve calibration 
performance of the predictive test. This approach derives PPV and NPV by using each 
study’s own observed prevalence and combining that with the univariate meta-analysis 
values for sensitivity and specificity, which gives an the E/O statistic very close to 1 for 
all thresholds. For example, an E/O of 0.98 at the threshold of 65% shows that it is 
comparatively better at calibration performance of the predictive test (PPV and NPV) 
than using PPV and NPV from other approaches, and so using the study’s observed 
prevalence helps to improve calibration. Thus, due to heterogeneity in prevalence, using 
an unstratified or meta-analytic summary of prevalence is inadequate for individual 
settings, and results are only improved by tailoring prevalence to the intended 
population. 
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Table 5.6: E/O ratios using 5 approaches for McLeod  study at the 0-20 minute’s time-point 
Approach No. of 
hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 11.16 12 0.93 0.53 1.64 0.75 1 0.75 0.11 5.31 11.91 13 0.92 0.53 1.58 
>50 11.71 12 0.98 0.55 1.72 0.71 1 0.71 0.10 5.03 12.42 13 0.96 0.55 1.64 
>60 9.66 10 0.97 0.52 1.79 1.82 3 0.61 0.20 1.88 11.47 13 0.88 0.51 1.52 
>65 8.69 9 0.97 0.50 1.86 2.39 4 0.60 0.22 1.59 11.09 13 0.85 0.50 1.47 
>70 8.50 9 0.94 0.49 1.82 2.42 4 0.60 0.23 1.61 10.92 13 0.84 0.49 1.45 
>72 8.20 9 0.91 0.47 1.75 2.45 4 0.61 0.23 1.63 10.65 13 0.82 0.48 1.41 
>80 6.72 7 0.96 0.46 2.01 4.00 6 0.67 0.30 1.48 10.72 13 0.82 0.48 1.42 
>90 2.69 4 0.67 0.25 1.79 8.13 9 0.90 0.47 1.74 10.82 13 0.83 0.48 1.43 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 11.73 12 0.98 0.55 1.72 0.72 1 0.72 0.10 5.13 12.45 13 0.96 0.56 1.65 
>50 11.88 12 0.99 0.56 1.74 0.72 1 0.72 0.10 5.13 12.60 13 0.97 0.56 1.67 
>60 10.76 10 1.08 0.58 2.00 1.74 3 0.58 0.19 1.80 12.50 13 0.96 0.56 1.66 
>65 9.78 9 1.09 0.57 2.09 2.31 4 0.58 0.22 1.54 12.09 13 0.93 0.54 1.60 
>70 9.42 9 1.05 0.54 2.01 2.35 4 0.59 0.22 1.57 11.78 13 0.91 0.53 1.56 
>72 9.29 9 1.03 0.54 1.98 2.36 4 0.59 0.22 1.57 11.65 13 0.90 0.52 1.54 
>80 6.78 7 0.97 0.46 2.03 3.86 6 0.64 0.29 1.43 10.64 13 0.82 0.48 1.41 
>90 2.37 4 0.59 0.22 1.58 9.65 9 1.07 0.56 2.06 12.02 13 0.92 0.54 1.59 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 5.57 12 0.46 0.26 0.82 0.28 1 0.28 0.04 1.99 5.85 13 0.45 0.26 0.78 
>50 5.86 12 0.49 0.28 0.86 0.28 1 0.28 0.04 1.98 6.13 13 0.47 0.27 0.81 
>60 5.86 10 0.59 0.32 1.09 0.68 3 0.23 0.07 0.71 6.54 13 0.50 0.29 0.87 
>65 5.45 9 0.61 0.32 1.16 0.91 4 0.23 0.09 0.61 6.36 13 0.49 0.28 0.84 
>70 5.29 9 0.59 0.31 1.13 0.93 4 0.23 0.09 0.62 6.22 13 0.48 0.28 0.82 
>72 5.33 9 0.59 0.31 1.14 0.93 4 0.23 0.09 0.62 6.26 13 0.48 0.28 0.83 
>80 3.96 7 0.57 0.27 1.19 1.55 6 0.26 0.12 0.57 5.51 13 0.42 0.25 0.73 
>90 1.42 4 0.36 0.13 0.95 4.13 9 0.46 0.24 0.88 5.56 13 0.43 0.25 0.74 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 20.17 12 1.68 0.95 2.96 1.80 1 1.80 0.25 12.78 21.97 13 1.69 0.98 2.91 
>50 19.48 12 1.62 0.92 2.86 1.82 1 1.82 0.26 12.90 21.30 13 1.64 0.95 2.82 
>60 15.76 10 1.58 0.85 2.93 4.25 3 1.42 0.46 4.39 20.01 13 1.54 0.89 2.65 
>65 13.99 9 1.55 0.81 2.99 5.52 4 1.38 0.52 3.68 19.52 13 1.50 0.87 2.59 
>70 13.38 9 1.49 0.77 2.86 5.63 4 1.41 0.53 3.75 19.01 13 1.46 0.85 2.52 
>72 12.93 9 1.44 0.75 2.76 5.67 4 1.42 0.53 3.78 18.60 13 1.43 0.83 2.46 
>80 9.29 7 1.33 0.63 2.78 8.90 6 1.48 0.67 3.30 18.18 13 1.40 0.81 2.41 
>90 3.17 4 0.79 0.30 2.11 19.51 9 2.17 1.13 4.17 22.68 13 1.74 1.01 3.00 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 12.55 12 1.05 0.59 1.84 0.80 1 0.80 0.11 5.67 13.35 13 1.03 0.60 1.77 
>50 12.65 12 1.05 0.60 1.86 0.80 1 0.80 0.11 5.67 13.45 13 1.03 0.60 1.78 
>60 11.32 10 1.13 0.61 2.10 1.92 3 0.64 0.21 1.99 13.25 13 1.02 0.59 1.76 
>65 10.26 9 1.14 0.59 2.19 2.54 4 0.64 0.24 1.69 12.80 13 0.98 0.57 1.70 
>70 9.88 9 1.10 0.57 2.11 2.59 4 0.65 0.24 1.72 12.47 13 0.96 0.56 1.65 
>72 9.72 9 1.08 0.56 2.07 2.60 4 0.65 0.24 1.73 12.32 13 0.95 0.55 1.63 
>80 7.08 7 1.01 0.48 2.12 4.23 6 0.71 0.32 1.57 11.31 13 0.87 0.51 1.50 
>90 2.47 4 0.62 0.23 1.64 10.48 9 1.16 0.61 2.24 12.95 13 1.00 0.58 1.72 
Now, the Lo [142] study results are presented. 
Table 5.7 shows the E/O ratio for the calibration of PPV and NPV calculated using the 
unstratified prevalence, sensitivity and specificity (approach 1); clearly these PPV and 
NPV dramatically over predicts the number of events, with an E/O of 2.16 for the 65% 
threshold. Using PPV and NPV based on Approach 2 (where the univariate prevalence, 
sensitivity and specificity are used) leads to a poorer calibration performance of the 
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predictive test with an E/O ratio of 2.38 at 65%.  When using the lower bound of the 
95% prediction interval for the prevalence (approach 3), the calibration performance of 
the predictive test (PPV and NPV) is much improved, with an E/O of 1.27 at the 65% 
threshold, although it still over predicts. 
Table 5.7: E/O ratios using 5 approaches for Lo study at the 0-20 minute’s time-point 
Approach No. of hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia who 
tested negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 21.70 11 1.97 1.09 3.56 1.12 0    22.82 11 2.07 1.15 3.75 
>50 19.39 11 1.76 0.98 3.18 1.39 0    20.78 11 1.89 1.05 3.41 
>60 20.63 11 1.88 1.04 3.39 2.83 0    23.46 11 2.13 1.18 3.85 
>65 20.13 11 1.83 1.01 3.30 3.62 0    23.75 11 2.16 1.20 3.90 
>70 19.83 11 1.80 1.00 3.26 3.69 0    23.52 11 2.14 1.18 3.86 
>72 20.27 11 1.84 1.02 3.33 3.64 0    23.91 11 2.17 1.20 3.93 
>80 15.12 10 1.51 0.81 2.81 6.64 1 6.64 0.93 47.11 21.76 11 1.98 1.10 3.57 
>90 10.75 10 1.08 0.58 2.00 13.14 1 13.14 1.85 93.27 23.89 11 2.17 1.20 3.92 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 22.80 11 2.07 1.15 3.74 1.08 0    23.88 11 2.17 1.20 3.92 
>50 19.67 11 1.79 0.99 3.23 1.41 0    21.09 11 1.92 1.06 3.46 
>60 22.99 11 2.09 1.16 3.77 2.72 0    25.71 11 2.34 1.29 4.22 
>65 22.64 11 2.06 1.14 3.72 3.49 0    26.14 11 2.38 1.32 4.29 
>70 21.99 11 2.00 1.11 3.61 3.59 0    25.58 11 2.33 1.29 4.20 
>72 22.94 11 2.09 1.15 3.77 3.51 0    26.46 11 2.41 1.33 4.34 
>80 15.26 10 1.53 0.82 2.84 6.40 1 6.40 0.90 45.45 21.66 11 1.97 1.09 3.56 
>90 9.48 10 0.95 0.51 1.76 15.58 1 15.58 2.19 110.62 25.06 11 2.28 1.26 4.11 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 10.84 11 0.99 0.55 1.78 0.42 0    11.26 11 1.02 0.57 1.85 
>50 9.70 11 0.88 0.49 1.59 0.55 0    10.24 11 0.93 0.52 1.68 
>60 12.52 11 1.14 0.63 2.06 1.07 0    13.59 11 1.24 0.68 2.23 
>65 12.62 11 1.15 0.64 2.07 1.38 0    14.00 11 1.27 0.70 2.30 
>70 12.35 11 1.12 0.62 2.03 1.42 0    13.77 11 1.25 0.69 2.26 
>72 13.16 11 1.20 0.66 2.16 1.39 0    14.55 11 1.32 0.73 2.39 
>80 8.91 10 0.89 0.48 1.66 2.57 1 2.57 0.36 18.24 11.48 11 1.04 0.58 1.88 
>90 5.69 10 0.57 0.31 1.06 6.68 1 6.68 0.94 47.41 12.36 11 1.12 0.62 2.03 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 39.21 11 3.56 1.97 6.44 2.70 0    41.91 11 3.81 2.11 6.88 
>50 32.27 11 2.93 1.62 5.30 3.56 0    35.83 11 3.26 1.80 5.88 
>60 33.67 11 3.06 1.69 5.53 6.62 0    40.29 11 3.66 2.03 6.61 
>65 32.41 11 2.95 1.63 5.32 8.36 0    40.77 11 3.71 2.05 6.69 
>70 31.22 11 2.84 1.57 5.13 8.59 0    39.81 11 3.62 2.00 6.54 
>72 31.94 11 2.90 1.61 5.24 8.43 0    40.37 11 3.67 2.03 6.63 
>80 20.90 10 2.09 1.12 3.88 14.76 1 14.76 2.08 104.79 35.66 11 3.24 1.80 5.85 
>90 12.69 10 1.27 0.68 2.36 31.52 1 31.52 4.44 223.75 44.21 11 4.02 2.23 7.26 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 12.50 11 1.14 0.63 2.05 0.50 0    12.99 11 1.18 0.65 2.13 
>50 11.12 11 1.01 0.56 1.83 0.65 0    11.77 11 1.07 0.59 1.93 
>60 14.15 11 1.29 0.71 2.32 1.26 0    15.41 11 1.40 0.78 2.53 
>65 14.21 11 1.29 0.72 2.33 1.63 0    15.84 11 1.44 0.80 2.60 
>70 13.89 11 1.26 0.70 2.28 1.67 0    15.56 11 1.41 0.78 2.55 
>72 14.75 11 1.34 0.74 2.42 1.64 0    16.39 11 1.49 0.83 2.69 
>80 9.96 10 1.00 0.54 1.85 3.02 1 3.02 0.43 21.46 12.98 11 1.18 0.65 2.13 
>90 6.33 10 0.63 0.34 1.18 7.80 1 7.80 1.10 55.40 14.13 11 1.28 0.71 2.32 
Where blank, this is due to observed cases being 0 so an E/O ratio was not possible 
In approach 5, when using the studies observed prevalence of 0.11 and combining that 
with the univariate meta-analysis values for sensitivity and specificity to derive PPV 
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and NPV, the calibration performance of the predictive test is closer to 1 than when 
using PPV and NPV derived using approaches 1 and 2, as the 65% threshold yields an 
E/O of 1.44. 
This analysis shows again that using the unstratified or average univariate meta-analysis 
results for sensitivity, specificity and prevalence to derive PPV and NPV in this 
particular study does not give accurate predictions for clinical use as the calibration is 
poor. A key reason for this is that the average prevalence across all studies (0.21) is very 
different to this settings prevalence (0.11). When using the study’s observed prevalence, 
or indeed the similar lower bound of the predicted interval for prevalence, the 
calibration is markedly improved. However, there is still some over-prediction in the 
performance of the predictive test (PPV and NPV), which may be due to chance (small 
number of events and patients) but may also be due to additional heterogeneity in the 
sensitivity and specificity for this study compared to the averages used. This is 
evaluated in a formal meta-analysis of the E/O statistics across studies later in section 
5.4.3. 
Now the Lombardi [143] study results are presented. 
Table 5.8 shows the E/O ratio calculated using the unstratified prevalence, sensitivity 
and specificity (approach 1). When this approach is used to derive PPV and NPV, it is 
found the number of events is under-predicted with an E/O of 0.62 for the 65% 
threshold. The use of the second approach (where the univariate prevalence, sensitivity 
and specificity are used) to derive PPV and NPV, results in slightly better calibration 
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performance, with an E/O ratio of 0.68 at 65%.  When using the upper bound of the 
95% prediction interval for the prevalence (approach 4), an even better calibration 
performance (of PPV and NPV) is obtained compared to the use of the first two 
approaches to derive PPV and NPV, with an E/O of 1.10 at the 65% threshold. 
In approach 5, when PPV and NPV are derived using the study’s observed prevalence 
of 0.31 and combining that with the univariate meta-analysis values for sensitivity and 
specificity, the calibration performance (E/O ratio) is closer to 1 than compared to the 
calibration performance of PPV and NPV derived from approaches 1 and 2, as the 65% 
threshold yields an E/O of 0.88. This again indicates that when using the study’s own 
prevalence, calibration performance is more accurate for this study, as the study’s 
observed prevalence of 0.31 is much higher than the average study prevalence of 0.21. 
Table 5.8: E/O ratios using 5 approaches for Lombardi study at the 0-20 minute’s time-point 
Approach No. of 
hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 8.37 15 0.56 0.34 0.93 0.90 1 0.90 0.13 6.37 9.27 16 0.58 0.35 0.95 
>50 9.15 15 0.61 0.37 1.01 0.77 1 0.77 0.11 5.45 9.91 16 0.62 0.38 1.01 
>60 8.78 14 0.63 0.37 1.06 1.66 2 0.83 0.21 3.31 10.43 16 0.65 0.40 1.06 
>65 7.78 13 0.60 0.35 1.03 2.20 3 0.73 0.24 2.27 9.98 16 0.62 0.38 1.02 
>70 8.03 13 0.62 0.36 1.06 2.16 3 0.72 0.23 2.23 10.19 16 0.64 0.39 1.04 
>72 7.72 13 0.59 0.34 1.02 2.20 3 0.73 0.24 2.27 9.92 16 0.62 0.38 1.01 
>80 7.28 11 0.66 0.37 1.20 3.45 5 0.69 0.29 1.66 10.73 16 0.67 0.41 1.10 
>90 1.34 2 0.67 0.17 2.69 7.66 14 0.55 0.32 0.92 9.01 16 0.56 0.34 0.92 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 8.79 15 0.59 0.35 0.97 0.87 1 0.87 0.12 6.15 9.66 16 0.60 0.37 0.99 
>50 9.28 15 0.62 0.37 1.03 0.78 1 0.78 0.11 5.56 10.06 16 0.63 0.39 1.03 
>60 9.78 14 0.70 0.41 1.18 1.59 2 0.80 0.20 3.18 11.37 16 0.71 0.44 1.16 
>65 8.75 13 0.67 0.39 1.16 2.12 3 0.71 0.23 2.19 10.87 16 0.68 0.42 1.11 
>70 8.90 13 0.68 0.40 1.18 2.10 3 0.70 0.23 2.18 11.00 16 0.69 0.42 1.12 
>72 8.74 13 0.67 0.39 1.16 2.12 3 0.71 0.23 2.19 10.86 16 0.68 0.42 1.11 
>80 7.35 11 0.67 0.37 1.21 3.33 5 0.67 0.28 1.60 10.68 16 0.67 0.41 1.09 
>90 1.19 2 0.59 0.15 2.37 9.09 14 0.65 0.38 1.10 10.27 16 0.64 0.39 1.05 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 4.18 15 0.28 0.17 0.46 0.34 1 0.34 0.05 2.39 4.52 16 0.28 0.17 0.46 
>50 4.58 15 0.31 0.18 0.51 0.30 1 0.30 0.04 2.14 4.88 16 0.30 0.19 0.50 
>60 5.33 14 0.38 0.23 0.64 0.62 2 0.31 0.08 1.25 5.95 16 0.37 0.23 0.61 
>65 4.88 13 0.38 0.22 0.65 0.84 3 0.28 0.09 0.86 5.71 16 0.36 0.22 0.58 
>70 5.00 13 0.38 0.22 0.66 0.83 3 0.28 0.09 0.86 5.83 16 0.36 0.22 0.59 
>72 5.01 13 0.39 0.22 0.66 0.84 3 0.28 0.09 0.86 5.85 16 0.37 0.22 0.60 
>80 4.29 11 0.39 0.22 0.70 1.34 5 0.27 0.11 0.64 5.63 16 0.35 0.22 0.57 
>90 0.71 2 0.36 0.09 1.42 3.90 14 0.28 0.16 0.47 4.61 16 0.29 0.18 0.47 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 15.13 15 1.01 0.61 1.67 2.16 1 2.16 0.30 15.33 17.29 16 1.08 0.66 1.76 
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Approach No. of 
hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
>50 15.22 15 1.01 0.61 1.68 1.97 1 1.97 0.28 13.97 17.19 16 1.07 0.66 1.75 
>60 14.33 14 1.02 0.61 1.73 3.87 2 1.94 0.48 7.74 18.20 16 1.14 0.70 1.86 
>65 12.52 13 0.96 0.56 1.66 5.08 3 1.69 0.55 5.25 17.60 16 1.10 0.67 1.80 
>70 12.64 13 0.97 0.56 1.67 5.04 3 1.68 0.54 5.20 17.67 16 1.10 0.68 1.80 
>72 12.17 13 0.94 0.54 1.61 5.09 3 1.70 0.55 5.26 17.26 16 1.08 0.66 1.76 
>80 10.06 11 0.91 0.51 1.65 7.68 5 1.54 0.64 3.69 17.75 16 1.11 0.68 1.81 
>90 1.59 2 0.79 0.20 3.17 18.38 14 1.31 0.78 2.22 19.97 16 1.25 0.76 2.04 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 11.84 15 0.79 0.48 1.31 1.37 1 1.37 0.19 9.75 13.22 16 0.83 0.51 1.35 
>50 12.22 15 0.81 0.49 1.35 1.24 1 1.24 0.18 8.82 13.46 16 0.84 0.52 1.37 
>60 12.15 14 0.87 0.51 1.47 2.50 2 1.25 0.31 4.99 14.65 16 0.92 0.56 1.49 
>65 10.74 13 0.83 0.48 1.42 3.30 3 1.10 0.36 3.42 14.04 16 0.88 0.54 1.43 
>70 10.88 13 0.84 0.49 1.44 3.28 3 1.09 0.35 3.39 14.16 16 0.88 0.54 1.44 
>72 10.57 13 0.81 0.47 1.40 3.31 3 1.10 0.36 3.42 13.88 16 0.87 0.53 1.42 
>80 8.81 11 0.80 0.44 1.45 5.11 5 1.02 0.43 2.46 13.92 16 0.87 0.53 1.42 
>90 1.40 2 0.70 0.18 2.81 13.20 14 0.94 0.56 1.59 14.60 16 0.91 0.56 1.49 
The results of calibration for 0-20 minutes for other studies are shown in APPENDIX B 
and reveal similar findings.  
5.3.2.2 1-2 hours 
Now consider the time-point of 1-2 hours and the E/O ratio when the patients are pooled 
together across all studies in Table 5.9 and treated as one big dataset. 
Table 5.9: E/O ratios for all the patients combined using the unstratified and univariate meta-
analysis approaches at the 1-2 hours’ time-point 
% PTH 
Decrease 
No. of 
hypocalcaemia who 
tested positive 
95% 
CI 
No. of hypocalcaemia 
who tested negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
 E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
Approach 1               
>40 34.54 44 0.79 0.58 1.05 1.55 3 0.52 0.17 1.60 36.09 47 0.77 0.58 1.02 
>50 35.35 44 0.80 0.60 1.08 1.55 3 0.52 0.17 1.60 36.91 47 0.79 0.59 1.05 
>60 37.36 40 0.93 0.69 1.27 1.55 7 0.22 0.11 0.46 38.91 47 0.83 0.62 1.10 
>65 36.56 38 0.96 0.70 1.32 2.33 9 0.26 0.13 0.50 38.90 47 0.83 0.62 1.10 
>70 37.90 38 1.00 0.73 1.37 2.33 9 0.26 0.13 0.50 40.23 47 0.86 0.64 1.14 
>72 36.42 38 0.96 0.70 1.32 3.74 9 0.42 0.22 0.80 40.16 47 0.85 0.64 1.14 
>80 31.98 32 1.00 0.71 1.41 7.91 15 0.53 0.32 0.87 39.89 47 0.85 0.64 1.13 
>90 25.00 16 1.56 0.96 2.55 15.96 31 0.51 0.36 0.73 40.96 47 0.87 0.65 1.16 
Approach 2               
>40 35.07 44 0.80 0.59 1.07 1.40 3 0.47 0.15 1.45 36.47 47 0.78 0.58 1.03 
>50 35.87 44 0.82 0.61 1.10 1.41 3 0.47 0.15 1.45 37.28 47 0.79 0.60 1.06 
>60 37.74 40 0.94 0.69 1.29 1.40 7 0.20 0.10 0.42 39.14 47 0.83 0.63 1.11 
>65 37.77 38 0.99 0.72 1.37 2.09 9 0.23 0.12 0.45 39.85 47 0.85 0.64 1.13 
>70 38.18 38 1.00 0.73 1.38 2.11 9 0.23 0.12 0.45 40.28 47 0.86 0.64 1.14 
>72 36.62 38 0.96 0.70 1.32 3.54 9 0.39 0.20 0.76 40.16 47 0.85 0.64 1.14 
>80 32.81 32 1.03 0.73 1.45 7.16 15 0.48 0.29 0.79 39.98 47 0.85 0.64 1.13 
>90 25.00 16 1.56 0.96 2.55 14.60 31 0.47 0.33 0.67 39.60 47 0.84 0.63 1.12 
When using the unstratified approach to derive PPV and NPV, Table 5.9 shows that the 
E/O ratio combined for predicting those who get hypocalcaemia is less than 1 
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consistently. When using the univariate approach to derive PPV and NPV, similar 
results are found with the E/O ratio being under 1. 
Now, each study on its own will be assessed. As in the 0-20 minute’s analysis, the 
calibration performance of the predictive test (PPV and NPV) in each study is improved 
when using the study’s observed prevalence (approach (5)). 
Table 5.10:  E/O ratios using 5 approaches for McLeod study at the 1-2 hours’ time-point 
Approach No. of 
hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 9.77 12 0.81 0.46 1.43 0.20 0    9.97 12 0.83 0.47 1.46 
>50 9.46 12 0.79 0.45 1.39 0.26 0    9.71 12 0.81 0.46 1.43 
>60 10.76 12 0.90 0.51 1.58 0.26 0    11.02 12 0.92 0.52 1.62 
>65 9.71 11 0.88 0.49 1.59 0.43 1 0.43 0.06 3.07 10.14 12 0.85 0.48 1.49 
>70 10.83 11 0.98 0.55 1.78 0.42 1 0.42 0.06 2.97 11.25 12 0.94 0.53 1.65 
>72 10.51 11 0.96 0.53 1.72 0.68 1 0.68 0.10 4.81 11.18 12 0.93 0.53 1.64 
>80 9.14 9 1.02 0.53 1.95 1.50 3 0.50 0.16 1.55 10.64 12 0.89 0.50 1.56 
>90 7.00 7 1.00 0.48 2.10 3.20 5 0.64 0.27 1.54 10.20 12 0.85 0.48 1.50 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 9.92 12 0.83 0.47 1.46 0.21 0    10.12 12 0.84 0.48 1.49 
>50 9.59 12 0.80 0.45 1.41 0.26 0    9.86 12 0.82 0.47 1.45 
>60 10.86 12 0.91 0.51 1.59 0.27 0    11.13 12 0.93 0.53 1.63 
>65 10.03 11 0.91 0.51 1.65 0.44 1 0.44 0.06 3.10 10.47 12 0.87 0.50 1.54 
>70 10.91 11 0.99 0.55 1.79 0.43 1 0.43 0.06 3.04 11.34 12 0.94 0.54 1.66 
>72 10.56 11 0.96 0.53 1.73 0.72 1 0.72 0.10 5.14 11.29 12 0.94 0.53 1.66 
>80 9.38 9 1.04 0.54 2.00 1.53 3 0.51 0.16 1.58 10.90 12 0.91 0.52 1.60 
>90 7.00 7 1.00 0.48 2.10 3.26 5 0.65 0.27 1.57 10.26 12 0.86 0.49 1.51 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 4.82 12 0.40 0.23 0.71 0.08 0    4.90 12 0.41 0.23 0.72 
>50 4.91 12 0.41 0.23 0.72 0.10 0    5.01 12 0.42 0.24 0.74 
>60 6.39 12 0.53 0.30 0.94 0.10 0    6.49 12 0.54 0.31 0.95 
>65 6.00 11 0.55 0.30 0.99 0.17 1 0.17 0.02 1.19 6.17 12 0.51 0.29 0.91 
>70 7.17 11 0.65 0.36 1.18 0.16 1 0.16 0.02 1.16 7.34 12 0.61 0.35 1.08 
>72 7.12 11 0.65 0.36 1.17 0.28 1 0.28 0.04 1.98 7.40 12 0.62 0.35 1.09 
>80 6.90 9 0.77 0.40 1.47 0.60 3 0.20 0.06 0.62 7.50 12 0.63 0.36 1.10 
>90 7.00 7 1.00 0.48 2.10 1.33 5 0.27 0.11 0.64 8.33 12 0.69 0.39 1.22 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 16.55 12 1.38 0.78 2.43 0.52 0    17.08 12 1.42 0.81 2.51 
>50 15.03 12 1.25 0.71 2.21 0.68 0    15.71 12 1.31 0.74 2.31 
>60 14.80 12 1.23 0.70 2.17 0.69 0    15.49 12 1.29 0.73 2.27 
>65 13.46 11 1.22 0.68 2.21 1.11 1 1.11 0.16 7.88 14.57 12 1.21 0.69 2.14 
>70 13.59 11 1.24 0.68 2.23 1.09 1 1.09 0.15 7.75 14.69 12 1.22 0.70 2.15 
>72 12.94 11 1.18 0.65 2.12 1.81 1 1.81 0.26 12.85 14.75 12 1.23 0.70 2.16 
>80 10.85 9 1.21 0.63 2.32 3.66 3 1.22 0.39 3.78 14.50 12 1.21 0.69 2.13 
>90 7.00 7 1.00 0.48 2.10 7.31 5 1.46 0.61 3.51 14.31 12 1.19 0.68 2.10 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 10.58 12 0.88 0.50 1.55 0.23 0    10.81 12 0.90 0.51 1.59 
>50 10.17 12 0.85 0.48 1.49 0.29 0    10.46 12 0.87 0.50 1.54 
>60 11.34 12 0.94 0.54 1.66 0.30 0    11.63 12 0.97 0.55 1.71 
>65 10.45 11 0.95 0.53 1.72 0.48 1 0.48 0.07 3.42 10.93 12 0.91 0.52 1.60 
>70 11.26 11 1.02 0.57 1.85 0.47 1 0.47 0.07 3.35 11.73 12 0.98 0.56 1.72 
>72 10.88 11 0.99 0.55 1.79 0.80 1 0.80 0.11 5.67 11.67 12 0.97 0.55 1.71 
>80 9.58 9 1.06 0.55 2.05 1.68 3 0.56 0.18 1.73 11.26 12 0.94 0.53 1.65 
>90 7.00 7 1.00 0.48 2.10 3.57 5 0.71 0.30 1.72 10.57 12 0.88 0.50 1.55 
Where blank, this is due to observed cases being 0 so an E/O ratio was not possible 
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For example, Table 5.10 shows the calibration performance (E/O ratio) for the McLeod 
[144] study and at a 65% threshold, when using the observed prevalence along with 
univariate sensitivity and univariate specificity to derive PPV and NPV (approach (5)) 
the E/O ratio is 0.91, but 0.87 using the univariate meta-analysis values to derive PPV 
and NPV (approach (2)) and 0.85 when using the unstratified values for prevalence, 
sensitivity and specificity to derive PPV and NPV (approach (1)).   
Table 5.11: E/O ratios using 5 approaches for Lam study at the 1-2 hours’ time-point 
Approach No. of 
hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 7.33 12 0.61 0.35 1.08 0.38 0    7.71 12 0.64 0.36 1.13 
>50 6.99 12 0.58 0.33 1.03 0.39 0    7.38 12 0.61 0.35 1.08 
>60 7.93 12 0.66 0.38 1.16 0.35 0    8.28 12 0.69 0.39 1.21 
>65 8.00 12 0.67 0.38 1.17 0.52 0    8.52 12 0.71 0.40 1.25 
>70 9.47 12 0.79 0.45 1.39 0.48 0    9.95 12 0.83 0.47 1.46 
>72 9.81 12 0.82 0.46 1.44 0.74 0    10.54 12 0.88 0.50 1.55 
>80 8.38 11 0.76 0.42 1.38 1.62 1 1.62 0.23 11.50 10.00 12 0.83 0.47 1.47 
>90 8.00 8 1.00 0.50 2.00 3.20 4 0.80 0.30 2.13 11.20 12 0.93 0.53 1.64 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 7.44 12 0.62 0.35 1.09 0.39 0    7.83 12 0.65 0.37 1.15 
>50 7.09 12 0.59 0.34 1.04 0.40 0    7.49 12 0.62 0.35 1.10 
>60 8.01 12 0.67 0.38 1.17 0.36 0    8.37 12 0.70 0.40 1.23 
>65 8.26 12 0.69 0.39 1.21 0.52 0    8.78 12 0.73 0.42 1.29 
>70 9.54 12 0.80 0.45 1.40 0.49 0    10.03 12 0.84 0.47 1.47 
>72 9.86 12 0.82 0.47 1.45 0.79 0    10.65 12 0.89 0.50 1.56 
>80 8.59 11 0.78 0.43 1.41 1.65 1 1.65 0.23 11.69 10.24 12 0.85 0.48 1.50 
>90 8.00 8 1.00 0.50 2.00 3.26 4 0.82 0.31 2.17 11.26 12 0.94 0.53 1.65 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 3.62 12 0.30 0.17 0.53 0.15 0    3.77 12 0.31 0.18 0.55 
>50 3.63 12 0.30 0.17 0.53 0.15 0    3.78 12 0.32 0.18 0.55 
>60 4.71 12 0.39 0.22 0.69 0.14 0    4.84 12 0.40 0.23 0.71 
>65 4.94 12 0.41 0.23 0.73 0.20 0    5.15 12 0.43 0.24 0.76 
>70 6.27 12 0.52 0.30 0.92 0.19 0    6.46 12 0.54 0.31 0.95 
>72 6.64 12 0.55 0.31 0.97 0.30 0    6.95 12 0.58 0.33 1.02 
>80 6.33 11 0.58 0.32 1.04 0.65 1 0.65 0.09 4.60 6.98 12 0.58 0.33 1.02 
>90 8.00 8 1.00 0.50 2.00 1.33 4 0.33 0.12 0.89 9.33 12 0.78 0.44 1.37 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 12.42 12 1.03 0.59 1.82 0.99 0    13.40 12 1.12 0.63 1.97 
>50 11.11 12 0.93 0.53 1.63 1.01 0    12.13 12 1.01 0.57 1.78 
>60 10.90 12 0.91 0.52 1.60 0.92 0    11.83 12 0.99 0.56 1.74 
>65 11.08 12 0.92 0.52 1.63 1.33 0    12.41 12 1.03 0.59 1.82 
>70 11.89 12 0.99 0.56 1.75 1.25 0    13.14 12 1.10 0.62 1.93 
>72 12.08 12 1.01 0.57 1.77 1.98 0    14.05 12 1.17 0.66 2.06 
>80 9.94 11 0.90 0.50 1.63 3.95 1 3.95 0.56 28.02 13.89 12 1.16 0.66 2.04 
>90 8.00 8 1.00 0.50 2.00 7.31 4 1.83 0.69 4.87 15.31 12 1.28 0.72 2.25 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 9.87 12 0.82 0.47 1.45 0.62 0    10.49 12 0.87 0.50 1.54 
>50 9.12 12 0.76 0.43 1.34 0.63 0    9.75 12 0.81 0.46 1.43 
>60 9.57 12 0.80 0.45 1.40 0.58 0    10.15 12 0.85 0.48 1.49 
>65 9.79 12 0.82 0.46 1.44 0.84 0    10.63 12 0.89 0.50 1.56 
>70 10.87 12 0.91 0.51 1.59 0.78 0    11.65 12 0.97 0.55 1.71 
>72 11.11 12 0.93 0.53 1.63 1.25 0    12.37 12 1.03 0.59 1.81 
>80 9.38 11 0.85 0.47 1.54 2.57 1 2.57 0.36 18.23 11.95 12 1.00 0.57 1.75 
>90 8.00 8 1.00 0.50 2.00 4.95 4 1.24 0.46 3.30 12.95 12 1.08 0.61 1.90 
Where blank, this is due to observed cases being 0 so an E/O ratio was not possible 
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Similarly, in the Lam [141] study E/O is 0.71, 0.73 and 0.89 when using the unstratified 
(approach (1)), univariate meta-analysis average (approach (2)), or observed study 
prevalence (approach (5)) to derive PPV and NPV (Table 5.11) to assess calibration 
performance of the predictive test. Results for other studies are shown in APPENDIX B. 
Similar conclusions were found at 6 hours (see APPENDIX B). 
5.3.3 Meta-analysis of E/O estimates 
5.3.3.1 0-20 minutes time-point 
To display the range of E/O values across studies at each threshold and to examine if 
the variation is due to chance or heterogeneity, a meta-analysis is possible. Now take the 
threshold of 65% as an example, and consider a meta-analysis of the calibration 
performance of PPV and NPV derived from approaches 1, 2 and 5. Approaches 3 and 4 
are not considered here as they are extreme examples due to the low and high values of 
prevalence used in those approaches. Approaches 1, 2 and 5 represent a more realistic 
approach in practice.  
(i) Approach 1: 
This approach used the unstratified prevalence, sensitivity and specificity to derive PPV 
and NPV for the predictive test. 
Figure 5.1 shows that although the average E/O value is at 1.02, 95% CI: (0.56, 1.86), 
the values for individual studies differs as some are lower than 1 and some are above 1. 
This is reflected in the heterogeneity as I-squared=85.5%, which is very high, with 
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statistical significance of heterogeneity in E/O (p<0.001). The 95% prediction interval 
as shown in Figure 5.1 is very wide reflecting the uncertainty in the E/O value when the 
unstratified approach is used to derive PPV and NPV to any one setting. 
(ii) Approach 2: 
This approach used the univariate prevalence, univariate sensitivity and univariate 
specificity to derive PPV and NPV for the predictive test. 
Figure 5.1 shows that, although the average E/O value is at 1.11 (0.61, 2.03), the values 
for individual studies still differ as some are lower than 1 and some are above 1. This is 
reflected in the heterogeneity as I-squared=85.7% which is again very high, with 
statistical significance (p<0.001). The 95% prediction interval as shown in Figure 5.1 is 
also very wide reflecting in the uncertainty surrounding E/O in a single setting.  Thus, 
using PPV and NPV as derived from either approaches 1 and 2 appears to calibrate well 
on average across all studies, but the wide prediction interval and large heterogeneity 
indicate potentially poorer calibration performance in individual clinical settings. 
(iii) Approach 5: 
This approach uses the study’s observed prevalence, univariate sensitivity and 
univariate specificity to derive the PPV and NPV of the predictive test. 
Figure 5.1 shows that the average E/O value is at 1.05 (0.80, 1.37), and now the E/O 
values for individual studies are quite similar to this. This is reflected in very little 
heterogeneity as I-squared=31.2% and p-value=0.21. Thus by using the observed 
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prevalence in each study, the heterogeneity in E/O statistics is reduced drastically and 
any variation across studies appears potentially due to chance. Further the summary E/O 
of 1.05 indicates the calibration performance of the predictive test is very good, though 
the 95% CI is wide. Of particular interest are the Lo [142] and Lombardi [143] studies; 
using the first two approaches to derive PPV and NPV, the calibration performance is 
shown to be over and under predicting greatly, whilst using fifth approach to derive 
PPV and NPV has much better calibration performance with the E/O much closer to 1 
(Figure 5.1). 
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Figure 5.1: Meta-analysis of E/O for the 3 different approaches at the 0-20 minute’s time-point 
 
5.3.3.2 1-2 hours’ time-point 
The same finding can be seen in the meta-analysis at 1-2 hours (Figure 5.2). Although 
there is no heterogeneity in any analysis (I-squared=0%), the approach utilising the 
study’s own prevalence to derive PPV and NPV improves the calibration performance 
of the predictive test with an E/O of 0.94, closer to 1 than the unstratified (0.83) and 
univariate (0.85) approaches. 
NOTE: Weights are from random effects analysis
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Figure 5.2: Meta-analysis of E/O for the 3 different approaches at the 1-2 hours’ time-point 
 
5.3.3.3 Meta-analysis results for Approaches 1, 2 and 5 for the thresholds 60-80 
In sections 5.4.3.1 and 5.4.3.2, threshold 65% was used for meta-analysis, in terms of 
the E/O ratio across the studies at the two time-points of 0-20 minutes and 1-2 hours (as 
6 hours only had 2 studies contributing data, this was not meta-analysed). Now 
presented are the meta-analysis results from other thresholds 60-80% to show a general 
overview in Table 5.12.  
NOTE: Weights are from random effects analysis
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For the 0-20 minute’s time-point, in general deriving PPV and NPV using approach 1 
gives a good average effect around 1.00 of the calibration performance of the predictive 
test, but also has high heterogeneity with I-squared being around 60%. Deriving PPV 
and NPV using approach 2 gives the same level of heterogeneity but with a slightly 
higher average effect around 1.09 of the calibration performance. Deriving PPV and 
NPV using approach 5 has a good average effect around 0.99 of the calibration 
performance, apart from the 80% threshold which has an E/O of 0.92, and there is no 
heterogeneity present which shows deriving PPV and NPV using the studies observed 
prevalence combined with the univariate values for sensitivity and specificity eliminates 
between-study heterogeneity. 
For the 1-2 hours’ time-point, the results are interesting, as there is no between-study 
heterogeneity present in the calibration performance of PPV and NPV derived from any 
of the approaches used. The calibration performance of PPV and NPV derived from 
approach 1 has an average E/O around 0.85, with the calibration performance of PPV 
and NPV derived from approach 2 having similar E/O ratios but slightly higher. In this 
example, the calibration performance (E/O) improves for PPV and NPV derived from 
approach 5 compared to the calibration performance of PPV and NPV derived from the 
first two approaches, with the E/O being around 0.95. Although there is no between-
study heterogeneity in the calibration performance of the PPV and NPV derived from 
the first two approaches, the calibration is poorer compared to the PPV and NPV 
derived from approach 5 as it is almost 0.1 lower, which could make an important 
difference in clinical practice. 
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Table 5.12: Meta-analysis values for E/O for various thresholds at the 0-20 minutes and 1-2 hour 
time-points 
 Pooled 95% 
CI 
  95% 
PI 
0-20minutes E/O Lower Upper I
2 𝝉𝟐 Lower Upper 
Approach (1)        
>60 0.99 0.61 1.61 60.0% 0.17 0.21 4.61 
>65 1.00 0.60 1.66 63.3% 0.20 0.19 5.13 
>70 1.00 0.62 1.64 61.0% 0.18 0.21 4.81 
>72 1.00 0.60 1.66 63.7% 0.20 0.19 5.19 
>80 1.03 0.65 1.63 55.4% 0.14 0.25 4.23 
Approach (2)        
>60 1.08 0.66 1.75 60.5% 0.17 0.23 5.06 
>65 1.09 0.65 1.81 63.9% 0.20 0.21 5.65 
>70 1.08 0.66 1.78 61.8% 0.19 0.22 5.31 
>72 1.09 0.65 1.83 64.6% 0.21 0.20 5.84 
>80 1.03 0.65 1.62 54.8% 0.14 0.25 4.14 
Approach (5)        
>60 0.99 0.75 1.32 0% 0.00 0.63 1.58 
>65 0.99 0.74 1.32 0% 0.00 0.62 1.57 
>70 0.98 0.74 1.31 0% 0.00 0.62 1.56 
>72 0.99 0.75 1.32 0% 0.00 0.62 1.58 
>80 0.92 0.69 1.23 0% 0.00 0.58 1.47 
1-2 hours        
Approach (1)        
>60 0.83 0.62 1.12 0% 0.00 0.52 1.34 
>65 0.83 0.62 1.12 0% 0.00 0.52 1.35 
>70 0.87 0.65 1.16 0% 0.00 0.54 1.40 
>72 0.86 0.65 1.16 0% 0.00 0.54 1.39 
>80 0.86 0.64 1.16 0% 0.00 0.53 1.39 
Approach (2)        
>60 0.84 0.63 1.13 0% 0.00 0.53 1.35 
>65 0.86 0.64 1.15 0% 0.00 0.54 1.38 
>70 0.88 0.65 1.17 0% 0.00 0.55 1.41 
>72 0.87 0.65 1.17 0% 0.00 0.54 1.40 
>80 0.88 0.66 1.17 0% 0.00 0.55 1.41 
Approach (5)        
>60 0.93 0.70 1.25 0% 0.00 0.58 1.50 
>65 0.95 0.71 1.27 0% 0.00 0.59 1.52 
>70 0.95 0.71 1.27 0% 0.00 0.59 1.52 
>72 0.94 0.70 1.26 0% 0.00 0.59 1.51 
>80 0.95 0.71 1.28 0% 0.00 0.59 1.53 
5.3.4 Approach 6, 'internal-external' cross-validation 
In Chapter 3, it was found that few articles performed external validation, with most 
preferring internal validation, but a few articles used the IECV approach. This approach 
will now be applied to the PTH data in relation to the calibration performance of PPV 
and NPV derived for using the predictive test in practice.  
Here the IECV approach is used to examine if using the summary sensitivity and 
specificity from four studies in the meta-analysis phase can be combined with a study-
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specific prevalence to obtain PPV and NPV values that are well-calibrated for use in the 
omitted study. This is a similar idea to Willis and Hyde [156], who suggest examining 
whether tailored meta-analysis results are need for individual settings, rather than 
naively applying summary meta-analysis results everywhere. Note that there is only  a 
small decision tree here to validate using IECV; there are two branches (predicted risk 
based on either positive or negative PTH values), which is typical in a diagnostic (or 
short-term prognostic) test situation where a threshold us used to make clinical decision 
based on positive (high) or negative (low) levels of a test. However, this situation is 
similar to the use of a risk score from a prediction model containing multiple variables, 
which is then dichotomised at a particular threshold (to provide high and low levels) to 
inform clinical decision making. 
Table 5.13 shows the summary sensitivity and specificity values along with their tau-
squared values from the univariate meta-analysis for each combination of four studies 
plus one study excluded, where one study is left out each time and the univariate meta-
analysis is performed on the remaining four studies. Also, the prevalence for each of the 
excluded studies is stated along with the PPV and NPV values.  
Table 5.13 shows that the sensitivity and specificity values are similar to those when all 
five studies are analysed together, although some of these combinations are lower, i.e. 
when Lam 03 was excluded the sensitivity and specificity were slightly lower whilst the 
tau-squared values were similar. But when Lombardi 04 was excluded the sensitivity 
values were higher but the specificity values were similar to the univariate analysis with 
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all 5 studies. Also, the tau-squared values for sensitivity were much larger at 34.61 for 
the first three thresholds. 
Table 5.13 contains the columns PPV and NPV predicted for the excluded study; these 
values were calculated in the excluded study using the study’s own prevalence, 
combined with the summary sensitivity and specificity values calculated for the four 
development studies (akin to approach 5). In Table 5.14, each of the five combinations 
is shown with E/O having being calculated for each threshold. 
Table 5.13: Sensitivity and specificity values when 'internal-external' cross-validation approach 
compared to the univariate approach for the 1-2 hours’ time-point 
% PTH 
Decrease 
Sensitivity Specificity Ʈ2Sens Ʈ
2
Spec Prevalence 
in 
excluded 
study 
PPV 
predicted 
for 
excluded 
study 
NPV 
predicted 
for 
excluded 
study 
Approach 2        
>40 95.56 52.14 0.00 0.00    
>50 95.56 63.31 0.00 0.01    
>60 95.56 80.34 0.00 0.00    
>65 93.33 82.19 0.00 0.02    
>70 93.33 88.03 0.00 0.00    
>80 77.78 94.02 0.00 0.00    
>90 55.56 100.00 0.00 0.06    
Approach 6 Univariate (4 studies) Lam 03 [141] excluded 
>40 93.94 48.35 0.00 0.00 0.31 44.97 94.67 
>50 93.94 58.24 0.00 0.00 0.31 50.26 95.53 
>60 93.94 76.92 0.00 0.00 0.31 64.65 96.58 
>65 90.91 80.22 0.00 0.00 0.31 67.37 95.16 
>70 90.91 86.81 0.00 0.00 0.31 75.59 95.51 
>80 72.73 92.31 0.00 0.00 0.31 80.95 88.28 
>90 47.99 100.00 4.88 0.00 0.31 100.00 81.06 
Approach 6 Univariate (4 studies) Lombardi 04 [143] excluded 
>40 99.93 52.66 34.61 0.06 0.31 48.68 99.94 
>50 99.93 65.89 34.61 0.04 0.31 56.83 99.95 
>60 99.93 79.42 34.61 0.05 0.31 68.57 99.96 
>65 93.10 80.50 0.00 0.01 0.31 68.20 96.29 
>70 93.10 87.80 0.00 0.00 0.31 77.42 96.59 
>80 79.31 94.22 0.00 0.11 0.31 86.04 91.02 
>90 44.14 100.00 5.32 0.00 0.31 100.00 79.94 
Approach 6 Univariate (4 studies) McLeod 06 [144] excluded 
>40 93.94 56.52 0.00 0.00 0.23 39.22 96.90 
>50 93.94 65.45 0.00 0.03 0.23 44.82 97.31 
>60 93.94 82.61 0.00 0.00 0.23 61.74 97.86 
>65 93.94 84.78 0.00 0.02 0.23 64.83 97.91 
>70 93.94 90.22 0.00 0.00 0.23 74.15 98.03 
>80 78.79 95.65 0.00 0.00 0.23 84.40 93.79 
>90 50.21 100.00 5.93 0.00 0.23 100.00 87.05 
Approach 6 Univariate (4 studies) Warren 02 [145] excluded 
>40 97.67 51.37 0.00 0.01 0.18 30.60 99.01 
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% PTH 
Decrease 
Sensitivity Specificity Ʈ2Sens Ʈ
2
Spec Prevalence 
in 
excluded 
study 
PPV 
predicted 
for 
excluded 
study 
NPV 
predicted 
for 
excluded 
study 
>50 97.67 63.45 0.00 0.02 0.18 36.97 99.20 
>60 97.67 80.73 0.00 0.00 0.18 52.66 99.37 
>65 95.35 83.55 0.00 0.04 0.18 55.99 98.79 
>70 95.35 87.16 0.00 0.00 0.18 61.98 98.84 
>80 79.07 93.58 0.00 0.00 0.18 73.00 95.32 
>90 56.52 100.00 3.74 254523.70 0.18 100.00 91.29 
Approach 6 Univariate (4 studies) Warren 04 [146] excluded 
>40 95.24 52.29 0.00 0.04 0.11 19.79 98.89 
>50 95.24 64.16 0.00 0.05 0.11 24.72 99.09 
>60 95.24 81.91 0.00 0.00 0.11 39.42 99.29 
>65 92.86 85.11 0.00 0.00 0.11 43.53 98.97 
>70 92.86 88.30 0.00 0.00 0.11 49.52 99.01 
>80 78.57 94.80 0.00 0.05 0.11 65.13 97.28 
>90 56.98 100.00 2.90 2450.74 0.11 100.00 94.95 
 
Table 5.14: E/O ratios for all combinations of excluded studies 
 No. of 
hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
 E/O for Lam study [141] when it was excluded 
>40 10.98 12 0.92 0.52 1.61 0.28 0    11.26 12 0.94 0.53 1.65 
>50 10.31 12 0.86 0.49 1.51 0.38 0    10.69 12 0.89 0.51 1.57 
>60 11.73 12 0.98 0.56 1.72 0.39 0    12.12 12 1.01 0.57 1.78 
>65 11.02 11 1.00 0.55 1.81 0.42 1 0.42 0.06 2.97 11.44 12 0.95 0.54 1.68 
>70 11.86 11 1.08 0.60 1.95 0.41 1 0.41 0.06 2.94 12.28 12 1.02 0.58 1.80 
>80 10.13 9 1.13 0.59 2.16 1.55 3 0.52 0.17 1.60 11.68 12 0.97 0.55 1.71 
>90 7.00 7 1.00 0.48 2.10 3.89 5 0.78 0.32 1.87 10.89 12 0.91 0.52 1.60 
 E/O for Lombardi 04 [143] study when it was excluded 
>40 15.58 15 1.04 0.63 1.72 0.01 1 0.01 0.00 0.08 15.59 16 0.97 0.60 1.59 
>50 17.05 15 1.14 0.69 1.89 0.01 1 0.01 0.00 0.07 17.06 16 1.07 0.65 1.74 
>60 14.40 15 0.96 0.58 1.59 0.01 1 0.01 0.00 0.09 14.41 16 0.90 0.55 1.47 
>65 14.32 15 0.95 0.58 1.58 1.11 1 1.11 0.16 7.90 15.44 16 0.96 0.59 1.57 
>70 14.71 15 0.98 0.59 1.63 1.09 1 1.09 0.15 7.75 15.80 16 0.99 0.61 1.61 
>80 12.05 12 1.00 0.57 1.77 3.32 4 0.83 0.31 2.21 15.37 16 0.96 0.59 1.57 
>90 10.00 10 1.00 0.54 1.86 8.22 6 1.37 0.62 3.05 18.22 16 1.14 0.70 1.86 
 E/O for McLeod [144] study when it was excluded 
>40 10.98 12 0.92 0.52 1.61 0.28 0    11.26 12 0.94 0.53 1.65 
>50 10.31 12 0.86 0.49 1.51 0.38 0    10.69 12 0.89 0.51 1.57 
>60 11.73 12 0.98 0.56 1.72 0.39 0    12.12 12 1.01 0.57 1.78 
>65 11.02 11 1.00 0.55 1.81 0.42 1 0.42 0.06 2.97 11.44 12 0.95 0.54 1.68 
>70 11.86 11 1.08 0.60 1.95 0.41 1 0.41 0.06 2.94 12.28 12 1.02 0.58 1.80 
>80 10.13 9 1.13 0.59 2.16 1.55 3 0.52 0.17 1.60 11.68 12 0.97 0.55 1.71 
>90 7.00 7 1.00 0.48 2.10 3.89 5 0.78 0.32 1.87 10.89 12 0.91 0.52 1.60 
 E/O for Warren 02 [145] study when excluded 
>40 1.22 1 1.22 0.17 8.69 0.06 1 0.06 0.01 0.42 1.28 2 0.64 0.16 2.57 
>50 1.48 1 1.48 0.21 10.50 0.05 1 0.05 0.01 0.34 1.53 2 0.76 0.19 3.05 
>60 1.58 1 1.58 0.22 11.22 0.04 1 0.04 0.01 0.31 1.62 2 0.81 0.20 3.25 
>65 1.68 1 1.68 0.24 11.92 0.08 1 0.08 0.01 0.60 1.76 2 0.88 0.22 3.53 
>70 0.62 1 0.62 0.09 4.40 0.10 1 0.10 0.01 0.74 0.72 2 0.36 0.09 1.45 
>80 0.73 1 0.73 0.10 5.18 0.42 1 0.42 0.06 2.99 1.15 2 0.58 0.14 2.30 
>90 0.00 0    0.87 2 0.44 0.11 1.74 0.87 2 0.44 0.11 1.74 
 E/O for Warren 04 [146] study when excluded 
>40 2.77 3 0.92 0.30 2.86 0.13 0    2.90 3 0.97 0.31 3.00 
>50 2.97 3 0.99 0.32 3.07 0.13 0    3.09 3 1.03 0.33 3.20 
>60 3.55 3 1.18 0.38 3.67 0.12 0    3.67 3 1.22 0.39 3.79 
>65 3.92 3 1.31 0.42 4.05 0.18 0    4.09 3 1.36 0.44 4.23 
>70 2.97 3 0.99 0.32 3.07 0.20 0    3.17 3 1.06 0.34 3.28 
>80 2.61 2 1.30 0.33 5.21 0.60 1 0.60 0.08 4.25 3.20 3 1.07 0.34 3.31 
>90 0.00 0    1.31 3 0.44 0.14 1.36 1.31 3 0.44 0.14 1.36 
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In Figure 5.3, the E/O values for the 65% threshold are meta-analysed to look at the 
predictive performance of each study in a meta-analysis. Each of these studies is taken 
from the IECV approach, where each study was the validation study (excluded from 
meta-analysis phase). On average it appears the calibration performance of derived PPV 
and NPV for the predictive test (E/O) is close to 1, with Warren 02 [145] study being 
0.88 and Warren 04 [146] study being 1.36 being the worst. However, these are smaller 
studies as shown by their weighting and actually there is no between-study 
heterogeneity present as I-squared=0% with a p=0.98.  
As shown in Figure 5.2, using approach 5 to derive PPV and NPV yields an overall 
calibration performance result of 0.94 (0.74, 1.19); however, approach 5 did not 
examine performance in independent data to the meta-analysis. This is resolved by 
using the IECV approach (as performance is checked in new data), and reassuringly it 
gives a similar calibration performance result of 0.96 (0.80, 1.16) with a narrower 95% 
confidence interval. This again shows the PPV and NPV to use in clinical practice need 
to be tailored from the meta-analysis by using the study-specific prevalence with the 
meta-analysis results for sensitivity and specificity. Crucially, this finding was missed 
by Noordzij et al. [94] in their original publication, who recommended PPV and NPV 
values based on the unstratified prevalence. 
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Figure 5.3: Meta-analysis of E/O values from 'internal-external' cross validation approach for 
threshold 65% and time-point 1-2 hours 
 
5.4 Results II -What is the best threshold? 
In this final analysis section, the aim is to illustrate issues in choosing the best threshold 
for PTH based on the univariate and unstratified meta-analysis results 
5.4.1 Illustration of how meta-analysis can change the best threshold decision 
based on sensitivity and specificity alone 
Consider first that sensitivity and specificity are deemed equally important, and so the 
greatest sum from Youden’s statistic (Equation 4.4) is preferred. To illustrate how the 
unstratified approach and meta-analysis approach may change inferences about the 
choice of threshold, consider a meta-analysis of just two of the studies (the same two 
studies providing data for the 6 hour time point, Lam [141] and Lombardi [143]) at the 
NOTE: Weights are from random effects analysis
.       (0.71, 1.30)with estimated predictive interval
Overall  (I-squared = 0.0%, p = 0.978)
ID
McLeod
Lombardi
Study
Warren 2002
Warren 2004
Lam
0.96 (0.80, 1.16)
E/O (95% CI)
0.95 (0.61, 1.47)
0.96 (0.75, 1.22)
0.88 (0.37, 2.07)
1.36 (0.47, 3.98)
0.95 (0.59, 1.53)
100.00
Weight
17.97
58.92
%
4.71
3.00
15.40
  
10.3 3.9820.5
Meta-analysis of E/O values from 'internal-external' cross-validation approach
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1-2 hours’ time point. Table 5.15 shows the unstratified and univariate results at each 
threshold, and Table 5.16 indicates that the unstratified approach identifies a 70% 
threshold value as optimal but the meta-analysis identifies now suggests either a 65% or 
70% as optimal.  
Table 5.15: Sensitivity and Specificity of PTH assay in predicting postoperative hypocalcaemia for 
1-2 hours using the same two studies that provided data for the 6 hours analysis; univariate meta-
analysis results 
1-2 hours  95% CI  95% CI 
% PTH 
Decrease 
Sensitivity Lower Upper Specificity Lower Upper 
Approach 1       
>40 96.43 82.29 99.37 57.38 44.90 68.98 
>50 96.43 82.29 99.37 67.21 54.72 77.66 
>60 96.43 82.29 99.37 86.89 76.20 93.20 
>65 96.43 82.29 99.37 90.16 80.16 95.41 
>70 96.43 82.29 99.37 91.80 82.21 96.45 
>72 89.29 72.80 96.29 91.80 82.21 96.45 
>80 82.14 64.41 92.12 96.72 88.81 99.10 
>90 64.29 45.83 79.29 100.00 94.08 100.00 
Approach 2       
>40 96.43 78.58 99.50 57.38 44.76 69.10 
>50 97.56 62.64 99.90 69.04 48.94 83.84 
>60 96.43 78.58 99.50 86.88 75.90 93.30 
>65 96.43 78.58 99.50 90.16 79.79 95.51 
>70 96.43 78.58 99.50 90.16 79.79 95.51 
>72 90.63 57.84 98.55 91.82 81.73 96.58 
>80 83.11 60.27 94.10 97.29 80.95 99.67 
>90 64.29 45.38 79.59 100.00  100.00 
Table 5.16: Table for Youden’s statistic comparing the two approaches for 1-2 hours, using the two 
studies that have provided data for the 6 hour time point 
1-2 hours Youden’s statistic 
% PTH Decrease Approach 1 Approach 2 
>40 153.81 153.81 
>50 163.64 166.60 
>60 183.32 183.31 
>65 186.59 186.59 
>70 188.23 186.59 
>72 181.09 182.45 
>80 178.86 180.37 
>90 164.29 164.29 
5.4.2 What is the best threshold? 
In the original paper by Noordzij et al. [94], the choice of optimal threshold was based 
on sum of sensitivity and specificity, where harm and benefit were regarded as being 
equally important. But the best threshold choice will depend on whether it is more 
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important to have the least number of false negatives only or it is also important to 
identify the least number of false positives. Now, in this clinical setting, false positives 
will be patients who are testing positive but will not become hypocalcaemic so actually 
will be fine and so stay in hospital longer than necessary. But, a false negative will be a 
patient who will become hypocalcaemic but test negative, and so the patient will 
wrongly be sent home, then develop hypocalcaemia and be treated late, with potentially  
troublesome consequences and distress. Thus it could be argued that only patients who 
are wrongly sent home are a concern, and thus minimises the number of false-negatives 
is a priority. 
A threshold formula is now considered, where the aim is to minimise the output value to 
determine the optimal threshold as specified in the book “Decision making in health and 
medicine” [157] by Myriam Hunink et al.: 
 
𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 =
ℎ𝑎𝑟𝑚
(ℎ𝑎𝑟𝑚 + 𝑏𝑒𝑛𝑒𝑓𝑖𝑡)
 
(Equation 5.9) 
Values closest to 1 indicates the preferred threshold and this formula has been 
multiplied by 100 for this thesis. 
5.4.2.1 Harm and benefit I 
In this instance, regard harm as (1-NPV) and benefit as NPV. Thus we are only 
interested in those who test negative (those who test positive are ignored). 
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When we regard harm and benefit as being equal this formula then gives us a threshold 
of: 
Threshold = (1-NPV)/((1-NPV)+NPV)) 
= (1-NPV) 
Thus we are using the largest NPV to determine the best threshold. 
Table 5.17: Largest NPV for 0-20 minutes 
Thresholds Approach 1 Approach 2 
 
PPV NPV PPV NPV 
>40 31.00 96.26 32.57 96.39 
>50 36.59 97.05 37.12 96.99 
>60 43.89 94.66 48.91 94.87 
>65 45.75 93.53 51.46 93.76 
>70 47.22 93.64 52.35 93.81 
>72 48.26 93.72 54.62 93.94 
>80 56.00 90.91 56.50 91.23 
>90 67.20 84.36 59.25 81.45 
 
Table 5.17 shows that 50% is the best threshold to obtain the largest NPV at the time-
point of 0-20 minutes, this means that we consider the best threshold to be the one that 
has the lowest number of false negatives. False negatives are patients who are 
incorrectly classified as being negative when they actually will be getting the disease in 
question. From a patients perspective this is most important, thus this method suggests 
50% as the best threshold for this time-point. At other time-points Tables 5.18 and 5.19 
suggest that 60% or 65% is the best threshold. 
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Table 5.18: 1-2 hours 
Thresholds Approach 1 Approach 2 
 
PPV NPV PPV NPV 
>40 34.89 97.77 35.42 97.71 
>50 41.11 98.15 41.71 98.11 
>60 56.61 98.54 57.18 98.50 
>65 57.13 97.84 59.01 97.82 
>70 67.67 98.01 68.17 97.96 
>72 70.04 96.92 70.42 96.71 
>80 76.15 94.00 78.13 93.90 
>90 100.00 89.34 100.00 89.12 
Table 5.19: 6 hours 
Thresholds Approach 1 Approach 2 
 
PPV NPV PPV NPV 
>40 41.27 98.51 41.83 98.47 
>50 51.31 98.75 51.89 98.72 
>60 64.83 98.90 65.38 98.87 
>65 74.69 98.96 75.13 98.94 
>70 78.03 97.98 78.42 97.93 
>72 82.00 97.05 82.71 97.38 
>80 80.04 94.28 80.50 94.23 
>90 90.30 90.31 90.50 90.10 
 
5.4.2.2 Harm and benefit II 
Now we consider hypothetically that harm outweighs benefit by 20: 1, 50:1 and 100:1, 
i.e. meaning it is 20/50/100 times worse for someone to be sent home incorrectly. For 
example, for the 20:1 ratio, Equation 5.9 becomes:  
(1-NPV)/ ((1-NPV) + (1/20*NPV)) 
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Table 5.20: Worse to send someone home incorrectly for 0-20 minutes 
Thresholds 20:1 50:1 100:1 
 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
>40 43.73 42.83 66.02 65.19 79.53 78.93 
>50 37.81 38.30 60.31 60.81 75.25 75.63 
>60 53.01 51.96 73.83 73.00 84.94 84.39 
>65 58.05 57.10 77.57 76.89 87.37 86.94 
>70 57.60 56.89 77.25 76.74 87.17 86.84 
>72 57.27 56.34 77.01 76.33 87.01 86.58 
>80 66.66 65.78 83.33 82.78 90.91 90.58 
>90 78.76 82.00 90.26 91.93 94.88 95.79 
Regard highest threshold value as the best threshold. These are bold. 
Table 5.21: Worse to send someone home incorrectly for 1-2 hours 
Thresholds 20:1 50:1 100:1 
 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
>40 31.33 31.91 53.28 53.96 69.52 70.09 
>50 27.38 27.81 48.52 49.06 65.34 65.83 
>60 22.86 23.35 42.56 43.23 59.70 60.36 
>65 30.63 30.83 52.47 52.70 68.82 69.03 
>70 28.88 29.40 50.38 51.01 67.00 67.56 
>72 38.86 40.49 61.37 62.98 76.06 77.28 
>80 56.07 56.51 76.14 76.46 86.46 86.66 
>90 70.47 70.94 85.64 85.92 92.27 92.43 
Table 5.22: Worse to send someone home incorrectly for 6 hours 
Thresholds 20:1 50:1 100:1 
 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
>40 23.23 23.71 43.06 43.72 60.20 60.84 
>50 20.20 20.59 38.76 39.33 55.87 56.46 
>60 18.20 18.61 35.74 36.36 52.66 53.33 
>65 17.37 17.65 34.45 34.88 51.24 51.72 
>70 29.19 29.71 50.76 51.38 67.34 67.88 
>72 37.81 34.98 60.31 57.36 75.25 72.90 
>80 54.82 55.05 75.21 75.38 85.85 85.96 
>90 68.21 68.73 84.29 84.60 91.47 91.66 
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Tables 5.20-5.22 show that for 0-20 minutes, 1-2 hours and 6 hours this threshold 
formula gives a different optimal threshold than found previously in the largest NPV 
approach which is 90%. This is when harm is regarded as (1-NPV) and benefit is 
regarded as NPV. 
5.4.2.3 Harm and benefit III 
In this instance regard harm as (1-NPV) + (1-PPV) and benefit as NPV+PPV 
When we regard harm and benefit as being equal this formula then gives us a threshold 
of: 
Treatment threshold = ((1-NPV) + (1-PPV))/ (((1-NPV) + (1-PPV)) + (NPV+PPV)) 
= ((1-NPV) + (1-PPV))/2 
This is given in the tables and also the 20:1, 50:1 and 100:1 hypothetical situations. 
I.e. for the 20:1 the threshold is = ((1-NPV) + (1-PPV))/ (((1-NPV) + (1-PPV)) + 
(1/20(NPV+PPV))) 
Table 5.23: Harm and benefit equal and worse to send someone home for 0-20 minutes 
Thresholds Equal 20:1 50:1 100:1 
 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
>40 
36.37 35.52 91.96 91.68 96.62 96.50 98.28 98.22 
>50 
33.18 32.95 90.85 90.76 96.13 96.09 98.03 98.01 
>60 
30.73 28.11 89.87 88.66 95.69 95.13 97.80 97.51 
>65 
30.36 27.39 89.71 88.30 95.61 94.97 97.76 97.42 
>70 
29.57 26.92 89.36 88.05 95.45 94.85 97.67 97.36 
>72 
29.01 25.72 89.10 87.38 95.33 94.54 97.61 97.19 
>80 
26.55 26.14 87.85 87.62 94.76 94.65 97.31 97.25 
>90 
24.22 29.65 86.47 89.39 94.11 95.47 96.97 97.68 
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For this method it appears the choice of optimal threshold differs as the optimal 
threshold in this instance is 40% (see Table 5.23). This shows that when we assign what 
is more important in terms of harm and benefit and the different choices available, our 
choice of optimal threshold can vary drastically.. 
Table 5.24: Harm and benefit equal and worse to send someone home for 1-2 hours 
Thresholds Equal 20:1 50:1 100:1 
 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
>40 
33.67 33.44 91.03 90.95 96.21 96.17 98.07 98.05 
>50 
30.37 30.09 89.72 89.59 95.62 95.56 97.76 97.73 
>60 
22.43 22.16 85.25 85.06 93.53 93.44 96.66 96.61 
>65 
22.52 21.59 85.32 84.63 93.56 93.23 96.67 96.49 
>70 
17.16 16.94 80.56 80.31 91.20 91.07 95.39 95.32 
>72 
16.52 16.44 79.83 79.73 90.82 90.77 95.19 95.16 
>80 
14.93 13.99 77.82 76.48 89.77 89.05 94.61 94.21 
>90 
5.33 5.44 52.96 53.50 73.79 74.20 84.92 85.19 
Table 5.25: Harm and benefit equal and worse to send someone home for 6 hours 
Thresholds Equal 20:1 50:1 100:1 
 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
Approach 
1 
Approach 
2 
>40 
30.11 29.85 89.60 89.49 95.56 95.51 97.73 97.70 
>50 
24.97 24.70 86.94 86.77 94.33 94.25 97.08 97.04 
>60 
18.14 17.88 81.59 81.32 91.72 91.58 95.68 95.61 
>65 
13.18 12.97 75.22 74.87 88.35 88.16 93.82 93.71 
>70 
12.00 11.83 73.16 72.84 87.20 87.02 93.16 93.06 
>72 
10.48 9.96 70.06 68.86 85.40 84.68 92.13 91.71 
>80 
12.84 12.64 74.66 74.31 88.05 87.85 93.64 93.53 
>90 
9.70 9.70 68.23 68.24 84.30 84.30 91.48 91.48 
Tables 5.24-5.25 both give the same optimal threshold of 40%, this is because PPV + 
NPV and ((1-PPV) + (1-NPV)) are regarded as having equal importance. What this 
means is that it is equally important to identify patients who will stay in hospital who 
will be getting the disease as is identifying the patients who will not get the disease and 
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who should be sent home. This might be important for a hospital so they can only keep 
patients who will be getting the disease. But for a patient it is more important to be 
correctly diagnosed negatively and not to be sent home if they can get the disease. 
Therefore the largest NPV and the approach where harm and benefit are just regarded as 
(1-NPV) and NPV respectively is the most important method of defining the optimal 
threshold from a patient’s perspective based on the risks posed by being incorrectly 
classified as being negative. The original authors say it is important to identify as early 
as possible those at high risk of hypocalcaemia and decide which patients not to send 
home. Thus it appears using the NPV (and (1-NPV) for threshold formula) alone is the 
best way to determine the optimal threshold. 
So, the authors’ original recommendation of 65% as the best threshold based on the 
largest combination of sensitivity and specificity in this instance appears reasonable, 
although in a different scenario the best threshold could have been completely different, 
as these conclusions were obtained in this section by a different route. 
5.5 Discussion 
In Chapter 4, the unstratified analysis performed by Noordzij et al. [94] was replicated 
and then compared to meta-analysis results for discrimination. In this chapter, the 
approaches have now been compared in regards to PPV and NPV, and to assess 
calibration performance using the E/O ratio. This chapter has shown that the method of 
analysis (unstratified/univariate) can lead to different values for PPV and NPV, as can 
the choice of prevalence to use in the clinical population for application. For the PTH 
test, the choice of prevalence was shown to be especially important in improving the 
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calibration performance for individual studies, so that the PPV and NPV yield an E/O 
ratio that is closer to 1 in all clinical settings (not just on average) when compared to 
using the average prevalence. To help establish this, the IECV approach was useful, as 
it allowed the calibration of PPV and NPV from meta-analysis to be checked in new 
data (independent to that used to derive the summary sensitivity and specificity results). 
Even though the analysis to determine the best threshold for PTH agreed with the 
original author’s original recommendation of 65%, this work shows that the value of 
PPV and NPV for the PTH test depends heavily on the prevalence in the intended 
population, and so clinicians must use their own population prevalence (but can use the 
summary sensitivity and specificity meta-analysis results) when deriving PPV and NPV. 
5.5.1 Key findings 
In Chapter 4, it was found that the sensitivity and specificity results from the three 
methods (unstratified, univariate and bivariate methods) are often similar, but here the 
differences are more dramatic when assessing calibration performance of the predictive 
test. In particular, when using each study’s own prevalence the calibration performance 
of PPV and NPV improves dramatically compared to using the overall unstratified or 
univariate prevalence. 
This chapter has also shown that the 'internal-external' validation approach can be 
applied to test accuracy research and indicates that this can help to evaluate calibration 
performance of a test’s PPV and NPV values. Here it revealed that, for the PTH test, 
PPV and NPV need to be derived using the summary sensitivity and specificity results 
(from meta-analysis), with knowledge of the prevalence in the location of 
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implementation. This work has further backed up the conclusions obtained by Debray et 
al. [82] that accounting for heterogeneity in study prevalence is crucial. 
Noordzij et al. [94] used their IPD to investigate the predictive ability of PTH for 
hypocalcaemia. They analysed all the IPD together (unstratified approach) to show its 
high predictive accuracy. This new meta-analysis further confirmed the ability of PTH 
assay in predicting hypocalcaemia, but crucially identified that heterogeneity in 
prevalence can seriously impact upon PTH performance in individual settings, and so 
population-specific prevalence’s must be used when applied the test to new populations. 
This recommendation was missed by Noordjiz et al. [94], who provided PPV and NPV 
based on the unstratified prevalence. 
Noordzij et al. [94] state in their discussion: “Obtaining a preoperative PTH value is 
suggested so that percent PTH decrease can be calculated. Routine use of this assay 
should be considered to improve postoperative management of total and completion 
thyroidectomy patients. Patients identified as low risk for hypocalcemia could be 
discharged sooner. Conversely, patients identified as high risk for hypocalcemia 
developing could be treated earlier, potentially shortening the duration of their 
hypocalcemic symptoms and hospitalization.” With this recommendation in mind, I also 
performed an analysis to determine the best threshold in terms of minimising the 
number of false negatives, so that people are not sent home wrongly. In this situation 
sensitivity and specificity are not equally important, but this had been assumed by 
Noordzij et al. [94]. Based on this the best threshold appears to be between 60-70% 
(based on the first two combinations and 1-2 hour and 6-hour time-points). So, the 
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authors’ [94] original recommendation of 65% as the best threshold based on the best 
combination of sensitivity and specificity in this instance remains reasonable. 
Another key finding is that the internal-external cross-validation approach of Royston et 
al. [101] may be valuable for test accuracy research. This has so far been proposed in a 
multivariable model context, but this chapter shows that it generalises nicely to the 
single test/predictor setting and helps examine validation in external data. A paper by 
Debray et al. [82] uses this internal-external cross-validation process. Debray et al. [82] 
develop a multivariable logistic regression model from an IPD meta-analysis with 
potential between-study heterogeneity. They propose strategies for choosing a valid 
model intercept for when the model is to be validated or applied to new individuals or 
study samples. This is similar in concept to using a study specific prevalence. Their 
results indicate that stratified estimation of model intercepts facilitates the derivation of 
a study specific model intercept, even when it is to be applied to a new study that was 
not considered during model development. They state [82] that their “framework allows 
the development (through stratified estimation), implementation in new individuals 
(through focused intercept choice) and evaluation (through internal-external validation) 
of a single, integrated prediction model using IPD from multiple studies in order to 
achieve improved model performance and generalizability.” 
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5.5.2 What this Chapter adds? 
Parts of this chapter have been submitted for publication, and the key findings are 
summarised in table 5.26. The next part of the thesis is to assess the impact of missing 
thresholds using a single imputation method, since the full IPD is available for this PTH 
dataset, this will be used to simulate missing data and to then perform the imputation 
approach. This is ideal as the full data is already available so it will be straight forward 
to compare the imputation results to the original data. 
Table 5.26: What chapter five adds? 
What is known / what is the problem? 
 Chapter four assessed the issue of clustering in this data, and found due to almost zero 
heterogeneity, the results were similar for the meta-analysis and unstratified approaches  
 Now the issue is whether we should use these average values for sensitivity and specificity to 
make prediction in individual settings?  
 It is important to assess how well this model predicts and compare this to the observed values 
What this study adds? 
 The E/O ratio has been calculated using PPV and NPV (which have been calculated using 
sensitivity, specificity and prevalence)  
 Initially unstratified prevalence was used but E/O had considerable heterogeneity 
 When using each study’s observed prevalence, E/O had no heterogeneity 
 If average sensitivity and specificity are combined with each study’s observed prevalence, there 
is reduced error in prediction (almost perfect), and this is new 
 Currently in Cochrane it is recommended to use the average sensitivity, specificity, which 
doctors/clinicians may go and use to calculate average PPV and NPV and this results in poor 
predictions As the PPV and NPV may be wrong if the particular population has a different 
prevalence to the average 
 This study shows the average sensitivity and specificity don’t give accurate predictions unless 
combined with each study’s observed prevalence 
What is needed next? 
 More work is needed in this area, i.e. this example used a dataset that had very little to no 
heterogeneity within it, if there was heterogeneity this may cause more issues  
 Can we even use the average sensitivity and specificity? Or will the sensitivity and specificity 
have to be calculated for each study too?  
 These are important questions that need to be considered 
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 A SIMULATION STUDY TO CHAPTER 6:
EMPIRICALLY EVALUATE AN IMPUTATION 
METHOD FOR DEALING WITH MISSING 
THRESHOLDS IN META-ANALYSIS OF A 
PREDICTIVE TEST  
6.1 Introduction 
In the evaluation of a potential diagnostic or predictive test, meta-analysis methods are 
required to synthesise test accuracy from multiple studies. Most meta-analysis methods 
proposed in the literature use a single two by two table from each study, which provides 
the number of true positives, true negatives, false positives, and false negatives. Such 
methods univariate and bivariate methods were used in Chapters 3 and 4, applied to 
each threshold separately. IPD was used in Chapters 4 and 5 to derive the two by two 
tables, however in practice researchers usually do not have IPD and are reliant on 
published two by two tables. When the test is measured on a continuous scale many 
published studies report test performance at multiple thresholds (often to try and 
determine the optimal threshold), usually by reporting several two by two tables (one 
for each threshold) or an ROC curve (to show discriminative ability of each threshold 
on the same graph). In this situation meta-analysts using published results tend to either 
utilise the results for just one of the thresholds per study (the most common threshold 
across studies that is available), or perform a separate meta-analysis for each of the 
thresholds independently [158]. However, usually the set of thresholds reported by each 
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study differ, and so the meta-analyst is faced with an incomplete set of threshold results 
from each study. 
The aim of this chapter is to empirically evaluate the use of a linear imputation method, 
as suggested by Riley et al. [158], for meta-analysis of test accuracy studies when the 
set of thresholds reported by each study differ. In each study, the method imputes two 
by two tables for any missing thresholds that are bounded between two reported 
thresholds; this enables additional studies to be included in each threshold's meta-
analysis. In an applied example, Riley et al. [158] found that the method revealed lower 
diagnostic test accuracy when compared to results from a standard meta-analysis for 
each threshold independently. This indicates potential selective reporting bias [8, 159], 
as thresholds are less likely to be reported when they give a lower test accuracy 
estimate. Riley et al. [158] therefore suggest the method is a useful sensitivity analysis 
to examine the impact of missing thresholds. However, they have not evaluated their 
method through any theoretical or simulation procedure.  
The aim of this chapter is to assess whether this imputation method works in a case 
study where IPD are available, and thus all thresholds are known, but through 
simulation some thresholds are removed to generate 'missing' thresholds. The aims are 
to evaluate whether the method produces estimates similar to original data, and to 
examine how the method impact upon the precision and heterogeneity of estimates. 
Different patterns of selective reporting (different thresholds will be made missing) will 
be assessed to determine to what degree this method corrects the bias that is introduced. 
Firstly, the details of the imputation method are described in full, with an applied 
example, and then the simulation procedure is described and implemented. 
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The work performed in this chapter has contributed to a publication in Systematic 
Reviews (Riley et al. [43]), where I am the second author. My work has been used to 
demonstrate whether the imputation method proposed by Riley is robust, using the 
empirical evaluation based on the PTH data described in full in this chapter. I also 
contributed heavily to drafting relevant sections and revising the published paper. 
6.2 Methodology of the imputation approach 
6.2.1 Details of the method 
Riley et al. [158] proposed the following approach is used in each study to impute two 
by two tables for any missing thresholds that are bounded between any two reported 
thresholds. 
Step 1: imputation of missing threshold results between two available thresholds 
When a certain threshold has missing results (2 by 2 table is missing), and if thresholds 
above and below are available, then this missing threshold must have sensitivity and 
specificity values constrained between the sensitivity and specificity values of the two 
available thresholds. A linear imputation approach is proposed to impute the results for 
this missing threshold, as follows. 
Firstly sensitivity and specificity values are transformed to the logit scale: 
Logit ‐ sensitivity = ln (
sensitivity
1 − sensitivity
) 
(Equation 6.1) 
Logit ‐ specificity = ln (
specificity
1 − specificity
) 
(Equation 6.2) 
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Then by assuming a 1-unit increase in threshold value corresponds to a constant 
reduction in logit-sensitivity and constant increase in logit-specificity, imputation of the 
missing logit-sensitivity and logit-specificity are carried out. An example scenario of 
how this imputation occurs can be shown using the Noordzij et al. [94] thresholds; if 
thresholds 40% and 65% are available and 50% and 60% are missing (a difference of 
25% between the lower and upper thresholds, with 50% being at 2/5 of the difference 
and 60% being at 4/5 of the difference), then the imputed logit-sensitivity at threshold 
50% is (where logit-sens is logit-sensitivity): 
logit‐ sens50% = logit ‐ sens40% + (
2(logit‐ sens65% − logit‐ sens40%)
5
) 
(Equation 6.3) 
And similarly for 60% the imputed logit-sensitivity is: 
 
logit‐ sens60% = logit ‐ sens40% + (
4(logit‐ sens65% − logit‐ sens40%)
5
) 
(Equation 6.4) 
The imputed sensitivity and specificity can be obtained from the imputed logit-
sensitivity and logit-specificity by back transforming: 
imputed sensitivity =
exp(imputed logit‐ sensitivity)
(1 + exp(imputed logit‐ sensitivity))
 
(Equation 6.5) 
imputed specificity =
exp(imputed logit‐ specificity)
(1 + exp(imputed logit‐ specificity))
 
(Equation 6.6) 
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The 2 by 2 table can then be calculated by: 
imputed true positive = imputed sensitivity ∗ total diseased 
(Equation 6.7) 
imputed false negative =  total diseased − imputed true positive 
(Equation 6.8) 
imputed true negative =  imputed specificity ∗ total non‐ diseased 
(Equation 6.9) 
imputed false positive =  total non‐ diseased − imputed true negative 
(Equation 6.10) 
For each pair of observed threshold results, there is a key assumption being made that 
there is a constant change in the logit values for each 1-unit change in the threshold 
results. It is important to note that this method does not impute above the highest 
threshold available or below the lowest threshold available; this requires further 
assumptions. Also, no imputation is possible if only one threshold was available for a 
study. If a study has a zero cell in the 2 by 2 table for a threshold then logit-values are 
not calculable. Thus, in order to impute values on the logit scale as desired, it was 
necessary to apply a continuity correction by adding 0.5 to each cell in the 2 by 2 table, 
to ensure that both sensitivity and specificity can be calculated. 
Step 2: Meta-analysis at each threshold separately using actual and imputed data 
After step 1 has been performed, each threshold has observed and imputed study results, 
which can be used in a meta-analysis. For example, the bivariate meta-analysis of Chu 
and Cole [153] at each threshold separately can be applied to the observed and the 
imputed data. By applying the exact binomial within-study distribution, we avoid the 
need to apply a continuity correction. This also accounts for any between-study 
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correlation in sensitivity and specificity. The models were given previously in Chapter 
4, but are written here again for ease: 
A univariate meta-analysis of sensitivity is: 
r+vei  ~ Bin (ρSensi , Ndiseasedi) 
Logit (ρSensi) ~ N (θSens, τSens
2 ) 
(Equation 6.11) 
Where r+veiis the number of true positives, ρSensi is the true sensitivity in study i, 
Ndiseasedi represents the total number with hypocalcaemia, θSens is the average logit-
sensitivity across studies, τSens
2  is the between-study heterogeneity in the logit-
sensitivity. 
For specificity: 
r−vei  ~ Bin (ρSpeci , Nnon−diseasedi) 
Logit (ρSpeci) ~ N (θSpec, τSpec
2 )  
(Equation 6.12) 
Where r−veiis the number of true negatives, ρSpeci is the true specificity in study i, 
Nnon−diseasedi represents the total without hypocalcaemia, θSpec is the average logit-
specificity across studies, τSpec
2  is the between-study heterogeneity in the logit 
specificity. 
The meta-analysis models utilise the exact binomial distribution within each study, and 
estimate the average sensitivity and specificity across studies [150, 151], and the 
variability of sensitivity and specificity across studies.  
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r+vei  ~ Bin (ρSensi , Ndiseasedi) 
r−vei  ~ Bin (ρSpeci , Nnon−diseasedi) 
Logit (ρSensi)
Logit (ρSpeci)
 ~ N (
θSens
θSpec
 , [
τSens
2 τSens,Spec
τSens,Spec τSpec
2 ]) 
(Equation 6.13) 
           
 
In this model, the parameters are as defined previously, with the addition of τSens,Spec 
which is the between-study covariance in logit sensitivity and logit specificity. 
Covariance might arise because both sensitivity and specificity are being estimated 
together, so there may be some correlation between them. The between-study 
covariance matrix is given, which contains the between-study variances and the 
between-study correlation in logit-sensitivity and logit-specificity. If between-study 
correlation  is zero, the model then reduces to a separate univariate analysis for each of 
sensitivity and specificity (equation 6.12). But, this is often poorly estimated at +1 or -1 
[160] and therefore it is sensible to adopt two separate univariate models here [159].  
The models presented can be estimated using adaptive Gaussian quadrature [161], for 
example using ‘PROC NLMIXED’ in SAS [162], or the ‘XTMELOGIT’ command in 
Stata [149]. The Stata [149] code used for meta-analysis has been provided in 
APPENDIX C. 
6.2.2 Example of how this method works for the McLeod study [144] 
To illustrate how this methodology works, the McLeod study [144] from the Noordzij et 
al. [94] dataset will be used. The 65% threshold will be deleted and then imputed using 
the method of Riley et al. 
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Figure 6.1: Illustrating the Imputation method using the McLeod study 
 
Figure 6.1 illustrates the imputation. Threshold 65% is missing and the imputation 
method uses the values from 60% and 70% to impute the 65% logit-sensitivity and 
logit-specificity. A straight dashed line is visible from 60% to 70% with the imputed 
value being in the middle of this line outlined by a circle.  The dashed rectangular boxes 
around the two imputed values show that this method imputes the threshold at the 
central point of the region of all logically possible points. In other situations there may 
be several of these lines for a single study or none at all if only one threshold is present. 
The imputed 2 by 2 table is presented in Table 6.1; this shows the values for thresholds 
60%-70%. 
Table 6.1: 2 by 2 table for thresholds 60%-70%, showing what the values are after imputation 
Threshold % TP FP FN TN Imputed? 
60 13 8 1 19 No 
65 12.58 6.95 1.42 20.05 Yes 
70 12 6 2 21 No 
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6.2.3 Example of the imputation approach 
Consider now a real meta-analysis of a predictive test with missing thresholds. 
The clinical question relates to new born babies, and whether the Apgar score is a good 
test for those babies who will die during the first 28 days of life (known as neonatal 
mortality) and how the threshold changes sensitivity and specificity. 
The word APGAR comes from the acronym (Appearance, Pulse, Grimace, Activity, and 
Respiration). The Apgar score is determined by evaluating the babies against five 
criteria which each give a score of 0-2. A low score is worse for a baby, and these 
scores are usually measured at one minute and five minutes after birth, and repeated 
later if low scores are observed initially [163]. The Apgar data being used relates to 
those babies who were < 2500g or pre-term (born before the full term of the pregnancy). 
Data are available from 11 studies which report up to 10 thresholds, but most only 
report one or two (Table 6.2). There are 40318 babies in total with 1238 deaths. 
Table 6.2: Summarising the studies evaluating the Apgar score 
Study 
name 
No of 
babies 
Number of 
deaths 
Outcome 
Prevalence 
Apgar thresholds presented (Sensitivity, Specificity) 
Apgar 2422 311 0.128 0 (0.06, 1.00), ≤1 (0.36, 0.96), ≤2 (0.54, 0.93), ≤3 
(0.61, 0.90), ≤4 (0.68, 0.85), ≤5 (0.76, 0.79), ≤6 (0.81, 
0.71), ≤7 (0.86, 0.59), ≤8 (0.93, 0.35), ≤9 (0.99, 0.10) 
Beeby 623 88 0.141 ≤3 (0.56, 0.75) 
Behnke 748 161 0.215 ≤3 (0.70, 0.75), ≤6 (0.92, 0.44) 
Drage 1617 151 0.093 ≤3 (0.67, 0.90), ≤6 (0.85, 0.71) 
Heller 32561 188 0.006 ≤3 (0.52, 0.96), ≤6 (0.78, 0.85) 
Ikonen 568 100 0.176 ≤3 (0.35, 0.95), ≤6 (0.55, 0.85) 
Issel 702 72 0.103 ≤3 (0.28, 0.93), ≤7 (0.72, 0.73) 
Kato 228 6 0.026 ≤4 (1.00, 0.66) 
Luthy 246 35 0.142 ≤3 (0.74, 0.78) 
Serenius 211 73 0.346 ≤3 (0.38, 0.78) 
Tejani 392 53 0.135 ≤6 (0.89, 0.58) 
Overall 40318 1238 0.031  
Table 6.2 summarises the studies available for meta-analysis and the number of babies, 
deaths and thresholds in each. The only thresholds that can be imputed are ≤4, ≤5 and 
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≤6, because they are the only thresholds in the studies that have thresholds present that 
are lower and higher than them, which is essential for this imputation method to work. 
Table 6.3: Univariate meta-analysis results for data before and after imputation 
Thresholds 
No. of studies 
contributing 
data 
Summary 
Sensitivity 
Ʈ2Sens Summary 
Logit-
sens 
Standard 
Error 
(logit-
sens) 
Summary 
Specificity 
Ʈ2Spec Summary 
Logit-
spec 
Standard 
Error 
(logit-
spec) 
Non-
Imputed 
         
0 1 0.06 0.00 -2.73 0.06 1.00 0.00 6.27 0.25 
≤1 1 0.36 0.00 -0.57 0.01 0.96 0.00 3.20 0.01 
≤2 1 0.54 0.00 0.15 0.01 0.93 0.00 2.52 0.01 
≤3 9 0.54 0.36 0.14 0.21 0.88 0.57 1.98 0.26 
≤4 2 0.69 0.00 0.80 0.12 0.77 0.28 1.23 0.38 
≤5 1 0.76 0.00 1.16 0.02 0.79 0.00 1.34 0.00 
≤6 6 0.82 0.44 1.51 0.29 0.71 0.49 0.90 0.29 
≤7 2 0.81 0.12 1.43 0.29 0.66 0.09 0.68 0.22 
≤8 1 0.93 0.00 2.63 0.05 0.35 0.00 -0.60 0.00 
≤9 1 0.99 0.00 4.34 0.25 0.10 0.00 -2.23 0.01 
Imputed          
≤4 7 0.65 0.51 0.60 0.30 0.85 0.55 1.75 0.28 
≤5 6 0.71 0.47 0.88 0.29 0.82 0.44 1.50 0.27 
≤6 7 0.80 0.50 1.36 0.28 0.72 0.45 0.97 0.25 
Table 6.3 displays the univariate meta-analysis results for each threshold before and 
after imputation data. For the three points, the sensitivity is slightly lower after 
imputation and specificity is slightly higher. For example, the≤4 threshold gives a 
sensitivity of 0.69 and specificity of 0.77 before imputation, and a sensitivity of 0.65 
and specificity of 0.85 after imputation. The improvement in specificity is higher than 
the decrease in sensitivity. This is also indicated by the ROC curves in Figure 6.2, with 
a slightly higher C statistic of 0.82 after imputation. Note also the smoother, more 
sensible ROC shape after imputation. Before imputation, the summary specificity 
wrongly decreased from thresholds 4 to 5, due to the different studies for threshold 4. 
Interestingly Figure 6.2 displays a non-monotonic summary curve, which is due to the 
discrepant numbers of studies contributing to the summary points at the thresholds 
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defining the curve. At threshold 5, only one study contributed data, whereas four studies 
contributed data at threshold 4 and six studies contributed data to threshold 6, which can 
explain the potential over optimism in specificity for threshold 5 and the non-monotonic 
nature of the curve. Now after imputation with more data, the ordering is improved. 
In contrast to Riley et al. [158] who showed test accuracy decreased after imputation, 
these results reveal slightly better test accuracy after imputation. From this meta-
analysis, Apgar score appears to be predictive, and a C statistic of 0.82 indicates Apgar 
score can discriminate rather well between those babies that will have a neonatal death 
and those that will not. 
Figure 6.2: ROC curve comparing before and after imputation data 
 
6.3 Methods for a simulation study of the imputation method 
To evaluate the imputation method further, a simulation study is now presented. In this 
study an existing dataset with all thresholds in all studies is used, so that known meta-
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analysis estimates are possible at all thresholds. Then using simulation missing 
thresholds are generated and the imputation approach applied, to ascertain if it reduces 
the missing data problem appropriately by 'filling in' the missing data. Four different 
scenarios of missing thresholds are investigated. The simulation is now detailed. 
6.3.1 Dataset 
The simulation used the Noordzij dataset [94] introduced previously in Chapter 4, but 
with a slight modification: a value of one was added to all the 2 by 2 table cells in all 
studies to ensure no zero cells to ease computational burden. The accuracy of PTH at 1-
2 hours is of interest, with five studies available. All thresholds are known in all studies, 
and hence the true meta-analysis results are available at all thresholds. Seven thresholds 
are considered: 40%, 50%, 60%, 65%, 70%, 80% and 90%. 
Figure 6.3: ROC curves for all five studies for the 1-2 hour time-point from Noordzij data 
 
Results for sensitivity and specificity using PTH at 1-2 hours and 6 hours are 
summarised in Table 6.4. Most meta-analysis of diagnostic test studies use bivariate 
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meta-analysis method, as this models the correlation between sensitivity and specificity 
which is negative in this dataset. There is very little difference between the univariate 
and bivariate approaches for this dataset, as the between-study heterogeneity for all 
thresholds is very small or zero and the correlation is poorly estimated when using the 
bivariate method. This issue was discussed in Chapter 4. In a simulation study the 
problems of having inestimable correlation structures would cause issues and the 
univariate method avoids that; thus, given there is no real difference between the 
estimates from both methods, univariate shall be used from here on in. 
Table 6.4: Sensitivity and Specificity of PTH assay in predicting postoperative hypocalcaemia for 1-
2 hours: univariate and bivariate results 
1-2 hours Sensitivity 95% CI Specificity 95% CI Ʈ2Sens Ʈ
2
Spec Correlation 
% PTH 
Decrease 
 Lower Upper  Lower Upper    
Univariate          
>40 95.6 83.9 98.9 52.1 43.1 61.0 0.0 0.0 - 
>50 95.6 83.9 98.9 63.3 53.8 71.9 0.0 0.0 - 
>60 95.6 83.9 98.9 80.3 72.2 86.6 0.0 0.0 - 
>65 93.3 81.3 97.8 82.2 74.7 88.9 0.0 0.0 - 
>70 93.3 81.3 97.8 88.0 80.8 92.8 0.0 0.0 - 
>72 88.9 76.0 95.3 89.7 82.8 94.1 0.0 0.0 - 
>80 77.8 63.4 87.6 94.0 88.0 97.1 0.0 0.0 - 
>90 55.6 41.0 69.2 100.0 Not 
given 
100.0 0.0 0.1 - 
Bivariate          
>40 95.6 83.1 99.0 52.2 42.7 61.6 0.1 0.0 -1 
>50 95.9 79.6 99.3 63.2 53.0 72.3 0.3 0.0 1 
>60 95.6 83.9 98.9 80.3 72.2 86.6 0.0 0.0 0.6 
>65 92.9 78.2 98.0 82.6 71.4 90.0 0.2 0.1 1 
>70 93.3 81.3 97.8 88.0 80.8 92.8 0.0 0.0 1 
>72 88.9 76.0 95.3 89.7 82.8 94.1 0.0 0.0 -1 
>80 77.8 63.1 87.8 94.1 87.2 97.4 0.0 0.0 1 
>90 55.6 41.0 69.2 100.0 Not 
given 
100.0 0.0 4.7 -0.1 
6.3.2 Simulation of 1000 datasets with missing threshold 
To assess the performance of the imputation method, missing thresholds were first 
generated in the Noordzij dataset. Four scenarios of missing data were considered: 
 Scenario I) Probability of missing data for all thresholds in all studies equals 
0.5. This scenario was chosen as it will on average have 50% missing data and 
reflects those cases where half the results are presented on average.  
203 
 
 Scenario II) Thresholds 60% and 70% have a 0.1 probability of being missing, 
and the remaining thresholds have a 0.5 probability of being missing. This was a 
selective reporting scenario where most papers would report the most important 
thresholds which are taken as 60 and 70%. As 65% is the best threshold 
recommended by Noordzij, this scenario gives the chance to assess how this 
approach works for the best threshold and also to reflect a more realistic 
scenario than Scenario I.  
 Scenario III) Data not missing at random; thresholds with observed 
sensitivity<0.90 have a 0.5 probability of being missing, but if observed 
sensitivity is ≥ 0.90, then those thresholds are never missing. This is an extreme 
scenario where data is never missing if sensitivity ≥ 0.90, assessing how this 
approach works when certain thresholds are always reported and remaining ones 
are missing with probability=0.5. 
 Scenario IV) A second missing not at random scenario; the first and last 
thresholds are always present, but data have a 0.5 probability of being missing 
for the other thresholds if the specificity is <0.80. This is an extreme scenario to 
consider imputation from extreme ends of the threshold spectrum. This reflects 
an extreme scenario where the first and last thresholds are always presented, and 
thresholds are missing based on specificity values. This scenario allows all the 
data to be imputed to assess in a different manner how well it works. 
Three steps are then repeated for each scenario. 
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 Step 1) Take the original IPD, and create a new dataset with random functions 
used to omit data. for example for Scenario I, probability of missing data for all 
thresholds in all studies equals 0.5. 
 Step 2) Repeat step 1, until 1000 different meta-analysis datasets are available. 
 Step 3) Use the imputation method to impute missing threshold results in each 
study in each of the 1000 datasets. 
6.3.3 Meta-analysis of missing data and imputed data 
A further two steps are used to meta-analyse the data before and after imputation: 
 Step 4) Perform a univariate meta-analysis of sensitivity and specificity for each 
of the 1000 datasets, with and without imputation data, using equation (6.12). 
For each meta-analysis, for each threshold the following are calculated: 
sensitivity, tau-squared for logit-sensitivity, logit-sensitivity, and standard error 
of logit-sensitivity, specificity, tau-squared for logit-specificity, logit-specificity, 
and standard error of logit-specificity. 
 Step 5) Across all 1000 datasets in each scenario, the mean and median of 
parameter estimates, and coverage of confidence intervals was calculated and 
compared to the true estimates (from complete data) 
Thus in each scenario there are three comparisons of interest: analysis of complete data 
(the true estimates), analysis with missing data without imputation and analysis with 
missing data but with imputation. Of interest, is whether meta-analysis results within 
imputation are preferred to a meta-analysis without imputation, in reference to the 
original meta-analysis results with complete data. 
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6.3.4 Programming code 
The first step of the programming code involved creating a loop to repeat 1000 times 
which uses the original dataset. For each repetition, missing data is generated based on 
each scenario, for example scenario I, the probability of a threshold being missing 
equals 0.5 for all thresholds in all studies. Once this loop has been run 1000 times, each 
individual dataset is then appended to create an overall dataset containing the 1000 
iterations. This becomes the 'before imputation' dataset, which is meta-analysed and 
then the Riley method applied to it in order to impute the missing thresholds, before 
meta-analysis again (see APPENDIX C). 
Programming code was developed to perform the meta-analysis. This code took into 
account that meta-analysis needs to be performed within each dataset and threshold 
separately, so seven meta-analyses occur within each dataset (seven thresholds), and 
then this was performed a thousand times (for a thousand datasets). Therefore 14000 
(7000 for analysis with data missing and 7000 for analysis with imputed data) meta-
analyses were performed for each scenario. A univariate meta-analysis could only be 
performed for a threshold if two or more studies provided data for it (i.e. they were not 
missing); if only one study provided data for the threshold then sensitivity and 
specificity were calculated using the 2 by 2 table, and if no studies provided data then 
the sensitivity and specificity were not calculated and were missing. The data extracted 
for each meta-analysis included the pooled logit-sensitivity, standard error of the pooled 
logit-sensitivity and the tau-squared value for logit-sensitivity, and the equivalent was 
extracted for logit-specificity. 
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6.3.5 Statistical measures 
To assess bias the pooled estimates for sensitivity and specificity were calculated from 
the meta-analysis. To assess the precision, the standard errors of the sensitivity and 
specificity estimates were compared for the different meta-analyses. To assess the 
heterogeneity of the estimates, the tau-squared estimates were compared. The mean, 
standard deviation of the mean, median and its upper and lower quartiles were 
calculated. 
6.4 Results of the simulation study of the imputation method 
The results are now presented for each simulation scenario separately.  The tables give 
the mean values for the analysis of complete data, along with the mean, standard 
deviation, median and its upper and lower quartiles for the analysis with data without 
imputation (contains missing threshold data) and analysis with imputed data (may 
contain some missing threshold data). These statistical estimates are given for the 
sensitivity, tau-squared for sensitivity, sensitivity transformed on the logit scale and its 
standard error, this is repeated for specificity. Box plots are presented to visualise these 
values, comparing the results for analysis with and without imputation. The standard 
errors have been plotted against each other from the analysis with data missing versus 
analysis with imputed data. 
6.4.1 Scenario I: Probability of missing equals 0.5 for all thresholds 
The summary meta-analysis results, with and without imputation are shown in Table 
6.5. Every threshold has on average about 50% missing data before imputation. The 
results for thresholds 40% and 90% are identical given missing data, as no imputation 
occurs at these end thresholds. At other thresholds the imputation method reduces the 
207 
 
amount of missing data considerably. For example at threshold 65% the missing data is 
reduced to just 12.16% of studies after imputation. 
6.4.1.1 Pooled estimates 
The sensitivity and specificity meta-analysis results before and after imputation are very 
similar on average and close to the mean estimate from the complete data. For example, 
for the 65% threshold the mean value from the complete data for sensitivity is 0.85, 
whilst the mean/median before imputation is 0.84/0.85 and the mean/median after 
imputation is 0.84/0.84 (see Figures 6.4-6.5). 
6.4.1.2 Standard error of pooled estimates 
The standard error of the pooled logit-sensitivity and logit-specificity estimates before 
imputation are much larger than those mean values from the complete data. After 
imputation the standard errors are much closer to those of true estimated values. For 
example, at the 65% threshold the mean from the complete data for standard error of 
logit-sensitivity is 0.38. Before imputation the average standard error is 0.63, but after 
imputation it is 0.42, much closer to the mean value of 0.38 (see Figures 6.6-6.7).  
6.4.1.3 Between-study variances 
The 𝜏2 estimates for the pooled logit-sensitivity and logit-specificity are zero in the true 
results. The median estimates of τSens
2  and τSpec
2
 are also zero before and after 
imputation. 
In summary, scenario I suggests the imputation method obtains estimates on average 
very close to the estimates from the complete data but with substantially improved 
precision compared to the analysis with missing data.
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Table 6.5: Scenario I, Probability of missing equals 0.5 for all thresholds 
Parameter of interest Mean values from complete data Meta-analysis without imputation Meta-analysis with imputed data 
% PTH Decrease Mean S.d. Median Lower quartile Upper quartile Mean S.d. Median Lower quartile Upper quartile 
40%  *Missing data =49.60% Missing data =49.60% 
Sensitivity 0.87 0.86 0.08 0.88 0.82 0.90 0.86 0.08 0.88 0.82 0.90 
Ʈ2Sens 0.00 0.22 0.38 0.00 0.00 0.21 0.22 0.38 0.00 0.00 0.21 
Logit-sens 1.93 1.87 0.51 1.95 1.52 2.22 1.87 0.51 1.95 1.52 2.22 
S.E. (logit-sens) 0.40 0.67 0.22 0.61 0.50 0.75 0.67 0.22 0.61 0.50 0.75 
Specificity 0.52 0.52 0.06 0.52 0.51 0.56 0.52 0.06 0.52 0.51 0.56 
Ʈ2Spec 0.00 0.17 0.36 0.00 0.00 0.06 0.17 0.36 0.00 0.00 0.06 
Logit-spec 0.08 0.09 0.24 0.08 0.03 0.24 0.09 0.24 0.08 0.03 0.24 
S.E. (logit-spec) 0.18 0.25 0.07 0.24 0.20 0.28 0.25 0.07 0.24 0.20 0.28 
50%  Missing data =49.82% Missing data =25.46% 
Sensitivity 0.87 0.86 0.08 0.88 0.82 0.90 0.86 0.04 0.87 0.85 0.88 
Ʈ2Sens 0.00 0.22 0.38 0.00 0.00 0.21 0.04 0.17 0.00 0.00 0.00 
Logit-sens 1.93 1.90 0.49 1.95 1.52 2.22 1.88 0.28 1.93 1.76 1.99 
S.E. (logit-sens) 0.40 0.66 0.22 0.61 0.48 0.75 0.50 0.13 0.45 0.41 0.53 
Specificity 0.62 0.63 0.05 0.62 0.58 0.66 0.63 0.04 0.63 0.61 0.65 
Ʈ2Spec 0.00 0.18 0.36 0.01 0.00 0.07 0.03 0.11 0.00 0.00 0.02 
Logit-spec 0.50 0.52 0.24 0.51 0.31 0.65 0.54 0.16 0.55 0.47 0.63 
S.E. (logit-spec) 0.18 0.26 0.07 0.26 0.21 0.31 0.23 0.05 0.22 0.19 0.25 
60%  Missing data =50.68% Missing data =14.64% 
Sensitivity 0.87 0.85 0.08 0.87 0.82 0.89 0.86 0.03 0.85 0.85 0.87 
Ʈ2Sens 0.00 0.23 0.38 0.00 0.00 0.21 0.03 0.20 0.00 0.00 0.00 
Logit-sens 1.93 1.86 0.51 1.93 1.52 2.14 1.81 0.22 1.77 1.76 1.93 
S.E. (logit-sens) 0.40 0.67 0.22 0.61 0.50 0.75 0.44 0.07 0.41 0.39 0.46 
Specificity 0.78 0.77 0.05 0.78 0.75 0.81 0.76 0.02 0.76 0.75 0.78 
Ʈ2Spec 0.00 0.17 0.36 0.00 0.00 0.07 0.01 0.04 0.00 0.00 0.01 
Logit-spec 1.26 1.25 0.28 1.26 1.09 1.42 1.17 0.12 1.17 1.09 1.25 
S.E. (logit-spec) 0.21 0.30 0.08 0.30 0.25 0.36 0.24 0.04 0.23 0.21 0.25 
65%  Missing data =51.14% Missing data =12.16% 
Sensitivity 0.85 0.84 0.07 0.85 0.82 0.88 0.84 0.03 0.84 0.82 0.85 
Ʈ2Sens 0.00 0.20 0.38 0.00 0.00 0.11 0.04 0.15 0.00 0.00 0.00 
Logit-sens 1.77 1.71 0.45 1.77 1.49 1.98 1.66 0.19 1.64 1.54 1.77 
S.E. (logit-sens) 0.38 0.63 0.22 0.56 0.48 0.71 0.42 0.08 0.38 0.37 0.44 
Specificity 0.80 0.80 0.05 0.80 0.78 0.83 0.80 0.02 0.80 0.80 0.81 
Ʈ2Spec 0.00 0.17 0.37 0.00 0.00 0.02 0.00 0.03 0.00 0.00 0.00 
Logit-spec 1.41 1.40 0.30 1.41 1.25 1.58 1.40 0.11 1.41 1.36 1.46 
S.E. (logit-spec) 0.22 0.31 0.07 0.31 0.26 0.37 0.24 0.03 0.23 0.22 0.25 
70%  Missing data =48.9% Missing data =14.74% 
Sensitivity 0.85 0.83 0.08 0.85 0.82 0.88 0.81 0.04 0.82 0.80 0.84 
Ʈ2Sens 0.00 0.18 0.36 0.00 0.00 0.00 0.06 0.18 0.00 0.00 0.00 
Logit-sens 1.77 1.69 0.48 1.77 1.49 1.98 1.50 0.24 1.50 1.39 1.64 
S.E. (logit-sens) 0.38 0.61 0.22 0.53 0.45 0.64 0.41 0.09 0.38 0.35 0.44 
Specificity 0.85 0.85 0.03 0.85 0.84 0.87 0.84 0.02 0.84 0.83 0.85 
209 
 
Parameter of interest Mean values from complete data Meta-analysis without imputation Meta-analysis with imputed data 
% PTH Decrease Mean S.d. Median Lower quartile Upper quartile Mean S.d. Median Lower quartile Upper quartile 
Ʈ2Spec 0.00 0.15 0.36 0.00 0.00 0.00 0.00 0.06 0.00 0.00 0.00 
Logit-spec 1.74 1.76 0.20 1.74 1.64 1.90 1.69 0.11 1.68 1.62 1.74 
S.E. (logit-spec) 0.25 0.36 0.16 0.33 0.29 0.38 0.27 0.04 0.26 0.24 0.29 
80%  Missing data =50.88% Missing data =26.36% 
Sensitivity 0.73 0.71 0.07 0.73 0.68 0.76 0.70 0.05 0.71 0.68 0.73 
Ʈ2Sens 0.00 0.17 0.37 0.00 0.00 0.00 0.04 0.17 0.00 0.00 0.00 
Logit-sens 0.98 0.93 0.33 0.98 0.77 1.14 0.87 0.23 0.89 0.77 0.99 
S.E. (logit-sens) 0.30 0.45 0.15 0.41 0.35 0.49 0.37 0.10 0.34 0.31 0.41 
Specificity 0.91 0.91 0.02 0.91 0.89 0.92 0.91 0.02 0.91 0.90 0.91 
Ʈ2Spec 0.00 0.17 0.37 0.00 0.00 0.00 0.02 0.14 0.00 0.00 0.00 
Logit-spec 2.26 2.29 0.31 2.27 2.10 2.44 2.27 0.18 2.26 2.17 2.36 
S.E. (logit-spec) 0.30 0.46 0.19 0.40 0.36 0.52 0.37 0.08 0.35 0.32 0.39 
90%  Missing data =50.76% Missing data =50.76% 
Sensitivity 0.55 0.51 0.11 0.55 0.50 0.58 0.51 0.11 0.55 0.50 0.58 
Ʈ2Sens 0.00 0.20 0.38 0.00 0.00 0.18 0.20 0.38 0.00 0.00 0.18 
Logit-sens 0.18 0.05 0.48 0.18 0.00 0.32 0.05 0.48 0.18 0.00 0.32 
S.E. (logit-sens) 0.27 0.46 0.26 0.36 0.31 0.47 0.46 0.26 0.36 0.31 0.47 
Specificity 0.96 0.96 0.01 0.96 0.96 0.97 0.96 0.01 0.96 0.96 0.97 
Ʈ2Spec 0.00 0.18 0.38 0.00 0.00 0.00 0.18 0.38 0.00 0.00 0.00 
Logit-spec 3.19 3.16 0.26 3.19 3.07 3.34 3.16 0.26 3.19 3.07 3.34 
S.E. (logit-spec) 0.46 0.70 0.18 0.59 0.59 0.73 0.70 0.18 0.59 0.59 0.73 
*Average missing data across all 1000 datasets 
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Figure 6.4: Box plots of Sensitivity, Logit-Sensitivity, S.E’s for Logit-Sensitivity and Tau-squared for Sensitivity against Threshold %, comparing Non-Imputed and 
Imputed data (Scenario I) 
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Figure 6.5: Box plots of Specificity, Logit-Specificity, S.E's for Logit-Specificity and Tau-squared for Specificity against Threshold %, comparing Non-Imputed and 
Imputed data (Scenario I) 
212 
 
Figure 6.6: S.E's of Logit-Sensitivity for each threshold (Scenario I) in each of the 1000 datasets, before 
and after imputation 
 
Figure 6.7: S.E's of Logit-Specificity for each threshold (Scenario I)in each of the 1000 datasets, before 
and after imputation 
 Although 1000 simulations were performed, there are only 32 different permutations of missing studies for each threshold. 
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6.4.2 Scenario II: 60% and 70% thresholds have probability missing of 0.1, and the 
remaining thresholds have probability missing of 0.5 
This scenario relates to when some thresholds are more common than others. The results are 
shown in Table 6.6. Thresholds 60% and 70% have on average 10% of studies missing, 
whilst the remaining thresholds have on average 50% of studies missing. As before, the 
imputation method reduces the amount of missing data greatly, especially for threshold 65% 
with only 2.6% of studies being missing after imputation.  
6.4.2.1 Pooled estimates 
The average meta-analysis results for sensitivity and specificity are very similar before and 
after imputation, and when compared to the mean from the complete data. For example, at the 
65% threshold the mean from complete data for sensitivity is 0.85. Whilst the mean/median 
estimate before imputation is 0.83/0.85 and after imputation is 0.85/0.85 (see Figures 6.8-
6.9). 
6.4.2.2 Standard error of pooled estimates 
The average standard errors before imputation are much larger than those from the mean 
values from complete data, but after imputation the average standard errors are much closer. 
For example, at the 65% threshold the mean standard error for logit-sensitivity is 0.38, whilst 
before imputation it is 0.62 on average, but after imputation it is 0.38 on average (see Figures 
6.10-6.11).   
6.4.2.3 Between-study variances 
The Ʈ2 estimates for pooled logit-sensitivity and logit-specificity are zero in the results from 
complete data and similar median results are obtained before and after imputation. 
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Table 6.6: Scenario II, 60% and 70% thresholds have probability missing of 0.1, and the remaining thresholds have probability missing of 0.5 
Parameter of interest Mean values from complete data Meta-analysis with data missing Meta-analysis with imputed data 
% PTH Decrease Mean S.d. Median Lower quartile Upper quartile Mean S.d. Median Lower quartile Upper quartile 
50%   Missing data =50.86% Missing data =24.76% 
Sensitivity 0.87 0.85 0.08 0.87 0.82 0.91 0.87 0.03 0.87 0.85 0.88 
Ʈ2Sens 0.00 0.23 0.39 0.00 0.00 0.21 0.04 0.17 0.00 0.00 0.00 
Logit-sens 1.93 1.87 0.53 1.93 1.52 2.27 1.91 0.26 1.93 1.76 1.99 
S.E. (logit-sens) 0.40 0.67 0.23 0.61 0.48 0.75 0.50 0.13 0.47 0.40 0.52 
Specificity 0.62 0.62 0.06 0.62 0.58 0.66 0.63 0.04 0.63 0.61 0.65 
Ʈ2Spec 0.00 0.19 0.37 0.01 0.00 0.07 0.03 0.13 0.00 0.00 0.02 
Logit-spec 0.50 0.51 0.25 0.50 0.31 0.65 0.53 0.16 0.53 0.47 0.62 
S.E. (logit-spec) 0.18 0.26 0.07 0.26 0.21 0.30 0.23 0.04 0.22 0.19 0.25 
60%  Missing data =9.88% Missing data =2.72% 
Sensitivity 0.87 0.87 0.02 0.87 0.87 0.87 0.87 0.01 0.87 0.87 0.87 
Ʈ2Sens 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 
Logit-sens 1.93 1.92 0.14 1.93 1.93 1.93 1.91 0.08 1.93 1.93 1.93 
S.E. (logit-sens) 0.40 0.43 0.05 0.40 0.40 0.44 0.41 0.02 0.40 0.40 0.40 
Specificity 0.78 0.78 0.02 0.78 0.78 0.78 0.78 0.01 0.78 0.77 0.78 
Ʈ2Spec 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
Logit-spec 1.26 1.26 0.09 1.26 1.26 1.26 1.25 0.06 1.26 1.22 1.26 
S.E. (logit-spec) 0.21 0.23 0.03 0.21 0.21 0.24 0.22 0.01 0.21 0.21 0.21 
65%  Missing data =49.72% Missing data =2.6% 
Sensitivity 0.85 0.83 0.08 0.85 0.82 0.88 0.85 0.01 0.85 0.85 0.85 
Ʈ2Sens 0.00 0.20 0.38 0.00 0.00 0.11 0.01 0.06 0.00 0.00 0.00 
Logit-sens 1.77 1.69 0.48 1.77 1.49 2.01 1.75 0.08 1.77 1.77 1.77 
S.E. (logit-sens) 0.38 0.62 0.21 0.53 0.47 0.64 0.39 0.02 0.38 0.38 0.38 
Specificity 0.80 0.80 0.05 0.80 0.78 0.83 0.81 0.01 0.80 0.80 0.81 
Ʈ2Spec 0.00 0.17 0.37 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 
Logit-spec 1.41 1.39 0.30 1.41 1.25 1.58 1.42 0.06 1.41 1.41 1.46 
S.E. (logit-spec) 0.22 0.31 0.07 0.29 0.26 0.37 0.23 0.01 0.23 0.22 0.23 
70%  Missing data =9.42% Missing data =2.66% 
Sensitivity 0.85 0.85 0.02 0.85 0.85 0.85 0.85 0.01 0.85 0.84 0.85 
Ʈ2Sens 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.08 0.00 0.00 0.00 
Logit-sens 1.77 1.77 0.12 1.77 1.77 1.77 1.73 0.10 1.77 1.63 1.77 
S.E. (logit-sens) 0.38 0.41 0.04 0.38 0.38 0.38 0.39 0.03 0.38 0.38 0.38 
Specificity 0.85 0.85 0.01 0.85 0.85 0.85 0.85 0.01 0.85 0.85 0.85 
Ʈ2Spec 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Logit-spec 1.74 1.74 0.06 1.74 1.74 1.74 1.73 0.05 1.74 1.74 1.74 
S.E. (logit-spec) 0.25 0.26 0.03 0.25 0.25 0.28 0.25 0.01 0.25 0.25 0.25 
80%  Missing data =51.48% Missing data =25.54% 
Sensitivity 0.73 0.71 0.07 0.72 0.68 0.76 0.71 0.05 0.71 0.69 0.73 
Ʈ2Sens 0.00 0.18 0.39 0.00 0.00 0.00 0.04 0.16 0.00 0.00 0.00 
Logit-sens 0.98 0.93 0.35 0.96 0.77 1.14 0.89 0.23 0.89 0.80 1.00 
S.E. (logit-sens) 0.30 0.46 0.16 0.41 0.35 0.49 0.37 0.10 0.35 0.31 0.39 
Specificity 0.91 0.90 0.03 0.90 0.89 0.92 0.90 0.01 0.91 0.90 0.91 
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Parameter of interest Mean values from complete data Meta-analysis with data missing Meta-analysis with imputed data 
% PTH Decrease Mean S.d. Median Lower quartile Upper quartile Mean S.d. Median Lower quartile Upper quartile 
Ʈ2Spec 0.00 0.18 0.39 0.00 0.00 0.00 0.02 0.12 0.00 0.00 0.00 
Logit-spec 2.26 2.29 0.33 2.23 2.08 2.43 2.26 0.17 2.26 2.17 2.35 
S.E. (logit-spec) 0.30 0.47 0.20 0.40 0.36 0.52 0.37 0.08 0.35 0.32 0.39 
*Average missing data across all 1000 datasets 
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Figure 6.8: Box plots of Sensitivity, Logit-Sensitivity, S.E's for Logit-Sensitivity and Tau-squared for Sensitivity against Threshold %, comparing Non-Imputed and 
Imputed data (Scenario II) 
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Figure 6.9: Box plots of Specificity, Logit-Specificity, S.E's for Logit-Specificity and Tau-squared for Specificity against Threshold %, comparing Non-Imputed and 
Imputed data (Scenario II) 
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Figure 6.10: S.E's of Logit-Sensitivity for each threshold (Scenario II) in each of the 1000 datasets, before 
and after imputation 
 
Figure 6.11: S.E's of Logit-Specificity for each threshold (Scenario II) in each of the 1000 datasets, before 
and after imputation 
 Although 1000 simulations were performed, there are only 32 different permutations of missing studies for each threshold. 
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6.4.3 Scenario III: Data not missing at random, thresholds with sensitivity<0.90 having 
a probability of 0.5 of being missing, but otherwise are reported 
The results of this scenario are shown in Table 6.7. This scenario is a missing not at random 
scenario, where if sensitivity ≥ 0.90, it is always reported but not otherwise (selective 
reporting). This is a realistic scenario, as biased reporting is a major problem in observation 
research [164]. Missing data is again reduced impressively after imputation. For example, at 
threshold 65% before imputation 39.88% of studies are missing, but after imputation 8.34% 
are missing. 
6.4.3.1 Pooled estimates 
The sensitivity and specificity meta-analysis results before imputation are on average being 
overestimated in comparison to the complete data values (see Figures 6.12-6.13), due to the 
selective reporting. However, the use of imputed data reduces this over estimation. For 
example, at the 50% threshold the mean value from complete data for sensitivity is 0.87, 
whilst the median estimate before imputation is 0.90 but the median estimate after imputation 
is 0.87. For the 80% threshold, the mean value from complete data for sensitivity is 0.73, 
whilst the median estimate before imputation is 0.75 and the median estimate after imputation 
is 0.71. In the latter, the imputation method underestimates. 
6.4.3.2 Standard error of pooled estimates 
As in other scenarios, the standard errors before imputation occurs are much larger than the 
values from the complete data, but after imputation these are closer to the complete data 
values (see Figures 6.14-6.15). For example, for threshold 50% the mean standard error for 
the pooled logit-sensitivity is 0.40, whilst the median standard error before imputation is 0.52 
and the median after imputation is 0.44. 
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6.4.3.3 Between-study variances 
As previously, the Ʈ2estimates are zero in the results from complete data and before and after 
imputation. 
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Table 6.7: Scenario III; Data not missing at random, thresholds with sensitivity<0.90 having a probability of 0.5 of being missing, but otherwise are reported 
Parameter of interest Mean values from complete data Meta-analysis with data missing Meta-analysis with imputed data 
% PTH Decrease Mean S.d. Median Lower quartile Upper quartile Mean S.d. Median Lower quartile Upper quartile 
50%   Missing data =30.58% Missing data =15.5% 
Sensitivity 0.87 0.89 0.02 0.90 0.88 0.91 0.88 0.02 0.87 0.87 0.88 
Ʈ2Sens 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.12 0.00 0.00 0.00 
Logit-sens 1.93 2.15 0.24 2.22 1.95 2.35 2.01 0.17 1.93 1.93 2.01 
S.E. (logit-sens) 0.40 0.53 0.10 0.52 0.47 0.61 0.46 0.07 0.44 0.40 0.48 
Specificity 0.62 0.64 0.02 0.64 0.63 0.66 0.64 0.02 0.64 0.62 0.65 
Ʈ2Spec 0.00 0.04 0.04 0.04 0.02 0.07 0.01 0.02 0.00 0.00 0.02 
Logit-spec 0.50 0.59 0.08 0.59 0.53 0.67 0.58 0.07 0.59 0.51 0.63 
S.E. (logit-spec) 0.18 0.26 0.06 0.26 0.23 0.31 0.21 0.04 0.20 0.18 0.23 
60%  Missing data =29.64% Missing data =8.72% 
Sensitivity 0.87 0.89 0.02 0.90 0.87 0.91 0.87 0.02 0.87 0.87 0.87 
Ʈ2Sens 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.16 0.00 0.00 0.00 
Logit-sens 1.93 2.14 0.23 2.22 1.93 2.30 1.94 0.15 1.93 1.93 1.93 
S.E. (logit-sens) 0.40 0.52 0.10 0.48 0.45 0.53 0.44 0.06 0.40 0.40 0.47 
Specificity 0.78 0.79 0.01 0.79 0.78 0.79 0.77 0.01 0.77 0.77 0.78 
Ʈ2Spec 0.00 0.03 0.04 0.00 0.00 0.04 0.01 0.02 0.00 0.00 0.00 
Logit-spec 1.26 1.31 0.08 1.30 1.25 1.35 1.23 0.07 1.22 1.19 1.26 
S.E. (logit-spec) 0.21 0.28 0.07 0.26 0.23 0.30 0.23 0.03 0.21 0.21 0.24 
65%  Missing data =39.88% Missing data =8.34% 
Sensitivity 0.85 0.87 0.03 0.86 0.84 0.89 0.85 0.02 0.85 0.84 0.85 
Ʈ2Sens 0.00 0.06 0.18 0.00 0.00 0.00 0.04 0.15 0.00 0.00 0.00 
Logit-sens 1.77 1.89 0.24 1.82 1.69 2.11 1.71 0.16 1.77 1.63 1.77 
S.E. (logit-sens) 0.38 0.54 0.14 0.49 0.44 0.61 0.41 0.06 0.38 0.38 0.43 
Specificity 0.80 0.82 0.03 0.82 0.80 0.84 0.81 0.01 0.80 0.80 0.81 
Ʈ2Spec 0.00 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Logit-spec 1.41 1.51 0.18 1.51 1.39 1.64 1.43 0.09 1.41 1.36 1.46 
S.E. (logit-spec) 0.22 0.31 0.06 0.28 0.26 0.36 0.24 0.02 0.23 0.22 0.25 
70%  Missing data =39.72% Missing data =11.38% 
Sensitivity 0.85 0.87 0.03 0.86 0.84 0.89 0.83 0.03 0.84 0.81 0.85 
Ʈ2Sens 0.00 0.06 0.18 0.00 0.00 0.00 0.08 0.20 0.00 0.00 0.00 
Logit-sens 1.77 1.88 0.23 1.82 1.69 2.11 1.59 0.20 1.63 1.46 1.76 
S.E. (logit-sens) 0.38 0.54 0.14 0.49 0.44 0.61 0.41 0.08 0.38 0.36 0.45 
Specificity 0.85 0.86 0.02 0.85 0.85 0.87 0.84 0.01 0.84 0.83 0.85 
Ʈ2Spec 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Logit-spec 1.74 1.79 0.16 1.76 1.70 1.90 1.70 0.10 1.69 1.62 1.74 
S.E. (logit-spec) 0.25 0.33 0.07 0.31 0.29 0.38 0.26 0.03 0.25 0.24 0.28 
80%  Missing data =49.86% Missing data =25.18% 
Sensitivity 0.73 0.75 0.07 0.75 0.70 0.79 0.71 0.04 0.71 0.69 0.73 
Ʈ2Sens 0.00 0.02 0.11 0.00 0.00 0.00 0.05 0.18 0.00 0.00 0.00 
Logit-sens 0.98 1.15 0.42 1.07 0.83 1.30 0.89 0.21 0.89 0.78 1.00 
S.E. (logit-sens) 0.30 0.45 0.12 0.41 0.36 0.49 0.37 0.10 0.34 0.31 0.39 
Specificity 0.91 0.90 0.03 0.90 0.89 0.91 0.91 0.01 0.91 0.90 0.91 
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Parameter of interest Mean values from complete data Meta-analysis with data missing Meta-analysis with imputed data 
% PTH Decrease Mean S.d. Median Lower quartile Upper quartile Mean S.d. Median Lower quartile Upper quartile 
Ʈ2Spec 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.12 0.00 0.00 0.00 
Logit-spec 2.26 2.20 0.29 2.23 2.05 2.35 2.28 0.17 2.26 2.18 2.36 
S.E. (logit-spec) 0.30 0.41 0.10 0.39 0.35 0.47 0.36 0.07 0.35 0.32 0.39 
*Average missing data across all 1000 datasets 
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Figure 6.12: Box plots of Sensitivity, Logit-Sensitivity, S.E's for Logit-Sensitivity and Tau-squared for Sensitivity against Threshold %, comparing Non-Imputed 
and Imputed data (Scenario III) 
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Figure 6.13: Box plots of Specificity, Logit-Specificity, S.E's for Logit-Specificity and Tau-squared for Specificity against Threshold %, comparing Non-Imputed 
and Imputed data (Scenario III) 
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Figure 6.14: S.E's of Logit-Sensitivity for each threshold (Scenario III) in each of the 1000 datasets, 
before and after imputation 
 
Figure 6.15: S.E's of Logit-Specificity for each threshold (Scenario III) in each of the 1000 datasets, 
before and after imputation 
 
Although 1000 simulations were performed, there are only 32 different permutations of missing studies for each threshold. 
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6.4.4 Scenario IV: Missing not at random, with the first and last thresholds always 
being present. The data has a probability of missing equals 0.5 for the other thresholds 
if the specificity is <0.80 
This case study is a second missing not at random scenario, where the thresholds within each 
study have a 50% chance of missing if the specificity < 0.80. But they are not missing for 
specificity ≥ 0.80 and the first and last threshold. This is an extreme 'selective reporting' 
scenario to allow the imputation method to always have the end thresholds available, thus 
always enabling missing thresholds to be imputed.  Table 6.8 shows the results for this 
scenario. 
The pooled estimates, standard errors and between-study variance show similar results as 
previous scenarios. In particular, the standard errors are considerably smaller after 
imputation, and the pooled estimates are close to the mean values from the complete data 
(either with or without imputation). There is 0% missing data after imputation; this is due to 
the first and last threshold always being present, resulting in every missing threshold being 
imputed.  
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Table 6.8: Scenario IV; missing not at random, with the first and last thresholds always being present. The data has a probability of missing equals 0.5 for the other 
thresholds if the specificity is <0.80 
Parameter of interest Mean values from complete data Meta-analysis with data missing Meta-analysis with imputed data 
% PTH Decrease Mean S.d. Median Lower quartile Upper quartile Mean S.d. Median Lower quartile Upper quartile 
50%   Missing data =49.54% Missing data =0% 
Sensitivity 0.87 0.86 0.05 0.87 0.85 0.89 0.87 0.01 0.87 0.87 0.87 
Ʈ2Sens 0.00 0.06 0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Logit-sens 1.93 1.90 0.35 1.93 1.76 2.14 1.89 0.07 1.93 1.93 1.93 
S.E. (logit-sens) 0.40 0.57 0.16 0.53 0.44 0.64 0.40 0.01 0.40 0.40 0.40 
Specificity 0.62 0.61 0.06 0.60 0.57 0.65 0.64 0.02 0.64 0.62 0.65 
Ʈ2Spec 0.00 0.02 0.03 0.00 0.00 0.03 0.01 0.01 0.00 0.00 0.01 
Logit-spec 0.50 0.45 0.26 0.41 0.27 0.62 0.56 0.07 0.56 0.50 0.63 
S.E. (logit-spec) 0.18 0.25 0.06 0.25 0.20 0.30 0.19 0.01 0.19 0.18 0.19 
60%  Missing data =29.62% Missing data =0% 
Sensitivity 0.87 0.88 0.02 0.88 0.86 0.90 0.86 0.01 0.87 0.85 0.87 
Ʈ2Sens 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Logit-sens 1.93 2.05 0.20 1.99 1.82 2.22 1.84 0.09 1.93 1.77 1.93 
S.E. (logit-sens) 0.40 0.48 0.06 0.48 0.44 0.52 0.39 0.01 0.40 0.38 0.40 
Specificity 0.78 0.81 0.02 0.80 0.79 0.81 0.77 0.01 0.77 0.76 0.78 
Ʈ2Spec 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.01 0.00 0.04 
Logit-spec 1.26 1.43 0.13 1.41 1.35 1.46 1.22 0.05 1.22 1.18 1.26 
S.E. (logit-spec) 0.21 0.26 0.04 0.26 0.24 0.27 0.22 0.01 0.22 0.21 0.23 
65%  Missing data =29.36% Missing data =0% 
Sensitivity 0.85 0.87 0.02 0.86 0.85 0.89 0.85 0.01 0.85 0.85 0.85 
Ʈ2Sens 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Logit-sens 1.77 1.96 0.18 1.82 1.77 2.10 1.76 0.04 1.77 1.77 1.77 
S.E. (logit-sens) 0.38 0.47 0.07 0.44 0.41 0.48 0.38 0.01 0.38 0.38 0.38 
Specificity 0.80 0.83 0.02 0.82 0.81 0.84 0.81 0.01 0.81 0.80 0.82 
Ʈ2Spec 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
Logit-spec 1.41 1.61 0.17 1.54 1.46 1.64 1.45 0.05 1.46 1.41 1.51 
S.E. (logit-spec) 0.22 0.28 0.05 0.26 0.24 0.28 0.23 0.01 0.23 0.23 0.23 
70%  Missing data =9.54% Missing data =0% 
Sensitivity 0.85 0.85 0.00 0.85 0.85 0.85 0.85 0.01 0.85 0.84 0.85 
Ʈ2Sens 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Logit-sens 1.77 1.77 0.00 1.77 1.76 1.77 1.70 0.07 1.77 1.63 1.77 
S.E. (logit-sens) 0.38 0.41 0.03 0.38 0.38 0.44 0.37 0.01 0.38 0.36 0.38 
Specificity 0.85 0.86 0.01 0.85 0.85 0.87 0.85 0.00 0.85 0.85 0.85 
Ʈ2Spec 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Logit-spec 1.74 1.82 0.08 1.74 1.74 1.90 1.73 0.02 1.74 1.74 1.74 
S.E. (logit-spec) 0.25 0.27 0.02 0.25 0.25 0.30 0.25 0.00 0.25 0.25 0.25 
80%  Missing data 0=% Missing data =0% 
Sensitivity 0.73 0.73 0.00 0.73 0.73 0.73 0.73 0.00 0.73 0.73 0.73 
Ʈ2Sens 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Logit-sens 0.98 0.98 0.00 0.98 0.98 0.98 0.98 0.00 0.98 0.98 0.98 
S.E. (logit-sens) 0.30 0.30 0.00 0.30 0.30 0.30 0.30 0.00 0.30 0.30 0.30 
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Parameter of interest Mean values from complete data Meta-analysis with data missing Meta-analysis with imputed data 
% PTH Decrease Mean S.d. Median Lower quartile Upper quartile Mean S.d. Median Lower quartile Upper quartile 
Specificity 0.91 0.91 0.00 0.91 0.91 0.91 0.91 0.00 0.91 0.91 0.91 
Ʈ2Spec 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Logit-spec 2.26 2.26 0.00 2.26 2.26 2.26 2.26 0.00 2.26 2.26 2.26 
S.E. (logit-spec) 0.30 0.30 0.00 0.30 0.30 0.30 0.30 0.00 0.30 0.30 0.30 
*Average missing data across all 1000 datasets 
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6.5 Discussion 
This chapter has found through a simulation study that the imputation method proposed 
by Riley et al. [158] appears to work well for the PTH example; in general, when 
missing values are generated, the mean meta-analysis values are brought closer to the 
true known values after imputation for missing sensitivity and specificity. Also the 
standard errors of the pooled logit-sensitivity and logit-specificity are closer to the true 
values after imputation, and there is substantial gain in precision by using additional 
imputed results. These findings were consistent across the different scenarios for 
generating missing data as investigated in this chapter. Although more work is required 
and other different datasets and scenarios should be investigated in the future, the initial 
findings appear to be promising.  
6.5.1 Strengths and limitations of simulation study 
Strength of this simulation study is in having the IPD available, as the observed meta-
analysis results at each threshold were known in a real dataset; thus the particular 
relationship between threshold value and sensitivity and specificity did not need to be 
specified, as the data was already available. In other words, this simulation study uses 
the real data so there was no need to make assumptions about the underlying ROC 
shape or assumption of any particular distribution (a downside of this is that the 'true' 
values were unknown, and so results are compared to the true estimates from complete 
data). In addition, the method of Riley et al. [158] had not previously been evaluated 
through a simulation study. This simulation study has also considered a few scenarios to 
reflect the availability of thresholds in real life, i.e. selective reporting. The scenarios 
considered ranged from certain probability of missing data, i.e. probability of 0.5 of 
thresholds being missing in a dataset to missing at random (MAR) to reflect those 
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instances where thresholds are presented based on how positive the result is (a 
sensitivity ≥ 0.90). 
A key limitation of the findings is that the results are all based on one dataset. This is 
one case study, and it is not possible to say whether the same results would be achieved 
in another case study. There was no heterogeneity at most thresholds in the Noordzij 
data, so further consideration in datasets with larger tau-squared values is required. 
Furthermore, the true values of sensitivity and specificity (exact values) were not known 
but rather the comparison was with true estimates, as noted above. 
6.5.2 Strengths and limitations of the imputation method 
A key strength of the imputation method is the ability to gain additional information for 
meta-analysis, which allows more studies to be included in a meta-analysis at each 
threshold. Due to it being a single imputation approach, it is simple and allows standard 
methods of meta-analysis to be used. This method offers a valuable opportunity for a 
sensitivity analysis to be performed; to assess whether the conclusions about 
heterogeneity, best threshold and test accuracy hold. This method appears to give 
similar estimates on average to the observed estimates, with less variability from the 
observed estimates than before imputation. Also, in the Apgar data it was flagged that 
the results may be better than originally thought after using the imputation method. If 
the standard error is smaller and the bias is the same, the mean squared error (MSE) 
must be better in the imputation method.  Coverage could not be evaluated as the truth 
was not known. 
An important limitation of this method is that it only uses a single imputation approach. 
As well as standard errors being potentially too small, and an assumption is made that 
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between two known thresholds the relationship is linear, which is impossible to 
validate. This method also does not force thresholds to be ordered and no imputation 
takes place at end thresholds or above/below the upper/lower observed thresholds. 
Extrapolation may be possible using further assumptions, for thresholds slightly above 
or below the observed range. 
6.5.3 Multivariate meta-analysis model approach 
Another approach to deal with multiple thresholds has been discussed by Riley et al. 
[158]. A multivariate meta-analysis model is used that assumes logit-sensitivity and 
logit-specificity follow a multivariate normal distribution, both within and between-
studies; this increases the information toward each threshold's meta-analysis by utilising 
within-study and between-study correlation across thresholds. But, this approach may 
need continuity corrections and can poorly estimate the correlations at +1 or -1. This 
model is being used increasingly to synthesise multiple outcomes which are correlated,  
in meta-analysis [163] and is known to improve the efficiency of summary estimates 
[139]. As well as reducing the outcome reporting bias issues [140]. 
There are a number of limitations have been discussed for this method. This method 
involves a time-consuming first step which involves obtaining logit-sensitivity, logit-
specificity, their variances and covariance's for each threshold in each study. When a 
zero cell arises in a 2 by 2 table then a continuity correction is required; also a within-
study correlation of 1 can arise which needs to be reduced or the results may not 
converge in the second step. In the second step, logit-sensitivity and logit-specificity 
both require an assumption of a within-study multivariate normal sampling distribution, 
which can result in lower estimation properties when compared to modelling the exact 
binomial distribution [153]. Another limitation to note is when the between-study 
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correlation for each pair of thresholds and each pair of sensitivity and specificity are 
poorly estimated at +1 or -1, this can inflate the between-study variance estimates, 
although the summary statistics remain unaffected and unbiased [160]. 
Due to these limitations, the imputation approach is potentially more appealing.  
6.5.4 Other methods 
Hamza et al. [148] proposed a multivariate random-effect meta-analysis approach and 
this applies to when all studies report all thresholds. In comparison, the Riley method 
allows a different set of thresholds per study and can also use studies which only 
provide one threshold. The Hamza et al. [148] approach models the linear relationship 
between threshold value and test accuracy within each study, which is not possible in 
those studies that report only one threshold. This method is susceptible to convergence 
issues, which prompted Putter et al. [135] to propose an alternative survival model 
framework for meta-analysing the multiple thresholds. But the model also requires 
multiple thresholds to be available in all studies. The methods proposed by Hamza et al. 
[148] or Putter et al. [135] both offer a more sophisticated option when there is a 
complete set of thresholds in all studies (or when IPD is available for all studies). These 
methods have been found to have estimation and convergence issues for data that 
contained missing thresholds across studies [135, 158]. 
The imputation method proposed by Riley et al. [158] does not assume a common linear 
relationship between observed pairs of thresholds, and allows different linear 
relationships in each pair. Therefore the method only assumes a straight line 
relationship between each pair of observed thresholds available. This is different in 
comparison to the Hamza et al. [148] approach where they assume a linear relationship 
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in logit ROC space. A single linear trend is assumed across the whole logit ROC space 
only when producing the summary ROC curve [163] through a model, to then constrain 
the summary estimates to be ordered. 
6.5.5 Conclusion 
Riley et al. [158] proposed a new meta-analysis approach to deal with multiple 
thresholds per study, and in this chapter this was evaluated through the simulation 
study. Across the four different scenarios, the general message is that the imputation 
approach appears suitable at least as a sensitivity analysis to assess how meta-analysis 
results change after imputation. If thresholds are missing at random, the mean values for 
pooled logit-sensitivity and logit-specificity are the same or very similar on average 
compared to the true estimated value. The standard errors are larger in the meta-analysis 
before imputation, and the meta-analysis after imputation brings these values closer to 
the true estimated standard errors. The median tau-squared values are very similar. 
For selective reporting scenarios, it removes the upwards bias in pooled results and 
reduces standard errors. In scenario III, although bias in most thresholds was removed 
on average, for some thresholds the imputation method was slightly too conservative 
(sensitivity and specificity reduced slightly too far). 
This method could potentially help meta-analysts to quickly evaluate the impact of 
missing and selectively reporting threshold results. This approach uses commonly 
known methods for diagnostic test accuracy meta-analysis and offers a more practical 
approach to more sophisticated methods [135, 148]  that require complete data or 
experience convergence issues. 
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6.5.6 What further research is needed? 
Further research is required to validate this imputation method. For example different 
types of datasets need to be used in simulation case studies such as this. A more 
heterogeneous dataset may give different results; it would be of interest to find out if the 
results are better, worse or in fact similar. Many more validation studies are required to 
then consider recommending this imputation method for wider use. But, in the longer 
term the method requires extension to multiple imputations. 
6.5.7 What this chapter adds? 
A summary of what the problem is, what this study adds and what is required next is 
described in Table 6.9. 
Table 6.9: What chapter six adds? 
What is known / what is the problem? 
 When performing a meta-analysis of thresholds presented in papers, there will be missing data as 
different papers will present different thresholds  
 Rarely do all papers report all thresholds, so it becomes difficult to get a clear view of what the 
best threshold is or how it compares to the others 
 An imputation approach has been considered in this chapter, which assumes a linear relationship 
between two known thresholds and imputes the threshold  
 The data from Noordzij is used here; as all of the IPD is available, missing thresholds are 
generated to replicate scenarios in practice 
What this study adds? 
 From the imputed results for sensitivity and specificity we can see the bias is reduced in 
comparison to having missing values, and is much closer to when we have the full data  
 Standard errors are also reduced and as a result the mean squared error is reduced 
 Thus gaining more information than compared to having missing values  
 This imputation approach is a good tool as a sensitivity analysis to assess how good the 
conclusions are compared to having missing threshold values, and may even change the 
conclusions depending on the results 
What is needed next? 
 More analysis is required, i.e. this dataset had almost no heterogeneity, a more heterogeneous 
dataset may not work as well in this imputation method and this requires further investigation  
 Also, a multiple imputation approach should be considered, as this approach used single 
imputation  
 There are many articles on publication bias and missing data, this is therefore an exploratory tool 
to assess whether the conclusions are robust due to the missing data  
 If imputation approach indicates conclusions are vulnerable it may be necessary to obtain the 
IPD to then calculate the thresholds with complete data 
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 DISCUSSION CHAPTER 7:
Systematic reviews and meta-analysis of risk prediction research are an important part 
of clinical research. This thesis has contributed to the growing body of work in this 
field, through application, development and evaluation of novel statistical methods for 
meta-analysis. In this final chapter, the key findings of the thesis are summarised and 
further research needs are addressed. 
7.1 Overview of the thesis 
Chapter 2 evaluated the benefit of a meta-analysis of aggregate data for summarising 
and comparing the performance of risk prediction models using a real example in breast 
cancer. A systematic review was performed and an attempt was made to meta-analyse 
the reported risk prediction models. Unfortunately, this was not possible due to a lack of 
complete reporting of the models proposed. It was thus decided to compare the models 
by performing a meta-analysis of their validation statistics (discrimination and 
calibration). Clear recommendations were difficult to form, as the models were 
generally validated in different datasets and validation statistics were often incompletely 
reported. Thus a key finding is that further external validation studies are required, 
which are powered and designed to allow all the competing models to be formally 
compared directly to each other.  
Given the difficulties of evaluating prediction models based on published aggregate 
data, Chapter 3 systematically reviewed the methods and reporting used in existing risk 
prediction model research that utilised IPD from multiple studies . The systematic 
review was based on an extensive list of questions, and showed that most articles 
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disregard clustering within their IPD (from multiple studies) and usually only validate 
their models internally, although a few studies used an 'internal-external cross-
validation' approach to maximise the data toward model development and external 
validation. The findings led to recommendations for improving the field, and a number 
of methodological questions were identified. It is important to note that the review only 
considered articles that develop and/or validate a prediction model. For risk prediction 
models to become more common in practice, research also needs to show they have a 
positive impact on health outcomes. Such impact studies are currently rare [19], but 
they should follow any IPD meta-analysis that develops and validates an accurate risk 
prediction model. 
A key methodology issue was addressed in Chapters 4 and 5: what is the impact of 
accounting for (versus ignoring) clustering of patients within studies, when using IPD 
from multiple studies to summarise the performance of a risk prediction tool? For 
simplicity, the prediction tool considered was a prognostic test (i.e. a model with a 
single predictor, dichotomised at a particular threshold). A prognostic test dataset was 
obtained from one of the papers from the systematic review in Chapter 3, which had 
ignored clustering. In the example, there was almost no heterogeneity in the sensitivity, 
specificity and C statistic values and the original conclusions generally appeared fine 
(although at some thresholds the CI’s for sensitivity and specificity were smaller by 
ignoring clustering) based on these values as the unstratified and meta-analysis 
approaches had similar values.  In contrast there appeared to be a problem with 
calibration of post-test probabilities (PPV and NPV) as there was heterogeneity in the 
prevalence, and so NPV and PPV based on the summary prevalence, sensitivity and 
specificity was poor in some studies. However, when summary sensitivity and 
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specificity were combined with a study's own prevalence, calibration was dramatically 
improved. Thus, in contrast to the original findings reported, the NPV and PPV for new 
populations should be tailored to each studies own population [156, 165], and not use 
the NPV and PPV based solely on summary meta-analysis results. Willis et al. [156] 
have also had similar findings about the need to check whether meta-analysis results for 
a particular test are reliable enough to be used in clinical practice. They suggest that 
tailoring meta-analysis results to particular clinical settings will improve the reliability 
(validity) of test accuracy results.  
Chapter 6 continued to examine meta-analysis for a single prognostic test, and how to 
deal with published aggregate data where the reported thresholds differ across studies.  
Simulation and IPD from real studies was used to evaluate a recently proposed method 
by Riley et al. for imputing missing threshold results in a study, which are bounded 
between two known thresholds.  In general, it was found this method performs well as 
an exploratory (sensitivity) analysis, as the imputation approach appears to give very 
little bias in pooled estimates at each threshold, but with substantially increased 
precision  compared to the original data with missing values. Further research is needed 
to extend the method to multiple imputations, and thereby produce more robust 
confidence intervals. 
7.2 Key findings and recommendations 
The work described above contributes important findings to the field of risk prediction 
research. Four papers have been published (based on the work in Chapter 2 [41], 
Chapter 3 [16], Chapters 4-5 [43] and Chapter 6 [43]), all the cover pages have been 
provided in APPENDIX D. The key findings and recommendations have been outlined 
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at the end of each chapter, and the major implications are summarised once more in 
Table 7.1. 
Table 7.1: Key findings and recommendations 
Key findings 
 Breast cancer risk prediction models are poorly reported, in terms of both model parameter 
estimates and validation results, and thus it is difficult to perform meta-analysis to summarise 
current evidence  
 IPD is needed in meta-analysis of risk prediction research, so that model estimates and validation 
statistics can be calculated and compared easily 
 In general, researchers currently ignore clustering of patients within studies when IPD is used to 
develop and/or validate risk prediction models from multiple studies 
 Researchers currently validate models mainly using internal validation, but an approach called 
internal-external cross-validation appears promising to overcome this 
 A real example of a prognostic test meta-analysis shows that it is very important to take 
clustering into account when 
 (i) assessing heterogeneity across studies for discrimination (sensitivity, specificity and C 
statistic), in order to recommend an appropriate threshold to be used across different settings; 
and  
 (ii) assessing heterogeneity in post-test probabilities (PPV and NPV); in particular,  if there is 
heterogeneity in the prevalence then calibration will be poor, and so summary meta-analysis 
results will need tailoring to particular populations according to their own prevalence 
 When dealing with missing threshold results in an aggregate data meta-analysis of the accuracy 
of a prognostic test, a single imputation method works well as an exploratory analysis, as it  
increases precision of pooled estimates and has very little bias, compared to the original analysis 
that ignores missing thresholds in the data  
Recommendations 
 Papers reporting risk prediction models need to improve their quality of reporting, especially in 
terms of reporting the actual model (with intercept term (if applicable) and all variables with a 
95% CI) 
 When risk prediction models are validated, their validation statistics should be presented with 
their uncertainty 
 It is important for IPD to be made available so when models are not presented or validation 
statistics are not presented, then one can calculate these with the IPD and directly compare 
competing models 
 It is essential to account for clustering and assess heterogeneity when using IPD from multiple 
studies to develop and/or validate a risk prediction model 
 Decisions on the best threshold for a prognostic test, and how to implement it in clinical practice, 
should evaluate test performance in new populations. In particular, researchers should check 
whether there is any heterogeneity in test accuracy and post-test probabilities 
 When dealing with meta-analysis of test accuracy studies with missing thresholds, researchers 
should use the imputation method of Riley et al. as an exploratory analysis to assess the potential 
impact of missing threshold data on their meta-analysis conclusions 
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7.3 Main messages for the risk prediction field 
This thesis has established through empirical examples and case studies that evaluating 
risk prediction models across multiple studies is very difficult without IPD. IPD enables 
models to be derived and compared, with external validation performance statistics 
calculated and summarised across studies in a meta-analysis. However, Chapter 4 
showed that even when IPD are available, problems may remain and researchers often 
do not make most use of the data at hand. Potential flaws were identified and ways to 
improve this recommended, in particular assessing discrimination and calibration in 
each study separately rather than performing these analyses disregarding clustering. 
This was shown to be pivotal for the PTH test, as the PPV and NPV proposed by 
Noordzij et al. were found to be unreliable, as they needed to be tailored to new 
populations according to their own prevalence. Leeflang et al. [166] have used a 
bivariate random-effects model and have not mentioned whether correlation was poorly 
estimated at ±1 or not. If it was, then it would have been better to use the univariate 
model. They have jointly analysed PPV and NPV, and state that prevalence will be the 
driving force behind correlation [166]. Whereas in this thesis I have tailored the PPV 
and NPV values using each studies observed prevalence, which is going beyond what 
they have done. Willis et al. [156] use a tailored meta-analysis approach where they 
only include studies in to the meta-analysis if the study fits within or is close-enough to 
a applicable region in the ROC space [156], this will exclude those studies that are 
deemed to be not in the applicable region. This is in contrast to the approach used in this 
thesis, where summary estimates are tailored to the individual study to improve 
calibration of the predictive test. 
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Although Chapters 4 to 6 focused on a single prognostic test, many of the issues raised 
are also applicable to multivariate prediction models (that contain multiple predictors). 
In particular, the internal-external cross-validation approach was identified as a key 
method. 
Debray et al. [82] develop a multivariable logistic regression model from an IPD meta-
analysis with potential between-study heterogeneity. They propose strategies for 
choosing a valid model intercept for when the model is to be validated or applied to new 
individuals or study samples. This is similar in concept to using a study specific 
prevalence. Their results indicate that stratified estimation of model intercepts facilitates 
the derivation of a study specific model intercept, even when it is to be applied to a new 
study that was not considered during model development. Where the intercept can be 
well-matched to the excluded study, Debray et al. [103] show that their framework 
allows an IPD meta-analysis to produce a single, integrated prediction model that can be 
implemented in practice and has improved model performance and generalisability. 
This echoes other recommendations to account for clustering in an IPD meta-analysis 
[102]. For survival data, this means that the baseline hazard should be modelled during 
model development and so researchers should move away from using Cox regression (a 
common approach used which does not estimate the baseline hazard) and rather use 
other approaches such as flexible parametric methods, like the Royston-Parmar model 
[101] that estimates the baseline hazard using restricted cubic splines [11, 18]. 
Klaveren et al. [27] have assessed the discriminative ability of a risk model in clustered 
data, they have used different methods to meta-analyse Harrell’s c-index and found that 
a 95% prediction interval is quite wide (0.60, 0.95). They have recommended to meta-
analyse the c-index at a cluster level, where it is worked out in each cluster separately 
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and then meta-analysed. This is similar to what I have done in Chapter 4 and found the 
results improved when performing a meta-analysis that accounts for clustering.  
Pennells et al. [130] have assessed a risk prediction model using IPD from multiple 
studies, they have assessed its’ predictive ability by using discrimination measures such 
as the C statistic. What they have not done is assessed its ability in making 
individualised predictions, looking at how well it predicts at a study level and how it 
calibrates. As found in this thesis, discrimination was found to be good, but calibration 
was poor until it was tailored to each study using their observed prevalence which is 
more important. 
Cochrane currently advise to use summary values for sensitivity, specificity, PPV and 
NPV from a meta-analysis. This may need to change if they want to do prognostic 
meta-analysis in the future [167], this is due to the findings of this research in Chapters 
4 and 5, which have shown summary values may discriminate well, but calibration is 
poor. But in another study with more heterogeneity, discrimination may be poor too, 
thus having to tailor the sensitivity and specificity values to each individual setting as 
well as the prevalence. 
7.4 Further research 
One of the main limitations of this thesis is that only one dataset was used within 
Chapters 4-6, to examine the impact of ignoring clustering and for evaluating the single 
imputation method. This dataset had almost zero heterogeneity, and there was only one 
predictor included. It would be interesting to examine whether findings are similar in 
more heterogeneous datasets in further research. Indeed, in some way the PTH dataset is 
probably not typical of what we would encounter in the real world; in general we would 
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find more heterogeneity within the dataset, and be focused on more than one predictor 
for inclusion in a multivariable prediction model. Nonetheless, although there are 
limitations of this dataset, it is a real clinical example where adjustment for clustering 
did not occur in the original research study. 
The dataset also did not suffer importantly from missing data. As missing outcome data 
can cause a big issue when developing a risk prediction model, further research needs to 
evaluate the issues considered in this context also. Recently an approach has been 
published by Burgess et al. [168] where they attempt to perform multiple imputation 
and meta-analysis together, although this requires further research. 
Other work that may be considered subsequent to this thesis are to perform an updated 
systematic review up until 2015 (update of Chapter 3), to assess whether anything has 
changed since the previous review of IPD meta-analysis of risk prediction studies up to 
2009. Perhaps standards have improved, for example clustering might be accounted for 
more often, or more authors are using the ‘internal-external’ cross-validation approach. 
Also, the imputation method needs to be robustly assessed using a more heterogeneous 
dataset; this will help gain a better insight as to how the imputation method works in a 
different setting. As well as using a multiple imputation approach instead of single 
imputation, as single imputation is a simple procedure that fills in the missing value 
between two known thresholds in this instance and importantly regards this imputed 
value as an equal to the data that has not been imputed. Whereas multiple imputations 
will simulate the possible missing values and the uncertainty around them, variability is 
taken in to account in the imputed data to find a range of suitable imputable values. 
Another extension is to extrapolate beyond the known thresholds. In this dataset if 50% 
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and 70% were only available in a missing data scenario, then only 60% and 65% would 
be imputed. But, if we assumed that the relationship between all thresholds was linear, 
then we could extrapolate out to 40% and 90% and even beyond those values (this could 
again be assessed as the full IPD is available). Riley et al. [169] have presented a 
multivariate-normal method [148] which deals with multiple and missing thresholds for 
studies in a meta-analysis, they use the correlation between thresholds to reduce the 
impact of missing thresholds and produce an ROC curve, which is in contrast to the 
method used here which performs a separate meta-analysis at each threshold. This 
method has previously been recommended by Hamza et al. [148] and the approach of 
meta-analysing with a multiple number of thresholds has been discussed by Dukic et al. 
[170] and Putter et al. [171]. 
Also, Chapters 4 to 6 looked at a threshold specific result. This required the continuous 
predictor to be dichotomised. An extension would be to re-assess the work performed in 
those chapters with them left as continuous, with the possibility of modelling non-linear 
trends. Also note, percentage change from baseline has been used for the analysis in this 
thesis. But we could include two predictors instead, one of baseline and one of the final 
score in the model to assess whether this is more powerful in comparison. Percentage 
change is used to reduce impact of different methods of measuring PTH across studies. 
More research is needed on how to deal with different methods of measurement. 
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Table 7.2: Further research recommendations 
Recommendations 
 Perform an updated systematic review up until 2015 for Chapter 3 to examine if 
standards have improved 
 Use a more heterogeneous dataset to assess impact of discrimination and calibration 
statistics when ignoring clustering 
 Assess the robustness on the single imputation method using a more heterogeneous 
dataset 
 Develop a multiple imputation approach instead of single imputation for dealing with 
missing thresholds in test accuracy meta-analysis 
 Extend the imputation methods by potentially assuming a linear relationship and 
extrapolating beyond known thresholds 
 Assess PTH as a prognostic test on its continuous scale instead of dichotomising into a 
binary predictor 
 Instead of % change from baseline, develop a multivariable model for risk of 
hypocalcaemia that uses at least two predictors, for example PTH at baseline and PTH 
after surgery 
 
7.5 Conclusions 
This thesis has shown through several chapters that IPD is crucial in the development 
and validation of risk prediction models and prognostic tests using multiple studies. IPD 
allows more robust model development, an internal-external cross-validation approach, 
the estimation and synthesis of validation performance statistics, and the identification 
of pertinent thresholds of implementing tests. When IPD are not available, the thesis has 
also shown the practical issues of a systematic review and, if possible, meta-analysis of 
published results, and empirically evaluated an imputation method for dealing with 
missing threshold results. Researchers wishing to undertake risk prediction research 
using multiple studies are highly recommended to seek IPD, and ensure they consider 
clustering in their analysis and assess heterogeneity in prediction performance, as this is 
the best approach to produce the most robust risk prediction findings that can be 
translated into clinical practice.
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APPENDIX A 
APPENDIX A.1: List of questions for systematic review 
1) Background information 
What country is the corresponding author located in? (I.e. what is the central location 
for the IPD project?) 
Is there a reference to a protocol for the IPD project, and, if so, were details given as to 
where it can be found? 
How the project was funded, and was ethics approval granted for the IPD project? If 
not,  
were reasons given as to why ethics approval was not necessary and, if so, what were 
the reasons? 
Number of studies/datasets included? 
What were the types of different studies included (e.g. studies, databases etc.)? 
Number of authors/researchers? 
2) Research objectives 
What was the key research aims of the paper in relation to prognosis/risk prediction? 
At baseline what was the condition of the patients being assessed? 
(E.g. what disease did they have, or what operation had they just had, or were they 
healthy etc., Note: If diagnostic prediction model; than suspicion of the disease is 
starting point). 
What outcomes or diseases were of interest for prediction? 
3) Identifying studies and their IPD 
What was the process used to identify relevant studies for the IPD project?  
(E.g. literature review or collaborative group). 
If a literature review, then what search strategy was used (e.g. search of Medline, 
Embase) and was a list of keywords given?  Also was a flow chart shown, giving the 
flow of studies into and out of the project? 
If collaborative group, how were studies or databases chosen to be included in the 
collaborative group? 
 (E.g. friends in the field, existing database, etc.) 
What are the types of studies for inclusion? e.g. RCTs, just placebo arms from RCTs, 
cohort study, hospital databases, insurance company registries etc. 
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Was the total sample size or total number of studies required for the model development 
and/or validation justified? E.g. sample size calculation, or did they ask for IPD from all 
studies available? 
Also info on number and types of outcomes, as these are related to power considerations 
together with the number of candidate predictors? 
And most importantly perhaps: number of pre-planned subgroup analyses (as this is the 
main idea for IPDs in at least therapeutic studies) 
4) Asking for and obtaining IPD 
How were authors of relevant studies approached for IPD (e.g. e-mail, letter, phone 
etc.)?  
How many studies (or collaborating groups) were ultimately approached for IPD, and 
what proportion of these studies/groups actually provided IPD? 
(If appropriate) what were the reasons given as to why some studies refused to provide 
IPD? 
How many studies ultimately provided IPD? 
What types of studies were they (e.g. RCT, cohort, etc.)? 
Was the number of patients within each of the IPD studies given? If not, was the 
number of patients across all studies given? 
Was the total number of events given for each predicted outcome, within each of the 
IPD studies?  If not, was the total number of events given across all studies? 
Was the number of events per candidate variable (predictor) given in each study? If not, 
was the number of events per variable given across all studies? 
Was the number of candidate predictors in total and per study given? 
Was a summary of the sample population given for each study separately (e.g. mean 
age, proportion male, treatments in use etc.); if not, was it given for the whole IPD 
combined? 
Did they synchronise prediction and outcome definitions and measurements? 
Did they have to do that? 
What attempts were made? 
Did they use proxies if not exactly same measurement method or definition? 
Did they delete studies due to absence or completely different predictor or outcome? 
Did the inclusion / exclusion criteria for an IPD study include an assessment of study 
quality?   
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If yes, what quality criteria were used to decide inclusion or exclusion (or ‘low’ quality 
and ‘high’ quality)?  
Were IPD still sought from low quality studies? 
5) Missing data 
At individual-level: Were details of any missing individual-level data within the 
available IPD given for each study, and, if so, what were they? (E.g. for some patients 
their age was unknown) (Note: Check tables to help with this) 
At study-level: Did all studies have all candidate predictors or outcomes of interest, or 
was there any missing data across studies? (E.g. for some studies, age was not recorded 
at all) 
If either of these were detailed, how was missing data handled in the analysis? 
6)  Model development: statistical analysis methods 
Are any articles referred to for methodology or any statistical methods cited? Especially 
if it relates to using data from multiple studies. (Note: for my own reference mainly) 
Was a statistical analysis plan for model development given or mentioned in the 
Methods section? 
Was the number of patients and events used from each study toward the prediction 
model development given? 
Were the prediction models developed using the IPD from multiple studies? If so, how 
was the data synthesised: 
‘One-step ignoring clustering’: lumping all the data together into one big dataset, and 
ignoring clustering by study or collaborative group; or 
‘A one-step analysis accounting for clustering’, where the data from all 
studies/collaborative groups are analysed together but with clustering by study/group 
accounted for (e.g. using a dummy variable for study); or 
A two-step approach, where the data are first analysed separately in each study, and 
then their model estimates are pooled together in second-step.  
Developed using a part of the dataset, and then validated using the remaining data 
What types of statistical models were used?  
In the two-step approach, details are needed here of how individual studies were 
analysed, and then how the model estimates were pooled using meta-analysis.  
In the one-step approach, again details are need here of the one-step model itself (Cox 
regression, logistic regression) and the meta-analysis assumptions therein (e.g. fixed or 
random-effects on the predictor effects)  
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Was between-study heterogeneity in the predictor/outcomes considered within the 
prediction model? If so how (e.g. using random-effects in the analysis; assessing 
heterogeneity using I-squared) 
How were continuous predictors in the prediction model analysed, on a continuous scale 
or categorized?  
If categorized 
Were reasons given as to why this was done? 
How many cut-points were used, and how were they chosen? 
If on a continuous scale 
Were non-linear trends assessed and, if so, how were they modelled? (E.g. splines, 
fractional polynomials) 
Was the continuous factor analysed on its original scale, or was it on a transformed 
scale and why? 
If multivariable models were fitted (i.e. prediction models that included multiple 
variables) 
What criteria were used to decide inclusion of a predictor in the model? (E.g. statistical 
criteria, such as p< 0.1, or clinical criteria such as a hazard ratio > 2 or inclusion of 
‘smoking’ variable regardless  
What selection procedure was used? (E.g. forward, backward, stepwise) 
Was the final model given in full (i.e. with parameter estimates and standard error or CI 
for each)?   If not, what was given? 
List all the problems that are stated or evident that limited the statistical analysis (E.g. 
different method of measurements, different predictors available in each study etc.) and 
how did the authors attempt to overcome these problems? 
7) Model validation 
Internal validation (using the same data used to generate the model): 
Was this done? 
If so, how? 
How good was the performance of the model after the validation?  
External validation (using different data than that used to generate the model)e.g. data 
from other centres not used to develop the model, or half of the data from each centre 
that was not used to develop and left to validate instead, etc.) 
Was this done? 
If so, how? 
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How good was the performance of the model after the validation?  
What discrimination, calibration, reclassification or other statistics (e.g. goodness of fit 
or R2) were used? 
Were any figures given to show model discrimination / accuracy / calibration? 
If so, what? 
Were the results presented with their CI’s or S.E’s? 
Was the number of studies used in the validation stated? 
Was the number of patients and events used from each study toward the prediction 
model validation given? 
8) Dealing with those studies not willing / able to provide their IPD 
(If appropriate) Was there an assessment or discussion of whether the available IPD 
studies were a biased set of all studies in the field? 
(If appropriate) for studies not providing IPD, were details given as to the number of 
patients and events in these studies 
(if appropriate) were there any other details provided on the qualitative or quantitative 
differences between those studies providing IPD and those studies not able to provide 
IPD? If so, what were these differences? 
9) Conclusions and discussion 
What were the main clinical conclusions of the IPD project in the Discussion, in relation 
to the use or implementation of the model? 
What limitations and problems of the IPD project were noted in the Discussion? 
Were totally different conclusions made given the results? 
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APPENDIX B 
APPENDIX B.1: The results of calibration for 0-20 minutes for the remaining 
studies 
Table for Warren 2002 study, 0-20 minutes 
Approach No. of 
hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 2.79 3 0.93 0.30 2.88 0.26 1 0.26 0.04 1.86 3.05 4 0.76 0.29 2.03 
>50 3.29 3 1.10 0.35 3.40 0.21 1 0.21 0.03 1.47 3.50 4 0.87 0.33 2.33 
>60 2.19 3 0.73 0.24 2.27 0.59 1 0.59 0.08 4.17 2.78 4 0.70 0.26 1.85 
>65 2.29 3 0.76 0.25 2.36 0.71 1 0.71 0.10 5.05 3.00 4 0.75 0.28 2.00 
>70 2.36 3 0.79 0.25 2.44 0.70 1 0.70 0.10 4.97 3.06 4 0.77 0.29 2.04 
>72 2.41 3 0.80 0.26 2.49 0.69 1 0.69 0.10 4.90 3.10 4 0.78 0.29 2.07 
>80 2.24 2 1.12 0.28 4.48 1.09 2 0.55 0.14 2.18 3.33 4 0.83 0.31 2.22 
>90 0.67 0    2.35 4 0.59 0.22 1.56 3.02 4 0.75 0.28 2.01 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 2.93 3 0.98 0.32 3.03 0.25 1 0.25 0.04 1.79 3.18 4 0.80 0.30 2.12 
>50 3.34 3 1.11 0.36 3.45 0.21 1 0.21 0.03 1.50 3.55 4 0.89 0.33 2.37 
>60 2.45 3 0.82 0.26 2.53 0.56 1 0.56 0.08 4.01 3.01 4 0.75 0.28 2.00 
>65 2.57 3 0.86 0.28 2.66 0.69 1 0.69 0.10 4.87 3.26 4 0.81 0.31 2.17 
>70 2.62 3 0.87 0.28 2.71 0.68 1 0.68 0.10 4.83 3.30 4 0.82 0.31 2.20 
>72 2.73 3 0.91 0.29 2.82 0.67 1 0.67 0.09 4.73 3.40 4 0.85 0.32 2.26 
>80 2.26 2 1.13 0.28 4.52 1.05 2 0.53 0.13 2.10 3.31 4 0.83 0.31 2.21 
>90 0.59 0    2.78 4 0.70 0.26 1.85 3.38 4 0.84 0.32 2.25 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 1.39 3 0.46 0.15 1.44 0.10 1 0.10 0.01 0.70 1.49 4 0.37 0.14 0.99 
>50 1.65 3 0.55 0.18 1.70 0.08 1 0.08 0.01 0.58 1.73 4 0.43 0.16 1.15 
>60 1.33 3 0.44 0.14 1.38 0.22 1 0.22 0.03 1.57 1.55 4 0.39 0.15 1.03 
>65 1.43 3 0.48 0.15 1.48 0.27 1 0.27 0.04 1.92 1.70 4 0.43 0.16 1.14 
>70 1.47 3 0.49 0.16 1.52 0.27 1 0.27 0.04 1.91 1.74 4 0.43 0.16 1.16 
>72 1.57 3 0.52 0.17 1.62 0.26 1 0.26 0.04 1.87 1.83 4 0.46 0.17 1.22 
>80 1.32 2 0.66 0.17 2.64 0.42 2 0.21 0.05 0.84 1.74 4 0.44 0.16 1.16 
>90 0.36 0    1.19 4 0.30 0.11 0.79 1.55 4 0.39 0.15 1.03 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 5.04 3 1.68 0.54 5.21 0.63 1 0.63 0.09 4.47 5.67 4 1.42 0.53 3.78 
>50 5.48 3 1.83 0.59 5.66 0.53 1 0.53 0.07 3.76 6.01 4 1.50 0.56 4.00 
>60 3.58 3 1.19 0.39 3.70 1.37 1 1.37 0.19 9.75 4.96 4 1.24 0.46 3.30 
>65 3.68 3 1.23 0.40 3.81 1.64 1 1.64 0.23 11.66 5.32 4 1.33 0.50 3.55 
>70 3.72 3 1.24 0.40 3.84 1.63 1 1.63 0.23 11.57 5.35 4 1.34 0.50 3.56 
>72 3.80 3 1.27 0.41 3.93 1.60 1 1.60 0.23 11.35 5.40 4 1.35 0.51 3.60 
>80 3.10 2 1.55 0.39 6.19 2.43 2 1.21 0.30 4.85 5.52 4 1.38 0.52 3.68 
>90 0.79 0    5.63 4 1.41 0.53 3.75 6.42 4 1.61 0.60 4.28 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 2.53 3 0.84 0.27 2.61 0.21 1 0.21 0.03 1.46 2.73 4 0.68 0.26 1.82 
>50 2.91 3 0.97 0.31 3.01 0.17 1 0.17 0.02 1.22 3.08 4 0.77 0.29 2.05 
>60 2.18 3 0.73 0.23 2.26 0.46 1 0.46 0.06 3.27 2.64 4 0.66 0.25 1.76 
>65 2.31 3 0.77 0.25 2.39 0.56 1 0.56 0.08 3.99 2.87 4 0.72 0.27 1.91 
>70 2.35 3 0.78 0.25 2.43 0.56 1 0.56 0.08 3.95 2.91 4 0.73 0.27 1.94 
>72 2.47 3 0.82 0.27 2.55 0.55 1 0.55 0.08 3.87 3.01 4 0.75 0.28 2.01 
>80 2.05 2 1.02 0.26 4.10 0.87 2 0.43 0.11 1.73 2.91 4 0.73 0.27 1.94 
>90 0.54 0    2.33 4 0.58 0.22 1.55 2.87 4 0.72 0.27 1.91 
Where blank, this is due to observed cases being 0 so an E/O ratio was not possible 
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Table for Warren 2004 study, 0-20 minutes 
Approach No. of 
hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 4.65 3 1.55 0.50 4.81 0.41 0    5.06 3 1.69 0.54 5.23 
>50 4.76 3 1.59 0.51 4.92 0.38 0    5.14 3 1.71 0.55 5.31 
>60 2.19 2 1.10 0.27 4.39 1.12 1 1.12 0.16 7.96 3.32 3 1.11 0.36 3.43 
>65 2.29 2 1.14 0.29 4.57 1.36 1 1.36 0.19 9.65 3.65 3 1.22 0.39 3.77 
>70 2.36 2 1.18 0.30 4.72 1.34 1 1.34 0.19 9.48 3.70 3 1.23 0.40 3.82 
>72 2.41 2 1.21 0.30 4.82 1.32 1 1.32 0.19 9.36 3.73 3 1.24 0.40 3.86 
>80 2.80 2 1.40 0.35 5.60 1.91 1 1.91 0.27 13.55 4.71 3 1.57 0.51 4.87 
>90 1.34 0    3.75 3 1.25 0.40 3.88 5.10 3 1.70 0.55 5.27 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 4.89 3 1.63 0.53 5.05 0.40 0    5.28 3 1.76 0.57 5.46 
>50 4.83 3 1.61 0.52 4.99 0.39 0    5.22 3 1.74 0.56 5.39 
>60 2.45 2 1.22 0.31 4.89 1.08 1 1.08 0.15 7.65 3.52 3 1.17 0.38 3.64 
>65 2.57 2 1.29 0.32 5.14 1.31 1 1.31 0.18 9.30 3.88 3 1.29 0.42 4.01 
>70 2.62 2 1.31 0.33 5.23 1.30 1 1.30 0.18 9.23 3.92 3 1.31 0.42 4.05 
>72 2.73 2 1.37 0.34 5.46 1.27 1 1.27 0.18 9.03 4.00 3 1.33 0.43 4.14 
>80 2.83 2 1.41 0.35 5.65 1.84 1 1.84 0.26 13.07 4.67 3 1.56 0.50 4.82 
>90 1.19 0    4.45 3 1.48 0.48 4.60 5.64 3 1.88 0.61 5.83 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 2.32 3 0.77 0.25 2.40 0.15 0    2.48 3 0.83 0.27 2.56 
>50 2.38 3 0.79 0.26 2.46 0.15 0    2.53 3 0.84 0.27 2.61 
>60 1.33 2 0.67 0.17 2.66 0.42 1 0.42 0.06 3.00 1.75 3 0.58 0.19 1.81 
>65 1.43 2 0.72 0.18 2.87 0.52 1 0.52 0.07 3.67 1.95 3 0.65 0.21 2.02 
>70 1.47 2 0.74 0.18 2.94 0.51 1 0.51 0.07 3.64 1.98 3 0.66 0.21 2.05 
>72 1.57 2 0.78 0.20 3.13 0.50 1 0.50 0.07 3.56 2.07 3 0.69 0.22 2.14 
>80 1.65 2 0.83 0.21 3.30 0.74 1 0.74 0.10 5.25 2.39 3 0.80 0.26 2.47 
>90 0.71 0    1.91 3 0.64 0.21 1.97 2.62 3 0.87 0.28 2.71 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 8.40 3 2.80 0.90 8.68 0.99 0    9.39 3 3.13 1.01 9.71 
>50 7.92 3 2.64 0.85 8.18 0.98 0    8.90 3 2.97 0.96 9.20 
>60 3.58 2 1.79 0.45 7.16 2.62 1 2.62 0.37 18.62 6.20 3 2.07 0.67 6.41 
>65 3.68 2 1.84 0.46 7.36 3.14 1 3.14 0.44 22.26 6.82 3 2.27 0.73 7.05 
>70 3.72 2 1.86 0.46 7.43 3.11 1 3.11 0.44 22.08 6.83 3 2.28 0.73 7.06 
>72 3.80 2 1.90 0.48 7.60 3.05 1 3.05 0.43 21.68 6.86 3 2.29 0.74 7.09 
>80 3.87 2 1.94 0.48 7.74 4.25 1 4.25 0.60 30.15 8.12 3 2.71 0.87 8.39 
>90 1.59 0    9.00 3 3.00 0.97 9.31 10.59 3 3.53 1.14 10.95 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 2.70 3 0.90 0.29 2.79 0.18 0    2.89 3 0.96 0.31 2.98 
>50 2.75 3 0.92 0.30 2.84 0.18 0    2.93 3 0.98 0.32 3.03 
>60 1.52 2 0.76 0.19 3.03 0.50 1 0.50 0.07 3.58 2.02 3 0.67 0.22 2.09 
>65 1.63 2 0.81 0.20 3.25 0.62 1 0.62 0.09 4.38 2.24 3 0.75 0.24 2.32 
>70 1.67 2 0.83 0.21 3.33 0.61 1 0.61 0.09 4.34 2.28 3 0.76 0.24 2.35 
>72 1.77 2 0.88 0.22 3.54 0.60 1 0.60 0.08 4.25 2.37 3 0.79 0.25 2.45 
>80 1.86 2 0.93 0.23 3.71 0.88 1 0.88 0.12 6.25 2.74 3 0.91 0.29 2.83 
>90 0.80 0    2.25 3 0.75 0.24 2.33 3.05 3 1.02 0.33 3.15 
Where blank, this is due to observed cases being 0 so an E/O ratio was not possible 
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APPENDIX B.2: The results of calibration for 1-2 hours for the remaining studies 
Table for Warren 2002 study, 1-2 hours 
Approach No. of 
hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 1.40 1 1.40 0.20 9.91 0.13 1 0.13 0.02 0.95 1.53 2 0.76 0.19 3.06 
>50 1.64 1 1.64 0.23 11.67 0.11 1 0.11 0.02 0.79 1.76 2 0.88 0.22 3.51 
>60 1.70 1 1.70 0.24 12.06 0.10 1 0.10 0.01 0.73 1.80 2 0.90 0.23 3.60 
>65 1.71 1 1.71 0.24 12.17 0.15 1 0.15 0.02 1.07 1.87 2 0.93 0.23 3.73 
>70 0.68 1 0.68 0.10 4.80 0.18 1 0.18 0.03 1.27 0.86 2 0.43 0.11 1.71 
>72 0.70 1 0.70 0.10 4.97 0.28 1 0.28 0.04 1.97 0.98 2 0.49 0.12 1.95 
>80 0.76 1 0.76 0.11 5.41 0.54 1 0.54 0.08 3.83 1.30 2 0.65 0.16 2.60 
>90 0.00 0    1.07 2 0.53 0.13 2.13 1.07 2 0.53 0.13 2.13 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 1.42 1 1.42 0.20 10.06 0.14 1 0.14 0.02 0.98 1.55 2 0.78 0.19 3.11 
>50 1.67 1 1.67 0.24 11.84 0.11 1 0.11 0.02 0.81 1.78 2 0.89 0.22 3.56 
>60 1.72 1 1.72 0.24 12.18 0.11 1 0.11 0.01 0.75 1.82 2 0.91 0.23 3.64 
>65 1.77 1 1.77 0.25 12.57 0.15 1 0.15 0.02 1.08 1.92 2 0.96 0.24 3.84 
>70 0.68 1 0.68 0.10 4.84 0.18 1 0.18 0.03 1.30 0.87 2 0.43 0.11 1.73 
>72 0.70 1 0.70 0.10 5.00 0.30 1 0.30 0.04 2.10 1.00 2 0.50 0.13 2.00 
>80 0.78 1 0.78 0.11 5.55 0.55 1 0.55 0.08 3.90 1.33 2 0.67 0.17 2.66 
>90 0.00 0    1.09 2 0.54 0.14 2.18 1.09 2 0.54 0.14 2.18 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 0.69 1 0.69 0.10 4.89 0.05 1 0.05 0.01 0.37 0.74 2 0.37 0.09 1.48 
>50 0.85 1 0.85 0.12 6.06 0.04 1 0.04 0.01 0.31 0.90 2 0.45 0.11 1.79 
>60 1.01 1 1.01 0.14 7.16 0.04 1 0.04 0.01 0.28 1.05 2 0.52 0.13 2.10 
>65 1.06 1 1.06 0.15 7.52 0.06 1 0.06 0.01 0.42 1.12 2 0.56 0.14 2.24 
>70 0.45 1 0.45 0.06 3.18 0.07 1 0.07 0.01 0.50 0.52 2 0.26 0.06 1.04 
>72 0.47 1 0.47 0.07 3.37 0.11 1 0.11 0.02 0.81 0.59 2 0.29 0.07 1.18 
>80 0.58 1 0.58 0.08 4.08 0.22 1 0.22 0.03 1.53 0.79 2 0.40 0.10 1.58 
>90 0.00 0    0.44 2 0.22 0.06 0.89 0.44 2 0.22 0.06 0.89 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 2.36 1 2.36 0.33 16.79 0.35 1 0.35 0.05 2.47 2.71 2 1.36 0.34 5.42 
>50 2.61 1 2.61 0.37 18.56 0.29 1 0.29 0.04 2.06 2.90 2 1.45 0.36 5.81 
>60 2.34 1 2.34 0.33 16.59 0.27 1 0.27 0.04 1.91 2.61 2 1.30 0.33 5.21 
>65 2.37 1 2.37 0.33 16.86 0.39 1 0.39 0.05 2.76 2.76 2 1.38 0.35 5.52 
>70 0.85 1 0.85 0.12 6.03 0.47 1 0.47 0.07 3.32 1.32 2 0.66 0.16 2.63 
>72 0.86 1 0.86 0.12 6.12 0.74 1 0.74 0.10 5.26 1.60 2 0.80 0.20 3.21 
>80 0.90 1 0.90 0.13 6.42 1.32 1 1.32 0.19 9.34 2.22 2 1.11 0.28 4.44 
>90 0.00 0    2.44 2 1.22 0.30 4.87 2.44 2 1.22 0.30 4.87 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 1.23 1 1.23 0.17 8.73 0.11 1 0.11 0.02 0.79 1.34 2 0.67 0.17 2.68 
>50 1.47 1 1.47 0.21 10.41 0.09 1 0.09 0.01 0.65 1.56 2 0.78 0.19 3.12 
>60 1.56 1 1.56 0.22 11.06 0.08 1 0.08 0.01 0.60 1.64 2 0.82 0.21 3.28 
>65 1.61 1 1.61 0.23 11.46 0.12 1 0.12 0.02 0.88 1.74 2 0.87 0.22 3.47 
>70 0.63 1 0.63 0.09 4.50 0.15 1 0.15 0.02 1.06 0.78 2 0.39 0.10 1.57 
>72 0.66 1 0.66 0.09 4.67 0.24 1 0.24 0.03 1.71 0.90 2 0.45 0.11 1.80 
>80 0.74 1 0.74 0.10 5.27 0.45 1 0.45 0.06 3.19 1.19 2 0.60 0.15 2.38 
>90 0.00 0    0.90 2 0.45 0.11 1.80 0.90 2 0.45 0.11 1.80 
Where blank, this is due to observed cases being 0 so an E/O ratio was not possible 
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Table for Warren 2004 study, 1-2 hours 
Approach No. of 
hypocalcaemia 
who tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 4.88 3 1.63 0.53 5.05 0.27 0    5.15 3 1.72 0.55 5.33 
>50 4.93 3 1.64 0.53 5.10 0.26 0    5.19 3 1.73 0.56 5.37 
>60 5.09 3 1.70 0.55 5.27 0.25 0    5.34 3 1.78 0.57 5.52 
>65 5.14 3 1.71 0.55 5.31 0.37 0    5.51 3 1.84 0.59 5.69 
>70 4.06 3 1.35 0.44 4.20 0.40 0    4.46 3 1.49 0.48 4.61 
>72 4.20 3 1.40 0.45 4.34 0.62 0    4.82 3 1.61 0.52 4.98 
>80 3.05 2 1.52 0.38 6.09 1.32 1 1.32 0.19 9.37 4.37 3 1.46 0.47 4.51 
>90 0.00 0    2.77 3 0.92 0.30 2.86 2.77 3 0.92 0.30 2.86 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 4.96 3 1.65 0.53 5.13 0.27 0    5.23 3 1.74 0.56 5.41 
>50 5.01 3 1.67 0.54 5.17 0.26 0    5.27 3 1.76 0.57 5.45 
>60 5.15 3 1.72 0.55 5.32 0.26 0    5.40 3 1.80 0.58 5.58 
>65 5.31 3 1.77 0.57 5.49 0.37 0    5.68 3 1.89 0.61 5.87 
>70 4.09 3 1.36 0.44 4.23 0.41 0    4.50 3 1.50 0.48 4.65 
>72 4.23 3 1.41 0.45 4.37 0.66 0    4.88 3 1.63 0.52 5.05 
>80 3.13 2 1.56 0.39 6.25 1.34 1 1.34 0.19 9.53 4.47 3 1.49 0.48 4.62 
>90 0.00 0    2.83 3 0.94 0.30 2.92 2.83 3 0.94 0.30 2.92 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 2.41 3 0.80 0.26 2.49 0.11 0    2.52 3 0.84 0.27 2.60 
>50 2.56 3 0.85 0.28 2.65 0.10 0    2.66 3 0.89 0.29 2.75 
>60 3.03 3 1.01 0.33 3.13 0.10 0    3.12 3 1.04 0.34 3.23 
>65 3.18 3 1.06 0.34 3.29 0.14 0    3.32 3 1.11 0.36 3.43 
>70 2.69 3 0.90 0.29 2.78 0.16 0    2.85 3 0.95 0.31 2.94 
>72 2.85 3 0.95 0.31 2.94 0.25 0    3.10 3 1.03 0.33 3.20 
>80 2.30 2 1.15 0.29 4.60 0.53 1 0.53 0.07 3.75 2.83 3 0.94 0.30 2.92 
>90 0.00 0    1.15 3 0.38 0.12 1.19 1.15 3 0.38 0.12 1.19 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 8.28 3 2.76 0.89 8.55 0.70 0    8.97 3 2.99 0.96 9.28 
>50 7.84 3 2.61 0.84 8.11 0.68 0    8.52 3 2.84 0.92 8.81 
>60 7.01 3 2.34 0.75 7.24 0.65 0    7.66 3 2.55 0.82 7.92 
>65 7.12 3 2.37 0.77 7.36 0.94 0    8.07 3 2.69 0.87 8.34 
>70 5.10 3 1.70 0.55 5.27 1.04 0    6.14 3 2.05 0.66 6.34 
>72 5.18 3 1.73 0.56 5.35 1.65 0    6.82 3 2.27 0.73 7.05 
>80 3.62 2 1.81 0.45 7.23 3.22 1 3.22 0.45 22.83 6.83 3 2.28 0.73 7.06 
>90 0.00 0    6.33 3 2.11 0.68 6.54 6.33 3 2.11 0.68 6.54 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 2.80 3 0.93 0.30 2.89 0.13 0    2.92 3 0.97 0.31 3.02 
>50 2.95 3 0.98 0.32 3.05 0.12 0    3.07 3 1.02 0.33 3.17 
>60 3.40 3 1.13 0.37 3.52 0.12 0    3.52 3 1.17 0.38 3.64 
>65 3.56 3 1.19 0.38 3.68 0.17 0    3.73 3 1.24 0.40 3.86 
>70 2.96 3 0.99 0.32 3.06 0.19 0    3.15 3 1.05 0.34 3.26 
>72 3.12 3 1.04 0.34 3.22 0.30 0    3.42 3 1.14 0.37 3.54 
>80 2.48 2 1.24 0.31 4.95 0.63 1 0.63 0.09 4.48 3.11 3 1.04 0.33 3.21 
>90 0.00 0    1.37 3 0.46 0.15 1.41 1.37 3 0.46 0.15 1.41 
Where blank, this is due to observed cases being 0 so an E/O ratio was not possible 
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Table for Lombardi study, 1-2 hours 
Approach No. of 
hypocalcaemia who 
tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 11.16 15 0.74 0.45 1.23 0.42 1 0.42 0.06 3.01 11.59 16 0.72 0.44 1.18 
>50 12.33 15 0.82 0.50 1.36 0.39 1 0.39 0.05 2.76 12.72 16 0.80 0.49 1.30 
>60 11.89 15 0.79 0.48 1.31 0.44 1 0.44 0.06 3.11 12.33 16 0.77 0.47 1.26 
>65 12.00 15 0.80 0.48 1.33 0.65 1 0.65 0.09 4.60 12.65 16 0.79 0.48 1.29 
>70 12.86 15 0.86 0.52 1.42 0.64 1 0.64 0.09 4.52 13.49 16 0.84 0.52 1.38 
>72 11.21 13 0.86 0.50 1.48 1.08 3 0.36 0.12 1.11 12.28 16 0.77 0.47 1.25 
>80 10.66 12 0.89 0.50 1.56 2.22 4 0.56 0.21 1.48 12.88 16 0.81 0.49 1.31 
>90 10.00 10 1.00 0.54 1.86 4.37 6 0.73 0.33 1.62 14.37 16 0.90 0.55 1.47 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 11.33 15 0.76 0.46 1.25 0.44 1 0.44 0.06 3.09 11.77 16 0.74 0.45 1.20 
>50 12.51 15 0.83 0.50 1.38 0.40 1 0.40 0.06 2.82 12.91 16 0.81 0.49 1.32 
>60 12.01 15 0.80 0.48 1.33 0.45 1 0.45 0.06 3.19 12.46 16 0.78 0.48 1.27 
>65 12.39 15 0.83 0.50 1.37 0.65 1 0.65 0.09 4.64 13.05 16 0.82 0.50 1.33 
>70 12.95 15 0.86 0.52 1.43 0.65 1 0.65 0.09 4.63 13.61 16 0.85 0.52 1.39 
>72 11.27 13 0.87 0.50 1.49 1.15 3 0.38 0.12 1.19 12.42 16 0.78 0.48 1.27 
>80 10.94 12 0.91 0.52 1.61 2.26 4 0.56 0.21 1.50 13.20 16 0.82 0.51 1.35 
>90 10.00 10 1.00 0.54 1.86 4.46 6 0.74 0.33 1.65 14.46 16 0.90 0.55 1.48 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 5.51 15 0.37 0.22 0.61 0.17 1 0.17 0.02 1.19 5.68 16 0.35 0.22 0.58 
>50 6.40 15 0.43 0.26 0.71 0.15 1 0.15 0.02 1.09 6.56 16 0.41 0.25 0.67 
>60 7.06 15 0.47 0.28 0.78 0.17 1 0.17 0.02 1.21 7.23 16 0.45 0.28 0.74 
>65 7.42 15 0.49 0.30 0.82 0.25 1 0.25 0.04 1.79 7.67 16 0.48 0.29 0.78 
>70 8.52 15 0.57 0.34 0.94 0.25 1 0.25 0.04 1.77 8.77 16 0.55 0.34 0.89 
>72 7.59 13 0.58 0.34 1.01 0.44 3 0.15 0.05 0.46 8.03 16 0.50 0.31 0.82 
>80 8.06 12 0.67 0.38 1.18 0.89 4 0.22 0.08 0.59 8.94 16 0.56 0.34 0.91 
>90 10.00 10 1.00 0.54 1.86 1.82 6 0.30 0.14 0.67 11.82 16 0.74 0.45 1.21 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 18.92 15 1.26 0.76 2.09 1.10 1 1.10 0.16 7.84 20.02 16 1.25 0.77 2.04 
>50 19.61 15 1.31 0.79 2.17 1.01 1 1.01 0.14 7.20 20.62 16 1.29 0.79 2.10 
>60 16.35 15 1.09 0.66 1.81 1.16 1 1.16 0.16 8.20 17.51 16 1.09 0.67 1.79 
>65 16.62 15 1.11 0.67 1.84 1.67 1 1.67 0.23 11.82 18.29 16 1.14 0.70 1.87 
>70 16.14 15 1.08 0.65 1.79 1.66 1 1.66 0.23 11.81 17.81 16 1.11 0.68 1.82 
>72 13.80 13 1.06 0.62 1.83 2.88 3 0.96 0.31 2.98 16.68 16 1.04 0.64 1.70 
>80 12.66 12 1.05 0.60 1.86 5.41 4 1.35 0.51 3.60 18.07 16 1.13 0.69 1.84 
>90 10.00 10 1.00 0.54 1.86 9.98 6 1.66 0.75 3.70 19.98 16 1.25 0.77 2.04 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 15.05 15 1.00 0.60 1.66 0.69 1 0.69 0.10 4.92 15.74 16 0.98 0.60 1.61 
>50 16.10 15 1.07 0.65 1.78 0.63 1 0.63 0.09 4.50 16.73 16 1.05 0.64 1.71 
>60 14.36 15 0.96 0.58 1.59 0.72 1 0.72 0.10 5.11 15.08 16 0.94 0.58 1.54 
>65 14.69 15 0.98 0.59 1.62 1.04 1 1.04 0.15 7.41 15.74 16 0.98 0.60 1.61 
>70 14.75 15 0.98 0.59 1.63 1.04 1 1.04 0.15 7.41 15.79 16 0.99 0.60 1.61 
>72 12.70 13 0.98 0.57 1.68 1.83 3 0.61 0.20 1.89 14.53 16 0.91 0.56 1.48 
>80 11.94 12 0.99 0.56 1.75 3.52 4 0.88 0.33 2.34 15.45 16 0.97 0.59 1.58 
>90 10.00 10 1.00 0.54 1.86 6.76 6 1.13 0.51 2.51 16.76 16 1.05 0.64 1.71 
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APPENDIX B.3: The results of calibration for 6 hours 
Table for Lam study, 6 hours 
Approach No. of 
hypocalcaemia who 
tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 7.43 12 0.62 0.35 1.09 0.25 0    7.68 12 0.64 0.36 1.13 
>50 8.21 12 0.68 0.39 1.20 0.24 0    8.45 12 0.70 0.40 1.24 
>60 9.08 12 0.76 0.43 1.33 0.23 0    9.31 12 0.78 0.44 1.37 
>65 10.46 12 0.87 0.49 1.53 0.22 0    10.68 12 0.89 0.51 1.57 
>70 10.92 12 0.91 0.52 1.60 0.42 0    11.35 12 0.95 0.54 1.67 
>72 10.66 12 0.89 0.50 1.56 0.65 0    11.31 12 0.94 0.54 1.66 
>80 9.60 11 0.87 0.48 1.58 1.32 1 1.32 0.19 9.34 10.92 12 0.91 0.52 1.60 
>90 7.22 7 1.03 0.49 2.16 2.62 5 0.52 0.22 1.26 9.84 12 0.82 0.47 1.44 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 7.53 12 0.63 0.36 1.10 0.26 0    7.79 12 0.65 0.37 1.14 
>50 8.30 12 0.69 0.39 1.22 0.24 0    8.55 12 0.71 0.40 1.25 
>60 9.15 12 0.76 0.43 1.34 0.24 0    9.39 12 0.78 0.44 1.38 
>65 10.52 12 0.88 0.50 1.54 0.22 0    10.74 12 0.90 0.51 1.58 
>70 10.98 12 0.91 0.52 1.61 0.43 0    11.41 12 0.95 0.54 1.67 
>72 10.75 12 0.90 0.51 1.58 0.58 0    11.33 12 0.94 0.54 1.66 
>80 9.66 11 0.88 0.49 1.59 1.33 1 1.33 0.19 9.42 10.99 12 0.92 0.52 1.61 
>90 7.24 7 1.03 0.49 2.17 2.67 5 0.53 0.22 1.28 9.91 12 0.83 0.47 1.45 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 3.86 12 0.32 0.18 0.57 0.10 0    3.96 12 0.33 0.19 0.58 
>50 4.64 12 0.39 0.22 0.68 0.09 0    4.74 12 0.39 0.22 0.70 
>60 5.84 12 0.49 0.28 0.86 0.09 0    5.93 12 0.49 0.28 0.87 
>65 7.47 12 0.62 0.35 1.10 0.09 0    7.56 12 0.63 0.36 1.11 
>70 8.11 12 0.68 0.38 1.19 0.17 0    8.28 12 0.69 0.39 1.21 
>72 8.38 12 0.70 0.40 1.23 0.22 0    8.60 12 0.72 0.41 1.26 
>80 7.32 11 0.67 0.37 1.20 0.52 1 0.52 0.07 3.71 7.84 12 0.65 0.37 1.15 
>90 6.27 7 0.90 0.43 1.88 1.08 5 0.22 0.09 0.52 7.35 12 0.61 0.35 1.08 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 11.78 12 0.98 0.56 1.73 0.67 0    12.45 12 1.04 0.59 1.83 
>50 11.84 12 0.99 0.56 1.74 0.63 0    12.47 12 1.04 0.59 1.83 
>60 11.66 12 0.97 0.55 1.71 0.61 0    12.27 12 1.02 0.58 1.80 
>65 12.44 12 1.04 0.59 1.83 0.58 0    13.02 12 1.08 0.62 1.91 
>70 12.68 12 1.06 0.60 1.86 1.11 0    13.78 12 1.15 0.65 2.02 
>72 12.04 12 1.00 0.57 1.77 1.46 0    13.51 12 1.13 0.64 1.98 
>80 10.99 11 1.00 0.55 1.80 3.20 1 3.20 0.45 22.70 14.19 12 1.18 0.67 2.08 
>90 7.69 7 1.10 0.52 2.31 6.06 5 1.21 0.50 2.91 13.76 12 1.15 0.65 2.02 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 9.68 12 0.81 0.46 1.42 0.42 0    10.10 12 0.84 0.48 1.48 
>50 10.17 12 0.85 0.48 1.49 0.39 0    10.56 12 0.88 0.50 1.55 
>60 10.55 12 0.88 0.50 1.55 0.38 0    10.93 12 0.91 0.52 1.60 
>65 11.62 12 0.97 0.55 1.71 0.36 0    11.98 12 1.00 0.57 1.76 
>70 11.96 12 1.00 0.57 1.76 0.69 0    12.66 12 1.05 0.60 1.86 
>72 11.51 12 0.96 0.54 1.69 0.92 0    12.43 12 1.04 0.59 1.82 
>80 10.44 11 0.95 0.53 1.71 2.07 1 2.07 0.29 14.71 12.51 12 1.04 0.59 1.84 
>90 7.51 7 1.07 0.51 2.25 4.07 5 0.81 0.34 1.96 11.59 12 0.97 0.55 1.70 
Where blank, this is due to observed cases being 0 so an E/O ratio was not possible 
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Table for Lombardi study, 6 hours 
Approach No. of 
hypocalcaemia who 
tested positive 
95% 
CI 
No. of 
hypocalcaemia 
who tested 
negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
Threshold E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
(1) Using the Unstratified prevalence, Unstratified sensitivity and Unstratified specificity 
>40 12.38 15 0.83 0.50 1.37 0.30 1 0.30 0.04 2.12 12.68 16 0.79 0.49 1.29 
>50 12.83 15 0.86 0.52 1.42 0.31 1 0.31 0.04 2.22 13.14 16 0.82 0.50 1.34 
>60 13.61 15 0.91 0.55 1.51 0.32 1 0.32 0.04 2.26 13.93 16 0.87 0.53 1.42 
>65 13.44 15 0.90 0.54 1.49 0.33 1 0.33 0.05 2.36 13.78 16 0.86 0.53 1.41 
>70 12.48 14 0.89 0.53 1.51 0.69 2 0.34 0.09 1.37 13.17 16 0.82 0.50 1.34 
>72 12.30 13 0.95 0.55 1.63 1.03 3 0.34 0.11 1.07 13.33 16 0.83 0.51 1.36 
>80 10.41 11 0.95 0.52 1.71 2.12 5 0.42 0.18 1.02 12.52 16 0.78 0.48 1.28 
>90 9.03 10 0.90 0.49 1.68 3.88 6 0.65 0.29 1.44 12.91 16 0.81 0.49 1.32 
(2) Using the univariate prevalence, univariate sensitivity and univariate specificity 
>40 12.55 15 0.84 0.50 1.39 0.31 1 0.31 0.04 2.17 12.86 16 0.80 0.49 1.31 
>50 12.97 15 0.86 0.52 1.43 0.32 1 0.32 0.05 2.27 13.29 16 0.83 0.51 1.36 
>60 13.73 15 0.92 0.55 1.52 0.33 1 0.33 0.05 2.33 14.06 16 0.88 0.54 1.43 
>65 13.52 15 0.90 0.54 1.50 0.34 1 0.34 0.05 2.41 13.86 16 0.87 0.53 1.41 
>70 12.55 14 0.90 0.53 1.51 0.70 2 0.35 0.09 1.41 13.25 16 0.83 0.51 1.35 
>72 12.41 13 0.95 0.55 1.64 0.92 3 0.31 0.10 0.95 13.32 16 0.83 0.51 1.36 
>80 10.47 11 0.95 0.53 1.72 2.13 5 0.43 0.18 1.03 12.60 16 0.79 0.48 1.29 
>90 9.05 10 0.91 0.49 1.68 3.96 6 0.66 0.30 1.47 13.01 16 0.81 0.50 1.33 
(3) Using the lower 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 6.43 15 0.43 0.26 0.71 0.12 1 0.12 0.02 0.84 6.55 16 0.41 0.25 0.67 
>50 7.26 15 0.48 0.29 0.80 0.12 1 0.12 0.02 0.87 7.38 16 0.46 0.28 0.75 
>60 8.76 15 0.58 0.35 0.97 0.12 1 0.12 0.02 0.89 8.89 16 0.56 0.34 0.91 
>65 9.61 15 0.64 0.39 1.06 0.13 1 0.13 0.02 0.93 9.74 16 0.61 0.37 0.99 
>70 9.27 14 0.66 0.39 1.12 0.27 2 0.13 0.03 0.54 9.54 16 0.60 0.37 0.97 
>72 9.67 13 0.74 0.43 1.28 0.35 3 0.12 0.04 0.37 10.02 16 0.63 0.38 1.02 
>80 7.93 11 0.72 0.40 1.30 0.84 5 0.17 0.07 0.40 8.77 16 0.55 0.34 0.89 
>90 7.83 10 0.78 0.42 1.46 1.60 6 0.27 0.12 0.59 9.43 16 0.59 0.36 0.96 
(4) Using the upper 95% prediction interval bound prevalence, univariate sensitivity and univariate specificity 
>40 19.64 15 1.31 0.79 2.17 0.79 1 0.79 0.11 5.58 20.43 16 1.28 0.78 2.08 
>50 18.50 15 1.23 0.74 2.05 0.83 1 0.83 0.12 5.87 19.33 16 1.21 0.74 1.97 
>60 17.49 15 1.17 0.70 1.93 0.85 1 0.85 0.12 6.01 18.33 16 1.15 0.70 1.87 
>65 15.99 15 1.07 0.64 1.77 0.88 1 0.88 0.12 6.27 16.88 16 1.05 0.65 1.72 
>70 14.49 14 1.03 0.61 1.75 1.79 2 0.90 0.22 3.58 16.28 16 1.02 0.62 1.66 
>72 13.90 13 1.07 0.62 1.84 2.32 3 0.77 0.25 2.40 16.22 16 1.01 0.62 1.65 
>80 11.91 11 1.08 0.60 1.95 5.14 5 1.03 0.43 2.47 17.05 16 1.07 0.65 1.74 
>90 9.62 10 0.96 0.52 1.79 8.98 6 1.50 0.67 3.33 18.60 16 1.16 0.71 1.90 
(5) Using the studies observed prevalence, univariate sensitivity and univariate specificity 
>40 16.13 15 1.08 0.65 1.78 0.49 1 0.49 0.07 3.48 16.62 16 1.04 0.64 1.70 
>50 15.89 15 1.06 0.64 1.76 0.51 1 0.51 0.07 3.66 16.41 16 1.03 0.63 1.67 
>60 15.82 15 1.05 0.64 1.75 0.52 1 0.52 0.07 3.73 16.35 16 1.02 0.63 1.67 
>65 14.94 15 1.00 0.60 1.65 0.55 1 0.55 0.08 3.88 15.49 16 0.97 0.59 1.58 
>70 13.67 14 0.98 0.58 1.65 1.12 2 0.56 0.14 2.24 14.80 16 0.92 0.57 1.51 
>72 13.28 13 1.02 0.59 1.76 1.46 3 0.49 0.16 1.51 14.75 16 0.92 0.56 1.50 
>80 11.31 11 1.03 0.57 1.86 3.33 5 0.67 0.28 1.60 14.64 16 0.92 0.56 1.49 
>90 9.39 10 0.94 0.51 1.75 6.04 6 1.01 0.45 2.24 15.43 16 0.96 0.59 1.57 
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Table for E/O ratios for all the patients combined using the unstratified and univariate meta-analysis approaches at the 6 
hour’s time-point 
% PTH 
Decrease 
No. of 
hypocalcaemia who 
tested positive 
95% 
CI 
No. of 
hypocalcaemia who 
tested negative 
95% 
CI 
Total with 
hypocalcaemia 
95% 
CI 
 E O E/O Lower Upper E O E/O Lower Upper E O E/O Lower Upper 
Approach 1               
>40 19.81 44 0.45 0.34 0.60 0.61 3 0.20 0.07 0.63 20.42 47 0.43 0.33 0.58 
>50 21.04 44 0.48 0.36 0.64 0.61 3 0.20 0.07 0.63 21.64 47 0.46 0.35 0.61 
>60 22.69 40 0.57 0.42 0.77 0.61 7 0.09 0.04 0.18 23.30 47 0.50 0.37 0.66 
>65 23.90 38 0.63 0.46 0.86 0.61 9 0.07 0.04 0.13 24.51 47 0.52 0.39 0.69 
>70 23.41 38 0.62 0.45 0.85 1.23 9 0.14 0.07 0.26 24.64 47 0.52 0.39 0.70 
>72 22.96 38 0.60 0.44 0.83 1.85 9 0.21 0.11 0.39 24.81 47 0.53 0.40 0.70 
>80 20.01 32 0.63 0.44 0.88 3.77 15 0.25 0.15 0.42 23.78 47 0.51 0.38 0.67 
>90 16.25 16 1.02 0.62 1.66 7.10 31 0.23 0.16 0.33 23.36 47 0.50 0.37 0.66 
Approach 2               
>40 20.08 44 0.46 0.34 0.61 0.55 3 0.18 0.06 0.57 20.63 47 0.44 0.33 0.58 
>50 21.27 44 0.48 0.36 0.65 0.55 3 0.18 0.06 0.57 21.82 47 0.46 0.35 0.62 
>60 22.88 40 0.57 0.42 0.78 0.55 7 0.08 0.04 0.16 23.43 47 0.50 0.37 0.66 
>65 24.04 38 0.63 0.46 0.87 0.55 9 0.06 0.03 0.12 24.59 47 0.52 0.39 0.70 
>70 23.53 38 0.62 0.45 0.85 1.11 9 0.12 0.06 0.24 24.64 47 0.52 0.39 0.70 
>72 23.16 38 0.61 0.44 0.84 1.46 9 0.16 0.08 0.31 24.62 47 0.52 0.39 0.70 
>80 20.13 32 0.63 0.44 0.89 3.38 15 0.23 0.14 0.37 23.51 47 0.50 0.38 0.67 
>90 16.29 16 1.02 0.62 1.66 6.49 31 0.21 0.15 0.30 22.78 47 0.48 0.36 0.65 
 
APPENDIX C 
APPENDIX C.1: Stata code used in Chapter 6  
**This part of the code is to generate 1000 different datasets each with a different combination of 50% missing data for each 
threshold, this part is used in all of the scenarios but the code is changed for each scenario depending on what  the missing data to be 
generated is. 
**Run through reps, storing estimates 
local reps=1000 //set reps 
local k=1 
while `k' <= `reps' { //loop though reps to run simulations 
 **generate some data, but first input original data from from Noordzij 
  use "C:\Users\Ikhlaaq\Documents\PhD\Chapter 6\1-2hrstudysim.dta", clear 
  gen iteration=`k' 
  **sort by study but keeping thresholds ascending 
  sort studyname, stable 
  by study: generate thresh=_n 
  **gen i and j values for all 35 observations and then for each threshold 
  gen num=_n 
  sort threshold, stable 
  by threshold: generate studyid=_n 
  **sort by study but keeping thresholds ascending 
  sort studyname, stable 
  di " ITERATION  `k' " 
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  **probability of missing at random being 50% 
  gen x1 = runiform() 
  gen p=x1 
  replace x1 = . if p < .5 
  count if x1!=. 
  replace tp = . if x1 == . 
  replace fn = . if x1 == . 
  replace fp = . if x1 == . 
  replace tn = . if x1 == . 
  **This next line calculates how many studies are providing data for each threshold,  important for M-A 
  egen nm = count(tp), by(thresh) 
  **advance to next replication - starts loop again and stores estimates this time in the next row of your 
tempfile 
  save iteration`k', replace 
  local k = `k'+1 
  } 
 **Merge all the datasets together  
 use iteration1, replace 
 for values k=2/1000 { 
  append using iteration`k' 
  } 
save originalmissing, replace 
**The data has been saved and now I prepare the data for meta-analysis, and also the next section adds 0.5 to each cell to avoid 
having any zero cells 
use originalmissing, replace 
//prep data for analysis 
replace tp=(tp+0.5) 
replace fn=(fn+0.5) 
replace fp=(fp+0.5) 
replace tn=(tn+0.5) 
save missingdata, replace  
**Meta-analysis for missing data, putting the data in to meta-analysis format, loop for 1000 datasets 
cd "C:\Users\Ikhlaaq\Documents\PhD\Chapter 6\50%" 
use "C:\Users\Ikhlaaq\Documents\PhD\Chapter 6\50%\missingdata.dta", clear 
**Convert to meta-analysis format 
capture drop n true n1 n0 true1 true0 study sens spec 
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gen long n1=tp+fn 
gen long n0=fp+tn 
gen long true1=tp 
gen long true0=tn 
gen long study= _n 
reshape long n true, i(study) j(sens) 
sort study sens 
gen byte spec=1-sens 
tab nm 
save data1, replace 
**Meta-analysis code 
tempname ests 
tempfile estimates_file 
postfile `ests' dataset ite sens seSens speci seSpeci lntausens lntauspec using `estimates_file', replace 
forvalues h = 1/1000 { 
 use data1, replace 
 drop if iteration!=`h' 
   { 
forvalues i = 1/7 { 
 save data, replace 
 drop if thresh!=`i' 
 drop if tp==. 
  if  nm<2 {*where nm is the number of studies providing data for each threshold 
   if nm == 1 { 
   gen sensitivity=(tp)/(tp+fn) 
   local lnsensitivity=ln(sensitivity/(1-sensitivity))  
   local lnsense= 1 / ((tp+fn)*(sensitivity)*(1-sensitivity)) 
   gen specificity=(tn)/(tn+fp) 
   local lnspecificity=ln(specificity/(1-specificity)) 
   local lnspecse= 1/ ((tn+fp)*(specificity)*(1-specificity)) 
     
   local sens = `lnsensitivity' 
   local seSens = `lnsense' 
   local speci = `lnspecificity' 
   local seSpeci = `lnspecse' 
260 
 
   local lntausens = 0 
   local lntauspec = 0 
   use data, replace 
    } 
   else if nm == 0 { 
    local sens = . 
    local seSens = . 
    local speci = . 
    local seSpeci = . 
    local lntausens = . 
    local lntauspec = . 
    use data, replace 
    } 
   } 
  else { 
  use data, replace 
  *Univariate meta-analysis code 
  capture xtmelogit true sens spec, nocons || study: sens spec if thresh == `i' & nm>1, nocons binomial(n)   
intpoints(1) variance 
  local sens = _b[sens] 
  local seSens = _se[sens] 
  local speci = _b[spec] 
  local seSpeci = _se[spec] 
  local lntausens = _b[lns1_1_1:_cons] 
  local lntauspec = _b[lns1_1_2:_cons] 
  }  
 local dataset = `h'  
 local ite =`i' 
 post `ests' (`dataset') (`ite') (`sens') (`seSens') (`speci') (`seSpeci') (`lntausens') (`lntauspec') 
 } 
 } 
 } 
postclose `ests' 
use `estimates_file', replace 
save MD-MA, replace 
**Postfile closed, and data saved 
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use missingdata,replace 
//code for adding the weight to each cut-off 
gen weight=0 
replace weight=0 if threshold==40 
replace weight=2 if threshold==50 
replace weight=4 if threshold==60 
replace weight=5 if threshold==65 
replace weight=6 if threshold==70 
replace weight=8 if threshold==80 
replace weight=10 if threshold==90 
**Missing data indicator 
gen missingind=0 
replace missingind=1 if tp==. 
**generating sensitivity and logit sensitivity for imputation 
gen sen=(tp)/(tp+fn) 
gen sens=ln(sen/(1-sen))  
gen spe=(tn)/(tn+fp) 
gen speci=ln(spe/(1-spe)) 
save missingdata1, replace 
**imputation for missing data 
capture program drop sim_impute 
program define sim_impute, rclass 
/* Syntax  
  D = Number of datasets 
  S = Number of studies 
  V = Vector of number of studies per dataset 
  T = Number of thresholds 
*/ 
 syntax [, D(int0) S(int 0) V(string) T(int 0)] 
/* Create a dataID to identify when a dataset begins and ends*/ 
gen idnum=_n 
if `s'>0 {  
 local obs = `s'*`t' 
 egen dataID = seq(), b(`obs') 
 } 
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 else { 
  gen dataID = 1 if idnum<=((`v'[1,1])*`t') 
   if `d'>1 { 
    local counter = (`v'[1,1])*`t' 
     forvalues j = 2/`d' { 
      local counter = `counter' + ((`v'[1,`j'])*`t') 
      replace dataID = `j' if dataID==. &idnum<=`counter' 
      } 
    } 
   } 
/* Save whole dataset and drop any extra meta-analytic datasets to enable analysis of each dataset 
  individually */ 
forvalues dataset=1/`d' { 
 save data_test, replace 
 drop if dataID!=`dataset' 
 preserve 
/* Check whether user has defined local "s", this indicates that there are the same number of studies 
 in each meta-analytic dataset. 
 If "s" is not defined then there are a variable number of studies in each meta-analytic dataset 
 and the number of studies in each dataset is defined in the matrix name "v" */ 
  if `s'>0 { 
  local ds=`s' 
  } 
  else { 
   local ds=`v'[1,`dataset'] 
   } 
 
/* Loop through the studies, dropping out all but one study to allow analysis of each study individually*/ 
forvalues studies=1/`ds' { 
 drop if studyid!=`studies' 
 local tminus=`t'-1 
/* Cycle through the thresholds looking for those without data, which could be imputed*/ 
Forvalues i=2/`tminus' { 
 if missingind[`i']==1 { 
  local down=`i'+1 
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/* Cycle down the list of thresholds, looking for the next threshold with data and store this data*/ 
  forvalues j=`down'/`t' { 
   if missingind[`j']==0 { 
    local DthreshNM= `j' 
    local DsensNM= sens[`j'] 
    local DspeciNM= speci[`j'] 
    local DweightNM= weight[`j'] 
    continue, break 
    } 
   if `j'==`t' { 
    local DsensNM= . 
    local DweightNM= . 
    } 
   } 
/* Cycle up the list of thresholds, looking for the next threshold with data and store this data*/ 
  Save looking_for_higher_thresh, replace 
  drop if thresh>`i' 
   forvalues k= 1/`i' { 
   local real_thresh=(`i'-`k') 
   if missingind[`real_thresh']==0 { 
    local UthreshNM= `real_thresh' 
    local UsensNM = sens[`real_thresh'] 
    local UspeciNM = speci[`real_thresh'] 
    local UweightNM = weight[`real_thresh'] 
    continue, break 
    } 
   if `real_thresh'==1 { 
    local UsensNM= . 
    local UweightNM= . 
    } 
   } 
/* Take the weight of the threshold without data, and the data stored from above and below thresholds 
 and use this to impute the new threshold data*/ 
  use looking_for_higher_thresh, replace 
  local w = weight[`i'] 
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  replace sens=(`UsensNM'+((`DsensNM'-`UsensNM')*((`w'-`UweightNM')/(`DweightNM'-`UweightNM')))) 
/// 
     if thresh==`i' 
  replace speci=(`UspeciNM'+((`DspeciNM'-`UspeciNM')*((`w'-`UweightNM')/(`DweightNM'-
`UweightNM')))) /// 
     if thresh==`i' 
   } 
  } 
/* Save the imputed data file for this study and then restore all studies data from memory*/ 
 Save imputed_study_data`studies', replace 
 restore, preserve 
 } 
/* Append all the study data files for one dataset, then restore the whole dataset and loop round to 
 analyse the next meta-analytic dataset*/ 
 use imputed_study_data1, replace 
 if `ds'>1 { 
  forvalues a=2/`ds' { 
   append using imputed_study_data`a' 
   save imputed_dataset_data`dataset', replace 
   } 
  } 
 restore, not 
 use data_test, replace 
} 
/* Append the multiple meta-analytic datasets with imputed data*/ 
if `ds'==1 { 
 use imputed_study_data1, replace 
 } 
 else { 
  use imputed_dataset_data1, replace 
   
  if `d'>1 { 
   forvalues a=2/`d' { 
    append using imputed_dataset_data`a' 
    save imputed_whole_IPD, replace 
    } 
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   } 
  } 
end 
************************************************************ 
cd "C:\Users\Ikhlaaq\Documents\PhD\Chapter 6\50%" 
set more off 
use missingdata1, clear 
sim_impute, d(1000) s(5) t(7) 
save imputeddata, replace 
**Imputation has occurred and data has been saved 
**put back in to 2*2 format (back-transforming) 
use "C:\Users\Ikhlaaq\Documents\PhD\Chapter 6\50%\imputeddata.dta", clear 
**indicator for imputed data 
gen impind=0 
replace impind=1 if missingind==1 &sens!=. 
**putting values back in from logitsens and logit spec 
replace sen=(exp(sens)/(1+exp(sens))) if impind==1 
replace spe=(exp(spec)/(1+exp(spec))) if impind==1 
**putting tp, tn, fn and fp values back in 
gen hypo=0 
gen normo=0 
replace hypo=14 if studyid==1 
replace normo=28 if studyid==1 
replace hypo=18 if studyid==2 
replace normo=37 if studyid==2 
replace hypo=14 if studyid==3 
replace normo=27 if studyid==3 
replace hypo=4 if studyid==4 
replace normo=10 if studyid==4 
replace hypo=5 if studyid==5 
replace normo=25 if studyid==5 
*These are true disease values 
**putting in values for tpetc with imputed sens and spec 
replace tp=sen*hypo if impind==1 
replace tn=spe*normo if impind==1 
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replace fn=hypo-tp if impind==1 
replace fp=normo-tn if impind==1 
drop sens speci 
drop sen spe 
save imputeddata1, replace 
**calculate nm for the imputed data as this has changed after the imputation has occured 
use imputeddata1, replace 
drop nm 
save imputeddata1, replace 
**generate new nm values for imputed data 
**Run through reps, storing estimates 
local reps=1000 //set reps 
local k=1 
while `k' <= `reps' { //loop though reps to run simulations 
  set more off 
  use "C:\Users\Ikhlaaq\Documents\PhD\Chapter 6\50%\imputeddata1.dta", clear 
  drop if iteration!=`k' 
  egen nm = count(tp), by(thresh) 
  /* advance to next replication - starts loop again and stores estimates this time 
   in the next row of your tempfile */ 
  save iterationind`k', replace 
  local k = `k'+1 
  } 
 //Merge all the datasets together  
 use iterationind1, replace 
 forvalues k=2/1000 { 
  append using iterationind`k' 
  } 
save imputeddata2, replace 
*data has been updated 
//imputed data MA 
//loop for 1000 datasets 
cd "C:\Users\Ikhlaaq\Documents\PhD\Chapter 6\50%" 
*Meta-analysis of Imputed data 
use "C:\Users\Ikhlaaq\Documents\PhD\Chapter 6\50%\imputeddata2.dta", clear 
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//meta-analysis format 
capture drop n true n1 n0 true1 true0 study sens spec 
gen long n1=tp+fn 
gen long n0=fp+tn 
gen long true1=tp 
gen long true0=tn 
gen long study= _n 
reshape long n true, i(study) j(sens) 
sort study sens 
gen byte spec=1-sens 
tab nm 
save data1, replace 
//set trace on 
set more off 
tempname ests 
tempfile estimates_file 
postfile `ests' dataset ite sens seSens speci seSpeci lntausens lntauspec using `estimates_file', replace 
forvalues h = 1/1000 { 
 use data1, replace 
 drop if iteration!=`h' 
   { 
forvalues i = 1/7 { 
 save data, replace 
 drop if thresh!=`i' 
 drop if tp==. 
  if  nm<2 { 
   if nm == 1 { 
   gen sensitivity=(tp)/(tp+fn) 
   local lnsensitivity=ln(sensitivity/(1-sensitivity))  
   local lnsense= 1 / ((tp+fn)*(sensitivity)*(1-sensitivity)) 
   gen specificity=(tn)/(tn+fp) 
   local lnspecificity=ln(specificity/(1-specificity)) 
   local lnspecse= 1/ ((tn+fp)*(specificity)*(1-specificity)) 
    
   local sens = `lnsensitivity' 
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   local seSens = `lnsense' 
   local speci = `lnspecificity' 
   loca lseSpeci = `lnspecse' 
   local lntausens = 0 
   local lntauspec = 0 
   use data, replace 
    } 
    
   else if nm == 0 { 
    local sens = . 
    local seSens = . 
    local speci = . 
    local seSpeci = . 
    local lntausens = . 
    local lntauspec = . 
    use data, replace 
    } 
   } 
 else { 
  use data, replace 
  capture xtmelogit true sens spec, nocons || study: sens spec if thresh == `i' & nm>1, nocons binomial(n)   
intpoints(1) variance 
  local sens = _b[sens] 
  local seSens = _se[sens] 
  local speci = _b[spec] 
  local seSpeci = _se[spec] 
  local lntausens = _b[lns1_1_1:_cons] 
  local lntauspec = _b[lns1_1_2:_cons] 
  }  
 local dataset = `h'  
 local ite =`i'  
 post `ests' (`dataset') (`ite') (`sens') (`seSens') (`speci') (`seSpeci') (`lntausens') (`lntauspec') 
 } 
 } 
 } 
postclose `ests' 
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use `estimates_file', replace 
save ID-MA, replace 
**Imputed results now saved 
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APPENDIX D 
APPENDIX D.1: Publication from Chapter 2
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APPENDIX D.2: Publication from Chapter 3 
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APPENDIX D.3: Paper submitted for publication from work in Chapters 4 & 5 
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APPENDIX D.4: Paper submitted for publication from work in Chapter 6 
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